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Preface

The prevalence of the Metabolic Syndrome (MetS), an entity defined as the coincidence in the same individual of obesity, insulin resistance, dyslipidemia,
hypertension and increased cardiovascular morbidity is increasing with a profile
that could be considered of epidemic proportions. It is clear that on top of its undeniable genetic contribution other environmental factors such as lack of physical
activity, diet, gut microflora and/or ageing are likely contributors to its progressive
acceleration. Despite the obvious public health and economic implications of MetS
as well as global research efforts to treat the disorder, the molecular and pathophysiological mechanisms linking the manifestations of MetS are still elusive. This may be
in part because of the difficulty in elucidating the primary pathogenic events given
the dynamic involvement of multiple interacting organ systems along the disease
processes.
Systems biology views and studies the biological systems in the context of complex interactions between their building blocks and processes, as well as with the
environment. Despite many traits which define the Metabolic Syndrome being highly
heritable, it is evident that the genetic contribution to these traits is mediated via
gene—gene and gene—environment interactions across several spatial and temporal
scales, and that some of these traits may even be a product of long-term adaptation
to the environmental factors including changes in energy balance. This makes the
Metabolic Syndrome a strong case for the adoption of systems approach.
The aim of this book is to provide the readers an overview about how the Metabolic
Syndrome can be tackled using a systems biology approach, identifying its challenges
and opportunities. The emphasis is on pathophysiology of MetS, not on the role of
genetic factors behind it. The specific aims correspond to the four main sections of
the book: (1) to give an introduction to pathophysiology of the Metabolic Syndrome
and medical systems biology, (2) to introduce the key biological processes involved
in the pathophysiology of MetS, (3) to introduce the emerging technologies utilized
using systems approached to study MetS, and (4) to introduce the novel mathematical
modeling approaches to study metabolic syndrome.
The present volume has two main purposes. It brings together current hypotheses
about the mechanisms of MetS and its co-morbidities as well as introduces emerging
systems biology approaches to tackle the underlying complexity of MetS. This will
v
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be of interest to researchers in the fields of medicine, biochemistry, biophysics and
computational biology. The book also provides a convenient reference work summarizing published work in the area of medical systems biology. We hope that this will
assist the research of a new generation of investigators drawn to this rapidly growing
field.
While the work leading to this book was supported from several sources, ten of the
chapters are from participants involved in the EU-funded project ‘Characterization
and modelling of dietary effects mediated by gut microbiota on lipid metabolism’ —
ETHERPATHS (FP7-KBBE-222639, http://www.etherpaths.org/). ETHERPATHS
is a project aiming to develop a platform for nutritional systems biology. Special
thanks therefore go to the European Commission for the financial support of the
research which had a major impact on this volume.
March 2013

Matej Orešič and Antonio Vidal-Puig
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Matej Orešič VTT Technical Research Centre of Finland, Tietotie 2, PO Box
1000, 02044 Espoo, Finland
Giuseppe Palasciano Clinica Medica “A. Murri”, Aldo Moro University of Bari,
Consorzio Mario Negri Sud, Via Nazionale 8A, 66030 Santa Maria Imbaro (Chieti),
Italy

xii

Contributors

Alexandre Panchaud BioAnalytical Science Department, Nestlé Research Centre,
Vers-chez-les-Blanc, 1000, Lausanne, Switzerland
Vincent Poitout Montreal Diabetes Research Center, CRCHUM—Technopôle
Angus, 2901 Rachel Est, Montréal, H1W 4A4, QC, Canada
Montserrat Romero Institute for Research in Biomedicine (IRB Barcelona),
C/Baldiri Reixac 10, 08028 Barcelona, Spain
Isabel Rubio-Aliaga BioAnalytical Science Department, Nestlé Research Centre,
Vers-chez-les-Blanc, 1000, Lausanne, Switzerland
Eytan Ruppin The Sackler School of Computer Sciences & School of Medicine,
Tel Aviv University, 69978 Tel Aviv, Israel
David Sanchez-Infantes Pennington Biomedical Research Center, Louisiana
State University, Baton Rouge 70808, LA, USA
David Sebastián Institute for Research in Biomedicine (IRB Barcelona), C/Baldiri
Reixac 10, 08028 Barcelona, Spain
Meriem Semache Department of Biochemistry, University of Montreal, Montreal,
QC, Canada
Irma Silva-Zolezzi BioAnalytical Science Department, Nestlé Research Centre,
Vers-chez-les-Blanc, 1000, Lausanne, Switzerland
Sergey Smirnov Institute for Systems Biology SPb, Leninskie Gory 1/75, Moscow,
Russia, 119992
Oleg Stepanov Institute for Systems Biology SPb, Leninskie Gory 1/75, Moscow,
Russia, 119992
Jacqueline M. Stephens Pennington Biomedical Research Center, Louisiana State
University, Baton Rouge 70808, LA, USA
Ilpo Vattulainen Department of Physics, Tampere University of Technology, PO
Box 692, 33101 Tampere, Finland

Contributors

xiii

Antonio Vidal-Puig Metabolic Research Laboratories Level 4, NIHR Cambridge Biomedical Research Centre, Addenbrooke’s Hospital, Institute of Metabolic
Science, University of Cambridge, Box 289, Cambridge CB2 0QQ, United Kingdom
Andrew J. Whittle Metabolic Research Laboratories Level 4, NIHR Cambridge Biomedical Research Centre, Addenbrooke’s Hospital, Institute of Metabolic
Science, University of Cambridge, Box 289, Cambridge CB2 0QQ, United Kingdom
Bader Zarrouki Department of Medicine, University of Montreal, Montreal, QC,
Canada
Antonio Zorzano Institute for Research in Biomedicine (IRB Barcelona), C/Baldiri
Reixac 10, 08028 Barcelona, Spain

List of Abbreviations

2D
3-OHPPr
3-OHPAc
3,4-OHBA
3,4-OHPPR
3,4-OHPAc
4-OHPPr
ABC
ACC
ADPN
AgRP
AIC
Akt
ALT
AMPK
AMT
ANOVA
ANCOVA
ApoA-I
ApoA-II
ApoAV
ApoB-100
ApoC-II
ApoC-III
ARC
ASCA
AST
ATF6
ATP
ATP III
BA
BAT

two-dimensional
3-(3×-Hydroxyphenyl)propionic acid
2-(3×-Hydroxyphenyl)acetic acid
3,4-Dihydroxybenzoic acid (Protocatechuic acid)
3-(3×,4×-Dihydroxyphenyl) propionic acid
2-(3×,4×-Dihydroxyphenyl)acetic acid
3-(4×-Hydroxyphenyl)propionic acid
aTP-binding cassette
acetyl-CoA carboxylase
adiponectin
agouti-related protein
akaike information criterion
protein kinase B
alanine aminotransferase
AMP-activated protein kinase
accurate mass tag
analysis of Variance
analysis of Covariance
apolipoprotein A-I
apolipoprotein A-II
apolipoprotein A-V
apolipoprotein B-100
apolipoprotein C-II
apolipoprotein C-III
arcuate nucleus of the hypothalamus
ANOVA-Simultaneous Component Analysis
Aspartate aminotransferase
activating transcription factor-6
adenosine triphosphate
ault Treatment Panel III
bile acid
brown adipose tissue
xv

xvi

BBB
BIC
BMI
BMP8b
CA
CAR
CART
CDCA
CD36
CETP
CJD
CHOP
ChREBP
CCA
CNS
CPT
CPT1
CSC
CSF
CT
CVD
CYP7A1
DDA
DF
DIA
DIGE
DMH
DNL
DPP4
ECD
END
ENL
ER
eIF2α
ESI
ETD
FA
FA
FABPs
FAO
FAS
FAT
FATP
FDR
FFA

List of Abbreviations

blood brain barrier
bayesian Information Criterion
body mass index
bone morphogenetic protein 8b
cholic acid
catch-and-release
cocaine and amphetamine regulated transcript
chenodeoxycholic acid
cluster differentiation protein-36
cholesteryl ester transfer protein
creutzfeldt-Jakob disease
C/EBP homologous protein
carbohydrate response element-binding protein
canonical Correlation Analysis
central nervous system
carnitine palmitoyltransferase
carnitine palmitoyltransferase 1
cell surface-capture
cerebrospinal fluid
computed tomography
cardiovascular disease
cholesterol 7α-hydroxylase
data-dependent acquisition
dietary fibre
data-independent acquisition
difference gel electrophoresis
dorsomedial nucleus of the hypothalamus
de novo lipogenesis
dipeptidyl-peptidase 4
electron-capture dissociation
enterodiol
enterolactone
endoplasmic reticulum
eukaryotic translation initiation factor 2 α
electrospray ionisation
electron-transfer dissociation
Factor Analysis
fatty acid
fatty acid binding proteins
fatty acid oxidation
fatty acid synthase
fatty acid translocase
fatty acid transport protein
False Discovery Rate
free fatty acid

List of Abbreviations

FOXO1
FP
FT-ICR
FXR
GE
GC
GGT
GIP
GLM
GLP-1
GLUT1
GLUT4
G-6-Pase
GPF
GSEA
HDL
HFD
HL
HMG-CoA
HPP
HSL
ICAT
ICPL
IDL
IR
IRF
IRS
IRE1
IT
iTRAQ
JNK
KNN
KSR2
LC
LCFA
LCFAs-CoA
LDA
LDL
LDLr
LHA
LMM
LPK
LPL
LOD
LRH-1

forkhead box protein O1
false positive
fourier-transform ion cyclotron resonance
farsenoid X receptor
gel electrophoresis
gas chromatography
gamma-glutamyltransferase
gastric inhibitory polypeptide
general Linear Model
glucagon-like peptide-1
glucose transporter type 1
glucose transporter type 4
glucose-6-phosphatase
gas-phase fractionation
gene Set Enrichment Analysis
high-density lipoprotein
high fat diet
hepatic lipase
hydroxymethyl-glutaryl coenzyme A
human proteome project
hormone-sensitive lipase
isotope-coded affinity tagging
isotope-coded protein labelling
intermediate-density lipoprotein
insulin resistance
isoelectric focusing
insulin receptor substrate
inositol-requiring protein-1
ion trap
isobaric tag for relative and absolute quantification
c-Jun N-terminal kinase
K-Nearest Neighbors
kinase suppressor of RAS 2
liquid chromatrography
long chain fatty acid
long chain fatty acids-CoA
linear Discriminant Analysis
low-density lipoprotein
low-density lipoprotein receptor
lateral hypothalamic area
Linear Mixed Models (LMM)
liver pyruvate kinase
lipoprotein lipase
limit of detection
liver receptor homolog-1

xvii

xviii

LSPAD
LXR
MetS
MS
MALDI
MANOVA
MANCOVA
MAPK
MetS
MCD
MetS
MRI
MS
MS/MS
MSE
MudPIT
mTOR
MTP
MUFA
NAFLD
NASH
NEFA
NMR
NPC1L1
NPY
NR
O-DMA
ODE
OA
OT
OxLDL
Ox-Phos
PAcIFIC
PAI
PCA
PCR
PDK4
PEPCK
PGC-1α
PI3K
PKA
PLS-DA
PMF
PMS

List of Abbreviations

localized statistics of protein abundance distribution
liver X receptor
Metabolic Syndrome
mass spectrometry
matrix-assisted laser desorption/ionisation
multivariate ANOVA
multivariate Analysis of Covariance
mitogen activate protein kinase
metabolic syndrome
malonyl-CoA decarboxylase
metabolic Syndrome
magnetic resonance imaging
mass spectrometry
tandem mass spectometry
precursor-independent acquisition of intact and fragment masses
multidimensional protein identification technology
mammalian target of rapamycin
microsomal transfer protein
monounsaturated fatty acid
nonalcoholic fatty liver
nonalcoholic steatohepatitis
non-esterified fatty acid
nuclear magnetic resonance
niemann-Pick C1-like 1
neuropeptide Y
nuclear receptor
O-Desmethylangolensin.
ordinary differential equations
oleic acid
orbitrap
oxidized low-density lipoprotein
oxidative phosphorylation
precursor acquisition independent from ion count
protein abundance index
principal Component Analysis
polymerase chain reaction
pyruvate dehydrogenase kinase 4
phosphoenolpyruvate carboxykinase
peroxisome proliferator-activated receptor-gamma coactivators 1alpha
phosphatidylinositol 3-kinases
protein kinase A
partial Least Squares Discriminant Analysis
peptide mass fingerprinting
peptide mass sequencing

List of Abbreviations

PMSS
PPAR
PP2A
POMC
PTP1B
PUFA
PVH
Q
ROS
RSTN
RT-PCR
SCD1
SCFA
SFA
SHP
SID
SILAC
sLDL
SOCS3
SpS
SREBPs
SVM
T2DM
T2D
T3
TG
TGs
TIM-1
TIM-2
TNF
TOF
TOFA
TSC
TUDCA
TZD
UCP1
UCP2
UCP3
UGT1A3
UPR
US
VLDL
WAT
Xbp1

peptide match score summarization
peroxisome proliferator-activated receptor
protein Phosphatase 2A
proopiomelanocortin
protein tyrosine phosphatase 1B
polyunsaturated fatty acid
paraventricular nucleus of the hypothalamus
quadrupole
reactive oxygen species
resistin
reverse-transcriptase polymerase chain reaction
stearoyil-CoA desaturase 1
short-chain fatty acid
saturated fatty acid
short heterodimer partner
stable-isotope dilution
stable-isotope labelling with amino acids in cell culture
small low-density lipoprotein
suppressor of cytokine signaling
spectrum sampling
sterol regulatory element binding proteins
support Vector Machines
type 2 Diabetes Mellitus
type-2 diabetes mellitus
triiodothyronine
triglyceride
triacylglycerols
TNO Intestinal Model 1 simulating the upper intestine
TNO Intestinal Model 2 simulating the colon
tumor necrosis factor
time-of-flight
5-(tetradecyloxy)-2-furoic acid
tuberous sclerosis complex
tauroursodeoxycholic acid
thiazolidinedione
uncoupling protein 1
uncoupling protein 2
uncoupling protein 3
UDP-glucuronosyltransferase 1–3
unfolded protein response
ultrasound
very low-density lipoprotein
white adipose tissue
X-box binding protein 1

xix

Part I

Introduction

Chapter 1

The Metabolic Syndrome and its Complex
Pathophysiology
Antonio Vidal-Puig

Abstract The Metabolic Syndrome (MetS) represents the association of common
pathologies such as obesity, diabetes, insulin resistance, dyslipidaemia, fatty liver
and associated cardiovascular complications. The MetS is important because of its
prevalence, potential severity and costs. The MetS is a challenge due to its undeﬁned
pathogenesis, clinical heterogeneity and complexity, lack of good risk predictors and
therapeutic options. Here we propose an adipocentric pathogenic model supported
by the concepts of adipose tissue expandability and peripheral lipotoxicity. We also
put forward the need for an allostatic perspective and a systems biology approach
to understand its pathogenesis, natural history, subphenotypes, potential diagnostic
and prognostic biomarkers and new therapeutic targets.
Keywords Obesity · Insulin resistance · Lipotoxicity · Inﬂammation · Adipose tissue
expandability · Allostasis

1.1 The Metabolic Syndrome (MetS) and Systems Biology
It is not uncommon to diagnose obesity, insulin resistance, diabetes, dyslipidaemia,
and fatty liver clustered in the same individual. The high prevalence of this association indicates that it is not a random event that occurs just by chance. Thus, it is likely
that these apparently diverse pathologies may share some common etiopathogenic
mechanisms. For this reason, and despite their pathogenic link not having been yet
deﬁned, it has been considered practical from the point of view of diagnostic, risk
assessment, educational and global treatment purposes, to integrate these manifestations under the concept of the Metabolic Syndrome (MetS) (Eckel et al. 2010; Alberti
et al. 2009; Eckel et al. 2005).
Globally considered, the pathological entities included within the concept of MetS
are the most important risk factors for cardiovascular disease, the major cause of morbimortality in obese and Type 2 Diabetes mellitus patients. Another useful aspect
A. Vidal-Puig ()
Metabolic Research Laboratories Level 4, Institute of Metabolic Science,
University of Cambridge, Addenbrooke’s Hospital Cambridge, Box 289,
CB2 0QQ Cambridge, United Kingdom
e-mail: ajv22@cam.ac.uk
M. Orešič, A. Vidal-Puig (eds.), A Systems Biology Approach to Study Metabolic Syndrome,
DOI 10.1007/978-3-319-01008-3_1, © Springer International Publishing Switzerland 2014
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related to the MetS concept is that despite its apparent simplicity, it is considered
complex and heterogeneous. This provides a degree of flexibility that will allow,
particularly as the information technology becomes more sophisticated and patient
epidemiological data are better integrated, to expand the pathological spectrum of the
MetS to include new pathologies likely to span from psychiatric disorders to some
specific forms of cancer. For these same reasons, its heterogeneity and complexity,
there is some disagreement about the suitability of the MetS as a risk prediction
model given that each of its component factors has different predictive strengths,
different importance, and that the traits used for T2DM and CVD risk prediction are
distinct(Eckel et al. 2010; Alberti et al. 2009, Eckel et al. 2005). However, it can be
argued that despite these limitations, the MetS provides diagnostic and therapeutic
awareness and this represents an advantage that outweighs the disadvantages resulting from its relatively obscure pathogenesis and unclear link between its components.
In any case, it is hoped that further research into the MetS will simultaneously identify
the root causes for these metabolic diseases identifying specific nosological entities
within the Syndrome. In this respect the two major goals of the research around the
MetS are: (1) to be able to accurately predict the risk of metabolic diseases and thus
optimally institute preventative intervention. (2) to identify the underlying pathophysiology of these related diseases with the hope of uncovering new therapeutic
and preventative measures.
By definition, a syndrome represents a specific pathological state originated by
different aetiologies. The MetS is not an exception, and it is likely to have different
aetiologies or entrances representing specific pathogenic subgroups with distinctive
early disease histories. The specific phenotype of the individual will probably depend
on the balance between organ specific pathogenic effector mechanisms and adaptive
allostatic responses (see below) ultimately leading to a global homeostatic failure.
Accumulating evidence suggests that defects in beta cells leading to primary hyperinsulinaemia, hepatic defects leading to fatty liver and insulin resistance, defects
in skeletal muscle leading to insulin resistance or primary defects in hypothalamus
causing defects in peripheral energy homeostasis, may all trigger the development
of the MetS. There is substantial experimental data supporting all these organs as
primary entrances that can initiate or contribute to the development of the MetS.
However, from the point of view of the diagnostic or therapeutic implications, the
key question is not only what these entrances to the MetS are, but how relevant these
entrances are. Ideally we want to know which ones represent marginally relevant
factors affecting a relatively small proportion of patients and which ones represent
major pathogenic “highways” affecting a high percentage of patients. On the other
hand, to define the entrance to the MetS may become totally irrelevant once the individual has developed a fully established severe MetS. It is unclear if at that stage it is
possible to identify the primary vulnerable organs or a specific clinical feature, which
is specifically related to the triggering factor. From this point of view, investigating
the pathogenesis of the MetS in individuals that have already developed the full
spectrum of the MetS, in whom it is difficult to identify the early pathogenic mechanisms, their primary effectors or the secondary allostatic adaptations, may simply be
impossible and irrelevant. At this stage a global diagnostic of MetS may be practical
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with respect to setting the spectrum of potential pathologies to be investigated in a
specific individual.
These considerations raise important points about the natural history of and the
best timing to study the MetS. In some way the best timing will depend on the main
question investigated. Ideally, to understand the natural history of the disease it is
interesting to combine both, (a) studies of the early stages to identify the potential
entrances to the syndrome, the specific pathogenic effectors linked to a specific entrance as well as the allostatic adaptations to maintain the homeostasis of the system
and (b) studies of advanced stage studies which may reveal late pathogenic effectors
common to different entrances, which may provide the basis for global blockbuster
therapeutic approaches. The attractiveness of focussing on the early stages of the disease is the potential identification of the early mechanisms stressing the homeostatic
system, the early allostatic adaptations and the signs suggestive of the individual’s
organ vulnerability. These early pathogenic mechanisms may actually provide the
basis for the personalised diagnosis and the rational for individualised treatments. At
the present moment we do not know how the syndrome evolves from its early manifestations to its ultimate global metabolic collapse. We do not know what the specific
interactions, the relative relevance, and hierarchical order of organ failure are. This
information may have an impact on identifying the best, evolutive stage specific,
therapeutic approaches and in helping to determine priori non obvious preventive
measures that could reinforce specific functions that may prevent or at least delay
the development of the MetS. These are good reasons to try to characterise the natural
history of the MetS, delineating the evolution from its initial specific manifestations
towards its progressive dedifferentiation and global homeostatic metabolic failure.

1.2 Allostasis as an Essential Concept to Understand
the Pathogenesis and Natural History of the
Allostasis refers to the concept of maintenance of normality at the expense of adaptive
changes. However, these changes are not for free, they may have a cost in terms of
energy requirements and in terms of collateral damage or side effects. In this respect
we think the concept of allostasis can be applied to the study of the MetS (Virtue and
Vidal-Puig 2010; Virtue and Vidal-Puig 2008). When studying the MetS we need to
consider not only the effector pathogenic mechanisms that drive the progression of
the pathology but also the attempts of the organism to maintain the homeostasis of
their metabolic systems. It may appear that homeostasis and allostasis are similar
concepts. However allostasis is a more useful concept in terms of including not only
the concept of a steady state that represents normality or health status (homeostasis)
but also the mechanisms required to maintain it, the metabolic stress induced by
these adaptive mechanisms and the concept of failure induced by these adaptive
mechanisms. An illustrative example is the struggle to maintain normal glycemia
levels in the context of positive energy balance at the expense of increasing insulin
secretion to overcome the progressive impairment of its insulin resistance. In this
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respect the increase in the secretion of insulin will be able to maintain glucose levels
under control for a while until the beta cells will fail under the metabolic pressure
to produce and secrete huge amounts of insulin causing ER stress. We consider the
MetS as a toxic syndrome induced by a relative excess of nutrients and whose specific
individual manifestations are determined by organ specific genetic vulnerability to
nutritional insults. From this definition we can introduce concepts such as allostatic
load defined as the level of stress induced by the adaptation to overcome the toxic
effects derived from overnutrition, and the concept of allostatic overload that refers to
a state of excessive allostatic load (overnutrition maintained for a long period of time)
that will inevitably lead to metabolic failure. Globally considered, a systems approach
to the metabolic syndrome should include and quatitate the level of allostatic load
and refer it to the organ vulnerability to determine the maximal threshold of tolerance
determining an allostatic overload state.

1.3 Taking Advantage of the Heterogeneity and Paradoxes
of the MetS to Understand its Pathogenesis
The pathologies of the MetS have a strong genetic component, with an estimated
40–70 % of the variation in obesity risk attributed to genetic factors. However, despite this stable genetic influence, which represents a stable vulnerability of the
system, the prevalence of obesity and MetS has steadily increased over the last
40–50 years, outlining the pathogenic relevance of an obesogenic environment contributing to the allostatic load. Although the MetS manifestations tend to coincide
in many individuals, it is also true that not all patients develop the whole spectrum
of MetS manifestations, nor is there strong evidence that develops the encompassed
pathologies in any specific or sequential order. Moreover, the degree of obesity
is not consistently linked with metabolic complications. Although it is true that
the higher the fat mass the higher the prevalence of the MetS, large numbers of
apparently healthy obese individuals can be found in addition to significant numbers of normal weight individuals who develop metabolic complications. On top
of this, the combination of changing globalised environments on specific ethnic
groups may contribute to this complexity, since metabolic complications occur at a
lower body fat level in Asians and the major diabetes epidemic currently occurs in
Asia.

1.4 An Adipocentric Model of the Pathogenesis of the MetS
To approach these intricate questions and to develop a working model of the MetS,
it is necessary to start somewhere and to enable this, some informed prioritisation
is required. From a simplistic point of view and departing from the evidence that
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Fig. 1.1 Adipocentric perspective of the metabolic syndrome. Excessive accumulation of lipids in
adipose tissue may overcome the storage capacity of this organ resulting in increased lipid spill
over and lipid induced inflammatory effects associated with qualitative and quantitative alterations
in the adipokine profile. Lipids and adipokines may contribute to induce a overnutrition related
toxicity in important metabolic organs configuring manifestations typically associated with the
MetS ultimately leading to cardiometabolic complications

most patients diagnosed of MetS are obese, we have proposed an adipocentric perspective of the MetS. We consider that defects in the expansion and functionality
of the adipose tissue, associated with obesity, are fundamental for the development
of the most common forms of the MetS. Most of the metabolic effects of obesity
are due to its deleterious effect on insulin sensitivity and we propose three potential
mechanisms contributing to obesity related metabolic complications. During states
of positive energy balance, adipose tissues will expand, occasionally until its maximal expandability is reached and eventually fail to store excess calories adequately
as fat. This results in: (i) the deposition of lipids in other metabolically relevant
tissues (e.g. muscle, liver, beta cells) not normally suited to fat storage, resulting in
tissue dysfunction via a phenomenon known as lipotoxicity (Vidal-Puig and Unger
2010) (Fig. 1.1); (ii) adipocytes become dysfunctional and produce an altered quantitatively and qualitative adipocytokine profile [decrease in adiponectin, increase
in resistin, increase in tumour necrosis factor α (TNFα), and interleukin 1 (IL-1)
production] which promotes IR; (iii) adipose tissue inflammation with macrophage
infiltration (ATMs) results in the production of pro-inflammatory cytokines, which
further prevents adipose tissue expansion and aggravates IR (Fig. 1.2).
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Fig. 1.2 Adipose tissue expandability and inflammatory changes in adipose tissue. The MetS is typically associated with macrophage infiltration of the adipose tissue associated to a proinflammatory
phenotype. This model suggests the failure of the adipocyte capacity to accumulate fat as a trigger
promoting macrophage infiltration and subsequent fat accumulation in macrophages leading to the
formation of foam cells. This model proposes a functional role of M2 antinflammatory macrophages
mediating adipose tissue remodelling in the context of positive energy balance and a pathophysiological effect secondary to M1 proinflammatory polarisation as a result of lipid induced toxicity in
macrophages. Finally our model proposes that regaining control of the adipocyte function prevents
or reverse the M1 proinflammatory effects

In our adipocentric model, when the adipose tissue develops insulin resistance and
functionally fails, this is associated with inappropriately increased rates of lipolysis
and overall non-esterified (‘free’) fatty acid flux. Increases in non-esterified fatty
acid delivery in combination with progressive development of hepatic IR is followed
by increases in hepatic glucose production (impaired fasting glycaemia), hepatic
lipid accumulation (hepatosteatosis) and hepatic production of large triacylglycerolrich lipoprotein particles (hypertriglyceridaemia). In turn, the combination of raised
plasma triglycerides and alteration in high-density lipoprotein (HDL) lipidation contributes to the reduction in HDL particles (low HDL). This overall increase in lipid
delivery to skeletal muscles promotes IR and reduces insulin-mediated glucose disposal (IMGD) rates (impaired glucose tolerance) therein. Finally, systemic IR and
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the associated hyperinsulinaemia contribute to endothelial dysfunction and hypertension. Exacerbating the shift towards a pathological state, the interdependence of
these tissues promotes a cycle of progressive deterioration in metabolism, which in
turn, worsens insulin resistance and fuels a metabolic vicious cycle.
Although we think this adipocentric model probably represents an important
model to the MetS, it is recognised that the concept of MetS represents a heterogeneous spectrum of clinical presentations. In some ways it would be expected that
a given individual’s spectrum is determined by their organ-specific vulnerability
modulated by genetic and environmental factors that interact with potentially confounding factors such as age, ethnicity or gender. This level of complexity poses
the challenge of creating a disease model that captures the complexity of the syndrome and simultaneously is able to explain its apparent paradoxes. In this respect,
focussing on phenotypes where expansion of fat mass is uncoupled from metabolic
complications, may provide new understanding of the link between obesity and these
metabolic complications. By ‘uncoupled’, we specifically refer to states characterized by severe obesity in otherwise metabolically healthy individuals or conversely
to those lean individuals with severe metabolic syndromes.
These obese healthy individuals exist and represent around 10–15 % of the
morbidly obese population. They have excessive body fatness predominantly accumulated in their subcutaneous adipose tissue and associated with less visceral
and ectopic fat and lower lean mass. These patients are remarkably insulin sensitive, exhibit a healthy lipid profile characterised by high HDL cholesterol and
low triglycerides, and their adipose tissue is remarkably healthy despite it being
maximally overstretched to store the excess fat. Typically their adipose tissue does
not present macrophage infiltration, nor proinflammatory markers and exhibits a
favourable adipokine profile with high adiponectin levels. Moreover, their healthy
adipose tissue is formed of relatively small adipocyte cells, which suggests facilitated
adipocyte differentiation and an excellent capacity to expand and meet the demands
for fat storage. The converse phenotype is typically observed in the lean metabolically
compromised patient. In these patients the adipose tissue is characterised by large
adipocytes, extensive macrophage infiltration and elevated inflammatory markers.
All such factors are compatible with impaired adipose tissue expansion and functionality, ultimately leading to adipose tissue failure and the accumulation of lipids
in peripheral metabolically relevant organs.
Altogether, the realisation of the heterogeneity and apparent paradoxes associated
to the MetS, allows hypothesising that (a) there must be specific factors linking
obesity and its metabolic complications which are not directly related to the amount
of fat stored adipose and (b) the most unknown mechanisms that protect some obese
people from developing metabolic complications, that if identified may provide a new
conceptual direction in the way we approach the therapy of the MetS. The relevance
of these questions stems from the possibility to identify biomarkers with diagnostic
and prognostic value able to target obese populations mechanistically at high risk
of developing metabolic complications and the possibility of identifying biomarkers
suitable for the development of novel therapeutic interventions.
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Reconciling the MetS with the Obese Healthy Phenotype:
The Adipose Tissue Expandability Hypothesis

There appears to be a difference between the amount of fat accumulated in adipose
tissue and its overall biological function. Alteration in the distribution of fat between
subcutaneous and visceral adipose depots without changes in the total amount of fat
can contribute to differences in metabolic complications. Similarly, interventions in
humans and murine models which facilitate fat deposition and increase expansion of
fat mass can paradoxically reduce metabolic complications. We consider that it is not
the amount of fat accumulated in the adipose tissue, but rather how well our adipose
tissue functions that counts. To explain these apparent paradoxes we have proposed
the adipose expandability hypothesis that states that the link between obesity and
metabolic complications does not depend on the total fat mass accumulated, but depends on the remaining capacity for expansion and functioning of the adipose tissue.
When the adipose tissue cannot expand further and becomes dysfunctional, excess
nutrients cannot be stored appropriately within adipose tissue and are stored ectopically, in other metabolically relevant organs. Ectopic lipid deposition, particularly
of lipid reactive species such as DAGs and ceramides, per se can cause insulin resistance, fatty liver, dyslipidaemia, beta cell failure and cardiovascular complications
as typically seen associated with obesity.
From our model it can be hypothesised that: (a) therapeutic strategies that optimise
the expansion and fat deposition in adipose tissue may uncouple obesity from its associated metabolic complications and may provide a palliative therapeutic strategy that
may at least prevent/delay the deleterious metabolic effects of obesity. (b) that strategies that prevent inappropriate ectopic fat deposition in metabolic relevant organs
and/or promote lipid oxidation may prevent or delay the development of the MetS,
and (c) we could envisage that strategies focused on modifying specific metabolic
routes diverting lipids from more toxic to less toxic pathways or from more vulnerable organs to less vulnerable, may provide an additional buffer capacity preventing
the deleterious effects of lipid induced toxicity.

1.6 What Factors Influence the Capacity of WAT Expandability
and Function? (Fig. 1.3)
Factors that may determine the expandability and functionality of the adipose tissue
include:
a) Insufficient capacity to generate new adipocytes from preadipocytes (Tang
et al. 2008) to cope with the nutrient storage demands. There is evidence from
genetic experiments that a limit on adipose tissue expansion under conditions of
positive energy balance leads to insulin resistance. The fact that there is a relatively
fixed turnover of adipocytes in humans (Arner et al. 2011; Spalding et al. 2008)
which is defective in the subcutaneous adipose tissue of obese individuals as they
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Fig. 1.3 Factors controlling adipose tissue expandability. Spectrum of factors that can determine
the adipose tissue expandability limit and may be manipulated for therapeutic purposes

age (25 % decrease between the age of 45 and 65 years) suggests that the number
of adipocytes is genetically determined and that this process may be modulated
by toxic environmental factors associated to positive energy balance and age.
It could be argued that this genetic insufficiency may be related to increased
storage demands accompanying the increased prevalence of obesity and that the
same adipose tissue genetic make up that was functionally competent 50 years
ago may now, under mounting nutritional pressures and in ageing population, fail
to cope with increasing storage demands.
b) Defective adipocyte membrane remodelling and functionality in response
to obesity. We have identified two phases in the progression towards the functional failure of the adipose tissue: The first phase represents a stage of metabolic
stress still compensated by allostatic responses that optimise the function of the
adipose tissue through adipocyte membrane lipid remodelling (Pietilainen et al.
2011). We have recently shown that adipose tissue in obesity is characterized by
enrichment of specific ether phospholipids containing arachidonic acid. Using
computational simulation of lipid plasma membranes based on lipidomics data,
we have shown that initial AT lipid remodelling is part of an adaptive process,
maintaining the normal membrane function but at the cost of higher vulnerability
to adipose tissue to inflammation. The second phase represents a more advanced
stage characterised by the breakdown of allostatic adaptations subjected to the
allostatic overload induced by adipocyte overloading. This leads to the failure of
adipose tissue to store fat appropriately and subsequently the ectopic accumulation of lipid in metabolically relevant organs such as liver, muscle, beta cells or
brain that contributes to the MetS.
c) Role of inflammation (Neels and Olefsky 2006). However, besides the genetic
component, there is evidence that as the MetS evolves, there is a progressive
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development of inflammation in WAT and liver. In this respect inflammation represents a second hit that can directly compromise insulin sensitivity, the expansion
of the adipose tissue and accelerates a vicious cycle which progressively impairs
the expansion of AT, promotes inflammation and extends the insulin resistance
systemically. This effect is mediated by the attraction and functional activation
of macrophages within the AT. Although it is clear that accumulation of proinflammatory M1 macrophages in AT can amplify a proinflammatory cascade with
deleterious metabolic effects, it is still unclear why these macrophages are attracted to the AT and more importantly why they become polarised towards a
proinflammatory phenotype(Olefsky and Glass 2010). We and others have proposed that these macrophage proinflammatory changes may be another lipotoxic
manifestation of ectopic fat deposition in macrophages as a result of adipocyte
functional failure(Prieur et al. 2011).
d) Altered endocrine function of the adipose tissue. Although the essential function of the adipose tissue is to serve as an energy storage organ, its function is
certainly more complex as it is required to maintain close communication with
the centres that control energy homeostasis, namely the CNS and key peripheral metabolic organs such as skeletal muscle, liver or BAT, to efficiently take
or release lipids on demand. To fulfil this and other missions, the WAT produces
and secretes proteins such as leptin and adiponectin. However, in the context
of the MetS there is a qualitative and quantitative alteration in the repertoire of
these proteins, which compromises the function of the adipose tissue and its peripheral target organs The reasons for these alterations are unclear but it can be
argued that as they tend to happen in the context of obesity, adipocyte hypertrophy, changes in membrane lipid composition, inflammation and that they are
reminiscent of immunological responses to infective agents, they may represent
artefacts or inappropriate regulation of physiological pathways not necessarily
related to their primary role. Whatever the mechanism, the dysregulation of these
adipokines can secondarily compromise the expansion and functionality of the
adipose tissue ultimately leading to adipose tissue failure.
e) Inappropriate angiogenesis and vascularisation (Rupnick et al. 2002; Cao
2007; Brakenhielm et al. 2004) may compromise the expansion and functionality
of the adipose tissue. It is clear that the expansion of the adipose tissue requires
good blood supply to support the tissue, to facilitate the accessibility of oxygen and
the nutrients as well as their release when required. The relevance of angiogenesis
in the control of adipose tissue mass is becoming the focus of attention, in part
from the paradoxical results of pharmacological interventions with TNP-470,
angiostatina y endostatina, angiogenic inhibitors that prevent the expansion of
the adipose tissue and but also result in improved insulin sensitivity (Cao 2007).
These unexpected findings raise the possibility that these drugs may have off
target effects that may result in negative energy balance. Irrespectively of this
controversial evidence, genetic factors affecting angiogenesis/vasculogenesis as
well as epigenetic changes determined by the excess of nutrients and metabolic
stress may contribute to limit the expansion and functionality of the AT.
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f) Defective extracellular matrix (ECM). Accumulating evidence indicates that
the AT of the obese patient requires remodelation to allow its expansion. This
requires the concerted action of specific metalloproteases (MMPs) and appropriate secretion of collagen fibres. The relevance of the effect of the ECM for the
control of adipose tissue expansion and associated metabolic disturbances has
been elegantly demonstrated through genetic experiments where the inhibition
in the biosynthesis of collages VI resulted in hypertrophic adipocyte cells and
paradoxically improved insulin sensitivity (Khan et al. 2009). Conversely disruption of MMP14 levels results in small adipocytes constrained within excessive
accumulation of collagen deposits. This process may also be relevant in common
forms of obesity where signs of fibrosis in adipose tissue have been identified.
It is unclear whether this represents a primary dysregulation of the remodelling
of EMC or more likely it is secondary to the excessive expansion of AT and the
process of tissue repair in the context of adipocyte cell death, inflammation or
hypoxia (Chun et al. 2006). It is possible that under these adverse metabolic
conditions the EMC remodelling is affected.

1.7 What are the Effectors of Lipotoxicity in Peripheral
Organs?
An essential question is whether the toxic effects derived from the excessive accumulation of lipids/nutrients in peripheral organs and/or CNS occurs through similar
mechanisms. Alternatively, each organ may have its own peculiar lipid metabolic
network and genetic vulnerability derived from activation of different organ specific
pathogenic mechanisms. It is conceivable that studies performed at specific time
points may identify organ-specific lipid species (e.g DAGs, ceramides, LysPCs)
or lipid networks accordingly with the peculiarities of the organ and/or specific
metabolism of nutritional interventions. However, these time windows may simply
capture snapshots of a heterogeneous organ-specific response, which is temporally
evolving through a progression that reflects a hierarchy of organ susceptibility. Both
possibilities are not necessarily exclusive and their elucidation has important therapeutic and diagnostic implications (see below). Our point of view is that lipid-induced
toxicity may activate stress mechanisms affecting different organelle responses, such
as ER stress, autophagy, ROS production and mitochondria toxicity or lipid-induced
signalling defects. Although it is clear that lipids have essential biological functions
including energy storage, signalling, or structural purposes, when in excess, in inappropriate proportions, or mislocalised, these lipid alterations have been associated
with insulin resistance and apoptosis. For instance, whereas ceramides, DAGs or specific phospholipids are normal cellular constituents, when in excess they may trigger
the activation of stress related proinflammatory kinases (e.g Jun N-terminal quinasa
(JNK), IKK/NF-κB, mTOR or proteín kinase C delta (PKCθ) ultimately leading to
insulin resistance and cellular stress(Summers 2006). However the relative relevance
of these mechanisms may differ amongst the target organs and the evolutive state
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of the MetS depending on the specific characteristics of the target organ and original metabolic insult. The characterisation of the effectors linking accumulation of
reactive lipid species with specific mechanisms of toxicity may offer global/organ
targeted therapeutic approaches to the pathologies of the Metabolic Syndrome.

1.8 The Output: Diagnostic and Prognostics Biomarkers
From the biomedical point of view, a key challenge is to identify whom amongst
the obese/lean population will develop metabolic complications. This information
helps to avoid human suffering and has enormous financial implications. Although
IR appears to play a major role in the development of obesity induced metabolic
complications, it is not yet useful as a tool to diagnose the MetS, neither is it helpful
as a point of reference for comparisons between studies. Early identification of those
healthy obese patients may allow non-urgent, relatively conservative and less expensive therapeutic approaches. Conversely, early identification of those individuals
likely to develop severe metabolic complications, despite not being severely obese
will identify opportunities for more aggressive interventions. Also if confirmed that
different organs have specificities in their lipid network, it may be feasible to identify
specific lipid signatures in plasma correlating with lipid induced toxic insults in specific organs. This may identify within an individual those organs most susceptible to
more severe pathologies and de facto address the problem of the heterogeneity of the
MetS. Useful biomarkers could predict the evolution from steatosis to steatohepatitis,
exacerbated insulin resistance or accelerated beta cell failure leading to diabetes.

1.9

Implications of the Adipose Tissue Expandability Model
for Biomarker and Therapeutic Target Selection

Based on our current knowledge it can be hypothesised that the following candidate
processes may provide markers with diagnostic and prognostic value and are likely
specific points for therapeutic intervention:
a) Mechanisms facilitating efficient fat deposition in adipose tissue and away
from liver, muscle and beta cells should prevent nutrition-induced toxic events in
the latter organs and protect from the development of metabolic obesity complications. This attractive model removes the principal driving factor behind multiple
metabolic complications including insulin resistance, NAFLD, adipose tissue
inflammation and demand on beta cell expansion.
b) Mechanisms involved in removing excess circulating lipid and increased
oxidation.Increased nutrient oxidation should protect from obesity-associated
complications. The strategy of removing excess circulating lipids is particularly
attractive. This includes strategies mimicking exercise and strategies facilitating
the development and activation of brown fat to oxidize the excess energy.
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c) Mechanisms that facilitate storage of ectopic lipids in less harmful forms.
The type of ectopic lipid residing in tissues is probably more important than
the amount of lipid accumulated. It is therefore conceivable to treat diabetes in
obesity by driving lipids deposited in ectopic depots into safe storage forms (such
as TAG) and away from more harmful forms, such as ceramides, DAGs and LPCs.

1.10 A Systems Biology Approach to the MetS
For a given degree of obesity, IR or adipose tissue dysfunction, different individuals
seem to have different susceptibility to the development of metabolic complications.
Moreover, unlike other systemic disorders, major tissues involved in metabolism
(liver, fat, muscle, pancreas and brain) are highly interdependent. Metabolically
relevant tissues are closely interlinked, and each tissue’s response to adipose dysfunction cannot be considered truly independent. Studies involving one organ should
be interpreted in the context of other tissues, whereas reactive and causative findings should also be clearly distinguished. Thus if we are going to understand the
pathogenesis of the MetS a systems-based approach, that integrates findings from
all organs and analyses the evolution of the MetS over time to capture the relative
contribution of each organ to the overall phenotype is required. The challenge posed
by this task is immense, since it requires an integrated multidisciplinary approach
that brings together biomedical expertise in each one of the components of the MetS,
technological analytical platforms to accurately measure things and sophisticated
informatics tools to integrate extremely heterogeneous data to deliver useful information to answer relevant biomedical questions and propose new ones amenable
to statistical validation. Even more challenging is to get the scientists behind all
these expertises to be able to communicate efficiently. This book is an attempt to
do exactly this, to bring together the different perspectives and tools required to address probably the most common, most important and most complex human health
problem.
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Chapter 2

Systems Biology in Human Health and Disease
Matej Orešič

Abstract If we are to study complex multi-factorial disorders such as Metabolic
Syndrome (MetS) by applying the state-of-the-art ‘omics’ technologies, the reductionist approach commonly applied in life sciences is no longer suitable. In order
to understand the adaptive changes in molecular networks in different stages of the
disease pathogenesis, a comprehensive view of the system is needed because activation of different pathways may still lead to the same functionality, but with different
metabolic costs. Systems biology emerged as an inter-disciplinary ﬁeld of study that
focuses on complex interactions within and between biological systems, using a
more holistic perspective approach to biological and biomedical research. While the
importance of the systems approach has already been recognized decades ago, the experimental and modeling techniques have matured to the level where comprehensive
characterization of biological systems at the molecular level is now feasible.
Keywords Allostasis · Allostatic load · Bioinformatics · Genomics · Gut microbiota ·
Lipid metabolism · Metabolic networks · Metabolomics · Proteomics · Systems
biology

2.1

Need for Systems Approach to Study Health and Disease

Molecular biology contributed many essential experimental tools used in today’s life
science research. However, its early days also introduced the still pervasive reductionist approach to study the biological systems. While the concepts such as ‘metabolic
control analysis’ (Kacser and Burns 1973) and ‘systems theory’ (von Bertalanffy
1969) to describe the biological systems had been introduced already in 1970s, their
practical utilization was limited due to the lack of quantitative experimental data
needed to parameterize the mathematical models. Instead, molecular biologists resorted to a simpler experimental paradigm, focusing on the elucidation of function
of single molecular components such as genes and their products by studying them
in isolation. In such setting, dependencies of speciﬁc biological functions on speciﬁc
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Fig. 2.1 Limitations of the reductionist approach when studying complex interconnected systems.
a Real biological network, showing nodes as molecular entities and edges as their interdependencies.
b Focus on single component only, X, will by experimentally modulating X lead to conclusion that
X controls functionality of Z. c Potential other networks that may regulate Z as well as modulate
function of X are disregarded by the reductionist approach

molecular components are usually sought, e.g., as established by singe-component
interventions such as by gene knock-down experiments. Following a series of well
thought-through experiments of that kind, a ‘mechanistic insight’ can be gained;
which in the field of molecular biology means that in a specific context a specific
component such as a gene controls a specific biological function.
The fundamental limitation of the reductionist approach as applied to molecular
biology has been highlighted in an entertaining essay ‘Can a biologist fix a radio?
Or, what I learned while studying apoptosis’ (Lazebnik 2002), where the author also
remarked that “an approach that is inefficient in analyzing a simple system is unlikely to be more useful if the system is more complex”. Particularly, the experimental
paradigm used in molecular biology does not account for global interconnectivity
of the system and is thus strongly context dependent. As a simplistic but illustrative
example, Fig. 2.1a shows a molecular network, where the nodes denote the interacting molecular components (genes, proteins, metabolites), while edges show their
interdependencies (e.g., via molecular interactions or biochemical reactions). The
investigation is focusing on the elucidation of the regulation of the molecule Z, which
is associated with a specific biological function. The hypothesis being investigated
is that Z is controlled by the molecule X. In order to test the hypothesis, function
of X is modulated (e.g., by knock-down), which following the experiment leads to
the conclusion that indeed function of Z depends on X (Fig. 2.1b). However, such
an approach disregards potential other networks that may regulate Z as well as modulate the function of X (Fig. 2.1c). The so-obtained ‘mechanistic models’ therefore
primarily describe the binary dependencies of molecular components and their functions. Given these binary relationships are usually acquired in different experimental
contexts, i.e., the ‘other networks’ cannot be controlled for, it is thus not surprising
that reproducibility of conclusions from molecular biology experiments is strikingly
poor (Begley and Ellis 2012). Perhaps most troublingly, putting these ‘mechanistic
models’ into practical use is very challenging because the global systemic context
is lacking, i.e., it is difficult to know under what circumstances a particular binary
dependency really holds.
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Fig. 2.2 Progression to complex disease, conceptionalized by a single imaginary variable denoted
as ‘disease pathway activity’. Adaptation and its metabolic cost play a key role in this process

While the discussion above mainly referred to the studies at the levels of cells,
the challenges are even bigger when attempting to apply the reductionist approach at
the whole-organism physiological level (Joyner and Pedersen 2011). In such setting,
the system’s components and their interactions occur at many levels and timescales,
from individual molecules to tissues and organs. The organisms have built-in robust
mechanisms which help to maintain the essential physiological functions such as
metabolism under the varying environmental challenges. When considering the experimental paradigm to address specific hypothesis at the whole-organism level,
the familiarity with the physiological concepts such as homeostasis, allostasis,
adaptation, robustness and resilience is thus essential. For example, maintenance
of lipid composition of the cell membranes is essential for cell functionality and
survival. Cellular lipid homeostasis is regulated by a family of membrane-bound transcription factors designated sterol regulatory element–binding proteins (SREBPs)
(Horton et al. 2002). While SREBP1c regulates the genes of membrane phospholipid
metabolism, SREBP2 preferentially activates the genes of cholesterol metabolism.
Surprisingly, knock-down of SREBP1c in vivo does not lead to disruption of phospholipid metabolism, which is because the loss of SREBP1c function is compensated
by overexpression of SREBP2. However, as a cost of such adaption, mice lacking
SREBP1c tend to accumulate more cholesterol (Horton et al. 2002). This is a good
example of allostatic adaptation (the concept introduced in Chap. 1) aimed at induction of short-term corrective changes to regulatory systems. However, when such
an adaptive response remains activated for long periods of time, the maintenance
of metabolic homeostasis might actually come at a metabolic cost, or ‘collateral
damage’, defined by McEwen as allostatic load (Korte et al. 2005). In the case
of SREBP1c knock-down, the allostatic load is for example the accumulation of
cholesterol due to the adaptive activation of SREBP2.
Development of a complex disorder, from early prodromal phases to clinically
manifest disease, is usually a complex process which proceeds in several phases
in which allostatic adaptations play an important role (Fig. 2.2, see also Chap. 1).
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Environmental triggers such as change in lifestyle may impose a pressure on the
organism to adapt (e.g., by changes in the underlying molecular networks) in order
to maintain the system homeostasis. In the case of Metabolic Syndrome (MetS), this
early phase corresponds to metabolically compensated obesity (or ‘healthy obesity’).
However, extended duration of the activated allostatic response eventually leads to
the accumulation of allostatic load, e.g., progressively losing the ability to store lipids
in obesity. In this phase also the disease vulnerability increases, i.e., the organism is
more sensitive to any triggers which may cause the disease, because it is reaching
the limit of adaptability. At a certain point, this limit is reached and the organism
is no longer able to adapt, leading to the overt disease (Fig. 2.2). The timelines
of this progression vary between the individuals and also depend on the genetic
make-up and the environment, including individual’s gut microbiota (Chap. 9). For
example, some individuals can become very obese but still remain metabolically
compensated while others soon develop metabolic co-morbidities of obesity such as
type 2 diabetes (Virtue and Vidal-Puig 2008). Since the allostatic load accumulates
over time, the earlier the stage of the progression to the disease, more likely the trend
can be reversed. For this reason, it is important to detect the disease early in the
process, prior to the appearance of clinical symptoms.
If we are to study diseases using the dynamic and physiological framework as described above, the reductionist approach is no longer viable. In order to understand the
adaptive changes in molecular networks in different stages of the disease pathogenesis, a comprehensive view of the system is needed because different pathways may
still lead to the same functionality, but with different allostatic load. Systems biology
emerged as an inter-disciplinary field of study that focuses on complex interactions
within and between biological systems, using a more holistic perspective approach to
biological and biomedical research. While the importance of systems approach has already been recognized decades ago (Kacser and Burns 1973; von Bertalanffy 1969),
the experimental techniques have also matured to the level where comprehensive
characterization of biological systems at the molecular level is possible.

2.2

Key Enabling Technologies and Modeling Approaches
of Systems Biology to Study Health and Disease

The ‘omics’ revolution empowered us with the tools for comprehensive characterization of biological systems. For example, genomics, proteomics and metabolomics
each cover a specific layer of biological organization (Fig. 2.3). At the genome level,
in addition to host genome one must also consider the microbial genomes which
together carry about 150-times as many genes as the host genome, primarily in the
gut (Chap. 9). Gut microbiota is sensitive to environmental factors including the diet
and can be considered as a ‘mediator’ between the environment and host biology.
Gene products such as proteins regulate many biological processes in the cells including the biochemical networks involving metabolites. Small changes in enzyme
concentrations and fluxes through their pathways may produce large changes in the
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Fig. 2.3 Factors influencing the metabolome and proteome and the key analytical platforms for systems biology to study health and disease. The metabolome is sensitive to genetic and environmental
factors which may together contribute to the disease. Metabolomics is thus a powerful phenotyping
platform in biomedical studies

concentrations of metabolites which are the end products of these pathways (Kell
2006). Gut microbes have distinct metabolomes and proteomes, which interact with
the host as well as contribute to the regulation of the host metabolism (Tremaroli and
Backhed 2012). In this context, the in vitro colon model described in Chap. 13 is a
particularly valuable tool to study how the food metabolome is transformed by the
gut microbes, thus providing physiologically relevant information about the foodderived metabolites entering the systemic host metabolism. In Part III, this book will
introduce the key emerging technologies which support the studies of MetS using
the systems biology approach, including in the context of nutrition. These include
proteomics, metabolomics, fluxomics as well as the in vitro colon model.
In order to interpret the ‘omics’ data in the physiological context, models are
needed which capture the relevant topology and dynamics of biological networks and
processes under investigation. Global reconstruction of human metabolic network
(Duarte et al. 2007; Thiele et al. 2013) has for example allowed for tissue-specific
modeling of metabolic networks, as dependent e.g., on genomic, proteomic and
metabolomics data (Chap. 14). Metabolic modeling is rapidly emerging as a powerful
tool which can also help in the identification of targets for interventions as well as
in the prediction of specific biomarkers (by predicting outgoing metabolic fluxes).
Not all metabolic functions can be conceptualized at the network level, however.
For example, lipids are key building blocks of cellular membranes and lipoprotein
particles. Changes of lipid levels in these structures lead to changes in their biophysical properties and thus also potentially affecting their function. While network-based
modeling involves statistical inference as dependent on the network structure,
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biophysical modeling requires in silico assembly of relevant molecular structures
such as membranes by using, e.g., molecular dynamics simulations. As an example
of such approach, recent study has shown that adipose tissue in obesity is characterized by enrichment of specific ether phospholipids containing arachidonic acid,
despite the lower dietary intake of polyunsaturated fatty acids (Pietiläinen et al.
2011). Using a novel computational approach to simulate lipid plasma membranes
based on lipidomics data, the study found that this lipid remodeling is part of an
adaptive process, maintaining the normal membrane function but at the cost of
higher vulnerability of adipose tissue to inflammation. Such an insight could not
have been gained without considering the observed lipid changes in obesity at the
level of their effect on cellular membrane properties. In general, modeling of lipid
metabolism at biophysical and physiological levels is very challenging and an emerging area of systems biology. In this book, both topics are covered in Chap. 15 and 17,
respectively.

2.3

Conclusions

In order to apply a systems approach to study specific disorders such as MetS, one
needs three essential components: (a) a system, (b) experimental techniques, and
(c) modeling techniques. These components are inter-connected by the so-called
‘systems biology cycle’ where measurements on a system are fed to a mathematical
model, which is then further refined, leading to novel hypotheses and experiments
etc. This book includes all three components, with the specific topics selected based
on relevance to the study of MetS. Part II reviews ‘the system’ as relevant to MetS,
which includes liver (Chap. 3), adipose tissue (Chap. 4), beta cell (Chap. 5), skeletal muscle (Chap. 6), central nervous system (Chap. 7), lipid metabolism (Chap. 8)
and gut microbiota (Chap. 9). Selected emerging experimental techniques are introduced in Part III, including proteomics (Chap. 10), metabolomics (Chap. 11),
fluxomics (Chap. 12) and in vitro colon model (Chap. 13). Part IV introduces specific modeling approaches which are particularly relevant to study MetS, including
genome-scale metabolic modeling (Chap. 14), biophysical modeling of lipid membranes and lipoproteins (Chap. 15), methods of computational statistics (Chap. 16),
and modeling of tissue cross-talk at the level of lipid metabolism (Chap. 17). Needless to say, the experimental and modeling techniques covered are not exclusive and
some widely adopted approaches such as genomics are not explicitly included in
this book. However, the methods covered in the book are particularly important if
one is to adopt the physiological framework described in this chapter. How these
techniques are connected into the ‘systems biology cycle’ ultimately depends on the
questions asked and the specific system studied. Some practical examples will be
provided in this book.
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Part II

Pathophysiology of Metabolic Syndrome

This section provides background to key components of metabolic syndrome. The
contributions show examples how systems approached were applied to study these
specific aspects of MetS.

Chapter 3

The Liver in Metabolic Syndrome
Simona D’Amore, Giuseppe Palasciano and Antonio Moschetta

Abstract The liver plays a major role in the regulation of pathways that govern systemic metabolic homeostasis. Hepatic regulation of glucose and lipid homeostasis is
under the control of a complex system of hormones, transcription factors, and signaling pathways. Hepatic steatosis is a condition characterized by an increased amount
of fat in the liver, mainly in the form of triglycerides, in a quantity greater than 5 %
of liver weight, or histologically deﬁned when 5 % or more of hepatocytes contains
visible intracellular triglycerides, that cannot be attributed to alcohol consumption.
Fatty liver is closely related to impairment in glucose, fatty acid, and lipoprotein
metabolism, and it is now widely recognized as the hepatic manifestation of the
Metabolic Syndrome. In the present chapter we will critically present the potential
mechanisms that link obesity, type 2 diabetes, hepatic lipid accumulation, and insulin
resistance. Indeed, although the correlation between fatty liver and insulin resistance
is well established, we will speciﬁcally discuss the combination of elevated serum
levels of glucose, fatty acids, and peripheral insulin resistance for the pathogenesis
of liver dysfunction in the Metabolic Syndrome.
Keywords Insulin resistance · Lipid metabolism · Metabolic Syndrome ·
Nonalcoholic fatty liver disease · Nonalcoholic steatohepatitis

3.1

Can Metabolic Syndrome Exist Without Fatty Liver?

Metabolic Syndrome (MetS) and nonalcoholic fatty liver disease are the clinical
expressions of the same metabolic impairment, both sharing the common pathogenic
factor and leading to an increased risk for diabetes and cardiovascular disease (CVD).
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Table 3.1 Criteria for clinical Clinical measure
diagnosis of Metabolic
Syndrome (ATP III, 2001).
(Grundy et al. 2005)
Abdominal obesity
Elevated
triglycerides
Reduced HDL-C

Blood pressure

Fasting glucose

Categorical cut-points (any 3 of
the following 5 features constitute
diagnosis of Metabolic Syndrome)
Waist circumference (WC) 102 cm in men
or 88 cm in women
Triglycerides ≥ 150 mg/dL
or on drug treatment for elevated
triglycerides
HDL-C < 50 mg/dL in men
or < 40 mg/dL in women
or on drug treatment for reduced HDL-C
≥ 130/85 mmHg
or on antihypertensive drug treatment for
hypertension
≥ 100 mg/dLa
or diabetes
or on drug treatment for elevated glucose

a
The 2001 definition identified fasting plasma glucose of
≥ 110 mg/dL (6.1 mmol/L) as elevated. This was modified in 2004
to be ≥ 100 mg/dL (5.6 mmol/L), in accordance with the American Diabetes Association’s updated definition of impaired fasting
glucose

MetS is a complex syndrome which involves different metabolic conditions, and
according to the Third Report of the National Cholesterol Education Program Expert
Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III, ATP III), is defined by the presence of three or more
of the following features; visceral adiposity, hypertriglyceridemia, hypertension,
glucose intolerance or type 2 diabetes, and low high-density lipoprotein (HDL) levels
(Table 3.1) (Anon 2002). Insulin resistance (IR) represents the key component and the
putative pathogenetic hit that links all features of the MetS (Balkau and Charles 1999;
Olufadi and Byrne 2008). Although fatty liver is still not included in the diagnostic
criteria of MetS, it is the primary hepatic complication of obesity and MetS.
The term “nonalcoholic steatohepatitis” was coined in 1980 to describe “the pathological and clinical features of nonalcoholic disease of the liver associated with the
pathological features most commonly seen in alcoholic liver disease itself” (Ludwig et al. 1980). Nonalcoholic fatty liver disease represents a heterogeneous cluster
of diseases, ranging from hepatic steatosis alone (nonalcoholic fatty liver, NAFLD),
to nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis (Matteoni et al. 1999;
Powell et al. 1990; Teli et al. 1995; Wanless and Lentz 1990a). The common
denominator is the presence of macrovescicular hepatic steatosis, resulting from
accumulation of triglycerides (TGs) within hepatocytes, in the absence of significant
alcohol intake.
If steatosis is a normal feature in the liver of migratory birds, that need to store
energy in order to face long periods of fasting, this condition is not a physiological
finding in humans (Capeau 2008). As a consequence, NAFLD is not a benign condition with a non-progressive course, as initially believed, but a progressive condition
leading to NASH, and finally to fibrosis, cryptogenic cirrhosis, and increased risk for
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hepatocellular carcinoma (Bugianesi 2005; Caldwell et al. 1999; Marrero et al. 2002).
When compared to general population, NAFLD is associated to a five times higher
mortality and morbidity, with an increased risk for CVD (Hamaguchi et al. 2007;
Matteoni et al. 1999; Musunuru 2010). In a simplistic way of thinking, NAFLD can
be considered the hepatic manifestation of the MetS, since both MetS and NAFLD
originate from the combination of modern diet, lifestyle, and socio-economic factors.
Over-nutrition, cheap high-energy food, and sedentary habits represent the starting
point of the pathogenetic mechanisms involved in hepatic lipids accumulation, and
in both hepatic and whole body IR (Bugianesi et al. 2005a; Korenblat et al. 2008;
Marchesini et al. 2001; Musso et al. 2008). However, temporal and causal relationships between hepatic steatosis and IR remain uncertain, since both these states can
potentiate each other, also it remains still unclear wheter IR or steatosis arises first.
If IR and the elevated plasma levels of glucose and fatty acids (FAs) are responsible
for increased hepatic lipogenesis, impaired β-oxidation, and hepatic lipid accumulation (Marchesini et al. 2001; Sanyal et al. 2001), on the other hand hepatic IR
can develop also independently from peripheral IR. As a confirmation, hepatic
IR and abnormal liver lipid storage can occur also in the absence of peripheral
IR (Kraegen et al. 1991; Larter et al. 2010; Rinella and Green 2004; Rizki et al.
2006; Schattenberg et al. 2005). Rats fed with a short term high fat diet develop
hepatic fat accumulation and hepatic IR, in absence of changes in the whole body IR
(Kraegen et al. 1991; Samuel et al. 2004). On the other hand, hyperglycemia, hyperinsulinemia, and decreased peripheral insulin sensitivity are also associated to the
development of both MetS and NAFLD, since they drive hepatic lipogenesis, and
promote the release of TGs in serum (hypertriglyceridemia), and the intrahepatic
(NAFLD) and peripheral (obesity and atherosclerosis) lipid accumulation, further
worsening IR (Unger 2003).
The following paragraphs cover an overview of the complex physiological mechanisms controlling glucose and lipid metabolism, together with a critical view on the
pathological role of the liver in the onset of the clinical manifestation of MetS and
NAFLD.

3.2

Role of the Liver in the Pathophysiology
of Metabolic Syndrome

The liver plays a major role in the regulation of functions necessary for the maintenance of systemic metabolic homeostasis. Thus, a metabolic imbalance of glucose
and lipid metabolism may results in hepatic steatosis. On the other hand, insulin is
responsible for the maintenance of glucose and lipid homeostasis in the liver, which
is its main site of action in addition to adipose tissue and skeletal muscle. A condition
of IR determines different pathogenetic effects depending on the metabolic pathway
involved, thus a refractory insulin-response leads to increased glucose production
in liver, and to activation of the lipid synthesis and dyslipidemia, which can lead
to hepatic steatosis. Fatty liver and IR present various reciprocal influences and can
potentiate each other.
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Glucose Metabolism and Insulin Resistance

During fast and fed conditions the role of the liver is to control different metabolic
processes to maintain serum glucose concentrations within physiological limits.
Glycogenolysis and gluconeogenesis increase plasma glucose; fatty acid oxidation
(FAO) generates available energy for gluconeogenesis, while lipogenesis provides
FAs (Fig. 3.1). Insulin controls serum glucose concentrations and induces the transcription of most of the metabolic enzymes involved in hepatic glucose production
and in glycogen synthesis (Foufelle and Ferre 2002). Glycogenolysis is activated
to produces glucose during short period of fast, whereas is suppressed by insulin
after food intake (Gastaldelli et al. 2001). During longer periods of fasting, glycogen
stores are depleted in the liver and, thus, gluconeogenesis is stimulated to maintain
normal serum glucose concentration (Boden 2003). Insulin is the primary hormone
promoting the storage of energy in the fed state and is secreted in response to nutrients into the portal circulation. High levels of insulin promote the fast-fed shift in
hepatic carbohydrate metabolism, stimulating glycogen synthesis and suppressing
both gluconeogenesis and glycogenolysis (Fig. 3.1).
In pathological states of absolute insulin deficiency, such as type 1 diabetes, or
of relative insulin deficiency, such as obesity and type 2 diabetes, gluconeogenesis
results activated via an impaired inhibition of its key enzymes, phosphoenolpyruvate carboxykinase (PEPCK), responsible of the conversation of oxaloacetic acid
to phosphoenolpyruvate, and glucose-6-phosphatase (G-6-Pase), responsible for dephosphorylation of glucose 6-phosphate to free glucose (Bischof et al. 2002; Roden
and Bernroider 2003). However, when the liver becomes fatty, insulin also fails to
inhibit gluconeogenesis (Bugianesi et al. 2005a), causing an increase of serum glucose and, then, of hyperinsulinemia. Therefore, in a state of IR, the major alterations
in glucose metabolism are represented by decreased ability of insulin to stimulate
glucose consumption and to suppress hepatic glucose production.

3.2.2

Lipid Metabolism and Hepatic Insulin Resistance

The FA and TG content of hepatocytes is the result of the balance between their uptake
and synthesis (dietary intake, increased lipolysis of adipose tissue, de novo synthesis
with esterification of TG) and their catabolism and export (impaired mitochondrial
oxidation and export of TGs); in general, lipids accumulation in the liver can occur
when the rate of FA input is greater than the rate of FA output. There are four primary
mechanisms that can be responsible for lipids accumulation in the liver : (1) increased
hepatic lipid uptake (2) increased intrahepatic lipid synthesis (3) impaired hepatic
lipid export, and (4) reduced hepatic FAO.
All these mechanisms are under the control of insulin signaling; insulin modulates
the degradation of lipids by FAO (Randle 1998), the free fatty acid (FFA) flux into
the liver, the lipoprotein synthesis and lipogenesis of FFA, and the very low-density
lipoprotein (VLDL) secretion (Horton et al. 2003). IR in skeletal muscle and adipose

Fig. 3.1 Role of the liver in the control of glucose and lipid metabolism. CD36 cluster differentiation protein-36, ChREBP carbohydrate response elementbinding protein, FXR farsenoid X receptor, HDL high-density lipoprotein, IDL intermediate-density lipoprotein, LDL low-density lipoprotein, LDLr lowdensity lipoprotein receptor, LXR liver X receptor, OxLDL oxidized low-density lipoprotein, Ox-Phos oxidative phosphorylation, sLDL Small low-density
lipoprotein, SREBPs sterol regulatory element binding proteins, TG triglyceride, VLDL very low-density lipoprotein
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tissue is responsible for the impairment of the insulin signal transduction in skeletal
muscle cells, adipocytes and also in hepatocytes. A consequence of the peripheral IR
is hepatic steatosis. Conversely, abnormalities in lipid and lipoprotein metabolism,
abnormal lipid accumulation and hepatic IR may determine and worsen total body
IR (Larter et al. 2010; Rinella and Green 2004; Rizki et al. 2006; Schattenberg et al.
2005).
Hepatic Lipid Uptake In obese subjects with NAFLD approximately 15 % of hepatic lipids comes from dietary FAs; 25 % are from de novo synthesis and 60 % from
FFAs, mainly from adipose tissue (Donnelly et al. 2005). Therefore, one of the major
sources of TGs are the dietary FAs delivered to the liver, a pathway activated in a
condition of IR, and the dietary glucose content, which is converted in glycogen and,
when in excess, enter in the glycolysis pathway and then “turbo boost” the FA synthesis. The FA synthesis pathway includes several enzymes induced by ingestion of
a high carbohydrate diet, such as ATP citrate lyase, acetyl-CoA carboxylase (ACC),
and fatty acid synthase (FAS) (Towle et al. 1997). FAs thus produced can be further
used to synthetize TGs, which can be stored within hepatocytes or packages into
VLDL released into the circulation (Fig. 3.1).
Dietary fat and cholesterol are directly absorbed into intestinal cells and incorporated in chylomicrons, which are secreted into bloodstream and then into capillaries
of several tissues, such as adipose tissue and skeletal muscle. The TGs content
of chylomicrons and circulating VLDL is reduced by the action of lipoprotein lipase (LPL, the rate-limiting step of tissue circulating TG uptake), thus leading to
the formation of chylomicrons remnants and LDL enriched in cholesterol (Westerbacka et al. 2007); LDL can be captured by the liver through the binding to
LDL receptor (LDLr) (Fig. 3.1) (Brown and Goldstein 1986; Tulenko and Sumner 2002). Patients with NAFLD present an increased VLDL production, elevated
plasma LDL (Zoltowska et al. 2001), and a reduced lipoprotein hydrolysis of the
TGs into chylomicrons due to inhibition of exportation of LPL to the vessel surface,
which causes an uptake of TGs-rich chylomicrons remnants by the liver (Capeau
2008). In addition LPL activity may be decreased by high levels of its inhibitor, the
apolipoprotein C-III (ApoC-III) (Jong et al. 1999); ApoC-III inhibits LPL-mediated
hydrolysis and clearance of TGs-rich lipoproteins, thus modulating plasma lipid profiles (Cohn et al. 2004; Ginsberg and Brown 2011; Yao and Wang 2012). ApoC-III
also promotes hepatic VLDL assembly and secretion; this mechanism promotes the
elimination of excess TGs from the liver, thus preventing the onset of NAFLD (Sundaram et al. 2010; Yao and Wang 2012). Multiple stimuli can modulate the hepatic
gene expression of ApoC-III, including insulin (inhibitor) and glucose (stimulator)
(Altomonte et al. 2004; Caron et al. 2011; Chen et al. 1994). In individuals with
IR, ApoC-III cannot be suppressed by insulin and is promoted by increased glucose,
leading to an overproduction of VLDL. Furthermore, recent studies have suggested a
genotype–phenotype relationship between ApoC-III and NAFLD, showing that some
single-nucleotide polymorphisms (SNPs) in the gene encoding APOC-III, may be
associated with hypertriglyceridemia and MetS (Guettier et al. 2005; Miller et al.
2007; Petersen et al. 2010). In fact, the ApoC-III polymorphisms T-455C and C-482T
were found associated with increased plasma ApoC-III and TG concentrations, and
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with increased prevalence of NAFLD (Miller et al. 2007; Petersen et al. 2010); these
findings have not been confirmed in each ethnic backgrounds (Kozlitina et al. 2011).
On the other hand, people with hereditary deficiencies in ApoC-III generally have
lower plasma TG levels (Pollin et al. 2008).
In the post absorptive and fasting states the major rate of FFA delivered to the liver
derived from lipolysis of peripheral tissue, mainly from adipose tissue. Lipolysis of
adipose tissue is under the control of the hormone-sensitive lipase (HSL), which
is an enzyme activated when the body needs to mobilize energy stores, whereas is
strongly inhibited by insulin in the post prandial feeding state. Adipose tissue IR
of NAFLD patients, which is characterized by the lack of suppression of lipolysis by insulin, determines increased HSL levels with a consequent deregulation of
adipose-derived FFA flux to the liver in the fasting state (Mittendorfer et al. 2009).
The excessive FFA release rates from adipose tissue into the systemic circulation
lead to an increased availability of FAs for uptake by the liver, facilitating intrahepatic lipids accumulation, and worsening hepatic IR (Boden and Shulman 2002).
Furthermore, among causes of lipid accumulation in NAFLD, a key role is also
played by fatty acid transporters and their regulators, fatty acid translocase/cluster
differentiation protein-36 (FAT/CD36), fatty acid transport protein (FATP) and fatty
acid binding proteins (FABPs), which could further enhance hepatic lipid uptake
(Greco et al. 2008). FAT/CD36 is a long chain fatty acid transporter, which mediates
FA uptake and intracellular transport from plasma into different cell types (skeletal
muscle cells, adipocytes and hepatocytes), and it is regulated by insulin (Fig. 3.1)
(Lavoie and Gauthier 2006). Different experimental approaches confirm the role of
these findings. Specific activation of FAT/CD36 leads to hepatomegaly and hepatic
steatosis (Zhou et al. 2008). On the other hand, deletion of FATP and FABPs reverses
hepatic steatosis (Doege et al. 2006; Newberry et al. 2006).
Intrahepatic Lipid Synthesis The de novo lipogenesis (DNL), which is under the
control of several transcription factors in response to feeding and fasting conditions,
converts carbohydrates into saturated fatty acids (SFAs), and it is increased after
consumption of a meal. DNL plays an important role in promoting hepatic fat accumulation, appearing significantly increased in subjects with NAFLD compared to
healthy subjects (Aarsland and Wolfe 1998; Korchak 1962). Thus DNL is responsible of 25 % of TGs stored in the liver of NAFLD patients and it is still unclear
the importance of this pathway in the pathogenesis of fatty liver. Intriguingly DNL
can be detected not only in hyperinsulinemic condition but also in healthy subjects
through a high-carbohydrate meal; acute fructose ingestion increases DNL and postprandial TG levels (Parks et al. 2008). Insulin and glucose both drive DNL, through
the respective activation of sterol regulatory element binding proteins (SREBPs) and
carbohydrate response element-binding protein (ChREBP), which transcriptionally
induce most genes involved in FA synthesis (Browning and Horton 2004).
SREBPs are transcription factors that control FA, TG, and cholesterol synthesis,
and play a key role in the homeostasis of lipid metabolism (Fig. 3.1). Three forms
have been identified; SREBP-1c and SREBP-2 are the predominant form in the rodent and human liver. SREBP-1c activates genes involved in FAs and TGs synthesis,
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whereas SREBP-2 mediates cholesterol synthesis; both 1c and 2 inhibit the expression of PEPCK when there is a high uptake of carbohydrates, lowering blood glucose
that is used for lipogenesis (Sozio and Crabb 2008). SREBP-1c is the predominant
isoform in the liver, and its expression is regulated by nutrients and nutrition-related
signals, resulting suppressed during fasting and induced in feeding state. Nutrients
such as carbohydrates and SFAs induce SREBP-1c, whereas polyunsaturated fatty
acids (PUFAs) are inhibitors of SREBP-1c. SREBP-1c is also regulated by insulin
(promoter) and glucagon (inhibitor). Insulin and hyperglycemia induce increased
SREBP-1c expression, as shown in obese, insulin resistant and hyperinsulinemic
conditions (Caballero et al. 2009; Higuchi et al. 2008; Nakamuta et al. 2005a; Shimomura et al. 2000; Tamura and Shimomura 2005). SREBP-1c is also inhibited by
protein kinase A (PKA) and by adenosine monophosphate-activated protein kinase
(AMPK), which are activated during energy-producing processes (Foretz et al. 1999).
Overexpression of SREBPs results in increased lipogenesis and in the development
of hepatic steatosis (Shimano et al. 1996; Shimano et al. 1997), through the transcription of target genes involved in FA and TG synthesis, such as FAS, ACC, long chain
fatty acid elongase, and stearoyil-CoA desaturase 1 (SCD1), which have been shown
to be increased in patients with NAFLD (Foufelle and Ferre 2002; Postic and Girard
2008). ACC converts acetyl-CoA to malonyl-CoA, whereas FAS catalyzes the last
step in FA biosynthesis, the conversion of malonyl-CoA into SFAs. High levels of
malonyl-CoA inhibit carnitine palmitoyltransferase-1 (CPT-1), which transport FAs
into mitochondria (Capeau 2008; Greco et al. 2008). SCD1 has an important role in
protection of the liver from lipotoxicity, converting SFAs to monounsaturated fatty
acids (MUFAs), that can be safely stored (Li et al. 2009).
In addition to the regulation of homeostasis of lipid metabolism SREBP-1c is
involved in the regulation of glucose metabolism by directly suppression of insulin
receptor substrate-2 (IRS-2), which plays a major role in the modulation of hepatic
insulin signaling during the fasting state, resulting in inhibition of the downstream
phosphatidylinositol 3-kinases/protein kinase B pathway (PI3K/Akt), and in a lack
of blocking of the forkhead box protein O1 (FOXO1). In normal conditions FOXO1
is a transcription factor that activates gluconeogenic pathways through glucagon
action, and is inhibited by insulin through phosphorylation by the kinase PI3K/Akt.
Overexpression of SREBP-1c induces FOXO1, which activates gluconeogenesis
through the expression of PEPCK and G-6-Pase (Wolfrum et al. 2004). A reduction in
IRS-2 activity leads to impaired insulin sensitivity, decreased glycogen synthesis, and
increased gluconeogenesis. This may activate SREBP-1c and ChREBP, thus favoring
the switch from glycogen synthesis to lipogenesis (Ide et al. 2004). Therefore, chronic
SREBP-1c activation has a crucial role in the hepatic lipotoxicity, and in the control
of glucose and lipid metabolism, causing both IR and lipids accumulation.
ChREBP is a transcription factor involved in lipid synthesis, which is activated
by high concentrations of glucose, independently of insulin; thus, it has an important role in states of hyperglycemia (Denechaud et al. 2008). ChREBP plays
a key role in the conversion of carbohydrates to TGs in response to glucose excess (Fig. 3.1) (Towle et al. 1997). ChREBP is activated directly from glucose, and
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indirectly from insulin through the induction of glucokinase which allows the conversion of phosphorylated glucose to xylulose-5-phosphate, with subsequent activation
of protein phosphatase 2A (PP2A) that dephosphorylates and activates ChREBP
(Kabashima et al. 2003). ChREBP is inhibited by phosphorylation that is mediated
by PKA and AMPK (Kawaguchi et al. 2001; Kawaguchi et al. 2002). Activated
ChREBP induces transcription of gene involved in glycolysis (liver pyruvate kinase,
LPK), gluconeogenesis (G-6-Pase), and, in synergy with SREBP, of lipogenic genes
(ACC and FAS) (Iizuka and Horikawa 2008). The final result is the conversion of
excess glucose to FAs (Browning and Horton 2004).
Hepatic Lipid Export After a meal, dietary lipids are transported from the gut into
the systemic circulation in the form of chylomicrons and then stored in the liver,
where they are assembled to form the VLDL (Fig. 3.1). VLDL are complex lipoprotein particles constituted by proteins (apolipoprotein B-100, ApoB-100), lipids (TGs
or cholesterol ester), and phospholipids. Hepatic VLDL packages involve the fusion
of an ApoB-100 molecule with lipid droplets of TG through the action of the microsomal transfer protein (MTP) within hepatocytes, preventing TGs accumulation
(Fabbrini et al. 2010). The lipid excess is oxidized or released as VLDL. However,
the hepatic ability to oxidized fat is limited; an increase in intrahepatic fat content
leads to an up-regulation of oxidative mechanisms which are less efficient due to
mitochondrial uncoupling (Gastaldelli et al. 2007; Sanyal et al. 2001). Unoxidized
intrahepatocellular FAs are esterified to TGs, which can be incorporated into VLDL,
secreted into the circulation and delivered to the peripheral tissue, or stored within
the liver.
In patients with NAFLD, VLDL synthesis and export are impaired. In a state
of IR the rates of VLDL secretion are increased and accelerated, with subsequent
enhancement of serum levels of LDL and of atherogenic small LDL (sLDL). The
delipidation chain is under the control of two enzymes; cholesteryl ester transfer
protein (CETP), and hepatic lipase (HL). CETP is a protein responsible for lipid
molecule interchange between lipoproteins, enriching VLDL in cholesterol, whereas
HL regulates plasma concentration of atherogenic lipoprotein, such as intermediatedensity lipoproteins (IDL) and sLDL. CETP activity is increased in NAFLD and
may favor, together with HL, the formation of sLDL (Lucero et al. 2011). Nevertheless, while patients with NAFLD present increased rates of secretion of VLDL
compared to control, this secretion rate reaches a plateau and results inadequate to
compensate the degree of intracellular TG accumulation (Adiels et al. 2006; Fabbrini et al. 2008). The mechanism responsible for the inadequate increase in hepatic
TG export is unknown, but it might be related to inability of the liver to secrete large
VLDL particles, which cannot be secreted through the sinusoidal endothelial pores
(Horton et al. 1999). In fact, secretion rate of VLDL-ApoB-100 is equal between
subjects with high and low intrahepatic TGs content, with consequent production
of very large TG-rich VLDL. Moreover, the hepatic synthesis of ApoB-100, which
represents the rate-limiting step in the formation of VLDL, has been shown markedly
altered by insulin (Dashti et al. 1989; Pullinger et al. 1989). Thus, a state of hyperinsulinemia may cause an impaired ApoB-100 synthesis and consequent accumulation
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of TGs within hepatocytes. Impaired secretion of VLDL may also be secondary to a
decreased activity of MTP, which is essential for the formation of VLDL, packaging
TGs with ApoB. Polymorphisms or high-fat diet-induced methylation of MTP are
associated with a decreased MTP activity and enhanced TG accumulation in the liver
(Chang et al. 2010; Namikawa et al. 2004).
Fatty Acid Oxidation Lipid accumulation determines injury of hepatocytes with
impairment in mitochondrial number and/or oxidative function. Mitochondria dysfunction could affect several cellular functions within hepatocytes, both directly,
through increased oxidative stress and reduced FAO, and indirectly, affecting energyrequiring processes. The intrahepatic FAO occurs mainly within mitochondria, and
lesser in peroxisomes and microsomes. As mentioned before FAs can be both esterified to TGs or oxidized with the production of adenosine triphosphate (ATP).
The uptake of FA into the mitochondria matrix is regulated by CPT-1 and -2. CPT-1
levels have been found decreased in patients with NAFLD, consequentially to the
inhibition by high levels of malonyl-CoA, suggesting a reduction in mitochondrial
FAO (Nakamuta et al. 2005a). However, although FAO appears to be increased in
liver of both NAFLD and NASH patients (Sanyal et al. 2001), this increase is not
sufficient per se to prevent TG accumulation. Overall, contrasting results have been
reported about FAO in NAFLD, so further studies are needed (Higuchi et al. 2008).
Mitochondrial dysfunction results in increased production of reactive oxygen
species (ROS) and, thus, oxidative stress. ROS can activates stress responses leading
to increased activity of mitogen activate protein kinase (MAPK) and c-Jun N-terminal
kinase (JNK), two kinases that inhibit IRS1 and IRS2, with consequent decreased
activation of PI3K.
PI3K activation is involved in the translocation of glucose transporter type 4
(GLUT4) to the plasma membrane, that facilitate glucose uptake and its utilization
in muscle and adipose tissue. Therefore, inhibition of PI3K results in reduced glucose
uptake in the organs, and in exacerbated IR. The excess of FFAs, due to impaired
FAO, can also trigger the endoplasmic reticulum (ER) stress (Kharroubi et al. 2004;
Ozcan et al. 2004), with consequent induction of the uncoupled protein response
that initiates an adaptive response, worsening hepatocyte IR (Wei et al. 2006). The
unfolded protein response (UPR) activates an adaptive response that results in increased levels of pro-apoptotic proteins and induction of SREBP-1c and SREBP-2
(Sozio and Crabb 2008).

3.3

Lipid Sensing Nuclear Receptors as Modulators
of Hepatic Metabolism

Nuclear receptors (NRs) are transcription factors that act as intracellular sensors for
endocrine hormones and dietary lipids. NRs are key players in the coordination of the
development, metabolism, circadian rhythms, cell growth and differentiation. NRs
function as ligand-dependent transcription factors transducing different signals into
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modulation of gene transcription (Browning and Horton 2004; Mangelsdorf et al.
1995; Shulman and Mangelsdorf 2005). NRs show considerable specificity in their
activation and tissue-specific expression (Bookout et al. 2006), and they can work as
monomers, homodimers, and heterodimers (Mangelsdorf et al. 1995) . In the human
genome 48 NRs have been identified, while in rodents there are 49 (Mangelsdorf et al.
1995). NRs are characterized by a conserved modular structure including a ligandindependent activation function domain (AF-1), a ligand-binding domain (LBD), a
DNA-binding domain (DBD, binding to a specific hormone response element), and a
region involved in the transcriptional activation of target-gene expression (Lanz et al.
1999; Mangelsdorf et al. 1995; McKenna and O’Malley 2002; Onate et al. 1998).
In the absence of ligand, the NR is bound to transcriptional co-repressor complexes
that cause chromatin condensation and gene silencing. Ligand binding to NRs induces a change in NR three-dimensional conformation, which results in increased
affinity and recruitment of tissue-specific co-regulators, leading to the activation of
the transcription machinery (Lonard and O’Malley 2007; Mangelsdorf et al. 1995;
McKenna and O’Malley 2001). We will focus on the lipid-sensing NRs, namely the
peroxisome proliferator-activated receptors (PPARs), the liver X receptors (LXRs),
and the farnesoid X receptor (FXR), which all form heterodimers with the retinoid
X receptors (RXR) and are active players in the control of mechanisms involved in
the pathogenesis of MetS, and NAFLD (hepatic lipid uptake and export, intrahepatic lipid synthesis, FAO, carbohydrate metabolism, and inflammation), and in the
development of their complications.

3.3.1

Liver X Receptor

LXRs are key members of the nuclear receptors family, which are recognized as
important regulators of cholesterol metabolism, lipid biosynthesis, regulation of the
storage and oxidation of dietary fat, and of glucose homeostasis (Kalaany et al.
2005; Steffensen and Gustafsson 2004). Increased levels of LXR have been reported
in patients with NAFLD, with direct correlation to the severity of NAFLD (Ai and
Chen 2007; Higuchi et al. 2008). To date two LXRs genes, LXR-α and -β, have
been described with different tissue distribution; LXR-β is ubiquitously expressed,
whereas LXR-α is mainly expressed in the liver, adipose tissue, macrophages, small
intestine, kidneys, and gonads (Repa and Mangelsdorf 2000). LXRs are activated
by their endogenous ligands, the oxidized cholesterol derivatives, referred to as
oxysterols (Janowski et al. 1996; Willy et al. 1995).
LXRs regulate cholesterol homeostasis through the control of bile acid (BA) production (in rodents), cholesterol influx, transport and efflux, and impact energy homeostasis through the regulation of glucose metabolism (in rodents). LXRs positively
regulate some aspects of BA metabolism, such as the transcription of cholesterol 7α
hydroxylase (CYP7A1), which represent a rate-limiting step in BA synthesis, and
the transcription of the BA-conjugating enzyme UDP-glucuronosyltransferase 1–3
(UGT1A3), which facilitate BA elimination (Barbier et al. 2009; Peet et al. 1998).
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The synthesis and secretion of BAs are essential for dietary lipid absorption and for
removal the excess of cholesterol from the liver. LXRs also modulate cholesterol
efflux through the regulation of several members of the ATP-binding cassette (ABC)
transporters.
In macrophages, LXRs activation stimulates the expression of ABCA1 and
ABCG1, which mediate the efflux of cholesterol and phospholipids to lipoprotein,
whereas in liver stimulates ABCG5 and ABCG8, which eliminate hepatic cholesterol
through its secretion into the bile (Chawla et al. 2001a). LXR also regulates intestinal
cholesterol absorption through the negative regulation of the intestinal sterol transporter Niemann-Pick C1-like 1 (NPC1L1) (Duval et al. 2006) and facilitates uptake
and storage of cholesterol by the liver through the expression of CEPT (Luo et al.
2001).
LXRs also regulate FA metabolism through the expression of SREBP-1c which
is, as mentioned before, a master regulator of FA synthesis (Repa et al. 2000).
Furthermore, LXRs directly up-regulate enzymes involved in FA synthesis and in
FA influx, such as FAS, ACC, FAT/CD36 (Cha and Repa 2007; Repa et al. 2000;
Tontonoz and Mangelsdorf 2003a; Zhou et al. 2008). These pro-lipogenic effects
limit the use of synthetic LXR agonists for therapeutically use (Cha and Repa 2007;
Joseph et al. 2002; Zhang et al. 2003). On the other hand, LXR promotes FAO
in skeletal muscle and adipocytes by stimulating pyruvate dehydrogenase kinase 4
(PDK4), which suppress glycolysis in favor of FAO (Kase et al. 2005; Stenson et al.
2009). LXR is also involved in the regulation of glucose metabolism through the
suppression of hepatic gluconeogenesis by inhibiting PEPCK, G-6-Pase, and peroxisome proliferator-activated receptor-gamma coactivators 1alpha (PGC-1α) and
by the up-regulation of GLUT4 in adipose tissue (Cao et al. 2003; Laffitte et al.
2003). These functions suggest that LXR plays a key role in cholesterol homeostasis,
lipogenesis, and also in response to nutritional state (Fig. 3.1).

3.3.2

Farsenoid X Receptor

FXR-α is the master regulator of bile acids physiology, and acts as bile acid sensor that
protect cells and organs from BAs toxicity. FXR-α is activated by cholic acid (CA)
and chenodeoxycholic acid (CDCA) (Chawla et al. 2001b; Makishima et al. 1999;
Parks et al. 1999; Wang et al. 1999). Two FXR genes have been identified: FXR-α and
FXR-β. FXR-β constitutes a pseudo-gene in humans and primates (Otte et al. 2003).
FXR-α is highly expressed in liver and intestine where it modulates the expression
of genes involved in bile acid (BA) conjugation, efflux from the liver, and re-uptake
of the reabsorbed BA by the enterohepatic circulation (Wagner et al. 2008; Zhang
and Edwards 2008).
FXR-α also mediates the reverse cholesterol transport and efflux, and up-regulates
phospholipids transfer proteins and several apolipoproteins to induce overall reduction of plasma lipids; treatment with FXR-α ligands reduces serum levels of VLDL,
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TGs and HDL (Watanabe et al. 2004a). Moreover, FXR-α contributes to the regulation of lipid- and carbohydrate-induced changes during the fast/feed shift, by
inducing genes involved in lipoprotein/clearance of TG-rich lipoprotein and in insulin sensitivity/signaling, and repressing hepatic genes involved in DNL (Fig. 3.1)
(Lee et al. 2006; Zhang et al. 2004).
CDCA showed the ability of lowering plasma TG levels in patients with cholesterol gallstones and hypertriglyceridemia (Bell et al. 1973; Carulli et al. 1981; Leiss
and Von 1982; Miller and Nestel 1974). FXR lowers circulating VLDL by different
mechanisms. FXR induces the expression of short heterodimer partner (SHP), that
inhibits the liver receptor homolog-1 (LRH-1)—mediated activation of SREBP-1c,
reducing DNL, and modulating the MTP-mediated packaging of TGs with ApoB-100
in VLDL, thus decreasing VLDL secretion (Bilz et al. 2006; Gutierrez et al. 2006;
Hirokane et al. 2004; Kast et al. 2001; Lambert et al. 2003; Ma et al. 2006; Shih et al.
2006; Sinal et al. 2000; Thomas et al. 2008; Vacca et al. 2011; Wagner et al. 2011;
Watanabe et al. 2004b; Zhang et al. 2006a; Zhang et al. 2006b).
FXR also induces the LPL activity by decreasing the hepatic expression of LPL
inhibitors (e.g. ApoC-III), while inducing the LPL cofactors apolipoprotein C-II
(directly) and apolipoprotein A-V (ApoAV, mechanism PPARα-mediated), thus increasing the VLDL clearance (Bilz et al. 2006; Gutierrez et al. 2006; Hirokane et al.
2004; Kast et al. 2001; Lambert et al. 2003; Ma et al. 2006; Pineda et al. 2003;
Savkur et al. 2005a; Shih et al. 2006; Sinal et al. 2000; Vacca et al. 2011; Wagner et al.
2011; Watanabe et al. 2004b; Zhang et al. 2006a; Zhang et al. 2006b). FXR activation
also decreases total serum cholesterol levels, reduces the expression of apolipoprotein A-I (ApoA-I), and increases HDL remodeling (Angelin et al. 1978; Bateson et al.
1978; Claudel et al. 2002; Lambert et al. 2003; Leiss and Von 1982; Shepherd et al.
1979; Urizar et al. 2000; Watanabe et al. 2004b). Additionally, FXR decreases LDL-C
plasma levels, enhancing the expression of the LDLr (Nakahara et al. 2002). In turn,
the inhibition of CYP7A1 in liver results in increased hepatocyte cholesterol and
oxysterols levels, that activates LXR, with a subsequent ubiquitination of the LDLr
(Tontonoz and Mangelsdorf 2003b; Zelcer et al. 2009). Long-term CDCA-mediated
FXR activation reduces plasma LDL-C levels (Cariou et al. 2006; Schoenfield and
Lachin 1981; Wang et al. 2006; Watanabe et al. 2004b; Zhang et al. 2006a).
Conversely, FXR deficiency in rodents is associated with a massive cholesterol and
TG deposition in the liver as well as elevated circulating FFA levels (Ma et al. 2006;
Sinal et al. 2000; Zhang et al. 2006a; Zhang et al. 2006b), and BA-sequestrating
agent treatment results in increased plasma TG and VLDL levels in dyslipidemic
patients (Angelin et al. 1978; Beil et al. 1982; Crouse 1987). FXR-α also modulates
glucose metabolism in SHP-dependent manner. SHP regulates energy and glucose
homeostasis through loss of repression of PGC-1α; stimulates hepatic gluconeogenesis, inhibits glycolysis, increases energy expenditure, improves glucose uptake
in skeleton muscle through GLUT4 and promotes insulin secretion in pancreatic
β-cells (Claudel et al. 2005; Vacca et al. 2011; Wagner et al. 2011; Wang et al.
2005). In addition activation of FXR results in increased phosphorylation of IRS-1
and IRS-2, which increase insulin sensitivity and decrease glucose plasma levels
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(Zhang et al. 2004). Finally FXR suppresses glycolysis and promotes FAO through
the up-regulation of hepatic PDK4 (Savkur et al. 2005b).

3.3.3

Peroxisome Proliferator-Activated Receptor

PPARs are members of the NRs superfamily that act as “fatty acid sensors” to control
metabolic programs and to regulate energy homeostasis (Tontonoz and Spiegelman
2008). Three PPARs isoforms have been identified in mammals, PPAR-α, -γ, -β/δ,
with tissue-specific distribution and different effects in terms of gene expression.
PPAR-α is predominantly expressed in tissues where active FA catabolism occurs
(e.g. liver, brown fat, kidney, heart, and skeletal muscle), while PPAR-γ is mainly expressed in adipose tissue, pancreatic β-cells, with lower levels in the liver, cardiac and
skeletal muscle. PPAR-α and -γ are also expressed in vascular endothelium, vascular
smooth muscle, and macrophages/foam cells. PPAR-β/δ is ubiquitously expressed
in many tissues. PPARs can accommodate a wide diversity of natural and synthetic
compounds, including native and modified (oxidized and nitrated) FAs, eicosanoids,
derivatives of PUFAs, fibrates and thiazolidinediones (TZDs) (Forman et al. 1995;
Gottlicher et al. 1992; Kliewer et al. 1992; Kliewer et al. 1994; Nolte et al. 1998;
Sohda et al. 1990; Spiegelman 1998).
In the liver, PPAR-α is a master transcriptional regulator of genes involved in
hepatic production and uptake of FA, mitochondrial and peroxisomal β-oxidation of
FA, inflammation, and vascular function (Bernal-Mizrachi et al. 2003; Koo et al.
2004; Reddy and Hashimoto 2001). PPAR-α lowers serum levels of TGs by various
mechanisms; by inducing the LPL activity through the inhibition of hepatic ApoCIII (LPL inhibitor) and the activation of ApoAV (LPL cofactor), by enhancing the
expression of gene involved in FA uptake through the activation of FAT/CD36, by
increasing the VLDL-ApoB-100 catabolism and the FAO via activation of CPT-1,
acyl-CoA dehydrogenase and cytochrome P450-ω-hydroxylase (Schoonjans et al.
1996; Staels et al. 1995). Activated PPAR-α also increases the hepatic expression of
ApoA-I and apolipoprotein A-II (ApoA-II), which raise HDL cholesterol levels, and
promote HDL mediated cholesterol efflux from macrophages through the induction
of ABCA1 and the reduction of CETP levels (Chinetti et al. 2001; Shah et al. 2010).
PPAR-α may play a role in NAFLD; PPAR-α null mice fed with high fat diet
develop fatty liver (Kersten et al. 1999; Lee et al. 1995). Moreover, PPAR-α is activated by intrahepatic FAs that have been synthesized de novo to maintain glucose
and lipid homeostasis (Chakravarthy et al. 2005). On the basis of this knowledge
pharmacological activation of PPAR-α could be beneficial for restoring the homeostasis of lipid metabolism and inflammation, and, thus, for hepatic steatosis. The
fibrates are utilized in clinical practice for their hypolipidemic properties, especially
in the treatment of hypertriglyceridemia and mixed hyperlipidemia.
The fibrates also improve liver steatosis in mouse models of NAFLD; however
these findings are not fully confirmed in humans, probably due to species-differences
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between rodents and humans (Harano et al. 2006; Kallwitz et al. 2008). In fact,
although fibrates ameliorate glucose and lipid profile in patients with NASH, weak
effects on liver function test and histology have been confirmed (Athyros et al. 2006;
Fernandez-Miranda et al. 2008; Laurin et al. 1996; Nakamuta et al. 2005b).
PPAR-γ regulates genes involved in adipocyte differentiation and proliferation,
FA uptake and storage, lipolysis, inflammation, and insulin signaling. Activated
PPAR-γ increases insulin sensitivity and promotes FA uptake and storage into adipose
tissue, through the modulation of several genes such as LPL, FATP, FABP, FAT/CD36
and PEPCK, which reduce plasma levels of FFA and redirect FA from the liver
to the adipose tissue (Kallwitz et al. 2008; Ribon et al. 1998; Shi et al. 2006;
Wu et al. 1998). PPAR-γ activation in adipose tissue appears to be protective against
hepatic steatosis through the induction of genes that participate in TG accumulation in
adipocytes, which leads to a decreased storage of FAs in the liver. In addition, PPARγ activation in adipocytes increases the production of adiponectin, which stimulates
FAO and glucose utilization, and improves insulin sensitivity by its activation of
AMPK (You et al. 2005). The protective role of PPAR-γ is confirmed in humans
with a dominant negative mutation of PPAR-γ, who develop NAFLD and MetS
(Savage et al. 2003). PPAR-γ is a potential therapeutic target for IR and hepatic
steatosis; thiazolidinediones (TZDs) are a class of PPAR-γ agonist widely used in
type 2 diabetes patients which restore cell sensitivity to insulin through a direct effects
on lipid metabolism in adipose tissue and by secondary effects on lipid and glucose
metabolism in liver and skeletal muscle (Jiang et al. 2002; Way et al. 2001). TZDs
promote a different adipocytes differentiation and the transcription of different sets of
genes involved in FFA flux, which increase their uptake and storage in subcutaneous
adipose tissue, rather than visceral tissue. The result is a reduction of serum FAs and
TGs, and a decreased of IR and blood glucose levels. Moreover PPAR-γ is believed
to increase glucose uptake into liver and skeletal muscle cells by the expression
and translocation to the cell surface of the glucose transporter type 1 (GLUT1) and
GLUT4 (Kramer et al. 2001). PPAR-γ agonist may also restore insulin sensitivity
through the reduction of TNF-α (Cabrero et al. 2002) and the induction of adiponectin
expression (Maeda et al. 2001). TZDs have been evaluated in NASH patients, with
promising but not fully supported results (Chinetti et al. 2001; Mayerson et al. 2002;
Sanyal et al. 2010).
PPAR-β/δ recognizes dietary FAs carried by VLDL, and regulates directly genes
involved in glucose and FA homeostasis, and indirectly the inflammatory responses
(Kersten et al. 2000). PPAR-β/δ regulates genes involved in FA transport and oxidation in adipocytes, such as long-chain acyl-CoA dehydrogenase, CPT-1, long-chain
acyl-CoA synthetase. Overexpression of PPAR-β/δ in adipose tissue protects from
diet-induced hypertriglyceridemia, obesity and hepatic steatosis (Wang et al. 2003).
PPAR-β/δ is also involved in the modulation of lipoprotein metabolism; in animal
models of atherosclerosis, PPAR-β/δ agonist GW501516 determines an increase of
HDL levels, and a decreased of both LDL and sLDL (Leibowitz et al. 2000; Oliver
Jr et al. 2001; Takata et al. 2008; Tanaka et al. 2003; Wallace et al. 2005). Although
in some pilot studies GW501516 treatment has promoted a substantial increase in
HDL (Riserus et al. 2008; Sprecher et al. 2007), the physiological relevance of
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PPAR β/δ-mediated HDL-raising effect remains still elusive in humans. Future insights may come from newer agonists, such as KD-3010 and MBX-8025, currently
in the pre-clinical phases of research (Billin 2008).

3.4

Liver External Factors Influencing Hepatic Function

The adipose tissue is a complex and potent endocrine organ, which expresses and
secretes factors with important endocrine functions, such as cytokines, adipokines,
and a series of hormonal peptides. In the presence of excess of visceral adipose
tissue it has been observed a low-grade state of inflammation that results in increased production of FFA and pro-inflammatory cytokines, such as tumor necrosis
factors-α (TNF-α) and interleukin-1, and a decreased production of adipokines. Systemic oxidative stress can also determine alterations in the production of adipokines.
Among these proteins adiponectin has been found to play an important role in FFA
metabolism (Xu et al. 2003). Plasma adiponectin concentrations have been found
lower in patients with NAFLD, type 2 diabetes mellitus, IR, obesity and other conditions associated with MetS, when compared to age- and sex-matched controls, and
inversely correlated with IR and hepatic steatosis (Bugianesi et al. 2005b; Hui et al.
2004; Shklyaev et al. 2003). Thus, low adiponectin levels may be involved in the
worsening of both steatosis and IR (Bugianesi et al. 2005a). The main target of
adiponectin action is the liver, where stimulates FAO and glucose utilization by its
activation of AMPK (You et al. 2005), and PPAR-α. Adiponectin also inhibits hepatic
glucose production through the inhibition of the expression of G-6-Pase (Capeau
2008). Moreover, the catabolism of VLDL and HDL is regulated by adiponectin;
abnormal levels decrease the catabolism of VLDL and increase catabolism of HDL.

3.5

Deranged Metabolism is not Enough to Justify Progression
of Hepatic Damage: Is the “Two Hits” Model Still Actual?

Only a minority of patients with NAFLD develop NASH. The factors responsible for
the switch from NAFLD to NASH remain elusive. However, the proposed “two hits”
model, although simplistic, provides a pathophysiological rationale to the progression of liver damage (Day and James 1998). According to the two mechanisms or
toxic “hit” of NAFLD etiopathogenesis, the first mechanism is the reversible increase
of the intrahepatic TG content, which leads to metabolic and molecular alteration
that sensitize liver to the second hit, referred as oxidative stress and cytokines induce
liver damage. As mentioned before, IR is believed to be a condition strongly associated to the pathogenesis of NAFLD, which involves multiple sites; the muscle, with
decreased glucose uptake and utilization, the adipose tissue, with impaired suppression of adipose tissue lipolysis and increased release of glycerol and non-esterified
fatty acids (NEFAs) into the systemic circulation, and the liver, with overproduction
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of glucose and increased DNL. In addition to increased efflux of FFAs from adipose
tissue to the liver (Lewis et al. 2002) and DNL, another source of hepatic TG is
represented by dietary intake; all these factors promote hepatic TG accumulation,
which culminates in NAFLD (Donnelly et al. 2005).
However, in a minority of patients, a second hit, capable of inducing necrosis, inflammation and fibrosis is required for the development of NASH (Day and
James 1998; James and Day 1999). The process by which NAFLD turns into NASH
remains uncertain despite this double-hit hypothesis. Indeed, the progression of
liver damage may depend on a complex interplay between exogenic factors (e.g.
drugs, moderate amounts of alcohol) and genetic predisposition (similar to those
responsible for the MetS) (Day 2006; Petta et al. 2009). Candidates for the second hit can be represented by oxidative stress, lipid peroxidation, and increased
production of ROS, with subsequent inflammation and fibrosis (McCullough 2006).
In patients with NASH, structural abnormalities in the mitochondria are more frequently observed compared to NAFLD, with a decreased activity of the mitochondrial
respiratory chain complexes and an inefficient ATP production. Consequent lipotoxicity from SFAs, abnormal production of adipokines, such as increased levels of
leptin (pro-inflammatory and pro-fibrotic), and decreased levels of adiponectin (antiinflammatory and insulin-sensitising), increased production of pro-inflammatory
cytokines, such as TNF-α, interleukin-6 and −1β, have been all evocated in causing
the progression of hepatocyte injury (Dowman et al. 2010).

3.6

Epidemiological Studies Identify NAFLD as a Travel
Companion of the Metabolic Syndrome

The prevalence of fatty liver is rapidly growing, tied closely to the enhanced prevalence of obesity, and it has become an emerging health problem and an increasingly
common cause of cirrhosis in the economically developed nations of the world. The
real prevalence remains unknown due to the absence of accurate and non-invasive diagnostic measures. It is estimated that approximately 20 % of the general population
has NAFLD, whereas 3 % has NASH (Falck-Ytter et al. 2001); these prevalence rates
are increased in certain subpopulations such as patients with obesity and type 2 diabetes. Recent epidemiological data have shown that fatty liver is closely associated
with one or more variables of the MetS. NAFLD association with the MetS is higher
than in general population; approximately 50–100 % of subjects with NASH are overweight, 50–60 % are hypertensive, and 50–60 % have dyslipidemias (Bacon et al.
1994). Autopsy studies on NAFLD patients have shown that steatosis occurs in 36 %
of lean patients, and in 72 % of obese patients. Furthermore, NASH is present in up
to 3 % of lean patients, and up to 19 % of obese patients (Wanless and Lentz 1990b).
The prevalence of NAFLD may be also different in relation to the ethnic group. A
population study on 2.287 multiethnic individuals using magnetic resonance imaging (MRI) to assess the presence of NAFLD has shown that prevalence was greater
in whites (33 %) and Hispanics (45 %) compared to blacks (24 %) (Browning et al.
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2004; Ruhl and Everhart 2003). This difference may be due to ethnic differences in
lipid metabolism, excess adiposity, and IR (Browning et al. 2004; Romeo et al. 2008).
Prevalence of NASH rises with age, and is greater between 50 and 60 years (Angulo et al. 1999), with a higher prevalence in females (60–83 %) (Ludwig et al. 1980;
Matteoni et al. 1999). However recent epidemiological data have shown an increase
in cases of NASH among children and among adult males. Browning et al. have
shown that the fatty liver in the white subpopulation prevails in males (42 %) than
women (24 %) (Browning et al. 2004). Age > 45 years represents an independent predictor factor for the risk of fibrosis and of progression of liver damage (Angulo et al.
1999; Matteoni et al. 1999). Probably age is associated to the duration of the liver
injury and with the exposition to other factors which increase the risk of fibrosis.

3.7

Clinical Presentation of Hepatic Disease
in the Metabolic Syndrome

The most common feature of hepatic disease in the MetS is NAFLD, which is believed
one of the most frequent causes of abnormal liver enzymes. NAFLD is a silent disease,
with a non-specific clinical presentation, and serum markers of hepatic damage often
within the normal ranges. The assessment of steatosis is instrumental, while the diagnosis of NAFLD is made after exclusion of all other causes of fatty liver. NAFLD is
mainly asymptomatic; right upper abdominal quadrant discomfort, unexplained hepatomegaly and chronic fatigue can be rarely recognized. Fatty liver (hyperechogenic
liver at ultrasound scan, US, and/or hepatomegaly) is detected incidentally in case of
imaging performed for other reasons, or when abnormal serum liver function tests
(elevated alanine aminotransferase, ALT, and gamma-glutamyltransferase, GGT) are
detected (Reid and Sanyal 2004). In this case NASH is strongly suspected. NASH
is characterized by ALT usually higher than aspartate aminotransferase (AST) and,
when AST:ALT ratio is greater than 1.0 it is suspicious of the progression through
fibrosis and cirrhosis (Angulo et al. 1999); in this case albumin levels and bilirubinaemia should also be taken in account (Oh et al. 2008). GGT is also frequently
elevated and has been proposed as marker of increased mortality (Ghouri et al. 2010;
Haring et al. 2009). However, the presence of normal serum liver enzymes does not
exclude the presence of NASH (Abrams et al. 2004). When NAFLD and NASH
are diagnosed, a complete metabolic assessment of patient should be performed to
investigate the presence of MetS and increased cardiovascular risk. Therefore, increased fasting serum glucose, serum insulin, triglyceridemia and cholesterol are
common features in patients with NAFLD/NASH. On the other hand, individuals
with obesity, diabetes and hypertriglyceridemia, and MetS should always be screened
(liver enzymes/US) for NAFLD/NASH. Many imaging options can be used for the
diagnosis of NAFLD, such as US, computed tomography (CT), MRI, and different
non-invasive scoring systems for histology prediction (Joy et al. 2003; Saadeh et al.
2002). US is the easiest and cheapest diagnostic technique, documenting an increased
echodensity of the liver (e.g. "brilliant liver"). However, the sensitivity of US is low,
since hepatic steatosis can be detected when the lipid accumulation involves more
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Table 3.2 Brunt scoring
system for NASH.
(Brunt et al. 1999)

Table 3.3 Brunt scoring for
fibrosis
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Grade2

Steatosis

Balloning of
hepatocytes

Degree of inflammation

1

≤ 33 %

Minimal

2

33–66 %

Present

3

≥ 66 %

Marked

Lobular mild-moderate,
portal absent-mild
Lobular mild-moderate,
portal mild-moderate
Lobular severe, portal
mild-moderate

Stage

Fibrosis

1
2

Focal or extensive perisinusoidal fibrosis
Focal or extensive perisinusoidal and periportal
fibrosis
Bridging fibrosis
Extensive bridging fibrosis, cirrhosis

3
4

than 30 % of the hepatic tissue, and US cannot assess the presence and/or degree of
inflammation and fibrosis (Harrison et al. 2003). On the other hand, the costs of CT
and MRI and their inability into distinguish simple steatosis, from steatohepatitis,
and/or fibrosis, do not motivate their common use. Several non-invasive diagnostic techniques and scoring systems have been developed with the aim of increasing
the non-invasive assessment of liver fibrosis and/or the presence of NASH. This
is the case of the elastography (FibroScan) that, assessing the strength (elasticity)
of the liver, can recognize the increased parenchymal echo texture and vascular
blurring (Sanyal 2002), and of different mathematical algorithms proposed as surrogate markers of NASH progression. Some examples are the APRI index (aspartate
transaminase AST-to platelet ratio index) (Cales et al. 2009; Shaheen and Myers
2007; Shaheen and Myers 2008), the Fibro-Test (Poynard et al. 2007) (combining
haptoglobin, α2-macroglobulin, ApoA-I, GGT, and total bilirubin to predict inflammation, steatosis and fibrosis in NAFLD), the Hepascore (predicting the extent of liver
fibrosis or cirrhosis in adults through the combination of bilirubin, GGT, hyaluronic
acid, α2-macroglobulin) (Stauber and Lackner 2007), and the Bard score (body mass
index, AST/ALT ratio, presence of diabetes), which is a simple scoring system used
to identify NAFLD in patients with a low risk of advanced disease (Harrison et al.
2008). All these surrogate markers may support the clinical decisions but, to date,
cannot replace the liver biopsy. Liver biopsy represents the gold standard for the diagnosis, providing the degree of steatosis, the presence of necroinflammatory lesions
and of fibrosis, which are the distinctive features of NASH from simple steatosis
(Brunt 2004). Brunt scoring system is the most accepted score for grading the histological degree of NASH, and is based on four main histological lesions: steatosis,
hepatocyte ballooning, inflammation, and fibrosis (Brunt et al. 1999). See Table 3.2
and 3.3 for details.
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Table 3.4 Pharmacological
treatment of NAFLD

Weight loss agents
Insulin sensitizing agents
Lipid-lowering agents

Anti-oxidants

Hepatoprotective agents

3.8

Orlistat
Metformin
Thiazolidinediones
Statins
Fibrate
Omega-3 fatty acids
Probucol
Vitamin E
Vitamin C
Probiotics
Ursodeoxycholic acid
Pentoxyfylline

From Pathophysiology to Treatment

Current treatments for MetS and NAFLD are focused on weight loss, amelioration of the metabolic balance, reduction of cardiovascular risk, and limiting disease
progression. Due to a poor compliance of the patients, the success rates of this treatment are not satisfactory; lifestyle changes are very difficult in an “obeso-genic”
environment. The first line approach to patients with MetS and NASH are lifestyle
changes, namely diet and increased aerobic physical exercise, in order to lose weight
and improve insulin sensitivity (Neuschwander-Tetri 2009). Weight loss represents
the mainstay in the non-pharmacological treatment in MetS and NAFLD patients.
Weight loss should not be fast in order to prevent the risk of progression of liver damage (Grattagliano et al. 2000; James and Day 1998). Patients should lose 5–10 % of
their baseline weight over 6–12 months, at a rate of 0.5–1.5 kg/week (Okita et al.
2001). Gradual weight loss and increased physical activity in obese patients with
liver disease result in improvement of serum insulin, markers of hepatic disease
progression (liver enzymes, steatosis, inflammation, and fibrosis), and in quality of
life (Andersen et al. 1991; Dixon et al. 2004; Hickman et al. 2004). In the treatment of MetS and NAFLD there is no diet that can be considered a “gold standard”.
The best dietary strategy probably consists in eating less, mainly healthy foods. It
should be limited the consumption of foods enriched in SFAs and carbohydrates at
high glycemic index, while it should be encouraged the consumption of vegetables,
legumes, fruit, soy derivatives, and fish. Alcohol, smoke, and potentially hepatotoxic
medications should be also avoided. The validated pharmacological approaches in the
treatment of MetS and NAFLD are summarized in Table 3.4. In the management of
NAFLD, the only pharmacological approaches that showed certain levels of success
are antioxidants and drugs improving IR (McClain et al. 2004; Sanyal et al. 2001).

3.9

Conclusions

The liver is the metabolic workhouse responsible for the maintenance of the whole
body lipid and glucose homeostasis. Liver impairment may have its origin in hyperinsulinemia and hyperglycemia, which lead to hepatic IR that could affect peripheral
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sites; alternatively peripheral decreased insulin sensitivity may cause both adipose
and hepatic IR. Fatty liver and IR are strongly associated, and both increase the
prevalence of CVD. Future clinical and basic research should address the molecular mechanisms that guide this vicious cycle in order to provide novel therapeutic
measures for MetS.
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Chapter 4

Role of Adipose Tissue in the Pathogenesis
and Treatment of Metabolic Syndrome
David Sanchez-Infantes and Jacqueline M. Stephens

Abstract Adipocytes are highly specialized cells that play a major role in energy
homeostasis in vertebrate organisms. Excess adipocyte size or number is a hallmark
of obesity, which is currently a global epidemic. Obesity is not only the primary
disease of fat cells, but also a major risk factor for the development of Type 2
diabetes, cardiovascular disease, hypertension, and metabolic syndrome (MetS).
Today, adipocytes and adipose tissue are no longer considered passive participants
in metabolic pathways. In addition to storing lipid, adipocytes are highly insulin
sensitive cells that have important endocrine functions. Altering any one of these
functions of fat cells can result in a metabolic disease state and dysregulation of
adipose tissue can profoundly contribute to MetS. For example, adiponectin is a fat
speciﬁc hormone that has cardio-protective and anti-diabetic properties. Inhibition
of adiponectin expression and secretion are associated with several risk factors for
MetS. For this purpose, and several other reasons documented in this chapter, we
propose that adipose tissue should be considered as a viable target for a variety of
treatment approaches to combat MetS.
Keywords Metabolic syndrome · Adipocyte · Adipose tissue · Adipokines

4.1

Metabolic Syndrome

“MetS” has been traditionally deﬁned as a condition whose major features consists
of obesity, insulin resistance, the development of Type 2 diabetes (T2DM), and
accelerated cardiovascular disease (Chen et al. 1999; Isomaa et al. 2001; Grundy
2004; Grundy et al. 2005; Grundy 2007; Lorenzo et al. 2007; Bruce and Byrne
2009). The development and appearance of other traditional risk factors, including
hypertension, dyslipidemia, and non-traditional risk factors such as inﬂammation
and coagulopathy, are also associated with this condition (Chen et al. 1999; Isomaa
et al. 2001; Grundy 2004; Grundy et al. 2005; Grundy 2007; Lorenzo et al. 2007;).
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Many other names have been used for this disease state including “syndrome X”
“cardio-metabolic syndrome”, “insulin resistance syndrome”, and “pre-diabetes”.
Regardless of the terminology used, there has been a steady rise in incidence of MetS
as a result of the staggering increase in the prevalence of obesity and T2DM that has
now reached epidemic proportions. In fact, a number of components of the MetS
have become increasingly prevalent in children (Ford et al. 2008; Tailor et al. 2010).
The MetS has been and will continue to represent one of the most important public
health problems facing society today. Given the known complications for MetS, it
is imperative that effective strategies are implemented to improve the underlying
pathophysiologic factors that contribute to the development of this disease.

4.2 Adipocytes
Adipocytes are highly specialized cells that play a major role in energy homeostasis
in vertebrate organisms. Excess adipocyte size or number is a hallmark of obesity,
which is currently a global epidemic. Obesity is not only the primary disease of fat
cells, but also a major risk factor for the development of T2DM, cardiovascular disease, hypertension, and metabolic syndrome. Obesity and its related disorders result
in dysregulation of the mechanisms that control the expression of metabolic genes in
adipocytes. Therefore, understanding adipocyte differentiation is relevant not only
for understanding the pathogenesis of metabolic diseases, but also for identifying
proteins or pathways which might be appropriate targets for pharmacological interventions. In the last fifteen years, significant advances towards understanding the
regulatory processes involved in adipocyte differentiation and fat cell function have
been made. These observations have an impact on understanding the pathogenesis
and treatment of MetS, a threatening cluster of metabolic diseases that decreases life
expectancy and pose an epidemic global threat.

4.3 Adipocyte Hypertrophy and Hyperplasia in MetS
A critical function of adipocytes is the storage of lipids. Adipocytes are the primary
constituent of adipose tissue and the lack of adipose tissue expandability can be
associated with the onset of metabolic syndrome (central obesity, dyslipidemia,
glucose intolerance and hypertension) (Mlinar and Marc 2011). An increase in fat
mass can occur as a result of increased intracellular lipids and greater adipocyte size
(hypertrophy) and/or by increasing adipocyte number (hyperplasia) (De Ferranti and
Mozaffarian 2008). Adipocyte hypertrophy, evident in both overweight and T2DM
patients (Bahceci et al. 2007), was originally considered the primary manner that
adipose tissue mass increased in adults. However, adipocyte hyperplasia is now
known to contribute to the increased adipose tissue mass of obesity (De Ferranti and
Mozaffarian 2008). Hyperplasia is dependent on the formation of new adipocytes in a
process referred to as adipogenesis, a developmental event that is initiated in utero and
occurs throughout life. There is evidence that the stages of adipocyte developmental
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are different in humans and rodents. In mice, expression of adipocyte markers can
be observed as early as day 15 (with a total of 21 days of gestation time) (Das et al.
2001). In humans, the differentiation of fat tissue, as judged by the appearance of
lipid-laden cells, can be observed during the second trimester of gestation (between
weeks 14 and 24 of gestation) (Deng and Scherer 2010). In recent years, a goal
of many investigators in both academia and industry was to identify inhibitors of
adipogenesis for potential use as treatment for metabolic diseases including obesity
and MetS. However, recent studies suggest that inhibitors of adipogenesis are a poor
choice for amelioration of metabolic disease states. A decade ago, Danforth proposed
that a failure in adipocyte differentiation could cause T2DM (Danforth 2000). As
discussed later, this hypothesis is generally recognized and supported by independent
lines of investigation in adipocyte biology.
Obesity is a major risk factor for comorbidities associated with MetS, including T2DM, stroke, hypertension, and cardiovascular disease (Grundy 2004). Energy
imbalance leads to storage of excess energy in adipocytes, which can exhibit both
hypertrophy and hyperplasia. It is known that the presence of lipid-laden adipocytes
correlates with insulin resistance (Unger 2002). In addition, adipose hypertrophy and
hyperplasia are associated with intracellular abnormalities of adipocyte function, including endoplasmic reticulum and mitochondrial stress. The consequences of these
stressors may cause increased rates of ROS production, mitochondrial dysfunction,
altered adipokines synthesis, changes in free fatty acids, and the presence of inflammatory mediators (De Ferranti and Mozaffarian 2008). The factors regulating adipose
hypertrophy and hyperplasia are not clearly understood, but circulating insulin and
glucocorticoid concentrations both appear to stimulate preadipocyte differentiation
(Avram et al. 2007).
It is important to point out that one of the key causal components of MetS is the
accumulation of “ectopic” fat (Bruce and Byrne 2009). In particular, an increase in
visceral fat is associated with insulin resistance (Despres 2001). Visceral fat accumulation, rather than whole body adiposity, has been implicated in the development
of diabetes, lipid disorders, hypertension, and atherosclerosis (Matsuzawa 2010).
There is evidence that inflammatory adipokines can be released from this visceral
fat and these inflammatory cytokines have a negative effect on the production of
adiponectin (Suganami et al. 2005). In addition, an accumulation of visceral fat impairs the suppression of free fatty acids that normally occurs through adipose tissue
lipolysis in response to insulin resistance (Jensen 2008). Therefore, the accumulation
of visceral fat may produce an alteration of circulating LDL-cholesterol and HDLcholesterol that is associated with impairments of endothelial function and increased
cardiovascular risk (Wyne 2003).

4.4 Adipose Tissue as an Endocrine Organ
Historically, adipose tissue has been considered an energy storage depot with few
interesting attributes. Due to the dramatic rise in obesity and its metabolic consequences, the study of adipose tissue has gained tremendous scientific interest in
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the past two decades (Rabe et al. 2008). Scientific discoveries in the last twenty
years have revealed that adipocytes and adipose tissue are highly active endocrine
cells/tissues that secrete several endocrine factors, termed adipokines, that comprise a
new hormonal network linking adipose tissue with other tissues and organs including
skeletal muscle, the adrenal cortex, various regions of the brain and the sympathetic
nervous system (Ronti et al. 2006). These adipose tissue produced mediators can
modulate food intake, energy balance, homeostasis, immunity, insulin sensitivity,
angiogenesis, blood pressure, and glucose and lipid metabolism (Ronti et al. 2006;
Ahima 2006; Deng and Scherer 2010). The changes in each individual adipokine are
the result of coordinated changes of specific transcriptional programs that affect entire groups of adipocyte gene products as well as posttranslational mechanisms that
affect the release and activity of these cellular mediators (Deng et al. 2010). Adipose
tissue expansion that occurs in obesity can substantially alter adipokine secretion and
profoundly contribute to the development of metabolic diseases (Lehr et al. 2011).

4.4.1 Adipokines Secreted by Adipose Tissue
Adipokines can be broadly defined as any hormone or cytokine produced from a cell
present in adipose tissue. Adipocytes represent the largest and most abundant type
of cell in adipose tissue and produce hormones, including leptin and adiponectin
that are exclusively produced and secreted from fat cells. The primary function of
these hormones appears to be endocrine in nature and these hormones act in distant
target tissues such as the brain, liver, and skeletal muscle. There are a variety of
other cell types in adipose tissue including immune cells such as macrophages and
T cells. These immune cells also contribute to the production of hormonal cellular
mediators. In particular, macrophages produce cytokines that appear to act in a
paracrine manner on adjacent adipocytes. These inflammatory mediators are often
referred to as adipocytokines, the most common of which include TNFα, IL-6, and
IFNγ. As indicated below and summarized in Table 4.1, several adipokines are
regulated in metabolic syndrome.

4.4.2

Leptin

The first hormone shown to be exclusively secreted from adipocytes was identified
by positional cloning of the obese gene (Zhang et al. 1994). Since its identification
in 1994, leptin has attracted much attention as one of the most important signals for
the regulation of food intake and energy homeostasis (Friedman and Halaas 1998;
Elmquist et al. 1999; Bates and Myers 2003). Leptin plays an important role in energy balance by inhibiting appetite, stimulating thermogenesis, enhancing fatty acid
oxidation, modulating glucose homeostasis, and reducing body weight by decreasing
fat mass (Ahima 2006). Leptin binds to its receptors in various regions of the central
nervous system, including the hypothalamus and brainstem where it activates neural
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Table 4.1 The function and regulation of adipokines in Metabolic Syndrome
Adipose tissue
source

Adipokine

Functions

Adipocytes

Leptin

Satiety signal
Increases energy
expenditure
Improves lipid
metabolism
Angiogenic activity
Improves insulin
sensitivity

Regulation in
metabolic syndrome

Decreased in U.S Pima
Indians with T2DM
Increased in obese
humans
Hyperleptinemia and
leptin insensitivity in
Israeli sand rat
Circulating leptin levels
predict development of
metabolic syndrome
Adiponectin Improves insulin
Decreased in obese,
sensitivity
insulin resistance and
Reduces inflammation
T2DM subjects
and atherosclerosis Decreased in rhesus
monkeys with obesity
and insulin resistance
Low plasma adiponectin
is associated with
metabolic syndrome
Resistin
Inflammation
Increased in obesity and
Insulin resistance
insulin resistance rat
and mouse models
Plasma resistin is
increased in metabolic
syndrome
Resistin levels are not
associated with
metabolic syndrome
Non Adipocytes PAI-1
Vascular homeostasis Increased in obese rats
Inflammation
Increased expression and
activity in metabolic
syndrome
TNFα
Inhibits adipocyte
Increased in lipoatrophic
differentiation
adipose tissue
Proinflammatory
Increased mRNA
Induces insulin
expression in adipose
resistance
tissue in obese mice
IFNγ
Inhibits adipocyte
Increased mRNA
differentiation
expression in adipose
Proinflammatory
tissue from obese
animals
IL-6
Proinflammatory
Increased in obese
Can be associated with
humans
insulin resistance

References
Fox et al. 1999
Ahima 2006
Zimmet et al.
1999
Franks et al.
2005;
Galletti
et al. 2007

Pajvany and
Scherer
2003
Hotta et al.
2001
Hulthe et al.
2003

Qatanani et al.
2009
Norata et al.
2007
Utzschneider
et al. 2005

Funahashi
et al. 1999
Mertens et al.
2006
Bastard et al.
2002b
Hotamisligil
et al. 1993
Rocha et al.
2008

Bruun et al.
2003;
Bastard
et al. 2006

PAI-1 Plasminogen Activator Inhibitor 1, TNF-α Tumor Necrosis Factor alpha, IFNγ Interferon
gamma, IL-6 Interleukin 6
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pathways that decrease appetite and increase sympathetic nervous system activity
and energy expenditure (Rahmouni et al. 2005; Hall et al. 2007). Blood leptin levels
are related with adiposity, but this correlation is only part of its regulation. Leptin
decreases quickly during fasting and produces an increase of glucocorticoids and
a reduction in thyroid hormones (T4), sex hormones and growth hormone (Ronti
et al. 2006). Some studies indicate that subcutaneous fat rather than visceral fat has
the greatest ability to increase leptin levels (Takahashi et al. 1996; Wajchenberg
2000; Fain et al. 2004). Leptin reduces intracellular lipid levels in the skeletal muscle, liver and β-pancreatic cells (Minokoshi and Kim 2002), and improves insulin
sensitivity (Liu et al. 1998; Gutierrez-Juarez et al. 2004). In fact, in patients with
lipodystrophy and leptin deficiency, leptin therapy improves glucose tolerance and
decreases triglycerides levels (Ronti et al. 2006). In rodents, both intravenous and
intracerebroventricular administration of leptin improves peripheral insulin action
(Liu et al. 1998; Gutierrez-Juarez et al. 2004). More recently, intriguing preclinical data suggests that pharmacological leptin doses may exert beneficial effects for
type 1 diabetics (Wang et al. 2010).
In addition, it has been suggested that hyperleptinemia and leptin resistance could
be a primary factor in the development of MetS. Individual variations in blood leptin levels have been shown to be related with factors that produce MetS (Leyva and
Godsland 1998). Epidemiological data also demonstrate that hyperleptinemia and hyperinsulinemia play a synergic central role in the genesis of the components of MetS
(Zimmet and Boyko 1999). Moreover, leptin may also affect the vascular system. In
fact, in vitro and in vivo studies indicate that leptin has angiogenic activity (SierraHonigmann et al. 1998) and may contribute to the arterial thrombosis due to its
interaction with platelet leptin receptor (Bodary et al. 2002). Collectively, these studies indicate that leptin therapy is limited to a subset of patients with lipodystrophy and
may be a future treatment for Type 1 diabetes. Given that leptin resistance is common
in obesity and evidence that leptin may be an important modulator of the vascular system, it is highly unlikely that leptin will be viable therapeutic for patients with MetS.

4.4.3 Adiponectin
The adiponectin gene is located in chromosome 3q27 at a locus susceptible to T2DM,
MetS and coronary heart disease (Yamauchi et al. 2003a). Adiponectin is secreted by
adipocytes and has been shown to have anti-diabetic and anti-atherogenic properties
(Yamauchi et al. 2003b). Native adiponectin exists as homotrimers that form dimers
of trimers (hexamers) and high molecular weight (HMW) complexes (Kadowaki and
Yamauchi 2005). Several studies have demonstrated that the HMW multimer form
of adiponectin is the most active form of this hormone (Waki et al. 2003; Ouchi et al.
2004; Kobayashi et al. 2004). Four mutations in the adiponectin globular domain
have been identified. The most frequent mutation is associated with low adiponectin
blood levels and individuals with this mutation have some characteristics of metabolic
syndrome including hypertension, hyperlipidemia, diabetes and/or atherosclerosis
(Kondo et al. 2002).
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Adiponectin levels in plasma are 5–30 μg/ml, and these levels tend to be lower in
men than in women. Although adiponectin is only secreted from adipocytes, blood
levels are lower in obese subjects as compared to non-obese subjects. In general,
this is the only adipokine whose expression is decreased in obesity as the majority
of other adipose tissue hormones have increased levels in obesity that correlate with
increased body mass (Arita et al. 1999). A large number of studies have demonstrated
a correlation between insulin sensitivity and high adiponectin levels in humans and
experimental animals (Yamauchi et al. 2001; Maeda et al. 2001; Combs et al. 2001;
Asensio-López et al. 2011). Circulating levels of adiponectin are decreased in obesity,
insulin resistance and T2DM (Pajvani and Scherer 2003). Low adiponectin levels
have also been observed in hypertension subjects, and the lowest levels can be found
in patients with coronary heart disease. The incidence of death in cardiovascular
disease is higher in patients with low adiponectin levels (Szmitko et al. 2007).
As indicated above, the HMW form of adiponectin appears to be the most active form. This complex has the most potent insulin-sensitizing activity of all the
adiponectin complexes (Pajvani et al. 2004), and it can suppress hepatic glucose
production (Waki et al. 2003). Although the mechanisms implicated in adiponectin
action are largely unknown, there is evidences that phosphorylation of 5 -adenosine
monophosphate—activated protein kinase may play a role in its action (Waki et al.
2003; Ouchi et al. 2004). Administration of adiponectin to rodents has been shown
to increase the tyrosine phosphorylation of insulin receptor and result in increased
insulin sensitivity (Berg et al. 2001; Combs et al. 2001). Similar studies have been
validated in humans (Yamauchi et al. 2001; Stefan et al. 2002). In rhesus monkeys that
spontaneously develop obesity and insulin resistance, adiponectin blood levels decrease proportionally to the progression of insulin resistance during the development
of T2DM (Hotta et al. 2001). A negative correlation between adiponectin levels and
body weight, and a positive correlation between adiponectin levels and glucose uptake were established in these monkeys. In addition, the decrease in the adiponectin
levels occurred before hyperglycemia. Adiponectin does not appear to have a direct action on insulin secretion, as insulin levels do not increase after adiponectin
injection. In addition, adiponectin injection could improve insulin sensitivity and
hyperglycemia in mice with obesity, diabetes and lipodistrophy (Yamauchi et al.
2001). However, mice lacking insulin receptors in adipocytes have an elevation
in plasma adiponectin (Bluher et al. 2004) and clinical studies demonstrate that
patients with antibodies against insulin receptors showed a significant increase in
serum adiponectin (Semple et al. 2006). These observations suggest that loss of insulin signaling may enhance adiponectin secretion (Deng et al. 2010). Despite these
observations, adiponectin appears to be a potential therapeutic for MetS as high
levels are associated with insulin sensitivity and cardiovascular health.

4.4.4

Resistin

Resistin was identified as a gene whose expression was suppressed by the insulin sensitizing drugs, thiazolidinediones (Steppan et al. 2001). In this study, the researchers
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suggested that this novel adipocyte expressed protein, could be a link between obesity and insulin resistance, and for this reason, they called it “resistin” (Steppan et al.
2001). Resistin acts to increase blood glucose and insulin levels and decrease glucose tolerance. In obese mice, immunoneutralization of resistin results in decreased
blood glucose levels and improved insulin sensitivity and support the hypothesis that
resistin induces insulin resistance and/or contributes to inhibiting insulin sensitivity
(Ronti et al. 2006). In mice, resistin is produced in adipocytes. However, in humans,
resistin is produced in macrophages. Despite the differences in the source of this
hormone, the function of resistin to promote insulin resistance is independent of it
source. An elegant transgenic model was produced that expressed human resistin
in mouse macrophages, rather than adipocytes. The modulation and function of the
hormone was similar in these mice despite the macrophage specific expression that
was employed to mimic expression of the human resistin gene (Qatanani et al. 2009).
Not surprisingly, TZDs have been shown to inhibit resistin gene expression in human
macrophages (Patel et al. 2003; Lehrke et al. 2004) and a decrease in serum resistin
levels has been observed in rodents as well as humans (Jung et al. 2005; Kamin
et al. 2005). The signaling mechanism(s) by which resistin impairs insulin action are
just beginning to be unraveled and the receptor for this adipokine is still unknown.
There is evidence to suggest that resistin inhibits the AMP-activated kinase (AMPK)
in liver and muscle (Satoh et al. 2004; Banerjee et al. 2004; Muse et al. 2004) and
it has also been shown to activate SOCS-3 in mouse adipose tissue (Steppan et al.
2005).
In humans, resistin expression is abundant in monocytes/macrophages, which
play an important role in inflammation and atherosclerosis (Patel et al. 2003; Savage et al. 2001). A correlation between circulating resistin levels and inflammation
markers has been established and research suggests this fact is predictive of coronary
atherosclerosis (Reilly et al. 2005). In addition, serum resistin levels show significant correlation with vascular inflammation (Choi et al. 2011). Given that MetS
is associated with insulin resistance and cardiovascular risk, the inhibition of resistin expression and/or activity may represent a viable therapeutic intervention for
metabolic syndrome.

4.4.5

Plasminogen Activator Inhibitor 1

Plasminogen Activator Inhibitor 1 (PAI-1) is a fibrinolysis system regulator that inhibits the plasminogen activator action and plasmin formation. PAI-1 is produced in
adipose tissue and its expression has been implicated in inflammation that accompanies obesity-associated diseases (Theodorou G et al. 2011). An increase of PAI-1
could promote a tendency to have thrombosis and may produce the thrombotic cardiovascular disease that can occur in visceral obesity and MetS (Funahashi et al.
1999). Increased expression and activity of PAI-1 has been demonstrated in MetS
(Mertens et al. 2006).
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Inflammatory Cytokines Produces in Adipose Tissue

During chronic inflammation, adipose tissue expresses elevated levels of acute phase
reactants and pro-inflammatory cytokines (Wellen and Hotamisligil 2005). The presence of infiltrating immune cells, such as macrophages and T cells is well documented
and studies in the last decade suggest that these cells are modulated in conditions
of obesity and T2DM. Inflammation may be one of the mechanisms by which high
postprandial insulin and glucose responses increase the risk of T2DM (Brand-Miller
et al. 2007). In the last decade, several pro-inflammatory cytokines have been shown
to be produced in adipose tissue including TNFα, IL-6 and IFNγ.

4.4.7

Tumor Necrosis Factor α and Interferon γ

It is well established that the tumor necrosis alpha (TNFα) (Torti et al. 1985) and
IFNγ (Keay and Grossberg 1980) are potent inhibitors of adipocyte differentiation.
TNFα is not secreted by adipocytes but it is secreted by infiltrating macrophages
that are present in adipose tissue (Mohamed-Ali et al. 1997; Xu et al. 2002). IFNγ
is produced from both NK cells (O’Rourke et al. 2009) and T cells (Duffaut et al.
2009; Rocha et al. 2008; Strissel et al. 2010; Yang et al. 2010) present in adipose
tissue. Of note, it is also known that both of these cytokines induce insulin resistance
in adipocytes (Stephens et al. 1992; Mcgillicuddy et al. 2009). Several mechanisms
have been proposed to explain the association between TNFα and obesity related
insulin resistance. Chronic exposure of adipocytes to TNFα results in an inhibition
of GLUT4 expression and a loss of insulin sensitive glucose uptake (Stephens et al.
1992). TNFα also results in a decrease of IRS-1 expression in adipocytes (Stephens
et al. 1997) and can cause an increase of fatty acids release from adipocytes (Bruun
et al. 2003). In addition, it has been demonstrated that TNFα can reduce adiponectin
expression and secretion (Arita et al. 1999; Maeda et al. 2001). Collectively these
studies indicate that there are several mechanisms in which TNFα can induce and
promote insulin resistance in adipocytes.
Another cause for inflammation has been attributed to endoplasmic reticulum
stress (ER stress) (Hotamisligil 2006). The ER is a major site for protein as well as
for lipid and sterol synthesis (Schroder and Kaufman 2005; Wang et al. 2005). ER
stress is increased in adipose tissue in response to both dietary and genetic obesity
(Ozcan et al. 2004; Boden et al. 2008), and several studies report that it can trigger
activation of several serine/threonine kinases, including c-Jun N-terminal kinase
(JNK) and IκB kinase. ER stress can produce an impairment of insulin action as
well as the ability to activate the synthesis and release of proinflammatory cytokines
(Hotamisligil 2006; Hirosumi et al. 2002; Boden et al. 2008).

4.4.8

Interleukin 6

Interleukin-6 (IL)-6 is produced by adipocytes and other cells (fibroblasts,
preadipocytes, endothelial cells, monocytes) in adipose tissue (Trayhurn and Wood
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2004; Bastard et al. 2006). Approximately 30 % of circulating IL-6 is derived from
white adipose tissue, with visceral fat producing higher levels of IL-6 than subcutaneous fat (Dube et al. 2008). It has been reported that plasma IL-6 concentrations
correlate positively with human obesity (Trayhurn and Wood 2004; Bastard et al.
2006; Bruun et al. 2003), insulin resistance (Bastard et al. 2000 and 2002a), hypertension and hyperlipidemia (Recasens et al. 2004). It has been suggested that
elevated IL-6 levels may be predictive of T2DM (Bastard et al. 2000) and this cytokine can have a negative effect on adiponectin secretion (Simons et al. 2007). IL-6
has metabolic effects that include reducing hepatic insulin sensitivity and decreasing
glucose uptake in adipocytes (Eder et al. 2009). There is also evidence that IL-6 promotes lipolysis and fat oxidation (Van Hall et al. 2003; Petersen et al. 2005). IL-6 is a
potent stimulator for the production of reactive oxygen and nitrogen by macrophages
and monocytes, and may produce an increase in oxidative stress (Fernández-Sanchez
et al. 2011). Therefore, this cytokine seems to play a key role in inflammation and
alteration in glucose and lipid metabolism that can occur with metabolic syndrome.

4.5 Adipocytes as Drugs Targets for the Metabolic Syndrome
A primary goal of treatment for patients with MetS should include changes in lifestyle
such as improving diet and physical activity. Adipose tissue plays a very important
role in MetS, and therefore represents a key target in the treatment of this disease.
There are a variety of drugs that are used in the treatment of metabolic syndrome. For
example, drugs that lower blood pressure are commonly used. In addition, statins
are used to reduce cholesterol levels. However, the beneficial effects of these drugs
are not mediated by primary effects on adipocytes. However, there is one class of
drugs that is used for treatment of metabolic syndrome that largely acts by improving
adipocyte development and fat cell function.
The glitazones or thiazolidinediones (TZDs) are oral drugs used to improve insulin
sensitivity and glucose tolerance in T2DM (Wang et al. 2010; Quinn et al. 2008).
TZDs exert beneficial effects on several components of the MetS and cardiovascular
risk markers (Sarafidis et al. 2010). In addition, TZDs have been reported to improve
cardiovascular prognosis in patients with insulin resistance (Reasner 2002). These
drugs are agonists of the nuclear receptor PPARγ, a transcription factor that regulates
the expression of many genes in adipocytes. As indicated above, insulin resistance
is often accompanied by an increase on pro-inflammatory cytokines that are derived
from adipose tissue macrophages and act in a paracrine manner on surrounding
adipocytes. TZDs have been shown to decrease the expression and release of these
cytokines and other insulin resistance mediators produced in adipose tissue (free fatty
acids and resistin), that results in an improvement in insulin sensitivity, particularly
in muscle and liver (Pittas and Greenberg 2002; Giles and Sander 2007).
TZD administration has also been shown to increase adiponectin plasma levels
in insulin resistance subjects. In fact, it has been demonstrated that these drugs can
increase adiponectin transcription (Maeda et al. 2001) as well as circulating hormone
levels. In normal subjects, a 14 days rosiglitazone treatment resulted in an increase in
adiponectin levels (Combs et al. 2001). HMW adiponectin has been reported to have
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a greater increase than total adiponectin levels in patients with T2DM treated with
TZDs (Pajvani et al. 2004). The precise mechanism(s) by which TZDs mediates the
increased release of adiponectin is not yet clear, but may be due to the up regulation of
several ER chaperons that could alleviate ER stress-induced adiponectin regulation
(Wang and Scherer 2008; Liu et al. 2008; Zhou et al. 2010). In addition, TZDs may
improve mitochondrial function and ROS levels that results in a favorable increase
of adiponectin secretion (Wilson-Fritch et al. 2003; Wilson-Fritch et al. 2004).
It can be readily argued that PPARγ activation caused by TZDs can promote
adipocyte differentiation of preadipocytes and result in an increase in fat body mass.
Currently available TDZs (e.g. rosiglitazone) are associated with important side
effects, such as edema and weight gain, suggesting that the investigation of alternative
TZDs with better pharmacological properties is warranted (Faine et al. 2011). A
recent novel synthetic compound, SR1664, has been identified that has a unique mode
of binding to PPARγ (Choi et al. 2011). These researchers report that this compound
completely lacks classical transcriptional agonism and inhibits the Cdk5-mediated
PPARγ phosphorylation in cultured adipocytes and in insulin-resistant mice. They
have observed that the non-agonist SR1664 has potent anti-diabetic activity that
is not accompanied by fluid retention and weight gain that are serious side effects
of many of TZDs. These recent studies suggest that designing therapeutics that
effect covalent modifications of PPARγ may be potentially effective treatments for
metabolic syndrome.
One treatment to target adipocytes that should not be considered for metabolic syndrome is the use of factors that inhibit adipocyte differentiation. As indicated above,
proinflammatory cytokines that inhibit adipocyte development also cause insulin resistance (Fig. 4.1). In fact, most inhibitors of adipogenesis are associated with insulin
resistance. In addition, there are new model systems that clearly suggest that limitations in adipose tissue expansion are associated with insulin resistance. Mice that are
very obese, but have unlimited adipose tissue expansion, are metabolically healthy
and insulin sensitive (Kim et al. 2007). Overall, these studies support Danforth’s
idea and indicate that inhibition of adipogenesis is associated with insulin resistance.
Emerging evidence of metabolically healthy obese individuals suggest that obesity
is likely preferable to insulin resistance in terms of overall health. Collectively, these
results indicate that inhibiting adipogenesis is not a viable therapeutic approach.
Another drug that has been demonstrated to be effective in the treatment of the
metabolic syndrome is metformin (N, N-dimethylimidodicarbonimidic diamide hydrochloride), a biguanide developed from galegine that is found in Galega Officinalis.
Despite its use in T2DM treatment for more than 50 years, the mechanism of metformin action is not entirely clear. In the last decade, a link between metformin
and AMP- activated protein kinase (AMPK) activity has been proposed (Zhou et al.
2001; Shaw et al. 2005). AMPK is considered as a master switch in regulating glucose and lipid metabolism. In adipose tissue, activated AMPK inhibits deposition
of fat, and enhances breakdown and burning of stored fat, resulting in a reduction
of body weight. These data suggest that AMPK may be a key player in the development of new treatments for obesity, T2DM and the metabolic syndrome (Misra
2008). In fact, metformin exerts cardioprotective actions via AMPK and increases the
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Fig. 4.1 Characteristics of adipose tissue in conditions of increased and decreased risk of Metabolic
Syndrome. Adipose tissue of comprised of various cell types including adipocytes, preadipocytes,
and infiltrated immune cells. Healthy adipose tissue does not contain immune cells that produce
proinflammatory cytokines such as TNFα and IFNγ. Healthy adipocytes are also insulin sensitive
and do no have impairments in adipogenesis. Adipose Tissue that is metabolically unhealthy contains
immune cells that produce IFNγ and TNFα that act in a paracrine manner on adipocytes to promote
insulin resistance and inhibit adipocyte development

expression of adiponectin and its receptors (adipoR1 and adipoR2) in skeletal muscle and adipose tissue (Asensio-López et al. 2011). Moreover, metformin activates
AMPK and reduces acetyl-CoA carboxylase protein levels in human adipose tissue
(Boyle et al. 2011). These results suggest that its effects on fat cells may mediate
some of the beneficial effect of metformin to improve glucose homeostasis.
Although it is a more challenging solution, particularly for those that are economically disadvantaged, proper nutrition should be considered as an option to
combat metabolic syndrome. There is some evidence of functional ingredients having the capability to modulate parameters that are altered in metabolic syndrome.
Adipose tissue can be a target for these ingredients, particularly if they are capable
of regulating adipokine levels via regulation of diet. It is known that the consumption of a high-carbohydrate and low-fiber meal results in a transient decrease in
adiponectin levels and dietary fiber intake can increase the levels of this adipocyte
specific hormone (Galisteo et al. 2005). Prolonged feeding of a 3.5 % Plantago
ovata husk-supplemented diet in Zucker rats resulted in decreased body weight gain,
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reduced hyperinsulinemia and dyslipidemia, and restored plasma adiponectin level.
In humans, a cross sectional analysis in women with T2DM revealed that the intake
of cereal fiber and fruit-fiber was significantly associated with increasing plasma
adiponectin levels (Qi et al. 2005). If the intake of functional foods may induce
an increase in the adiponectin levels, this approach could produce health benefits
associated with insulin action and glucose metabolism, but may also reduce the inflammatory state (Yannakoulia et al. 2008; Nilsson et al. 2008). Adiponectin has been
shown to reverse the deleterious effects of TNFα and other cytokines in cultured cells
(Ouchi et al. 1999; Okamoto et al. 2002). Perhaps the postprandial inflammatory response produced after high-fat, high-carbohydrate meal in obese individuals (Patel
et al. 2007), could be improved with dietary fiber and modulation of pro-inflammatory
cytokine levels (Esposito et al. 2003).
Dietary fiber can also decrease leptin levels, improving the development of leptin
resistance due to increased adiposity. In fact, it has been demonstrated that in conditions of high-sugar/low-fiber that it takes longer to observe a decrease in glucose and
leptin levels as compared to conditions of low-sugar/high-fiber (Spruijt-Metz et al.
2009). Moreover, a reduction in circulating leptin was reported after supplementation
with fungal chitosan in a high dietary fiber treatment that was associated with lower
fat mass development (Neyrinck et al. 2009). Accordingly, functional ingredients
such as particular dietary fibers could be an important tool to modulate glucose and
lipid metabolism and reduce inflammation to prevent the development of metabolic
syndrome.

4.6

Concluding Remarks

Metabolic Syndrome is a threat to industrialized nations that is usually accompanied
by abdominal obesity. Although there are metabolically healthy obese individuals,
obesity is a substantial risk factor for poor metabolic control and altered glucose and
lipid homeostasis. Today, adipocytes and adipose tissue are no longer considered
passive participants in metabolic pathways. In addition to storing lipid, adipocytes are
highly insulin sensitive cells that have profound endocrine functions. One hormone
that is produced exclusively in adipocytes, adiponectin, has cardio-protective and
anti-diabetic properties. For this reason, and several other reasons documented in
this chapter, we propose that adipose tissue should be considered as a viable target
for pharmacotherapeutic approaches to combat metabolic syndrome.
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Chapter 5

The Beta Cell in Metabolic Syndrome
Bader Zarrouki, Ghislaine Fontés, Meriem Semache, Julie Amyot
and Vincent Poitout

Abstract The pancreatic beta cell is equipped with a highly sophisticated machinery to precisely sense the metabolic status of the organism and secrete the exactly
appropriate amount of insulin to maintain blood glucose levels in a very narrow
range. When the Metabolic Syndrome develops, insulin resistance imposes an additional burden on the beta cell, which then hypersecretes insulin to meet the demand.
In the majority of individuals, the beta cell can sustain this additional workload
and maintain normoglycemia. In a subset of predisposed individuals however, this
compensatory response eventually fails and diabetes develops. Once diabetes is established, beta-cell function continues to deteriorate over time. The molecular and
cellular mechanisms underlying beta-cell failure are not fully understood, although
several hypotheses have been proposed. Amongst these, glucolipotoxicity; defective
mitochondrial metabolism and oxidative stress; inﬂammation; amyloid deposits, disruption of autophagic ﬂux; endoplasmic reticulum stress; beta-cell dedifferentiation
and exhaustion from chronic hypersecretion probably contribute to some extent, perhaps at various stages of the disease progression and differently between individuals.
Thus, beta-cell failure is likely mediated by a number of interrelated and complex
mechanisms, which is reﬂected in the inability of the current therapeutic options
to signiﬁcantly slow down disease progression. This provides a strong argument for
early interventions aimed at preventing the functional demise of pancreatic beta cells
in the Metabolic Syndrome.
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Introduction

The dramatic increase in the incidence of diabetes, which is expected to affect more
than 550 million people worldwide by 2030, represents a tremendous economical and
social burden (Whiting et al. 2011). Obesity is a major risk factor for type 2 diabetes
(T2D), which develops in a subset of genetically predisposed individuals (Lusis
et al. 2008) when insulin secretion becomes insufficient to adequately compensate
for insulin resistance. Genetic evidence supporting a critical role for the beta cell in the
pathogenesis of T2D lies in the observation that the vast majority of genes identified
in genome-wide association studies for T2D are related to beta-cell development
or function (Herder and Roden 2011). Nonetheless, the combined contribution of
identified polymorphisms to the risk of developing diabetes remains less than 10 %
(Herder and Roden 2011; Lusis et al. 2008), illustrating the polygenic nature of this
complex disease and the major role of environmental and/or epigenetic factors. In
addition, several longitudinal studies in humans have shown that beta-cell function
declines over time following the initial diagnosis (1995, 1998), and have suggested
that the beta-cell secretory capacity is already significantly impaired at the time
of diagnosis (Holman 1998). Therefore, identification of the early environmental
factors that impair beta-cell function and promote its demise is a key prerequisite to
any therapeutic strategy aimed at preserving insulin secretion and preventing T2D in
the context of the Metabolic Syndrome (MetS). In fact, all metabolic perturbations
that define the MetS, namely hypertriglyceridemia, reduced HDL cholesterol and
fasting hyperglycemia (Alberti et al. 2009), have been shown to contribute to beta-cell
dysfunction and failure.
The purpose of this chapter is to review our current understanding of the factors
underlying the progressive deterioration of beta-cell function in the context of the
MetS. We have particularly emphasized glucolipotoxicity, a major focus of interest
in our laboratory, but have also attempted to present recent findings supporting the
contribution of mitochondrial dysfunction, inflammation, autophagy, endoplasmic
reticulum (ER) stress, beta-cell dedifferentiation and exhaustion in beta-cell failure.
Not mentioned in this chapter, albeit clearly important, are the epigenetic changes
that occur in the beta cell in response to the foetal or neonatal environment and that
predispose to subsequent failure in the face of the MetS. These have been extensively
reviewed elsewhere (Nolan et al. 2011) and we will only focus here on the environmental factors proposed to contribute to beta-cell failure in the adult, once the MetS
is established.

5.2

Physiological Regulation of Pancreatic Beta-cell Function

The pancreatic beta cell is the key cell in the body that produces and secretes insulin,
the only hypoglycaemic hormone. Beta cells are located within the islets of Langerhans of the pancreas and represent approximately 80 % of the islet mass (which itself
represents 2–3 % of the total pancreatic mass), the remaining 20 % being accounted
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Fig. 5.1 Regulation of insulin secretion. The increase in ATP/ADP ratio following glucose
metabolism leads to the closure of the ATP-sensitive K + channel, membrane depolarization, opening of voltage-sensitive calcium channels, calcium influx, and insulin exocytosis. This pathway is
further amplified by other intracellular signals. Several extracellular molecules potentiate insulin
secretion through activation of GPCRs. These receptors are coupled to downstream signalling pathways leading to an increase in cAMP levels and/or intracellular calcium that synergize to amplify
insulin secretion. GLP-1 Glucagon-like peptide-1. FAs Fatty acids. M3R Muscarinic receptor 3.
This figure was produced using Servier Medical Art

for by glucagon-secreting alpha cells; somatostatin-secreting delta cells; and pancreatic polypeptide-secreting PP cells. Under normal circumstances, blood glucose
levels are maintained within a very narrow range despite large variations in food
intake and energy expenditure. This is achieved by a very tight regulation of insulin
secretion from the beta cell, which continuously adjusts its output in response to
metabolic, hormonal, and neuronal signals (Fig. 5.1). Amongst these, glucose is the
major regulator of insulin release. The beta cell is equipped with a glucose-sensing
apparatus consisting of the glucose transporter GLUT2 and the high-Km, lowaffinity isoform of hexokinase glucokinase, the kinetic properties of which ensure
that intracellular glucose concentrations rapidly equilibrate with extracellular levels
within the physiological and supraphysiological range of glycemia (approximately
5.5–16.7 mM). Following its uptake and phosphorylation, glucose (in the form of
glucose-6-phosphate) enters glycolysis to form pyruvate, which is then metabolized
into the Krebs cycle to generate ATP. Acceleration of glucose metabolism results in
an increase in intracellular ATP/ADP ratio, closure of the ATP-sensitive K + channel,
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membrane depolarization, opening of voltage-sensitive calcium channels, calcium
influx, and insulin exocytosis (Henquin 2000). This main—or triggering—pathway
of coupling between glucose and insulin secretion is complemented by additional,
amplifying pathways which essentially potentiate the secretory response to calcium
influx via additional glucose-derived metabolites, the nature of which remains debated (Henquin 2009). However, the amplifying pathway is not operative without
the triggering pathway being activated first (Henquin 2000). In addition, a number
of nutrient and non-nutrient secretagogues can potentiate glucose-induced insulin
secretion via G-protein coupled receptors, such as glucagon-like peptide-1 (GLP-1),
fatty acids, and muscarinic stimulation (Fig. 5.1).

5.3

Beta-cell Compensation to Insulin Resistance

Insulin resistance, a characteristic feature of the MetS, increases the burden on the
beta cell to produce more insulin to compensate for its decreased efficiency. In humans, this is believed to occur via two complementary mechanisms: enhanced insulin
secretion and increased beta-cell mass. It has been appreciated for a long time that
in obese humans, insulin secretion is considerably enhanced to maintain normoglycemia (Reaven et al. 1993). More recently, Butler et al. (Butler et al. 2003) have
shown that 1) beta-cell mass is increased in obese non-diabetic vs. lean individuals;
and 2) beta-cell mass is decreased in both obese individuals with impaired fasting
glucose and T2D patients. These observations suggest that part of the beta-cell compensation to insulin resistance involves an increase in mass that, as T2D occurs and
progresses, subsequently declines.
Whether the expansion in beta-cell mass results from proliferation of existing
beta cells or neogenesis from ductal or acinar cells remains an intense topic of debate. While beta-cell replication clearly plays a major role in mice (Dor et al. 2004),
evidence suggests that beta-cell proliferation rates are extremely low in adult humans (Meier et al. 2008) and that neogenesis from ductal cells contributes to newly
formed beta-cells (Inada et al. 2008). In addition, a recent study in primates (Saisho
et al. 2011) showed that neogenesis is the major supplier of newly formed adult
beta-cells (80 %).
The signalling and molecular mechanisms underlying beta-cell compensation to
insulin resistance in the MetS are essentially unknown; however, experimental evidence points to an important role for insulin signalling in both the liver and the
beta cell. Perturbation of insulin signalling in the liver results in insulin resistance
(Michael et al. 2000), which in turn is proposed to drive beta-cell hyperplasia, as
demonstrated for example by the large increase in beta-cell mass upon deletion of the
insulin receptor specifically in the liver (Escribano et al. 2009). Beta-cell proliferation
in response to liver insulin resistance is abolished by pancreatic vagotomy, pointing
to an important role of neuronal signals in mediating this response (Imai et al. 2008).
Alternatively, it has been suggested that liver-derived circulating factors could play
a role in beta-cell adaptation to insulin resistance (El Ouaamari et al. 2013).
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Fig. 5.2 Beta-cell dysfunction and failure in type 2 diabetes. The progressive decline in beta-cell
function and mass is a result of interrelated mechanisms occurring at various stages in a subset
of predisposed individuals. The relative contribution of each of these mechanisms is still not fully
understood. This figure was produced using Servier Medical Art

The initial observation that beta-cell specific deletion of the insulin receptor
leads to a decrease in beta-cell mass and defective glucose-induced insulin secretion (Kulkarni et al. 1999) provided the first demonstration for a role of insulin
signalling in the beta cell in glucose homeostasis. This has been confirmed by subsequent studies examining the consequences of beta-cell specific deletion of genes
encoding proteins in the insulin signalling pathway (reviewed in Kasuga 2006), such
as insulin receptor substrate-2 (IRS-2) (Choudhury et al. 2005; Kubota et al. 2004),
phosphatidyl-inositol-3 kinase (PI3K) (Kaneko et al. 2010), and 3-phosphoinositidedependent kinase 1 (PDK-1) (Hashimoto et al. 2006). In humans, Bouche et al.
(Bouche et al. 2010) have shown that preexposure of healthy subjects to exogenous
insulin potentiates endogenous insulin secretion in response to glucose independently
from changes in circulating free fatty acid levels (Lopez et al. 2011), supporting a role
for insulin signalling in beta-cell function. This effect depends on both the prevailing
levels of insulin sensitivity and the circulating insulin levels, but its relatively small
magnitude makes it unlikely to contribute significantly to beta-cell compensation in
the MetS (Mari et al. 2011).

5.4

Beta-cell Decompensation and Failure

In a subset of genetically predisposed individuals, the mechanisms described above
are insufficient to adequately compensate for insulin resistance, diabetes occurs, and
beta-cell function continues to deteriorate over time. A number of different phenomena have been proposed to contribute to beta-cell failure (Fig. 5.2). We consider it
unlikely that any of these phenomena alone is sufficient to explain beta-cell failure
in T2D, and they all probably contribute, to a variable extent depending on the individuals and the stage of the disease, to beta-cell dysfunction. Most of the studies
described below have been performed in vitro or in rodent models, and whether or
not the findings are relevant to human T2D remains, in the majority of the cases, to
be directly demonstrated. Despite these limitations, significant advances have been
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made in the past few years towards a better understanding of beta-cell dysfunction
in T2D.

5.4.1

Glucolipotoxicity

The MetS provides a situation in which dyslipidemia (lipotoxicity) and hyperglycemia (glucotoxicity) are simultaneously present and synergistically alter the
function of multiple organs, including the beta cell (Poitout and Robertson 2008).
Accordingly, a large number of ex vivo and in vivo studies in rodents have shown
that excessive fatty acids levels, in the presence of high glucose, have detrimental effects on beta-cell function and, in some cases, viability. Investigations in humans are
admittedly less conclusive, in part due to the inherent difficulty in designing clinical
studies to examine the long-term effects of nutrient excess on glucose homeostasis.
Nonetheless, Carpentier et al. (Carpentier et al. 1999) have shown that insulin secretion is increased upon acute lipid infusion in healthy subjects but diminished when
the infusion is prolonged to 48 h, although the latter finding was not confirmed in
other studies (Boden et al. 1995; Boden and Chen 1999). Interestingly, inhibition
of insulin secretion by prolonged lipid infusion appears specific to glucose, since
arginine-induced secretion was not affected (Carpentier et al. 2001). Finally, the susceptibility to the inhibitory effects of lipid infusion on insulin secretion appears to be
related both to the family history of T2D (Kashyap et al. 2003) and to the presence
of mild hyperglycemia (Carpentier et al. 2010), the latter being consistent with the
concept of glucolipotoxicity.
A large number of in vitro and preclinical studies have attempted to identify
the mechanisms underlying glucolipotoxicity. Convincing evidence has been presented in favour of metabolic dysfunction (Prentki and Madiraju 2008), ER stress
(Cnop et al. 2008), oxidative stress (Oprescu et al. 2007), and inflammation (BoniSchnetzler et al. 2009) as playing a role in glucolipotoxicity of the beta-cell. This list
of potential mechanisms illustrates the fact that, somewhat surprisingly, the precise
molecular and cellular mechanisms of glucolipotoxicity remain debated. We believe
that this is due to a number of confounding factors and differences in the experimental conditions, perhaps the most important being whether or not glucolipotoxicity is
studied under conditions where significant cell death is observed. This is dependent
upon the islet species as well as the concentration and nature of the fatty acids used.
For example, a 24 h exposure of human islets to elevated glucose and palmitate is
sufficient to observe apoptosis (El-Assaad et al. 2003), whereas cell death is not
observed in rat islets after 72 h of culture under similar conditions (Kelpe et al. 2003;
Moore et al. 2004; Fontes et al. 2009). Second, the fatty-acid potency is determined
by the very small fraction of the total concentration that is unbound to albumin, which
itself is a function of the molar ratio of fatty acids to albumin. For example, a total
concentration of 0.5 mM palmitate complexed to bovine serum albumin at a molar
ratio of 5:1 corresponds to an unbound concentration in the range of 20 nM (Poitout
et al. 2010). Since the mode of preparation and fatty acid to albumin molar ratio vary
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significantly between studies, the “biologically active” fraction varies as well and
with it the functional effects observed. Third, all fatty acids were not created equal
and, for example, saturated fatty acids are proapoptotic while unsaturated fatty acids
are not and are even protective against the effects of saturated fatty acids (Maedler
et al. 2003). Thus, the greater the ability of beta-cells to desaturate fatty acids the
better they survive a lipotoxic environment (Busch et al. 2005).
Another variable to consider when interpreting in vitro studies is whether the
effects of lipids were examined with (glucolipotoxicity) or without (lipotoxicity)
the concomitant presence of high glucose. In our experience, under conditions in
which cell viability is not affected, the deleterious effects of fatty acids on beta-cell
function are only observed when glucose levels are simultaneously elevated both in
vitro (Jacqueminet et al. 2000; Briaud et al. 2001) and in vivo (Briaud et al. 2002;
Hagman et al. 2008).
Finally, it is important to point out that the various functional effects of fatty
acids have different underlying mechanism. Fatty-acid inhibition of insulin secretion is observed with both unsaturated and saturated long-chain fatty acids (Moore
et al. 2004) and involves perturbations of the late stages of insulin exocytosis (Olofsson et al. 2007) by disrupting the association between calcium channels and secretory
granules (Hoppa et al. 2009; Olofsson et al. 2007). In contrast, fatty-acid inhibition
of insulin gene expression is restricted to saturated fatty acids such as palmitate
(Moore et al. 2004), because it is mediated by de novo synthesis of ceramide (Kelpe
et al. 2003) for which only palmitate can serve as a substrate. Palmitate inhibition
of the insulin gene is a transcriptional effect involving altered binding of pancreasduodenum homeobox-1 (Pdx-1) and mammalian homologue of avian MafA/L-Maf
(MafA) to the insulin gene promoter (Hagman et al. 2005). A newly identified player
in glucolipotoxicity of the beta cell is the serine-threonine kinase Per-Arnt-Sim kinase (PAS kinase). PAS kinase is an environmental sensor which was shown to play
an important role in glucose regulation of insulin promoter activity (da Silva Xavier
et al. 2004). In islets we have observed that palmitate blocks glucose-induced PASK
expression and that overexpression of PASK protects from palmitate inhibition of
the insulin gene (Fontes et al. 2009). Thus, our current working hypothesis is that
palmitate, through de novo ceramide synthesis, blocks PASK expression and thereby
alters the expression and/or activity of Pdx-1 and MafA, resulting in decreased insulin
gene expression (Fig. 5.3). The precise mechanisms whereby PASK regulates Pdx-1
and MafA function are currently under investigation in our laboratory. Recent observations in humans support an important role for PASK in beta-cell function. First,
PASK expression is reduced in islets from T2D patients (da Silva Xavier et al. 2010).
Second, a spontaneous mutation in the gene encoding for PASK identified in youngonset diabetes in humans results in increased kinase activity and enhanced basal
insulin secretion and gene expression (Semplici et al. 2011).
Recent efforts in our laboratory were aimed to examine whether the defect in
insulin gene expression upon glucoliptoxic conditions was also observed in vivo.
We established a rat model of chronic infusions of glucose + Intralipid (a triglyceride emulsion co-infused with heparin to raise circulating fatty-acid levels), and
showed that after 72 h of infusion insulin mRNA was reduced in islets, associated
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Fig. 5.3 Working model regarding the mechanisms of glucolipotoxicity. The impact of the synergistic effects of chronically elevated glucose and fatty acids is mediated at the cellular level by
different mechanisms. Our current hypothesis is that the beta-cell response to glucolipotoxicity in
vivo involves a detrimental arm and an adaptive arm. The detrimental arm is mediated by the intracellular generation of ceramide from palmitate, inhibition of PASK expression, and inhibition of
the binding of Pdx-1 and MafA to their cognate sequences on the insulin gene promoter resulting in
a decrease in insulin gene expression. The adaptive arm is mediated by insulin resistance, probably
at the liver, which through as yet unidentified circulating factors induces beta-cell proliferation via
the FoxM1 signalling pathway. It is also possible that the increase in beta-cell mass, if it produces
functionally immature beta cells, indirectly contributes to defective beta-cell function

with nuclear exclusion of Pdx-1, thus recapitulating our previous ex vivo findings
(Fontes et al. 2010; Hagman et al. 2008). Further, in 6-month-old rats a continuous
infusion of glucose + Intralipid for 72 h induces insulin resistance and beta-cell dysfunction, characterized by defective glucose-induced insulin secretion and proinsulin
biosynthesis (Fontes et al. 2010). Interestingly, this functional defect occurs despite a
marked increase in beta-cell mass, largely due to beta-cell proliferation. Since these
rats also develop insulin resistance in response to the infusion, these results are consistent with the possibility mentioned above that insulin resistance drives beta-cell
proliferation in this model. Accordingly, a recent transcriptomic analysis showed
that the most highly regulated pathways in islets from rats infused with glucose +
Intralipid are related to cell proliferation, including an increase in the expression of
the transcription factor FoxM1 and most of its targets (Zarrouki, Fontés, Poitout,
unpublished results). Since FoxM1is necessary for beta-cell proliferation in a number of experimental conditions (Zhang et al. 2010; Ackermann Misfeldt et al. 2008;
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Zhang et al. 2006) and is sufficient to induce beta-cell replication (Davis et al. 2010),
our results are consistent with the possibility that in older rats subjected to chronic
nutrient excess, insulin resistance promotes beta-cell proliferation via the FoxM1
pathway (Fig. 5.3). Thus, observations in this model indicate that the beta-cell response to metabolic stress includes a deleterious response (defective insulin gene
expression and insulin secretion) as well as an adaptive response (increased beta-cell
proliferation).
Intracellular accumulation of cholesterol has emerged in recent years as a novel
pathogenic mechanism of beta-cell dysfunction. Indeed, dyslipidemia associated
with the MetS is characterized by hypertriglyceridemia, decreased level of the
anti-atherogenic lipoprotein HDL and increased level of the small and dense LDL
pro-atherogenic lipoproteins (Alberti et al. 2009). Importantly, alterations of the lipid
profile occurs long before the occurrence of T2D and is considered as an independent
risk factor for the disease (von Eckardstein et al. 2000). In T2D patients, infusion
of physiological levels of reconstituted HDL acutely restores beta-cell function in
the absence of any improvement in insulin sensitivity (Drew et al. 2009). In addition, in vitro experiments have shown that HDL prevents beta-cell death induced by
cytokines and elevated glucose levels while enhancing insulin secretion (Rutti et al.
2009). In contrast, in vitro treatment with LDL inhibits insulin secretion through
the LDL receptor (Kruit et al. 2010; Rutti et al. 2009). Furthermore, oxidized LDL,
which are increased in T2D patients (Colas et al. 2010), promote beta-cell apoptosis
(Abderrahmani et al. 2007).
Intracellular cholesterol content is determined by cholesterol synthesis, uptake
and efflux, and perturbations of any of these processes could lead to cholesterol
accumulation. The efflux of cholesterol is mediated through the ABCA1 and ABCG1
transporters.
Patients suffering from Tangier disease due to loss-of-function mutations of
ABCA1 are at a high risk for developing diabetes (Villarreal-Molina et al. 2007;
Villarreal-Molina et al. 2008) and have defective insulin secretion (Koseki et al. 2009;
Vergeer et al. 2010). Insights into the molecular mechanisms involved were provided
by studies using a beta-cell specific mouse knock-out of ABCA1. Brunham et al.
(Brunham et al. 2007) showed that deletion of ABCA1 in beta cells leads to impaired
glucose tolerance due to defective insulin secretion in vivo as well as in isolated islets
ex vivo, due to intracellular cholesterol accumulation. In a follow-up study, the same
group showed that cholesterol accumulation in beta cells alters insulin exocytosis,
and that conversely acute reduction of cholesterol content restores insulin secretion
(Kruit et al. 2011). Another study addressed the role of ABCG1 in mice using betacell specific deletion (Sturek et al. 2010). The outcome was similar to that of the beta
cell ABCA1 knock-out mouse, except that total cellular cholesterol level was not
affected, but insulin secretory granule cholesterol composition was altered leading
to morphological changes of the granules and subsequent impairment of exocytosis.
Since mice fed a high-fat diet display an increase in islet cholesterol accumulation
(Peyot et al. 2010), these recent observations, supported by genetic evidence in humans, suggest that abnormalities in intracellular cholesterol homeostasis might play
a role in beta-cell failure in T2D.
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Mitochondrial Dysfunction and Oxidative Stress

As described in Sec 5.2, mitochondrial metabolism of glucose and other nutrient
secretagogues is crucial for the triggering pathway of insulin secretion. In humans,
ultrastructural analysis showed mitochondrial hypertrophy in beta cells from T2D
patients (Anello et al. 2005). This is associated with a decrease in insulin secretion
from T2D islets and a right-shift of the dose-response curve to glucose, without
changes in insulin secretion in response to arginine or sulfonylurea (Deng et al. 2004;
Fernandez-Alvarez et al. 1994). These observations suggest a defect in mitochondrial
glucose metabolism, supported by the observed decrease in glucose oxidation in islets
from diabetic donors (Del Guerra et al. 2005; Fernandez-Alvarez et al. 1994). In this
regard, studies in animal models of T2D have led to conflicting results. On the one
hand, Fex et al. (Fex et al. 2007) have shown that islets isolated from high-fat fed
mice have blunted insulin secretion in response to glucose associated with a decrease
in glucose oxidation. In contrast, mitochondrial metabolism of other fuels such as
palmitate was increased (Fex et al. 2007). On the other hand, in a similar model Peyot
et al. (Peyot et al. 2010) did not detect any alteration in glucose oxidation in islets from
high-fat fed mice despite a dramatic decrease in insulin secretion. Alternatively, it is
conceivable that a defect in glucose oxidation might indirectly result, at least in part,
from decreased glucokinase activity and reduced glucose flux through glycolysis
upstream of the Krebs cycle. For example, a recent study in islets from human T2D
donors showed that the impairment in insulin secretion and mitochondrial respiration
was restored by a glucokinase activator (Doliba et al. 2011).
Oxidative stress has long been considered as a potential mechanism underlying
beta-cell failure in T2D (Poitout and Robertson 2008), and mitochondrial metabolism
of glucose promotes ROS accumulation in beta cells (Newsholme et al. 2007; Turrens 2003). During electron transfer within complexes I and II, O2 is subjected to
a single electron reduction that produces the highly reactive superoxide anion O−
2.
The latter is converted into hydrogen peroxide (H2 O2 ) by the superoxide dismutase enzymes (SOD). Lastly, catalase and/or glutathione peroxidases (GPx) convert
H2 O2 into inert H2 O and O2 . It is now well accepted that ROS acutely generated in
response to glucose represent an important coupling factor for insulin secretion (Pi
et al. 2007; Leloup et al. 2009) but that excessive and sustained production of ROS
under glucotoxic conditions results in oxidative stress (Poitout and Robertson 2008 ),
to which the beta-cell is particularly sensitive due to an intrinsically low complement
of antioxidant enzymes (Lenzen et al. 1996; Robertson 2009; Tonooka et al. 2007).
Analysis of human T2D islets revealed high levels of oxidative stress markers
compared to control islets (Del Guerra et al. 2005). In the same study, a negative
correlation was found between oxidative markers and insulin secretion in islets.
Although the usefulness of antioxidant therapy in T2D remains debated (Golbidi
et al. 2011), Paolisso et al. (Paolisso et al. 1992) demonstrated that infusion of the
antioxidant glutathione improved glucose intolerance in aging patients. A role for
chronic oxidative stress in beta-cell failure is supported by a large number of studies
in rodents and isolated islets. Indeed, long-term culture of human islets in high glucose concentrations promotes cell death (Federici et al. 2001). In rodents, enhancing
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antioxidant defense by pharmacological or transgenic approaches mitigates beta-cell
dysfunction (Robertson 2009). For example, in vivo studies in leptin-receptor deficient Zucker Diabetic Fatty rat and db/db mice have reported beneficial effects of
the antioxidant N-acetylcysteine on blood glucose levels and beta-cell mass (Tanaka
et al. 1999). The underlying mechanisms, reviewed in (Robertson 2009), are proposed to involve modulation of expression of key beta-cell genes such as insulin,
Pdx-1 and MafA.

5.4.3

Inflammation

Obesity is associated with low-grade inflammation. More specifically, expansion of
visceral white adipose tissue triggers a systemic inflammatory process which negatively impact glucose homeostasis and create a vicious cycle contributing to the onset
of diabetes (Muoio and Newgard 2008). At the level of the beta cell, interleukin-1β
(IL-1β) is proposed to play a major role both in type 1 and type 2 diabetes (Donath
et al. 2003). Pioneering studies by the Donath group (Boni-Schnetzler et al. 2008;
Maedler et al. 2002) have shown that 1) mRNA levels of IL-1β are increased in
islets from T2D patients, 2) IL-1β is produced by islets upon long-term exposure to
nutrients, mainly glucose and fatty acids, and 3) in a vicious cycle, IL-1β promotes
its own production in islet through an autocrine/paracrine loop involving its own receptor (IL-1R). Importantly, IL-1β amplifies the inflammatory process by enhancing
islet production of other inflammatory molecules such as MCP-1 and IL-8 (BoniSchnetzler et al. 2008). The latter are potent chemoattractants for macrophages and
other immune cells, and indeed macrophage infiltration is observed in islets from
humans T2D pancreatic sections (Ehses et al. 2007). Compared to other tissues, beta
cells express very high levels of IL-1R, making it more sensitive to the deleterious
effect of IL-1β (Boni-Schnetzler et al. 2008). An important proof of concept that inhibition of IL-1β signalling might be beneficial for beta-cell function was provided
by the demonstration that an IL-1R antagonist (IL1-Ra) not only prevents hyperglycemia in the diabetic Goto-Kakizaki rat (Ehses et al. 2009), but also significantly
improves glycemic control in T2D patients (Larsen et al. 2007), an effect that lasts
several months after withdrawal of the drug (Larsen et al. 2009). Downstream of
IL-1β, a recent series of studies have demonstrated a novel role for a unique posttranslational modification, namely hypusination of the enzyme eIF5a, in cytokine
signalling in beta cells (Maier et al. 2010; Robbins et al. 2010).
Another cytokine proposed to modulate islet function in the metabolic syndrome
is IL-6. Circulating levels of IL-6 are increased in obesity and are predictive of T2D
(Spranger et al. 2003; Hoene and Weigert 2008), but recent studies point towards a
protective role for IL-6 through its effects on the alpha cell (Ellingsgaard et al. 2008;
Ellingsgaard et al. 2011). In response to exercise, skeletal muscle-derived IL-6 enhances glucagon like peptide-1 (GLP-1) production both from intestinal L cells and
pancreatic alpha cells, which in turn acts in a paracrine manner to potentiate insulin
secretion and lower glucose levels, without changes in systemic GLP-1 levels. This
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effect is mediated by an IL-6-induced switch in prohormones convertase expression
in alpha cells which favours the synthesis of GLP-1 over that of glucagon. Accordingly, exogenous IL-6 administration in nutritional and genetic models of obesity
has a similar impact on GLP-1 production from the alpha cells and the intestinal L
cells and improves glucose homeostasis. In contrast, neutralization of IL-6 in these
conditions worsens glycemic control in these mice.

5.4.4 Amyloid
Islet amyloid polypeptide (IAPP) is a 37 amino-acid peptide co-secreted with insulin
whose physiological role remains unclear (reviewed in Haataja et al. 2008; Westermark et al. 2011). The importance of IAPP in islet pathology stems from its ability,
restricted to the human isoform, to form amyloid deposits (Westermark 1977) and
from initial pathological findings that these amyloid deposits are more frequent in
diabetic pancreata (Westermark and Wilander 1978), an observation recently confirmed in islets from T2D patients (Butler et al. 2003). A cause-and-effect relationship
between amyloid formation and beta-cell dysfunction was provided by the generation
of rodent models expressing the human form of IAPP, which results in hyperglycemia
and diabetes (Butler et al. 2004; Janson et al. 1996; Verchere et al. 1996). In rats overexpressing human IAPP, the expansion of beta-cell mass that is normally observed
in wild-type animals does not occur (Matveyenko et al. 2009), suggesting a possible
role for amyloid deposits under conditions of nutrient excess. Consistent with this
possibility, circulating IAPP levels increase in response to high-fat feeding in mice
(Westermark et al. 1998). This could be due to the fact that the IAPP gene promoter
shares several regulatory elements with the insulin promoter (notably Pdx-1 binding sequences) (German et al. 1992), and that glucose induces expression of IAPP
via Pdx-1 (Watada et al. 1996). In addition, fatty acids promote the expression and
secretion of IAPP in insulin-secreting MIN6 cells (Qi et al. 2010) as well as amyloid fibril formation in islets (Ma and Westermark 2002). These observations raise
the interesting possibility that amyloid formation may be induced and contribute to
beta-cell failure in glucolipotoxic conditions, although this remains to be directly
tested.
The precise mechanism by which amyloid deposits are toxic to the beta-cell, and
whether it is due to the formation of insoluble IAPP oligomers or mature amyloid
fibrils, is still a matter of debate (Haataja et al. 2008; Zraika et al. 2010).

5.4.5 Autophagy
Recent evidence clearly shows that the process of autophagy not only has a housekeeping role in maintaining cellular homeostasis, but also is a highly regulated
process that could play an important role in the beta-cell response to environmental
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cues, particularly nutrient excess. Autophagy enables recycling of cellular components, such as defective or damaged organelles, ubiquitinated proteins and even
lipids droplets (Rabinowitz and White 2010). This takes place in autophagosomes,
which fuse with lysosomes to form autophagolysosomes. This phenomenon is critical for normal cellular function, especially in long-lived cells such as neurones
and beta cells, and its impairment is associated with age-related diseases such as
neurodegerative disorders and diabetes (Rabinowitz and White 2010). Autophagyrelated genes (Atgs) are the main regulators of autophagy, of which Atg1 regulates
the initiation steps, whereas in an intermediate phase Atg7 converts the cytosolic
form of the microtubule-associated protein 1 light chain 3 (LC3) into LC3-II, commonly used as a marker for autophagy. The autophagosome then interacts with the
lysosome-associated membrane protein type 2A (LAMP2A), allowing formation of
autophagolysosomes where the autophagosomal content is degraded by proteases and
lipases (Kaushik et al. 2010). The regulation of autophagy intersects with metabolic
processes at the level of the mammalian target of rapamycin (mTOR) pathway. mTOR
activation, that can occur in response to fuel excess, blocks the autophagic process,
and rapamycin treatment alleviates this inhibition and potentiates the autophagic flux
(Kaushik et al. 2010; Rabinowitz and White 2010). The importance of autophagy in
beta-cell function was initially proposed by Marsh et al. (Marsh et al. 2007), who
reported that autophagy regulates insulin content. Further, deletion of the Atg7 gene
specifically in beta cells leads to increased apoptosis, reduced proliferation, and
impaired insulin secretion associated with a dramatic reduction in insulin granule
number, a distended ER, and altered mitochondrial morphology (Ebato et al. 2008;
Jung et al. 2008). Interestingly, autophagosomes are increased in beta cells in nutritional and genetic models of T2D (Ebato et al. 2008). Likewise, insulin-secreting
INS1 cells exposed to fatty acids have an increased number of autophagosomes
associated with impaired insulin secretion and apoptosis (Choi et al. 2009; Ebato
et al. 2008). In this system, when autophagy was pharmacologically induced using rapamycin, the deleterious outcome of fatty acids was partially prevented (Choi
et al. 2009). Las et al. (Las et al. 2011) have recently shown that accumulation
of autophagosomes in beta-cells under lipotoxic conditions is due to their inability
to fuse with lysosomes to form autophagolysosomes. Thus, accumulation of autophagosomes occurs as a result of interrupted autophagic flux, and might impair
beta-cell function by triggering ER stress or increasing ROS levels due to inefficient
recycling of organelles and clearing of accumulating ubiquitinated proteins. Interestingly, analyses of pancreatic sections from T2D patients have shown an increase
in autophagosomes in beta cells (Masini et al. 2009).

5.4.6

Endoplasmic Reticulum Stress

As mentioned several times throughout this chapter, the initial beta-cell response
to the MetS is to secrete more insulin to compensate for insulin resistance. This
increased secretory flux enhances the workload on the ER, where proteins are synthesized and routed towards the secretory pathway. Conceivably, a continuous pressure
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on the ER might eventually overcome its capacity to properly ensure protein folding. Therefore, the unfolded protein response (UPR) and ER stress have emerged
as key players in beta-cell failure and apoptosis (Eizirik et al. 2008). Accumulation
of unfolded proteins activates a protective mechanism that allows deceleration of
the processing flux to permit proper folding of proteins. This relies on the activation of three separate pathways. Within the lumen of the ER, the immunoglobulin
heavy chain binding protein (BIP) is a chaperone that binds to and inhibits three
transmembrane proteins, namely inositol-requiring enzyme 1 (IRE1), PKR-like kinase (PERK) and activating transcription factor 6 (ATF6). As unfolded proteins
accumulate, BIP dissociates from PERK, which in turn becomes active and lead
to attenuation of translation through eIF2a. IRE-1 promotes splicing of the XBP1
mRNA into its active form, which stimulates genes encoding for UPR chaperones.
Finally, ATF6 translocates to the Golgi apparatus where it is cleaved into its active 50
kDa fragment which then translocates to the nucleus to upregulate genes encoding
for protein chaperones and the ER-associated protein degradation machinery (Scheuner and Kaufman 2008). The overall purpose of this sophisticated process is to slow
down protein synthesis and to enable proper folding of the accumulating proteins.
However, if the pressure on the ER continues and the UPR fails to restore normal
ER function, ER stress ensues and eventually leads to apoptosis (Eizirik et al. 2008).
Several studies have provided evidence for a role of the ER stress in nutrientinduced beta-cell dysfunction and death. In insulin-secreting cells, saturated fatty
acids such as palmitate induce ER stress to a greater extent than unsaturated fatty
acids (Karaskov et al. 2006). Palmitate was reported to activate the PERK branch of
the UPR (Cnop et al. 2007; Karaskov et al. 2006), to block ER-to-Golgi protein trafficking (Preston et al. 2009), and to deplete ER calcium stores (Gwiazda et al. 2009).
In vivo, Laybutt et al. (Laybutt et al. 2007) reported an increase in ER stress markers
in islets from db/db mice and T2D patients. Although chemical chaperones improve
glycemic control in several mouse models of diabetes (Ozcan et al. 2006), these
beneficial effects might be due to alleviation of ER stress in peripheral tissues (since
ER stress also plays a major role in insulin resistance). In humans ER stress is clearly
a mechanism involved in rare cases of monogenic diabetes due, for example, to mutations in the human orthologue of PERK in Wolcott-Rallison syndrome (Delepine
et al. 2000).

5.4.7

Beta-cell Exhaustion

Can hypersecretion of insulin, the initial attempt of the beta-cell to adapt to the
enhanced secretory demand in insulin resistance, be itself a factor of beta-cell demise
by leading, in the long-term, to beta-cell exhaustion and failure? This concept has led
to the proposal that “beta-cell rest”, i.e. reduction of endogenous insulin secretion,
might have benefical effects not only in type 1 but also in type 2 diabetes (reviewed
in Brown and Rother 2008) and might explain the so-called “secondary failure” of
sulfonylureas (Pontiroli et al. 1994). Convincing evidence in rodents suggests that
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inhibiting insulin secretion with the K-ATP channel opener diazoxide prevents betacell dysfunction in several diabetic models (Sako and Grill 1990; Leahy et al. 1994;
Kullin et al. 2000). In humans, beneficial effects of diazoxide treatment were reported
in both type 1 (Bjork et al. 1996; Ortqvist et al. 2004) and type 2 diabetes (Qvigstad
et al. 2004; Radtke et al. 2007), although in the latter it required the concomitant
administration of insulin at bedtime (Grill et al. 2009).
Indirectly supportive of this concept is genetic evidence in humans that insulin
hypersecretion might eventually lead to diabetes in the absence of insulin resistance
(reviewed in Aston-Mourney et al. 2008). Subjects with persistent hyperinsulinemic
hypoglycemia of infancy (PHHI), harbouring genetic mutations resulting in increased
insulin secretion, are at high risk for developing diabetes (Huopio et al. 2003). The
underlying mutations are in the genes encoding glucokinase (resulting in a shift to the
left of the glucose dose-responsiveness (Glaser et al. 1998; Christesen et al. 2008) ) or
the sulfonylurea receptor 1 (SUR1) (resulting in impaired channel activity (Huopio
et al. 2003)).
The precise mechanisms by which a reduction in insulin secretion might prove
beneficial for beta-cell function are unknown, and may be related to metabolic
deceleration and alleviation of ER stress associated with hypersecretion (Andrikopoulos 2010). Nonetheless, this concept raises the intriguing possibility that
current therapies aimed at enhancing insulin secretion, while clearly beneficial in
terms of glucose lowering, might also represent a “double-edge sword” and indirectly
contribute to beta-cell failure.

5.4.8

Beta-cell Dedifferentiation

The exquisite ability of the pancreatic beta cell to sense nutrients and accordingly
adjust insulin secretion relies on the expression of a specific set of genes, which all together define the identity of a differentiated beta cell. It has been proposed in rodents
that beta-cell dedifferentiation may contribute to beta-cell failure that occurs after
long period of metabolic stress, as is the case in MetS (Weir and Bonner-Weir 2004).
In that regard, in experimental models of chronic hyperglycemia induced by partial pancreatectomy the expression of beta-cell specific genes is lost as beta-cell
hypertrophy develops (Jonas et al. 1999; Laybutt et al. 2002). Interestingly, these
effects are reversed upon restoration of normoglycemia. Similar changes in gene
expression were reported in islets from partially pancreatectomized Zucker fatty rats
(Delghingaro-Augusto et al. 2009). In our own studies with 6-month old rats infused
with glucose and Intralipid for 72 h, we observed down-regulation of several key
beta-cell genes accompanied by defective insulin biosynthesis and secretion, despite
an increase in beta-cell mass and proliferation (Fontes et al. 2010). Collectively, these
observations support the possibility that beta-cell failure under conditions of chronic
nutrient excess results, at least in part, from a loss of beta-cell identity. Recently,
Talchai et al. (Talchai et al. 2012) provided a mechanistic basis for this phenomenon.
They showed that under metabolic stress, beta-cell specific deletion of the transcription factor FoxO1 leads to beta cells dedifferentiation giving rise to progenitor-like
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endocrine cells, a subset of which subsequently trans-differentiate into alpha cells.
This leads not only to relative hypoinsulinemia but also hyperglucagonemia, which
contributes to the loss of glucose homeostasis.

5.5

Conclusions

The pancreatic beta cell plays a key role not only in the maintenance of glucose
homeostasis but also in the transition from the MetS to overt T2D. In the face of insulin
resistance that characterizes the MetS, individuals whose beta cells are adequately
equipped to compensate for the increased demand will maintain normal glucose
homeostasis by hypersecreting insulin. In individuals whose beta-cells are more
susceptible, because of a genetic predisposition or epigenetic modifications related to
the prenatal or neonatal environment, the compensatory response eventually fails and
diabetes ensues. Despite intensive investigation, the precise mechanisms underlying
beta-cell failure and the continuous deterioration of its function at the cellular and
molecular level remain poorly understood. As reviewed in this chapter a number
of different mechanisms have been proposed, all of which probably contributing a
different role in different individuals at different stages of disease progression. The
complexity of the pathogenesis of T2D, which is a multifactorial syndrome rather
than a single disease, its slow progression spanning several years if not decades,
and methodological limitations in the study of beta-cell function in humans, most
notably the lack of reliable methods to non-invasively measure beta-cell mass, all
probably contribute to our relatively poor understanding of the disease process. It is
clear, however, that once the defect in beta-cell function is established, none of the
available therapeutic options are capable of significantly slowing down the relentless
degradation of glucose homeostasis (except for bariatric surgery, which is obviously
only indicated in a small proportion of subjects). Therefore, efforts must be aimed
at preventing the occurrence of the metabolic syndrome and preserving beta-cell
function before the point of no return is reached.
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Chapter 6

The Skeletal Muscle in Metabolic Syndrome
Antonio Zorzano, David Sebastián and Montserrat Romero

Abstract Skeletal muscle metabolism shows a considerable number of alterations
in the Metabolic Syndrome (MetS), these most probably linked to the development
of insulin resistance. The muscle of obese subjects and type 2 diabetic patients shows
lower capacity to take up glucose, to convert it into glycogen, and to oxidize it by
mitochondria. In addition, muscle in these individuals shows a higher capacity to
take up fatty acids, mainly as a result of increased lipid availability. Muscle shows
impaired insulin signaling, and most data point to altered IRS protein activity as
a result of enhanced phosphorylation in serine residues by protein serine kinases.
Inﬂammation, excessive lipid availability, and oxidative stress have been proposed
as potential causes to explain muscle insulin resistance in the MetS. A major question
pending in the ﬁeld is the identiﬁcation of the primary causes of this disorder and
the identiﬁcation of the major pathways responsible for the development of insulin
resistance and for the metabolic alterations present in skeletal muscle in humans.
Keywords Glucose metabolism · Glycogen · Insulin resistance · Lipid metabolism ·
Metabolic ﬂexibility · Muscle

6.1

Skeletal Muscle Shows Insulin Resistance
in the Metabolic Syndrome

Skeletal muscle plays a crucial role in the regulation of whole-body glucose homeostasis. Approximately 70–80 % of ingested glucose is taken up by skeletal muscle
and is either stored as glycogen or oxidized for energy, or to a lesser extent stored as
fat (DeFronzo et al. 1981; DeFronzo et al. 1985; Nuutila et al. 1992). Studies using
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Fig. 6.1 Insulin signaling pathways in human muscle cells

euglycemic-insulin clamps suggest that non-oxidative glucose metabolism is the
major pathway for glucose disposal in healthy subjects (DeFronzo et al. 1981). Moreover, during a hyperglycemic-hyperinsulinemic clamp, skeletal muscle accounts for
most glucose uptake in healthy humans and over 80 % of this polysaccharide is stored
as muscle glycogen (Shulman et al. 1990). After a standard meal, however, muscle
glycogen synthesis accounts for approximately 30 % of the glucose ingested (Woerle
et al. 2003).
A fundamental defect in the pathogenesis of type 2 diabetes mellitus is insulin
resistance. In the postprandial state, insulin-mediated glucose uptake and utilization
is greatly impaired in type 2 diabetic patients (Eriksson et al. 1992; DeFronzo et al.
1985; Shulman et al. 1990), and in glucose-tolerant first-degree relatives (Eriksson
et al. 1992; Henriksen et al. 1994). From in vivo tracer studies, the defect in wholebody glucose uptake in these patients has been localized to the non-oxidative pathway
for glucose metabolism (DeFronzo et al. 1981; Bonadonna et al. 1996; Shulman et al.
1990; Groop et al. 1989).
In addition, insulin resistance affects skeletal muscle in obesity and in type 2
diabetes, as assessed by in vitro preparations of human skeletal muscle. Thus, insulinstimulated skeletal muscle glucose transport is impaired in type 2 diabetes and in
obesity (Dohm et al. 1988; Goodyear et al. 1995). This impairment is a consequence
of a reduced recruitment of GLUT4 glucose transporters to the cell surface of muscle
fibers in type 2 diabetic patients (Ryder et al. 2000).

6.2 Alterations in Muscle Insulin Signaling in the Metabolic
Syndrome
The critical components of insulin signaling in human muscle cells are shown in
Fig. 6.1. Insulin signaling via the cell-surface receptor is linked to the phosphorylation
of IRSs, namely, IRS1 and IRS2 (White 2002). Insulin signaling can be transduced

6 The Skeletal Muscle in Metabolic Syndrome

113

Fig. 6.2 Major metabolic alterations detected in insulin-resistant muscles

along metabolic pathways involving phosphatidylinositol 3-kinase (PI3K) and Akt
or gene regulatory/mitogenic pathways including mitogen-activated protein kinases
(MAPKs), where each of these steps constitutes a critical node in the regulation
of metabolic and gene events controlling insulin sensitivity (Taniguchi et al. 2006).
Further complexity comes from the expression of multiple isoforms of substrates and
protein kinases at each of these nodes. Thus, in human myotubes, IRS1 signals to
Akt, whereas IRS2 signals to MAPK (Fig. 6.1). These observations thus indicate the
existence of isoform specificity in the transmission between nodes (Bouzakri et al.
2006).
Insulin signaling is negatively regulated through the activation of cell-surface
receptor signaling pathways that are responsive to cytokines such as TNF-α or IL6 (produced by macrophages that infiltrate adipose tissue in obesity) or through
excessive availability of glucose or lipid (Taube et al. 2009; Chibalin et al. 2008;
Schenk et al. 2008). Negative regulation of the insulin cascade occurs through serine
phosphorylation events at the level of IRS isoforms and perhaps of the insulin receptor
(Boura-Halfon and Zick 2009; Pirola et al. 2004; Draznin 2006).
There are many lines of evidence indicating that insulin signaling is deficient in
muscle of obese and type 2 diabetes subjects (Fig. 6.2). Results from studies of insulin receptor phosphorylation in the skeletal muscle of type 2 diabetic subjects are
contradictory. Insulin receptor phosphorylation appears to be normal or reduced in
non-obese type 2 diabetics (Nolan et al. 1994; Krook et al. 2000; Maegawa et al.
1991; Klein et al. 1995; Arner et al. 1987). Similarly, insulin receptor phosphorylation has been reported to be normal or decreased in obese non-diabetic subjects
(Goodyear et al. 1995; Nolan et al. 1994; Arner et al. 1987). Type 2 diabetic subjects have impaired insulin-stimulated tyrosine phosphorylation of IRS-1 in skeletal
muscle (Fig. 6.2). This impairment is not a consequence of decreased IRS-1 protein
expression (Krook et al. 2000; Bjornholm et al. 1997). A similar defect is observed at
the level of PI3K in type 2 diabetic muscle (Bjornholm et al. 1997; Krook et al. 2000;
Kim et al. 1999). Reduced insulin-stimulated tyrosine phosphorylation of IRS-1 and
of PI3K has been also reported in skeletal muscle of obese subjects (Kim et al. 1999;
Goodyear et al. 1995).
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Insulin-stimulated Akt phosphorylation is impaired in skeletal muscle of type 2
diabetic patients under in vitro conditions (Krook et al. 1998). In addition, insulinstimulated phosphorylation of the Akt substrate AS160 (also named TBC1D4) is
defective in skeletal muscle of type 2 diabetic subjects (Karlsson et al. 2005). AS160
is a Rab GTPase-activating protein that has emerged as a candidate Akt effector for
controlling GLUT4 trafficking in fat and muscle cells (Sano et al. 2003; Zeigerer
et al. 2004; Bruss et al. 2005; Eguez et al. 2005; Thong et al. 2007). In this respect,
recent data indicate that mice with a AS160/TBC1D4-Thr649Ala knock-in mutation
are glucose-intolerant and show altered GLUT4 trafficking (Chen et al. 2011).
It has been proposed that the reduced insulin signaling via the IRS-1/PI3K pathway
is attributable to the phosphorylation of IRS proteins in specific serine residues. This
notion is supported by two observations: a) serine phosphorylation of IRS proteins
reduces the capacity of IRS proteins to attract PI3K (Qiao et al. 1999; Qiao et al. 2002;
Aguirre et al. 2002; Birnbaum 2001; White 2003); and b) serine phosphorylation of
IRS-1 can also lead to an accelerated degradation of IRS-1 protein (Shah et al.
2004). Serine phosphorylation of IRS proteins can occur in response to a number
of intracellular serine kinases, such as p70 S6 kinase (S6K1 kinase), c-Jun NH2terminal kinase (JNK), protein kinase C, and IKK (Um et al. 2004; Pende et al.
2000; Hirosumi et al. 2002; Gao et al. 2004; Nguyen et al. 2005; Yuan et al. 2001;
Gao et al. 2002; Li et al. 2004; Bell et al. 2000; Kim et al. 2004). In this regard,
increased activities of PKC and JNK, have been found in skeletal muscle of obese
and type 2 diabetic subjects (Itani et al. 2001; Bandyopadhyay et al. 2005), thus
supporting a potential role of these serine kinases in the pathogenesis of insulin
resistance (Fig. 6.2).

6.3

Glucose Metabolism in Muscle During
Metabolic Syndrome

Insulin stimulates glucose uptake in skeletal muscle by inducing the translocation
of GLUT4 to the plasma membrane and therefore glucose transport into the cell.
Glucose is then phosphorylated by hexokinase and glucose-6-phosphate (G6P) and
either used in the glycolytic pathway or incorporated into glycogen by glycogen
synthase (GS).
Baseline muscle glycogen concentrations are 30 % lower in type 2 diabetic patients compared to matched controls (Carey et al. 2003; Shulman et al. 1990), and the
rate of glycogen synthesis is 50 % lower in diabetic subjects during hyperglycemichyperinsulinemic clamps (Shulman et al. 1990). Postprandrial increments in muscle
glycogen are also lower than in healthy subjects (Carey et al. 2003). Alterations
in insulin-mediated glucose disposal are also present in obese non-diabetic subjects (Kahn et al. 2006; Bogardus et al. 1984a) and individuals with hypertension
(Ferrannini et al. 1987), other features present in the Metabolic Syndrome.
The mechanisms underlying these alterations could affect several steps in the
glucose metabolism pathway. Thus, defects in GS (Bogardus et al. 1984b; Damsbo
et al. 1991; Wright et al. 1988) hexokinase (Kelley et al. 1996; Braithwaite et al. 1995;

6 The Skeletal Muscle in Metabolic Syndrome

115

Kruszynska et al. 1998; Bonadonna et al. 1996); and glucose transport (Rothman
et al. 1992; Bonadonna et al. 1996; Zierath et al. 1996; Dohm et al. 1988) have all
been implicated in the lower muscle glycogen synthesis in type 2 diabetes.

6.3.1

Glucose Transport

Activation of the insulin signaling pathway leads to the translocation of GLUT4 from
intracellular vesicles to the plasma membrane and the subsequent increase in glucose
uptake by skeletal muscle. Glucose transport is severely impaired in insulin-resistant
individuals with type 2 diabetes or obesity (Bonadonna et al. 1996; Zierath et al. 1996;
Rothman et al. 1992; Dohm et al. 1988) with normal or increased levels of GLUT4
mRNA or protein expression (Pedersen et al. 1990; Eriksson et al. 1992). These
observations suggest that impaired GLUT4 translocation or the intrinsic activity of
the glucose transporter is responsible for the defect in muscle glucose transport.
Moreover, the reduced phosphorylation of AS160 in muscle of type 2 diabetic patients points to impaired GLUT4 recruitment to the cell surface (Karlsson et al. 2005).

6.3.2

Glucose Phosphorylation

Once glucose is inside the muscle cell, it is phosphorylated to G6P by the action of
hexokinase II (HK-II). Glucose transport and phosphorylation are tightly coupled
processes. In human skeletal muscle, insulin increases cytosolic activity, protein
content and HK-II mRNA and this is associated with the translocation of the enzyme
from the cytosol to the mitochondria. There are discrepant data as to whether glucose phosphorylation is impaired in type 2 diabetic subjects, probably because of
the different methodologies used in the studies. Thus, some authors report that in
type 2 diabetic patients glucose phosphorylation is impaired to a greater extent than
glucose transport, suggesting that impaired HK-II activity is the rate-limiting step
for insulin action (Bonadonna et al. 1993; Bonadonna et al. 1996). In keeping with
this view, HK-II activity is reduced in muscle of type 2 diabetic patients (Kruszynska
et al. 1998). However, other studies demonstrated that the defect in glucose transport exceeds the impairment in phosphorylation (Cline et al. 1999), suggesting that
glucose transport is the rate-controlling step for insulin-stimulated glucose disposal
in type 2 diabetic subjects.

6.3.3

Glycogen Synthesis

G6P can be used for glycogen synthesis or for oxidation. Glycogen synthesis
is regulated by GS, a key insulin-regulated enzyme (Dent et al. 1990; YkiJarvinen et al. 1987). GS can be found in an active (dephosphorylated) or inactive
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(phosphorylated) form (Dent et al. 1990). Insulin triggers GS by stimulating a cascade
of phosphorylation-dephosphorylation reactions that lead to the dephosphorylation
of GS by the inhibition of GS kinase and activation of GS phosphatase or PP1. GS
mRNA and protein levels are decreased in muscle of type 2 diabetic patients (Vestergaard et al. 1993; Vestergaard et al. 1991). Moreover, under basal conditions, total
GS activity in type 2 diabetics is reduced, and the capacity of insulin to activate GS
is severely impaired (Damsbo et al. 1991). However, the major abnormality in GS
regulation in type 2 diabetes is its lack of activation by insulin, as a consequence of
the impairment of the insulin signaling pathway.
In mice, it has been recently reported that a major mechanism by which insulin
enhances GS activity in skeletal muscle is by activation induced by G6P (Bouskila
et al. 2010). In this respect, the concentrations of G6P during a hyperglycaemichyperinsulinemic clamp were lower in muscles of type 2 diabetic patients or firstdegree relatives compared to controls (Rothman et al. 1995). This is potentially the
major mechanism that explains defective glycogen synthesis.

6.3.4

Glucose Oxidation

Approximately 90 % of glucose entering the glycolytic pathway is metabolized by
aerobic glycolysis and 10 % is converted to lactate by the anaerobic glycolysis in
human muscle (Thiebaud et al. 1982). The key enzymes that regulate glycolysis
and glucose oxidation are phosphofructokinase (PFK) and pyruvate dehydrogenase
(PDH), respectively. PFK is not regulated by insulin but PDH is a key insulinregulated enzyme whose activity in muscle is acutely induced by insulin (Mandarino
et al. 1986). In type 2 diabetic subjects, the glycolytic/glucose oxidative pathway
has been shown to be impaired (Del Prato et al. 1993), with no alterations in PFK
activity (Vestergaard et al. 1993) but with defects in insulin-stimulated PDH activity
(Mandarino et al. 1986; Kelley et al. 1992).

6.4

Lipid Metabolism in Muscle During Metabolic Syndrome

Skeletal muscle plays a crucial role in lipid metabolism. In resting conditions, for
instance, skeletal muscle fatty acid oxidation accounts for around 90 % of the energy
requirements for this tissue (Dagenais et al. 1976; Kelley et al. 1993). Furthermore,
lipid metabolism is essential in the physiology of skeletal muscle, such as in the
metabolic switching that occurs during the transition from feeding to fasting conditions, and in adaptation to the energetic requirements of exercise (Achten et al. 2002).
However, the Metabolic Syndrome is characterized by altered lipid metabolism in
skeletal muscle and this change contributes to some of the pathological features
present in the disease, such as insulin resistance. In this section, a brief overview
of skeletal muscle lipid metabolism will be provided, followed by a description
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of the alterations present in the Metabolic Syndrome and discussion on how these
alterations may contribute to insulin resistance.
Fatty acid metabolism in skeletal muscle is complex and depends on many factors
at whole-body and at organ level. Although fatty acid availability (mainly determined
by lipolysis in adipose tissue) is an important factor in the use of fatty acids by
skeletal muscle, the regulation of lipid metabolism at muscular level is also relevant.
The processes regulated at muscular level are as follows: fatty acid transport into the
cell; fatty acid activation; fatty acid oxidation; fatty acid esterification or storage;
and lipolysis of intramuscular lipids. However, we will focus on the processes that
have been described to be altered in the Metabolic Syndrome.

6.4.1

Fatty Acid Transport

Plasma free fatty acids circulate bound to albumin (Campbell et al. 1964) and enter
the muscle cell through either diffusion or protein-mediated transport (Abumrad et al.
1998; Hamilton 1998). The proteins responsible for the transport of fatty acids into
the myocyte are the membrane-bound fatty acid transporters FAT/CD36 (fatty acid
translocase/CD36, glycoprotein IV), FABPpm (membrane-bound fatty acid binding
protein) and a family of fatty acid transport proteins (FATP 1 and 4) (Abumrad et al.
1998; Schaffer and Lodish 1994; Bonen et al. 1999; Schwieterman et al. 1988).
FAT/CD36, FABPpm, FATP1, and FATP4 are co-expressed in skeletal muscle and
all contribute to membrane transport, with recent evidence suggesting that FAT/CD36
and FATP4 are quantitatively the most important (Nickerson et al. 2009).

6.4.2

Fatty Acid Oxidation

Fatty acid oxidation takes place in the mitochondrial matrix by the coordinated action
of three metabolic pathways: β-oxidation, the Krebs cycle, and electron transport
chain (ETC). Long-chain fatty acyl-CoAs are transported into mitochondria by the
action of the carnitine palmitoyltransferase (CPT) system, which is composed by
CPT1, carnitine:acylcarnitine translocase (CACT) and CPT2 (McGarry and Brown
1997; Kerner and Hoppel 2000). The step catalyzed by CPT1 is tightly regulated
allosterically by malonyl-CoA and is considered the rate-limiting step in fatty acid
oxidation. Once inside the mitochondria, the fatty acid is degraded into two carbon
fragments (acetyl-CoA) during β-oxidation. β-Hydroxy acyl-CoA dehydrogenase
(β-HAD) is a key enzyme in β-oxidation and correlates with the rate of fatty acid
oxidation (Kiens 1997). Acetyl-CoA generated during this process enters the Krebs
cycle and through the electron transport chain ultimately leads to ATP generation.
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Fatty Acid Storage

Fatty acids that are not oxidized are directed to lipid synthesis, mainly triacylglycerides (TAG) (Dyck et al. 1997), although other lipid species can be synthesized
such as glycerolipids, phospholipids, sphingolipids and cholesterol esters. The flux
of stored fatty acids depends on the concentration of the incoming fatty acid, the type
of fatty acid (saturated or unsaturated), the muscle fiber type, the hormonal milieu
and the energy requirements of the muscle (Watt and Hoy 2012).

6.4.4 Alterations in Skeletal Muscle Lipid Metabolism
in the Metabolic Syndrome
Several alterations in lipid metabolism during obesity and type 2 diabetes have been
reported in skeletal muscle. These alterations may contribute to insulin resistance
but the precise mechanisms involved are unknown.
Intramuscular accumulation of lipid and its metabolites has been demonstrated in
human (Boden et al. 1991; Itani et al. 2002) and in animal models of obesity (Bruce
et al. 2009;Yu et al. 2002). Although TAGs are increased in muscle in obesity and type
2 diabetes, it is believed that other more reactive lipid species are responsible for lipidinduced insulin resistance, such as diacylglycerol (DAG) and ceramides. Several
studies have revealed an association between high intramuscular lipids (IMCLs) and
elevated levels of DAG and/or ceramide in obese insulin-resistant subjects (Adams
et al. 2004; Moro et al. 2009; Thrush et al. 2009). Furthermore, DAG and ceramides
are increased in skeletal muscle in obese subjects and contribute to insulin resistance
(Adams et al. 2004; Itani et al. 2002).
The accumulation of lipid metabolites in muscle could be explained by an increase
in fatty acid uptake and/or a decrease in their oxidation. Fatty acid uptake in skeletal
muscle is increased in obesity and type 2 diabetes, and fatty acid transporters may
play a critical role in this increase (Luiken et al. 2001; Bonen et al. 2004). Thus,
muscle FABPpm protein expression is elevated in individuals with type 2 diabetes
and obesity (Bruce et al. 2003; Simoneau et al. 1999), and there is a positive correlation between the sarcolemmal content of FAT/CD36 and TG levels in skeletal
muscle of obese and type 2 diabetic patients (Bonen et al. 2004; Sampson et al.
2003) and obese rats (Han et al. 2007; Hegarty et al. 2002). Further support for the
functional implication of FAT/CD36 in IMCL accumulation derives from a recent
study demonstrating a dramatic reduction in IMCL content after specific inhibition
of FAT/CD36 in myotubes obtained from obese patients (Aguer et al. 2010).
The deregulation of fatty acid oxidation during the Metabolic Syndrome is not
as clear as the increase in fatty acid uptake. Some studies have described reduced
oxidation of fatty acids in obesity (Kelley et al. 1999; Kim et al. 2000) and type 2
diabetes (Kelley and Simoneau 1994) while other studies have reported unchanged
oxidation rates in obese humans (Holloway et al. 2007) and type 2 diabetic patients
(Boushel et al. 2007). This discrepancy may arise from the different methodology
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used to assess fatty acid oxidative capacity since some studies analyzed whole muscle
fatty acid oxidation (Kelley et al. 1999; Kim et al. 2000) while others examined mitochondrial function in isolated mitochondria or normalized to mitochondrial content
(Boushel et al. 2007; de Feyter et al. 2008).
Fatty acid oxidation in muscle is increased in obese and in diabetic rodents (de
Feyter et al. 2008; Holloway et al. 2009), thus indicating that these animal models
are not similar to humans. In this regard, whole-body fatty acid oxidation assessed
measuring the respiratory quotient demonstrated that obese humans show increased
values compared to lean subjects, suggesting reduced fatty acid oxidation (Kelley
et al. 1999), while obese mice have a decreased value, which would indicate increased
fatty acid oxidation (Turner et al. 2007; Koves et al. 2008). It has been proposed that
the increase in this process does not match a subsequent rise in the TCA flux, and
then products of incompletely oxidized fatty acids, such as acylcarnitine derivatives,
accumulate (Koves et al. 2008). The accumulation of these by-products is linked
to impaired insulin action, although the mechanism has not been elucidated (Koves
et al. 2008).
New technologies based on magnetic resonance spectroscopy assessment of in
vivo mitochondrial function in humans have revealed compromised mitochondrial
metabolism in insulin-resistant offspring of type 2 diabetic patients and in obesity
and type 2 diabetes (Petersen et al. 2004; Befroy et al. 2007; Schrauwen-Hinderling
et al. 2007). These findings suggest that fatty acid oxidation is impaired in these
conditions. Moreover, the activity of some enzymes involved in fatty acid oxidation,
such as CPT1, β-hydroxyacyl CoA dehydrogenase, citrate synthase and cytochrome
oxidase, is decreased in obesity (Simoneau et al. 1999; Kim et al. 2000), and the
expression of genes involved in oxidative capacity has also been shown to be reduced
in skeletal muscle of obese and diabetic patients and of obese mice (Petersen et al.
2004; Sparks et al. 2005; Mootha et al. 2003; Patti et al. 2003).

6.5

Metabolic Inflexibility in the Metabolic Syndrome

Metabolic flexibility is defined in general as the ability of an organ, tissue or cell to
adjust fuel oxidation to fuel availability. In the context of skeletal muscle, metabolic
flexibility refers to the capacity of the tissue to switch from predominantly lipid oxidation and high rates of fatty acid uptake during fasting conditions to the suppression
of lipid oxidation and increased glucose uptake, oxidation and storage under insulinstimulated conditions (Kelley and Mandarino 2000). In healthy individuals, skeletal
muscle displays substantial metabolic flexibility, which is lost in obese and type 2
diabetic subjects. Under basal fasting conditions, glucose uptake and oxidation are
normal or even increased in obese subjects compared to lean subjects. Fatty acid uptake is also normal, but fatty acid oxidation is lower and its storage is elevated. In fed
state (operationally achieved by the hyperinsulinemic-euglycemic clamp), glucose
metabolism is not increased in obese subjects as it is in lean individuals, and although
fatty acid uptake is comparable between lean and obese subjects, fatty acid oxidation
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Fig. 6.3 Model for substrate oxidation during metabolic flexibility and metabolic inflexibility in
skeletal muscle. A respiratory quotient (RQ) close to 0.7 indicates high lipid oxidation whereas a
RQ close to 1 indicates high carbohydrate oxidation. After a meal, skeletal muscle switches from
lipid oxidation (which is the predominant fuel used during fasting) to glucose oxidation, and this
is reflected in the increase in RQ. During metabolic inflexibility, fasting lipid oxidation is lower
(higher value of RQ) and after a meal the switch from lipid to glucose oxidation is impaired (lower
value of RQ)

in much higher in the latter (Kelley et al. 1999) (Fig. 6.3). Therefore, obese and type
2 diabetic subjects show metabolic inflexibility in skeletal muscle and this alteration
can contribute to the accumulation of lipids and reduced insulin-stimulated glucose
disposal seen in skeletal muscle in obesity and type 2 diabetes.
Metabolic flexibility is influenced by both uptake and oxidation of glucose and
plasma-derived fatty acids. In general, in insulin-resistant conditions there is an
alteration of fatty acid utilization, and the impairments are present most clearly
under stimulated conditions. Thus, lower leg muscle rates of fatty acid oxidation
during fasting are related to decreased glucose storage during insulin stimulation in
obese women (Colberg et al. 1995); the suppression of fat oxidation during insulin
stimulation is defective in obese men and women (Kelley et al. 1999); fuel switching
after a meal is impaired in type 2 diabetes and glucose intolerant subjects (Corpeleijn
et al. 2008; Kelley and Simoneau 1994); and the increase in fat oxidation is blunted
during exercise in type 2 diabetic patients (Blaak et al. 2000).
It has been proposed that in order to understand how lipids accumulate in muscle
and cause insulin resistance, it is relevant to assess metabolic flexibility to high-fat diets (Galgani et al. 2008). Most studies addressing metabolic flexibility in the context
of the Metabolic Syndrome and insulin resistant conditions show that the capacity
to switch from fat to carbohydrate oxidation is generally impaired during a hyperinsulinemic clamp. However, this metabolic inflexibility is mostly the consequence
of defective cellular glucose uptake. Indeed, after controlling for insulin-stimulated
glucose disposal rate, metabolic flexibility is not altered in obesity regardless of the
presence of type 2 diabetes.
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Several factors are determinant in metabolic flexibility, such as fatty acid availability and the capacity for fatty acid uptake and oxidation in muscle. Furthermore,
there is increasing evidence that defects in substrate switching cluster with disturbances in mitochondrial content and/or function (Ritov et al. 2005; Petersen et al.
2004; Simoneau and Kelley 1997), although the causal link between metabolic flexibility, insulin resistance and mitochondrial dysfunction remains to be established
(Morino et al. 2006).

6.6

Mitochondrial Metabolism in Muscle

In skeletal muscle, the disruption of mitochondrial biology is evident in insulinresistant subjects years before they develop diabetes (Petersen et al. 2004; Befroy
et al. 2007; Patti et al. 2003). These individuals show a reduction in mitochondrial
activity in skeletal muscle characterized by a decrease in mitochondrial oxidative
and phosphorylation activity, and also increased fat accumulation in muscle and
liver (Petersen et al. 2003; Petersen et al. 2004). Skeletal muscle of type 2 diabetic
patients also shows a reduction in the activity of the Krebs cycle and of the respiratory
chain (Kelley et al. 2002). In keeping with these observations, plasma levels of lactate
are enhanced and the systemic appearance of lactate is also increased in these patients
(Consoli et al. 1990; Cusi et al. 1996).
Several mechanisms are implicated in alterations of mitochondrial activity in
insulin-resistant conditions, namely changes in mitochondrial density and morphology or alterations in mitochondrial function. Decreased mitochondrial mass has
been demonstrated in muscle of insulin-resistant offspring of type 2 diabetic patients
(Morino et al. 2005). In this regard, skeletal muscle of obese and type 2 diabetic
subjects shows a lower mitochondrial DNA content (Ritov et al. 2005), and the latter
present reduced citrate synthase activity (Kelley et al. 2002). In addition, several
lines of evidence indicate that mitochondrial size and network are reduced in obesity
and type 2 diabetes (Bach et al. 2003; Kelley et al. 2002; Toledo et al. 2006).
These alterations in mitochondrial morphology may indicate that mitochondrial
dynamics is altered in insulin-resistant states. In this regard, repression of the mitochondrial fusion protein Mnf2, at mRNA and protein level, has been reported in the
skeletal muscle of obese and type 2 diabetes subjects (Bach et al. 2003; Bach et al.
2005). This observation may be relevant as Mnf2-loss-of-function reduces glucose
oxidation, mitochondrial membrane potential, oxygen consumption and mitochondrial proton leak in cultured cells (Bach et al. 2003; Pich et al. 2005; Chen et al.
2005). In connection with these observations, Mingrone and collaborators showed
that, after bariatric surgery and massive weight loss, obese patients show induced expression of genes encoding for mitochondrial proteins, like Mnf2, associated with an
amelioration of insulin sensitivity (Mingrone et al. 2005), thereby suggesting a positive correlation between Mnf2 levels and insulin sensitivity. However, under similar
conditions, type 2 diabetic patients did not show any increase in the expression of
these genes in response to bariatric surgery (Hernandez-Alvarez et al. 2009).
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In addition to Mnf2, other proteins that participate in mitochondrial fusion and
fission might play a regulatory role in mitochondrial metabolism in the context of
obesity and type 2 diabetes. Thus, the expression of one of the mitochondrial proteases that is invoked in Optic atrophy 1 protein (OPA1) processing, PARL, is also
reduced in an animal model of diabetes (Walder et al. 2005). In humans, a positive
linear correlation has been reported between PARL mRNA levels and insulin sensitivity, as assessed by the hyperinsulinemic-euglycemic clamp. In addition, one study
found the polymorphic variant Leu262Val to be associated with increased plasma
insulin concentrations in one study (Walder et al. 2005), while this observation was
not replicated in another (Fawcett et al. 2006). The precise mechanisms of mitochondrial dynamics regulation by PARL are far from clear, and no data on OPA1 protein
abundance are available for obesity or type 2 diabetes. However, these data suggest
the occurrence of multiple alterations in mitochondrial fusion in insulin-resistant
states.
Regarding mitochondrial fission, Jheng and collaborators showed that skeletal
muscle of both genetic and diet-induced obese mice present smaller and shorter
mitochondria and increased expression of the mitochondrial fission components
dynamin-related protein (Drp1) and Fis1. In addition, palmitate induced mitochondrial fragmentation and increased Drp1 and Fis1 proteins in differentiated C2C12
muscle cells. Interestingly, acute inhibition of mitochondrial fission with Mdivi-1
compound improved muscle insulin signaling and reduced plasma insulin levels in
ob/ob mice (Jheng et al. 2012).
There is some discrepancy as to whether the muscle of type 2 diabetes patients
shows alterations in mitochondrial function that depend or not on changes in mitochondrial mass. Thus, some studies report that this muscle shows alterations in
mitochondrial function that persist after correction by mitochondrial mass (Mogensen et al. 2007; Ritov et al. 2005). However, in others, differences in electron
transport chain or in oxygen consumption were not detected (Kelley et al. 2002;
Boushel et al. 2007). One of the mechanisms proposed to explain the alterations in
mitochondrial function in type 2 diabetes is a reduction in the expression of genes
encoding for oxidative phosphorylation (Mootha et al. 2003; Patti et al. 2003). In
this context, several genetic studies have suggested that a common polymorphism
of the peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) gene
(Gly482Ser) is associated with the risk of type 2 diabetes (Barroso et al. 2006; Ek
et al. 2001; Hara et al. 2002). In turn, the muscle of patients with type 2 diabetes and
offspring of insulin-resistant subjects with this disease shows a decrease in the expression of the nuclear co-activators PGC-1α and PGC-1β (Patti et al. 2003; Mootha
et al. 2003). The reduced activity of these co-activators may explain, at least in part,
the defective expression of genes encoding respiratory chain subunits and the lower
mitochondrial biogenesis that occurs in muscle in type 2 diabetes (Mootha et al.
2004). In this regard, since the decrease of PGC-1α and PGC-1β expression in skeletal muscle (Mootha et al. 2003; Patti et al. 2003) is paralleled by Mnf2 repression
(Bach et al. 2003; Bach et al. 2005), PGC proteins were proposed to be implicated
in Mfn2 transcription. In support of this notion, PGC-1α overexpression enhances
Mnf2, at mRNA and protein levels, and also stimulates the transcriptional activity of
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the human Mnf2 gene promoter through transactivation of estrogen related-receptor
α (ERRα) in muscle cells (Soriano et al. 2006). PGC-1β also induces Mnf2 expression in C2C12 myoblasts and myotubes and enhances ERRα-dependent Mnf2
transcription (Liesa et al. 2008). On the basis of these results, it is feasible that alterations in the PGC-1α/Mnf2 and PGC-1β/Mnf2 axes confer susceptibility to the
development of metabolic alterations in cells.
In humans, there is some evidence of a parallelism between mitochondrial function and insulin sensitivity. In this regard, several intervention studies indicate that,
after physical exercise and weight loss, obese/overweight and type 2 diabetic subjects
show an increase in mitochondrial size. These subjects had an activation of electron
chain transport, citrate synthase and succinate dehydrogenase in muscle, in parallel
to ameliorated insulin sensitivity (Toledo et al. 2006; Menshikova et al. 2005; Menshikova et al. 2007; Toledo et al. 2007). However, other clinical studies indicate that
the amelioration of insulin resistance can occur in the absence of changes in mitochondrial function. Thus, obese/overweight subjects after dietary restriction for 16
weeks show improved insulin sensitivity without changes in mitochondrial function
(Toledo et al. 2008). In addition, the same results were observed in type 2 diabetic
patients after treatment for 8 weeks with rosiglitazone (Schrauwen-Hinderling et al.
2008).
The observation of a correlation between insulin resistance and mitochondrial
dysfunction in some human studies has led to the notion that mitochondrial dysfunction is a potential cause of insulin resistance. However, animal studies have shown
that not all alterations in muscle mitochondrial activity produce insulin resistance.
In this regard, ablation of the PGC-1α or PGC-1β gene in all tissues or in a tissuespecific manner in mice causes mitochondrial alterations in the absence of muscle
insulin resistance (Handschin et al. 2007; Lelliott et al. 2006; Leone et al. 2005; Lin
et al. 2004; Sonoda et al. 2007; Vianna et al. 2006). Moreover, apoptosis inducing
factor (AIF) or transcription factor A mitochondrial (Tfam) knock-out mice show
reduced respiratory chain activity in muscle tissues, without alterations in sensitivity
to insulin (Pospisilik et al. 2007; Wredenberg et al. 2006). In contrast, some animal
models display parallel modifications in mitochondrial activity and in insulin sensitivity. Thus, muscle-specific peroxisome proliferator activated receptor (PPAR) β
knock-out mouse shows a decrease in the abundance of oxidative muscle fibers and
reduced expression of genes involved in the mitochondrial respiratory chain before
developing obesity and insulin resistance (Schuler et al. 2006). In addition, Wang and
collaborators reported that transgenic mice overexpressing active PPARδ in skeletal
muscle show a higher number of oxidative muscle fibers and are resistant to obesity
and diabetes in response to a high fat diet (Wang et al. 2004). A tentative conclusion
from all these data is that mitochondrial dysfunction is not sufficient to induce insulin
resistance.
An alternative view is that insulin resistance has a negative impact on mitochondria. Thus, in myoblasts, insulin regulates the expression of genes encoding the
subunits I and IV of cytochrome c oxidase (Pawlikowska et al. 2006), and chemical
inhibition of PI3K results in the repression of citrate synthase expression (Kraft et al.
2006). Moreover, studies performed in humans reveal that insulin signaling has a
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direct impact on mitochondrial function in humans. Thus, administration of insulin
to non-diabetic insulin-sensitive subjects caused an increase in the mitochondrial
ATP production rate accompanied by stimulation in muscle mitochondrial protein
synthesis, effects that were not seen in diabetic patients (Stump et al. 2003; Boirie
et al. 2001; Halvatsiotis et al. 2002). Accordingly, a mosaic animal model with a
98 % reduction of insulin receptors displays enlarged mitochondria that show poorly
organized cristae and shows reduced expression of PPARγ, PGC-1α and uncoupling
protein 1 (UCP1) (Kitamura et al. 2004).
In summary, current information indicates that insulin signaling cascades are
crucial for mitochondrial function and that disruption of mitochondrial function is
not sufficient to induce insulin resistance. This view does not exclude the possibility
that specific alterations of mitochondrial function are crucial in the pathogenesis of
muscle insulin resistance in obesity or type 2 diabetes.

6.7

Molecular Mechanisms of Muscle Insulin Resistance and
of Defective Metabolism in the Metabolic Syndrome

The main causes that trigger insulin resistance in skeletal muscle in the Metabolic
Syndrome are not well known. The hypotheses with greatest experimental support
regarding muscle insulin resistance are that it: a) is a consequence of chronic lowgrade inflammation; or b) is a consequence of an excess of lipid availability.
The inflammation hypothesis proposes the occurrence of macrophage activation in adipose depots secondary to obesity. Under lean conditions, adipocytes
secrete factors, such as interleukin (IL)-13, that promote alternative activation of
macrophages. Alternatively, activated macrophages secrete anti-inflammatory mediators, such as IL-10, and may secrete insulin-sensitizing factors. Obesity induces
changes in adipocyte metabolism and gene expression, resulting in increased lipolysis and the release of pro-inflammatory free fatty acids and factors that recruit and
activate macrophages, such as monocyte chemotactic protein-1 (MCP-1) and tumor
necrosis factor α (TNFα). Activated M1 macrophages produce large amounts of proinflammatory mediators, such as TNFα, IL-1β, and resistin, which act on adipocytes
to induce an insulin-resistant state. This establishes a positive feedback loop that
further amplifies inflammation and insulin resistance. As a result, adipose depots
release a number of pro-inflammatory cytokines such as IL-6, IL-1 or TNF, which
may reach muscle cells and promote insulin resistance (Schenk et al. 2008; Olefsky
and Glass 2010 ). In keeping with this view, obese and type 2 diabetes subjects show
increased circulating levels of pro-inflammatory cytokines such as IL-6, IL-8, and
retinol-binding protein. In addition, circulating levels of non-esterified fatty acids
are also increased as a result of a higher rate of lipolysis in adipose tissue.
There is also evidence that increased macrophage accumulation occurs in skeletal
muscle in high-fat diet-induced obesity. Just as in the adipose tissue, these skeletal
muscle pro-inflammatory macrophages are generally positive for F4/80, CD11b, and
CD11c and exhibit an M1 macrophage-like phenotype (Nguyen et al. 2007; Patsouris
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et al. 2008). Histological studies indicate that these macrophages are localized mainly
in intermuscular adipose depots, which accumulate within skeletal muscle in obesity.
This finding raises the possibility that these skeletal muscle macrophages locally
contribute to insulin resistance through paracrine mechanisms. However, this is only
a hypothesis and it has not been demonstrated. In obesity, the number of macrophages
in skeletal muscle is lower than in adipose tissue or also lower than the number of
Kuppfer cells in liver.
The lipotoxic hypothesis is based on the observation that insulin resistance is
associated with elevated levels of free fatty acids in the bloodstream. Several observations support this hypothesis. The single best predictor for the presence of insulin
resistance in young, lean offspring of type 2 diabetic patients is the accumulation
of fat inside muscle cells. This accumulation blocks an intracellular chain of events
that normally triggers glucose transport into the cell. The buildup of DAGs inside
muscle or liver cells causes the shutdown of the insulin signaling pathway. In the
muscle cells, they achieve this by inhibiting the translocation of a protein, GLUT4,
to the cell membrane, where it would normally work to pump glucose into the
cell. Insulin-stimulated glucose transport no longer works efficiently, and the cell is
insulin-resistant.
Lipotoxicity can occur in muscle when the body does not store fat in adipose tissue.
This may occur due to various reasons: because adipose cells are already hypertrophic
and cannot grow; because there is no capacity of adipose depots to generate enough
adipose cells; or because lipid metabolism in muscle is dysfunctional and generates
lipids that are toxic to cells so the cells become insulin-resistant.
As mentioned in a previous section, mitochondrial dysfunction has been proposed
as a cause of insulin resistance, mainly on the basis of correlational observations.
More recent data indicate that conditions/agents, such as TNF, dexamethasone, and
chronic exposure to insulin or palmitate, which produce insulin resistance in muscle or adipose cells models share mitochondrial superoxide stress, which precedes
insulin resistance (Houstis et al. 2006; Hoehn et al. 2009). Thus, treatment of cells
with anti-oxidant compounds restores the capacity of cells to respond to insulin.
Moreover, treatment of insulin-resistant obese ob/ob mice or mice on a high-fat diet
with anti-oxidants showed improved glucose and insulin tolerance (Anderson et al.
2009; Hoehn et al. 2009; Houstis et al. 2006). In all, these data suggest a causal
role for muscle mitochondrial reactive oxygen species (ROS) generation in insulin
resistance.

6.8

Future Prospects

A major pending question in the field is to determine the primary causes of muscle
insulin resistance in susceptible individuals or in rodents subjected to insulinresistant challenges as well as to identify the elements of the pathway that trigger its
development. In particular, it will be relevant to determine whether the primary
causes of muscle insulin resistance are related to the activation of pro-inflammatory
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pathways or whether they are more associated with alterations in lipid metabolism in
skeletal muscle, independent of inflammation. On the basis of the proposed role of
specific mitochondrial dysfunction or mitochondrially generated ROS as a cause of
insulin resistance, it will be pertinent to determine whether insulin resistant subjects
show early alterations in these parameters. In this respect, and given the evidence
reported to date, it may be of interest to determine whether changes in the activity
of proteins involved in mitochondrial dynamics impair insulin sensitivity in muscle
or other insulin-sensitive tissues.
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Chapter 7

The Central Nervous System in Metabolic
Syndrome
Luís Martins, Andrew J. Whittle, Rubén Nogueiras, Antonio Vidal-Puig,
Carlos Diéguez and Miguel López
Abstract In the last decades obesity and its related metabolic disorders have
increased at an epidemic rate in the developed and developing world. Lipid accumulation in peripheral tissues, such as heart, skeletal muscle, liver, and pancreatic
β cells leads to lipotoxicity. It is an important factor contributing to type 2 diabetes,
steatotic liver disease, insulin resistance and heart failure, disorders that are usually
known as the Metabolic Syndrome (MetS). Recent work has demonstrated that hypothalamic sensing of circulating lipids and modulation of hypothalamic endogenous
fatty acid and lipid metabolism are mechanisms modulating energy homeostasis at
the whole body level. Enzymes, such as AMP-activated protein kinase (AMPK) and
fatty acid synthase (FAS), plus intermediate metabolites, such as malonyl-CoA and
long chain fatty acid-CoAs (LCFA-CoAs), have a key role in this neuronal network,
integrating peripheral signals with classical neuropeptide-based mechanisms. One
major point that needs to be addressed is whether impairment of lipid metabolism and
accumulation of speciﬁc lipid species in the hypothalamus, leading to lipotoxicity,
has deleterious effects on hypothalamic neurons that may contribute to MetS. In this
chapter, we discuss data about hypothalamic lipid metabolism, with emphasis on
the events typically associated to lipotoxicity such as endoplasmic reticulum (ER)
stress. More extensive knowledge about these molecular mechanisms will be of great
relevance for the treatment of obesity and metabolic syndrome.
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Energy Balance and the Obesity Epidemic

Increasing prevalence of obesity is now one of the main health issues in both developed and developing countries, causing enormous economic problems for these societies (Farooqi and O’Rahilly 2005; Flier 2004; Friedman 2003; Medina-Gomez and
Vidal-Puig 2005). Given that previous knowledge of the physiopathology of obesity
is likely to reveal novel pharmacological targets, much effort is focused on identifying
and characterizing the molecular mechanisms controlling energy balance and particularly feeding behaviour (Fruhbeck 2008; Medina-Gomez and Vidal-Puig 2005).
The reasons for the increasing prevalence of obesity are multifaceted, but social
and environmental factors together with genetic predisposition can lead overall
to positive energy balance. The altered energy homeostasis that elicits obesity is
associated to insulin resistance and type 2 diabetes, fatty liver and a range of other
disorders, globally known as the Metabolic Syndrome (Cota et al. 2007; Farooqi
and O’Rahilly 2005; Flier 2004; Fruhbeck 2008; Medina-Gomez and Vidal-Puig
2005; Plum et al. 2006; Sarafidis and Nilsson 2006), as well as several types of
cancer (Calle and Kaaks 2004). Recent investigations have shown that housekeeping
metabolic pathways, such as de novo lipogenesis, play an important role in the
regulation of energy balance. By responding to hormonal and nutrient signals in
peripheral tissues and also in the central nervous system (CNS) these housekeeping
mechanisms can in turn modify energy balance (Carling et al. 2008; Kahn et al. 2005;
Lage et al. 2008; Ruderman et al. 2003).

7.2 The Hypothalamus is a Key Brain Region Regulating
Energy Balance
The hypothalamus is the brain region located below the thalamus, comprising the
major portion of the ventral diencephalon, and regulates an enormous number of
homeostatic functions; among them, the regulation of endocrine axes and energy
balance are of particular importance. The hypothalamus is organized in anatomicallydefined neuronal clusters, called nuclei, which form interconnected neuronal circuits
via axonal projections (Fig. 7.1; Elmquist et al. 2005; Gao and Horvath 2007; López
et al. 2007a, b, 2009; Morton et al. 2006). These nuclei respond to changes in energy
status by altering the expression of specific neurotransmitters/neuromodulators that
result in changes in energy intake and expenditure (Elmquist et al. 2005; Gao and
Horvath 2007; López et al. 2007a, b, 2009; Morton et al. 2006).
The arcuate nucleus (ARC) is considered the “master hypothalamic centre” for
food intake control. Two different neuronal populations in the ARC receive peripheral nutritional/feeding signals. One set of neurons produces the orexigenic
(feeding-promoting) neuropeptides agouti-related protein (AgRP) and neuropeptide
Y (NPY) (Fig. 7.1). These neurons mostly project to other “second order” neurons
located in other hypothalamic nuclei, such as the paraventricular nucleus (PVH). A
second ARC population of neurons expresses the anorexigenic (feeding inhibitors)
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Fig. 7.1 Hypothalamic neuropeptides regulating food intake. The hypothalamus is structured in
several nuclei, such as the arcuate (ARC), dorsomedial (DMH), paraventricular (PVH), ventromedial
(VMH) and lateral hypothalamic area (LHA). Food intake is regulated at hypothalamic level by
orexigenic (feeding stimulators) and anorexigenic neuropeptides (feeding inhibitors). Neuropeptide
Y (NPY ), agouti-related protein (AgRP), orexins (OXs) and melanin-concentrating hormone (MCH)
exert orexigenic actions, whereas alpha-melanocyte stimulating hormone (α-MSH) and cocaine
and amphetamine-regulated transcript (CART ) are the main anorexigenic signals. The expression
of these neuropeptides is under the control of central and peripheral signals

products of proopiomelanocortin (POMC), the precursor of alpha-melanocyte stimulating hormone (α-MSH) and the cocaine and amphetamine regulated transcript
(CART). These neurons project their axons more broadly within the CNS, to secondary hypothalamic nuclei such as the dorsomedial nucleus (DMH), the lateral
hypothalamic area (LHA) and the perifornical area, as well as the PVH. Dorsal to
the ARC lies the VMH, which mainly collects projections from AgRP/NPY and
CART/POMC neurons in the ARC. Furthermore, the VMH neurons project their
axons to the ARC, DMH, LHA and brainstem regions such as the nucleus of the
solitary tract. Hypothalamic neurons respond to peripheral metabolic signals, such
as glucose, amino acids and lipids and also to hormones, such as leptin, ghrelin,
adiponectin (ADPN), resistin (RSTN), glucagón-like peptide-1 and insulin, by modifying the expression and synthesis of neuropeptides. When energy intake exceeds
expenditure, the expression of orexigenic neuropeptides such as AgRP and NPY
diminishes. On the other hand, the expression of anorexigenic neuropeptides such as
CART and POMC increases. Opposite changes happen when energy expenditure surpasses feeding (Elmquist et al. 2005; Gao and Horvath 2007; López et al. 2007a, b;
Morton et al. 2006).
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Lipid Sensing in the Hypothalamus

Circulating nutrients are derived either exogenously (via food intake) or endogenously (via hepatic glucose production and adipocyte lipolysis). Plasma long chain
fatty acids (LCFAs) are mainly bound to albumin and cross the blood brain barrier
(BBB) mostly by simple diffusion of the unbound form. A small proportion of
fatty acids enter the brain via direct uptake of lipoprotein particles mediated by
lipoprotein receptors on the luminal surface of the cerebrovascular endothelium
(Lam et al. 2005b; Qi et al. 2002; Rapoport 2001). In general, the rate of entry of
fatty acids into the brain is relative to its plasma concentration (Miller et al. 1987;
Rapoport 1996). After crossing the BBB, LCFAs are esterified to LCFAs-CoAs, a
reaction catalyzed by the long chain fatty acyl-CoA synthetase enzymes. This takes
place inside neurons and glial cells, where the LCFAs-CoAs are metabolized for
use in lipid biosynthesis and, to a much lesser extent, within oxidative pathways
such as β-oxidation via CPT1 (Lam et al. 2005b; Miller et al. 1987).
Whether alterations in the lipid sensing mechanism are pathophysiological mechanisms leading to obesity and comorbidities is still unclear. However, it is worth
mentioning that 1) impairment of this central nutrient-sensing pathway is sufficient
to disrupt energy homeostasis and induce obesity and 2) the anorectic response to
oleic acid (OA) depends on the nutritional state, being suppressed by short-term
overfeeding (Morgan et al. 2004; Pocai et al. 2006). In fact, the hypothalamic responses to LCFAs disappear in overfed animals, which did not show changes either
in AgRP or NPY after OA treatment (Morgan et al. 2004; Pocai et al. 2006). Bearing
in mind these data, it is conceivable that in hyperphagic and obese states there may
be a resistance to the satiety effects of LCFAs and a desensitization of the AgRP
and NPY responses to circulating fatty acids, which contributes to body weight
gain. Interestingly, inhibition of CPT1 activity restores lipid sensing, normalizing
the hypothalamic levels of LCFA-CoAs and markedly inhibiting feeding behavior
and hepatic glucose fluxes in overfed rats (Pocai et al. 2006). It is clear that in this
model central inhibition of lipid oxidation is enough to restore hypothalamic lipid
sensing, as well as glucose and energy homeostasis, and may be an efficient strategy
for the treatment of diet-induced obesity and insulin resistance. However, before this
can be carried out in a clinical setting the molecular underpinnings of this event,
which are partially unsolved, must be understood. Some lines of evidence suggest
that reactive oxygen species could be one of the mitochondrial effectors implicated
in both the hormonal (Andrews et al. 2008) and nutrient sensing at the level of the
hypothalamus (Benani et al. 2007). This is a very interesting idea but it implies the
presence of mechanisms downstream of β-oxidation. An alternative hypothesis may
be that excessive accumulation of LCFAs in hypothalamic neurons might be redirected to non-oxidative pathways, producing non-esterified fatty acids. This would
result in the production of toxic reactive lipid species and cause ER stress and neuronal lipotoxic effects that can affect neuronal function and affect the mechanisms
of energy homeostasis.
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Hypothalamic Lipid Metabolism: A Housekeeping
Pathway Regulating Energy Balance

Regardless of the well-established role of neuropeptides and peripheral signals in
feeding, current data demonstrates that modulation of hypothalamic lipid metabolism
is an important mechanism regulating food intake. Under lipogenic conditions, excess glucose in the cell is first converted to pyruvate via glycolysis in the cytoplasm.
Pyruvate enters the mitochondria and is converted to acetyl-CoA and transported
as citrate from mitochondria into cytoplasm. ATP citrate lyase then reconverts citrate to acetyl-CoA. The de novo fatty acid biosynthesis pathway comprises three
key enzymes, acetyl-CoA carboxylase (ACC), FAS and malonyl-CoA decarboxylase (MCD). ACC catalyzes the carboxylation of acetyl-CoA to malonyl-CoA in an
ATP-dependent manner. The synthesis step of malonyl-CoA is a reversible regulated
mechanism and MCD converts malonyl-CoA back to acetyl-CoA. Acetyl-CoA and
malonyl-CoA are then used as the substrates for the production of palmitate by FAS.
Malonyl-CoA is an intermediary in the biosynthesis of fatty acids but also an important modulator of the balance between de novo lipogenesis and fatty acid oxidation.
Levels of malonyl-CoA depend on the equilibrium between ACC, FAS and MCD
activities. The activities of ACC and MCD are regulated by phosphorylation by
AMPK. Activated AMPK phosphorylates and inhibits ACC, whilst activating MCD,
thereby reducing malonyl-CoA and the flux of substrates in the fatty acid biosynthetic pathway (Carling 2004; Kahn et al. 2005; Ruderman et al. 2003). Decreased
malonyl-CoA levels further stimulate carnitine palmitoyltransferase 1 (CPT1), the
enzyme importing LCFAs-CoA into mitochondria. Thus, by altering the flux through
the pathway, levels of malonyl-CoA can be regulated to activate or inhibit mitochondrial β-oxidation (Dowell et al. 2005; Lam et al. 2005b; López et al. 2007a;
Ruderman et al. 2003). Of relevance, ACC, AMPK, CPT1, FAS and MCD mRNA
and protein expression have been detected at elevated levels in the ARC, DMH,
PVH and VMH hypothalamic nuclei in rodents and humans (Kim et al. 2002;
López et al. 2006; Minokoshi et al. 2004; Sorensen et al. 2002), suggesting that
the fatty acid biosynthetic pathway is important in these cell clusters.
Despite the fact that anatomical support suggested fatty acid metabolism was
important in hypothalamic neurons, the interest in the role of fatty acid metabolism in
energy balance came from the field of oncology (Kuhajda et al. 1994). The discovery
that numerous tumours expressed high levels of FAS suggested that inhibition of this
enzyme could be a target for cancer treatment (Kuhajda et al. 1994). Remarkably,
treatments with FAS inhibitors, such as C75 and cerulenin, resulted in massive weight
loss, which was associated with marked hypophagia (Loftus et al. 2000). Noteworthy,
the anorectic effect of these drugs, especially C75, is mediated by the accumulation
of malonyl-CoA in the hypothalamus, replicating a signal of nutrient abundance (Hu
et al. 2003). In fact, simultaneous inhibition of FAS and ACC (by 5-(tetradecyloxy)2-furoic acid, TOFA), prevents malonyl-CoA accumulation and consequently does
not result in decreased food consumption (Hu et al. 2003; Loftus et al. 2000; López
et al. 2006). Conversely, reduction of malonyl-CoA levels by adeno-associated virusmediated gene transfer of MCD into the medial basal hypothalamus of rats results in
increased food intake and progressive weight gain (He et al. 2006; Hu et al. 2005).
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Despite the relevance of these data, they can appear contradictory in some ways:
FAS inhibitors are anorectic (Hu et al. 2003; Loftus et al. 2000; López et al. 2006),
implying that the activity of FAS (an anabolic enzyme) is usually involved in an orexigenic tone. On the other hand, CPT1 (a catabolic enzyme) is also orexigenic (Obici
et al. 2003; Wolfgang et al. 2006). The explanation for this apparent paradox is found
in the malonyl-CoA levels and the integrated nature of metabolism, illustrated by the
cooperative regulation of fatty acid synthesis and oxidation. Levels of malonyl-CoA
play a key role in this system by acting both as a substrate for FAS but also as a potent
allosteric inhibitor of CPT1, the enzyme importing fatty acyl-CoA into the mitochondria for β-oxidation (Dowell et al. 2005; López et al. 2007a; Ruderman et al. 2003).
In summary, selective inhibition of FAS leads to cytoplasmatic malonyl-CoA
accumulation in hypothalamic neurons, which consequently inhibits CPT1 activity,
leading to decreased feeding (López et al. 2006, 2008a, b; Wolfgang et al. 2006).

7.5

Hypothalamic AMP-Activated Protein Kinase a Cellular
Sensor Regulating Whole Body Energy Balance

AMP-activated protein kinase (AMPK) is the downstream component of a kinase
cascade that acts as a gauge of cellular energy levels (Carling et al. 2008; Kahn
et al. 2005; Ruderman et al. 2003). Accumulating evidence has demonstrated
that AMPK is also involved in the regulation of energy balance at the entire body
level. AMPK is a serine/threonine protein kinase composed of a catalytic subunit
(α1 or α2) and two regulatory subunits (β1, or β2 or β3 and γ1 or γ2 or γ3).
AMPK is activated by phosphorylation on Thr172 of the α subunit, a process
catalyzed by LKB1 or Ca + 2/calmodulin-dependent protein kinase kinase alpha
and beta (CaMKKα and CaMKKβ), (Carling et al. 2008; Kahn et al. 2005;
Ruderman et al. 2003). Recently, it has been reported that transforming growth
factor-beta-activated kinase (TAK1) also activates AMPK (Fig. 7.2; Xie et al. 2006).
Current data also point out that protein phosphatase 2C (PP2C) inactivates AMPK
activity by dephosphorylation (Steinberg et al. 2006). AMPK is allosterically
activated by AMP, which also inhibits PP2C, increasing phosphorylation in Thr172
and then activation of AMPK. Finally, a novel mechanism modulating AMPK
independently of AMP and phosphorylation/dephosphorylation processes has been
documented: cell-death-inducing like-effector A (Cidea) forms a complex with the
β subunit of AMPK, which promotes an ubiquitination-mediated degradation of
AMPK, reducing its activity (Qi et al. 2008). Whatever the mechanism, activated
(phosphorylated) AMPK is a counter-regulatory response in many tissues to switch
off ATP-consuming processes (such as fatty acid synthesis) whilst switching on
catabolic processes that produce ATP (such as fatty acid β-oxidation) and restore
the AMP:ATP ratio (Carling et al. 2008; Kahn et al. 2005; Ruderman et al. 2003).
Until recently, AMPK was viewed as a cellular energy gauge, modulating and
being modulated by the AMP:ATP ratio. However, current data are also showing
that AMPK plays a major role in hypothalamic neurons as a sensor and regulator of
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Fig. 7.2 Hypothalamic fatty acid metabolism integrates peripheral signals with neuropeptide
systems. In the hypothalamus, anorectic signals inhibit AMP-activated protein kinase (AMPK)
phosphorylation and activation, while orexigenic signals stimulate AMPK phosphorylation and
activation. These signals are integrated and progress through alterations in the tumor suppressor
LKB1 and the Ca + 2/calmodulin-dependent protein kinase kinase 2 pathways (CaMKK2). In the
particular case of ghrelin, activated AMPK in turn phosphorylates and inactivates acetyl-CoA carboxylase (ACC), decreasing the cytoplasmatic pool of malonyl-CoA. The net result of this action
is an increase in carnitine palmitoyltransferase 1 (CPT1) activity and then fatty acid beta oxidation,
which promotes the generation of reactive oxygen species, which are buffered by uncoupling protein 2 (UCP2). This mechanism is critical for ghrelin-induced electric activation of agouti-related
peptide/neuropeptideY (AgRP/NPY ) neurons. Ghrelin-induced upregulation of Agrp and Npy genes
is mediated through a mechanism involving hypothalamic homeobox domain transcription factor
(BSX), forkhead box O1 (FoxO1) and the phosphorylated cAMP response-element binding protein
(pCREB)

whole body energy homeostasis, linking metabolic status to classical neuropeptide/neurotransmitter systems and ultimately regulating feeding. Morphological
evidence has shown that AMPK is highly expressed in several key hypothalamic
nuclei, such as the ARC, PVH, VMH and the LHA (Lage et al. 2010; López et al.
2006, 2008a; McCrimmon et al. 2006; Minokoshi et al. 2004). Functional data have
also demonstrated that modulation of AMPK in the hypothalamus is part of the adaptive changes observed during physiological regulation of feeding. Fasting increases
AMPK activity in several hypothalamic regions, whilst refeeding inhibits it (Andersson et al. 2004; López et al. 2008a; Minokoshi et al. 2004). In line with this evidence,
activation of AMPK in the hypothalamus increases feeding and body weight gain,
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while inhibition of hypothalamic AMPK activity promotes hypophagia and weight
loss (Andersson et al. 2004; López et al. 2008a, 2010; Minokoshi et al. 2004).
Remarkably, hypothalamic AMPK has recently emerged as a new central regulator of peripheral metabolism and thermogenesis through the autonomic nervous
system. Data from our group have recently revealed that AMPK in the VMH mediates
the effects of thyroid hormone (triiodothyronine, T3), nicotine and bone morphogenetic protein 8b (BMP8b) (Cannon and Nedergaard 2010; López et al. 2010;
Martínez de Morentin et al. 2012; Whittle et al. 2012). Specifically, central T3
overfeeding or hyperthyroidism, and nicotine decrease the activity of hypothalamic
AMPK, and additionally to BMP8b, stimulate sympathetic nervous system activity
and upregulate thermogenic markers in brown adipose tissue (BAT), such as uncoupling proteins 1 and 3 (UCP1 and UCP3). Worth mentioning is that inhibition of
the lipogenic pathway in the VMH prevents centrally-mediated activation of BAT
by T3, nicotine and BMP8b and reverses the weight loss associated with hyperthyroidism and smoking. Equally, inhibition of thyroid hormone receptors in the
VMH prevents hyperthyroidism-induced leanness. Overall this evidence shows that
inhibition of AMPK activity induced by T3 and nicotine and the associated increase
in hypothalamic lipogenesis alongside with central BMP8b are a key regulators of
BAT thermogenesis (Cannon and Nedergaard 2010; López et al. 2010; Martínez de
Morentin et al. 2012; Whittle et al. 2012).

7.6

Hypothalamic AMPK in the Development of Obesity
and Disease-Associated Feeding Disorders

The importance of hypothalamic AMPK in energy balance is clear but its role in
the progression to obesity is vague. It has been recently demonstrated that impaired
responses of AMPK to leptin might be involved in leptin resistance in obese states
(Martin et al. 2006). In this sense, neuronal protein tyrosine phosphatase 1B (PTP1B)
KO mice, which are resistant to diet-induced obesity due to leptin hypersensitivity,
show decreased hypothalamic AMPK activity accompanied by alterations in neuropeptide expression and increased thermogenesis in BAT and muscle. Such changes
collectively promote leanness and increased energy expenditure (Xue et al. 2009).
Recent work has also demonstrated that disruption of kinase suppressor of RAS 2
(KSR2) in vivo impairs AMPK-regulated processes affecting fatty acid oxidation
and thermogenesis to cause obesity (Costanzo-Garvey et al. 2009). Despite their
increased adiposity, KSR2 KO mice are hypophagic and hyperactive but expend less
energy than wild-type mice. In addition, hyperinsulinemic-euglycemic clamp studies
reveal that KSR2 KO mice are profoundly insulin resistant. The expression of genes
mediating oxidative phosphorylation is also downregulated in the adipose tissue of
these mice. Overall, these data demonstrate that KSR2 KO mice are highly efficient in
conserving energy, revealing a novel role for the KSR2-AMPK duo in the regulation
of energy metabolism. Interestingly, KSR2 is mainly detected in the brain suggesting
that these actions are probably exerted within the CNS (Costanzo-Garvey et al. 2009).
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Numerous mouse models with selective deletions of AMPK subunits have been
produced (for extensive review see (Kahn et al. 2005; Long and Zierath 2006)). However, the global AMPKα2 KO fed a high fat diet (HFD) (Viollet et al. 2003) and the
AMPKα2 KO in POMC neurons (POMCα2KO) fed standard chow and HFD, display increased body weight and fat mass (Claret et al. 2007; Long and Zierath 2006).
On the contrary, mice with a targeted ablation of AMPKα2 in AgRP neurons
(AgRPα2KO) have an age-dependent lean phenotype (Claret et al. 2007). Together
these evidence point to a very important role for AMPK in the ARC on feeding control. Furthermore, it has been also recently reported that AMPKβ1 KO mice either fed
low fat diet or HFD have reduced food intake, reduced adiposity, and reduced total
body mass without changes in metabolic rate, physical activity, adipose tissue lipolysis, or lipogenesis (Dzamko et al. 2010). The main problem in the understanding of
these phenotypes is the pathway’s redundancy itself. In fact, the absence of marked
alterations in terms of body weight and feeding in some of the AMPK KOs is probably related to compensation by the remaining catalytic subunits, i.e. in the AMPKα2
KO mice, AMPKα1 is upregulated (Viollet et al. 2003). Whatever the case, additional experiments are necessary, given the fact that it has been recently demonstrated
that at least the obese phenotype in POMCα2 KO mice is not due to compensatory
upregulation of AMPKα1 (Claret et al. 2007). The development of other mouse
models specifically targeting AMPK subunits in precise hypothalamic nuclei or
even neuronal populations will help to elucidate the role of hypothalamic AMPK in:
(a) the pathophysiology of obesity and (b) the physiological response to peripheral
hormones and metabolites. Consistent with this, it has been recently demonstrated
that the deletion of AMPKα2 in hypothalamic POMC and AgRP neurons is essential for glucose sensing but not to mediate the effects of leptin and insulin (Claret
et al. 2007). Similar studies should be performed in mice with selective deletion
of AMPKα1 and 2 in the VMH, which seems to be the key hypothalamic nucleus integrating AMPK’s actions not just on food intake (Lage et al. 2010; López et al. 2008a)
and glucose homeostasis (Fan et al. 2009; McCrimmon et al. 2004; McCrimmon et al.
2006; McCrimmon et al. 2008) but also on energy expenditure (López et al. 2010).

7.7

Endoplasmic Reticulum Stress in the Hypothalamus Leads
to Impaired Energy Balance

Alterations to the function of protein folding machinery of the ER are usually known
as ER stress, and its induction is one of the mechanisms induced by lipotoxicity
(Basseri and Austin 2008; Eizirik et al. 2008; Hotamisligil 2008; Lin et al. 2008;
Oyadomari and Mori 2004; Ron and Walter 2007; Yang and Hotamisligil 2008).
The main function of the ER is the synthesis of secretory proteins and resident
proteins but the ER is also involved in diverse functions such as lipid biosynthesis,
metabolism, oligosaccharide synthesis, calcium storage, and drug detoxification
(Eizirik et al. 2008; Lin et al. 2008; Oyadomari and Mori 2004; Ron and Hubbard
2008; Ron and Walter 2007). In eukaryotic cells, most secreted and transmembrane
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Fig. 7.3 A model illustrating how prolonged and unresolved ER stress disrupts lipid homeostasis
and results in the development of metabolic syndrome. Under conditions of physiological ER stress,
cells respond by activating the unfolded protein response (UPR). The subsequent increase in the
expression of ER chaperones and phosphorylation of eukaryotic translation initiation factor 2 α
(eIF2α) reduces cellular stress (left side). However, if UPR signaling is impaired (right side),
increased C/EBP homologous protein (CHOP) expression and/or phosphorylation of eIF2α can
result in increased expression of lipogenic genes, as well as decreased expression of genes required
for fatty acid oxidation. These metabolic changes induced by ER stress can lead to the development
of metabolic syndrome hallmarks, such as hepatic steatosis

proteins fold and mature in the lumen of the ER in a process kept in check by the
unfolded protein response (UPR). Three different classes of UPR transducers have
been identified: (1) inositol-requiring protein-1 (IRE1), (2) activating transcription
factor-6 (ATF6) and (3) protein kinase RNA-like ER kinase (PERK) (Fig. 7.3; Eizirik
et al. 2008; Lin et al. 2008; Oyadomari and Mori 2004; Ron and Hubbard 2008; Ron
and Walter 2007). Activation of these pathways as part of the ER stress response,
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caused by accumulation of unfolded proteins in the lumen of the ER, results in a
coordinated transcriptional response associated to attenuation of protein synthesis
and upregulation of ER folding machinery (ER chaperones proteins, such as GRP78,
GRP94 and ERp72) and degradation of irreversibly misfolded proteins (Eizirik et al.
2008; Lin et al. 2008; Oyadomari and Mori 2004; Ron and Hubbard 2008; Ron and
Walter 2007). If this UPR adaptive response is not sufficient to resolve the proteinfolding defect, ER dysfunction can lead to cell dysfunction and ultimately apoptotic
cell death (Eizirik et al. 2008; Lin et al. 2008; Ron and Hubbard 2008; Ron and
Walter 2007).
Recent evidence shows that ER stress occurs under conditions of overnutrition in
both peripheral tissues and the CNS (Hosoi et al. 2008; Ozcan et al. 2009; Zhang
et al. 2008). Free fatty acids (FFAs) and hyperglycemia in β cells promote activation
of the UPR, leading to decreased insulin mRNA expression and inhibition of insulin
signaling (Cunha et al. 2008; El Assaad et al. 2003; Lipson et al. 2006, 2008). FFAs
and glucose have been involved in PERK-mediated eukaryotic translation initiation
factor 2 α (eIF2α) phosphorylation and IRE1α-mediated X-box binding protein 1
(Xbp1) mRNA splicing in vivo and in isolated rat islets (Cnop et al. 2007; Cunha
et al. 2008; El Assaad et al. 2003; Elouil et al. 2007; Lipson et al. 2006, 2008)
and adipose tissue of obese rodent models and humans (Boden et al. 2008; Sharma
et al. 2008). The type of lipids involved and particularly their degree of saturation
seems to be relevant, with saturated fat being particularly prone to promote a greater
UPR in β cells inducing Xbps, C/EBP homologous protein (CHOP, also known
as GADD153) and GRP78 expression (Cnop et al. 2001; Cunha et al. 2008; El
Assaad et al. 2003; Lipson et al. 2006, 2008). CHOP is a member of the C/EBP
family of transcription factors (Oyadomari and Mori 2004; Ron and Habener 1992)
and it is known to inhibit adipocyte differentiation in response to metabolic stress
(Tang and Lane 2000). Chop gene induction is preferentially regulated through the
PERK/eIF2α/ATF4 UPR pathway, although the IRE1α/XBP1 and ATF6α pathways
have also been implicated (Eizirik et al. 2008; Lin et al. 2008; Ron and Hubbard 2008;
Ron and Walter 2007). There is strong evidence demonstrating that impaired CHOP
function in peripheral tissues promotes alterations in energy homeostasis. Female
CHOPKO mice develop obesity; however no clear mechanisms involving either food
intake or thermogenesis have been identified (Ariyama et al. 2007). HFD feeding
results in obesity in female CHOPKO and heterozygous mice, although their caloric
intake does not differ from that of wild-type. Fat cell area is increased in mesenteric fat
but not in subcutaneous fat in CHOPKO mice fed a HFD (Ariyama et al. 2007). There
is evidence that the UPR promotes CHOP expression in other systems such as β cell
apoptosis and diabetes (Huang et al. 2007; Laybutt et al. 2007; Oyadomari et al. 2002;
Yusta et al. 2006). Further evidence indicates that genetic ablation of CHOP provides
an advantage to the β cell by preventing oxidative damage and promoting β cell
survival (Song et al. 2008). In the context of the CNS induction of CHOP has been
related to neuronal toxicity and death in diverse neurodegenerative diseases (Pennuto
et al. 2008; Schapansky et al. 2007; Silva et al. 2005). Thus, on the basis of these
data, it is tempting to speculate that CHOP could be a mediator or ER stress in the
hypothalamus following selective lipid damage. Further work will be necessary to
address this hypothesis.
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Recent evidence also links inflammation to hypothalamic ER stress and leptin resistance. Three recent works from three independent groups have demonstrated that
obesity and overnutrition elicit ER stress and initiate UPR signaling pathways in the
hypothalamus, which in turn leads to inhibition of leptin receptor signaling and leptin
resistance (Fig. 7.3; Hosoi et al. 2008; Ozcan et al. 2009; Zhang et al. 2008). Zhang
et al demonstrated that IKKβ/NF-κB, a well-known mediator of metabolic inflammation, is highly expressed in hypothalamic neurons although it normally remains
inactive (Zhang et al. 2008). Interestingly chronic (dietary or genetic obesity) or
acute (glucose or OA exposure) overnutrition activates hypothalamic IKKβ/NF-κB
through, at least in part, elevated hypothalamic ER stress leading to impaired insulin and leptin signaling through a mechanism partially mediated by suppressor of
cytokine signaling (SOCS3), an inhibitor of insulin and leptin signaling. Experimental activation of the IKKβ/NF-κB signaling pathway in the hypothalamus, through
virus-mediated introduction of a constitutively active IKKβ, leads to weight gain
and increased food intake together with impaired insulin and leptin signaling in the
hypothalamus in mice fed a HFD. Also, this work demonstrates that suppression of
IKKβ/NF-κB signaling in the mediobasal hypothalamus protects against insulin and
leptin resistance and obesity (Zhang et al. 2008). Finally, Zhang et al demonstrate that
obesity-induced ER stress in the hypothalamus due to diet could also be suppressed
by administration of tauroursodeoxycholic acid (TUDCA), a chemical chaperone that
improves the protein-folding capacity. Such treatment resulted in reduced food intake and decreased body weight (Zhang et al. 2008). Altogether, these data show that
the hypothalamic IKKβ/NF-κB program is a general neural mechanism for energy
balance underlying obesity and suggest that suppressing hypothalamic IKKβ/NFκB may represent a strategy to combat obesity and related diseases, perhaps even
hypothalamic lipotoxicity. In two additional studies Hosoi et al and Ozcan et al described that ER stress clearly inhibited leptin-induced signal transducer and activator
of transcription 3 phosphorylation and that ER stress-induced leptin resistance was
mediated through PTP1B. However, contrary to Zhang et al, this was not mediated
through SOCS3 (Hosoi et al. 2008; Ozcan et al. 2009). It is noteworthy that both
studies showed that treatment with chemical chaperones, such as 4-phenyl butyric
acid and TUDCA not only rescued ER stress in the CNS and reduced body weight
but also acted as leptin sensitizing agents, significantly improving ER stress-induced
leptin resistance (Hosoi et al. 2008; Ozcan et al. 2009). In accordance with these observations a recent study has shown that central administration of thapsigargin, an ER
stress inducer, inhibits the anorexigenic effects of leptin and insulin (Won et al. 2009).
The kinase known as mammalian target of rapamycin (mTOR) could also be
affected by ER stress. This kinase integrates different sensory inputs to regulate
protein synthesis rates in individual cells, and in the last years it has been related
to the regulation of food intake and body weight in the CNS (Cota et al. 2006,
2007, 2008; Martins et al. 2012; Proulx et al. 2008; Varela et al. 2012; Woods et al.
2008). Considering that both nutrients and inflammatory signaling could engage the
mTOR pathway, it could have an in important role in obesity-induced ER stress in
the CNS. Present data show that ER stress is a critical component of the pathologies
associated with dysregulated mTOR activity, and the evidence is as follows. To
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begin with, in a role distinct from the regulation of energy homeostasis, mTOR
modulates protein translation after ER stress induced by human cytomegalovirus
(Alwine 2008) or chronic hepatitis B virus infection (Yang et al. 2009). Research
from recent research has demonstrated that mTOR has a key role in the translational
control of gene expression during hypoxia- or oxidative-induced ER stress in both
normal and cancer cells (Endo et al. 2007; Jin et al. 2009; van den et al. 2006). In the
CNS, some cues can be found in the tuberous sclerosis complex (TSC), a neurogenetic
disorder caused by loss-of-function mutations in either the TSC1 or TSC2 genes.
Such mutations frequently result in prominent CNS-related symptoms, including
epilepsy, mental retardation, and autism spectrum disorder (Di Nardo et al. 2009).
Very recent data have demonstrated that loss of TSC1 or TSC2 leads to constitutive
mTOR activation in cell lines and mouse or human tumors and causes ER stress and
activation of the UPR (Ozcan et al. 2008). Also, hippocampal Tsc2-deficient neurons
and brain lysates from Tsc1-deficient mice show elevated ER stress, indicated by
increased expression of CHOP. This effect is completely reversed by the mTOR
inhibitor rapamycin both in vitro and in vivo (Di Nardo et al. 2009). This evidence
indicates that ER stress modulates mTOR activity in neurons through the TSC protein
complex and that ER stress is elevated in cells lacking this complex. Whether the
TSC-mTOR axis mediates ER stress in the hypothalamus needs to be investigated.
Recent work supports this theory, showing that hypothalamic Rip-TSC1KO mice
developed hyperphagia and obesity, suggesting that hypothalamic disruption of Tsc1
may dysregulate feeding circuits via mTOR activation. In fact, Rip-TSC1KO mice
displayed increased mTOR signaling and enlarged neuron cell size in a number of
hypothalamic populations, including POMC neurons. Additionally, Tsc1 deletion
with Pomc/Cre POMC-TSC1KO mice resulted in dysregulation of POMC neurons
and hyperphagia-driven obesity. Treatment with the mTOR inhibitor, rapamycin,
improved the hyperphagia, obesity, and the altered POMC neuronal morphology in
developing or adult POMC-TSC1KO mice (Mori et al. 2009). This work clearly
demonstrates that mTOR activation in POMC neurons blocks the catabolic function
of these cells to promote nutrient intake and increased adiposity. Whether these effects
are linked to specific changes in ER stress would need further research, but taking
into consideration the connection between both facts, this link is quite appealing.

7.8

Conclusions and Future Challenges

In the 1950’s we watched to the formulation of the Glucostatic, Lipostatic and Aminostatic Hypotheses, that proposed the sensing of circulating levels of metabolites such
as glucose, lipids and amino acids in the CNS and that feeding was modified according to levels of these molecules (Campfield et al. 1996; MAYER 1955). It took until
the 21st century to demonstrate that circulating LCFAs act as nutrient surplus signals
in the hypothalamus (Lam et al. 2005a; Le Foll et al. 2009; Morgan et al. 2004;
Obici et al. 2002; Pocai et al. 2005; Wang et al. 2006). The last decade’s work has
provided pharmacological, genetic and physiological evidence that energy balance
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at the whole body level is modulated by hypothalamic lipid metabolism (Andrews
et al. 2008; Loftus et al. 2000; López et al. 2006, 2008b, 2010; Minokoshi et al.
2004; Obici et al. 2003; Wolfgang et al. 2007). Still, there are three main questions
requiring an answer. First, can alterations in hypothalamic lipid metabolism impair
energy homeostasis and lead to obesity and the Metabolic Syndrome? Second, what
is the molecular nature of these alterations? And third, could hypothalamic lipotoxicity play a role in the pathophysiology of the Metabolic Syndrome? Some recent and
exceptional work gave evidence suggesting that this may be the case, demonstrating
that a key mechanism of lipid toxicity, the induction of ER stress, is a general neural
mechanism for energy homeostasis underlying obesity and leptin resistance (Hosoi
et al. 2008; Ozcan et al. 2009; Won et al. 2009; Zhang et al. 2008). However, this
connection relating lipotoxicity and ER-stress in the hypothalamus needs to be confirmed. Of note, these studies also show that pharmacological manipulation of ER
stress may be an ideal target for obesity treatment, acting as leptin-sensitizer (Hosoi
et al. 2008; Ozcan et al. 2009; Won et al. 2009; Zhang et al. 2008). This finding may
be essential for guiding the newly evolving strategies for drug design and targeting
ER stress could be a useful therapeutic solution to prevent or even revert obesity and
its metabolic complications in humans.
In conclusion these recent data point to hypothalamic ER stress as a key mechanism leading to some of the diverse manifestations of the metabolic syndrome.
The challenge over coming years will be to validate this hypothesis and identify the
molecular effectors linking central lipotoxicity, ER stress and the classical pathways
involved on energy homeostasis. We believe that a wider comprehension of these
mechanisms operating in the CNS will facilitate the development of more efficient
drugs against obesity and related metabolic disorders.
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Chapter 8

Lipid Metabolism in Metabolic Syndrome
Jan Borén and Martin Adiels

Abstract Lipoprotein metabolism is a complex system in which abnormal concentrations of various lipoprotein particles can result from alterations in their rates of
production, conversion and/or catabolism. To develop novel strategies for the prevention and treatment of dyslipidaemia, it is essential to better understand the lipid
disorders in humans. Here we discuss recent advances in the ﬁeld as well as show
how the use of tracers labeled with stable isotopes combined with mathematical
modelling provides a powerful tool for probing lipid and lipoprotein kinetics in vivo;
thus furthering our understanding of the pathogenesis of lipid disorders.
Keywords Lipid metabolism · Liver · Tracer studies · Very low density lipopoprotein

8.1

Introduction

Cardiovascular diseases (CVD), such as stroke and ischemic heart attack, are the
leading cause of death in the vast majority of the countries in the developed world,
reaching well over 50 % in some countries and accounting for 30 % of all deaths
worldwide (Gaziano 2005). Due to the rapid increase in obesity and sedentary
lifestyle there is an increase in co-morbities such as type 2 diabetes (Zimmet et al.
2001). This will likely portend a daunting increase in CVD in the coming decades.
Changes in blood lipids, commonly known as diabetic dyslipidaemia, is an important and frequent risk factor for CVD and is a common feature of metabolic diseases
thus playing an important role in the close link between metabolic diseases and
CVD.
Recent studies have recognized the complex nature of diabetic dyslipidaemia,
a cluster of potentially atherogenic lipid and lipoprotein abnormalities (Taskinen
2003). A better understanding of the pathophysiology behind diabetic dyslipidaemia
will allow us to tailor targeted goals for the lipid management.
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Lipoprotein Metabolism

The function of lipoprotein particles is to transport hydrophobic lipid molecules,
which are not water soluble, in the blood. The general structure of a lipoprotein
includes a core consisting of triglycerides and/or cholesterol esters surrounded by
a surface monolayer of phospholipids, unesterified cholesterol and specific proteins
(Mahley et al. 1984). Cholesterol is an important component of membranes in the
cell and is also important for the synthesis of steroid hormones. The function of
triglycerides is as energy source in tissue and for energy storage in adipose tissue. The
protein components of the lipoprotein are known as apolipoproteins which function as
cofactors for enzymes and ligands for receptors (Mahley et al. 1984). The lipoprotein
particles are classified according to their density and size (Table 8.1). The density is
primarily reflecting the triglyceride content of the particles with more triglycerides
in the lighter and larger particles. The metabolism of lipoproteins is schematically
illustrated in Fig. 8.1.
Chylomicrons Chylomicrons are triglyceride-rich lipoprotein particles synthesized
in the gut during uptake of triglycerides from the food. The chylomicrons are transported with the lymph vessels into the blood. In the blood the triglycerides are
catabolized by the enzyme, lipoprotein lipase (LPL), and fatty acids are released to
be used as energy source in the cells, or to be stored in adipose tissue as triglycerides.
The chylomicron remnant is finally taken up and catabolized by the liver. The main
protein component of chylomicrons is the apolipoprotein (apo) B48.
VLDL-IDL-LDL These lipoproteins, containing the protein apoB100, represent
a metabolic cascade of particles for triglyceride transport of endogenous origin.
Very low density lipoprotein (VLDL) is synthesized in the liver as a triglyceride-rich
lipoprotein particle. VLDL is catabolized by the enzyme LPL, and as the triglyceride
content is reduced the particle becomes smaller and denser. It is first transformed into
intermediate density lipoprotein (IDL), which to some extent is taken up by the liver,
or further catabolized to low density lipoprotein (LDL). The transition of IDL to
LDL is driven by the enzymes LPL and hepatic lipase. LDL particles are cholesterol
rich particles and about 80 % of the plasma cholesterol is carried in LDL. Most of
the LDL is taken up by the liver and excreted via the bile, in the form of cholesterol
or after transformation to bile acids.
The liver can secrete both large triglyceride-rich VLDL1 particles, and smaller
more cholesterol-containing VLDL2 . Intravascular lipolysis of these lipoproteins
gives rise to normal-size LDL that remains in the circulation for ∼ 2 days. However, when triglyceride levels are high, VLDL1 particles are initially converted to
large LDL particles. These large LDL particles are subsequently converted to small
dense LDL (sdLDL) with a retention time of ∼ 5 days by cholesterol ester transport protein (CETP) and hepatic lipase, which both are increased in type 2, diabetes
(Taskinen 2003) (Fig. 8.2). In addition to this, increased levels of VLDL1 alter the
composition of high density lipoproteins (HDL) ultimately leading to an increased
catabolism of these particles (Rashid et al. 2003). Thus, elevation of VLDL1 in
diabetic dyslipidemia leads to the generation of sdLDL and increased risk for CVD.
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Fig. 8.1 Metabolism of apolipoprotein B (apoB)-containing lipoproteins. Dietary lipids are packed
into chylomicrons (1). Once in the plasma (2), most triglyceride molecules in chylomicrons are
hydrolyzed by the action of lipoprotein lipase (LPL) (3) resulting in smaller chylomicron remnants
(4). The remnants are cleared from the circulation by the liver (5). LPL and hepatic lipase (HL)
convert liver-derived VLDL to smaller intermediate-density lipoprotein (IDL) and LDL (6), which
are removed from the circulation by the liver

Fig. 8.2 Metabolism of triglyceride-rich lipoproteins (TRLs) and generation of sdLDL. The concentration of fasting triglycerides and the magnitude of postprandial lipoproteinemia have striking
influences on LDL subclasses. The long residence time of triglyceride-rich lipoproteins (TRL) particles in circulation due to impaired triglyceride hydrolysis and delayed remnant removal results in
increased exchange of core lipids, that is, triglycerides and cholesterol esters, between TRLs and
LDL, mediated by cholesterol ester transfer protein (CETP). In this process, LDL particles become
triglyceride-enriched. Large triglyceride-rich particles are good substrates for hepatic lipase (HL),
which is commonly increased in type 2 diabetes. Taken together, the formation of small, dense LDL
depends on the rate of triglyceride transfer to LDL and on the rate of its hydrolysis by HL; both
processes are enhanced in diabetic dyslipidemia. In addition to this, increased levels of TRL alter
the composition of HDL ultimately leading to an increased catabolism of these particles
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The presence of sdLDL has been correlated with an increased risk of coronary
heart disease, but this has not been shown to be fully independent of related factors
such as elevated plasma triacylglycerol concentrations (Lada and Rudel 2004).
HDL These are the smallest and most dense lipoproteins with a relatively high
content of phospholipids. The function of HDL is complex. The particle is secreted as
a lipid-poor apoAI particle which associates with phospholipids to form a disc-shaped
particle. Through uptake of cholesterol from cells and tissue, a core of cholesterol
ester is formed. In the atherosclerotic plaque the cholesterol is taken up from the
lipid filled macrophages. From HDL the cholesterol can be transported to the liver
via two routes; HDL can either be taken up by the liver, or alternatively cholesterol
can be transferred to LDL particles via the transport protein CETP.

8.3 Assembly of VLDL in the Secretory Pathway of the Cell
The assembly of VLDL involves a stepwise increase of the lipidation of the structural
protein apoB100 (Olofsson and Boren 2005). It starts in the rough endoplasmic
reticulum (ER) when apoB100 enters the secretory pathway co-translationally (Boren
et al. 1992) and is simultaneously lipidated by the microsomal triglyceride transfer
protein (MTP) (Olofsson et al. 1999; Olofsson and Boren 2005). The nascent VLDL
particle is converted to a smaller VLDL2 by additional lipidation (Stillemark-Billton
et al. 2005). In situations with increased lipid load, the liver can also form a larger
triglyceride-rich VLDL1 particle. Studies have demonstrated that the secretion of
VLDL1 increases with increasing concentrations of liver lipids (Adiels et al. 2006b).
Thus, the formation of VLDL1 is regulated by the availability of lipids, and increased
lipid load results in that more VLDL1 particles are secreted (Adiels et al. 2005a).
Thus, the assembly of VLDL1 requires several steps: the formation of nascent VLDL
particle, its conversion to VLDL2 , and further addition of triglycerides (Stillemark
et al. 2000).

8.3.1

Regulators VLDL Assembly and Secretion

To date it is still unclear how the liver is able to regulate the amount of triglycerides
incorporated into VLDL particles to produce either large VLDL1 particles or smaller
VLDL2 particles. Substantial evidence indicates that the synthesis and release of
VLDL1 and VLDL2 particles are independently regulated. Two key regulators of
VLDL secretion has been shown to be fatty acids flux and insulin. An inflow of fatty
acids to the liver increases the triglyceride formation which explains the influence of
the fatty acids on the formation of VLDL (Adiels et al. 2008). Insulin has also been
shown been shown to reduce VLDL1 formation (Adiels et al. 2007). The balance
between VLDL1 and VLDL2 is also regulated by peroxisome proliferator-activated
receptor alpha (PPARα) agonists. Such agonists have a fundamental influence on the
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assembly of VLDL1 ; thus, they increase the biosynthesis of apoB100 and decrease
the formation of triglycerides (Lindén et al. 2002). This promotes secretion of VLDL2
particles instead of the larger triglyceride-rich VLDL1 particles.

8.3.2

Regulators of VLDL Turn Over

In the circulation, VLDL particles are converted to denser particles by the removal
of triglycerides, primarily by lipoprotein lipase. Thus, converting the large VLDL1
to the denser VLDL2 , and subsequently VLDL2 to IDL. In turn IDL are converted
to LDL by removal of triglycerides by hepatic lipase. Removal of lipoprotein from
the circulation may occur by LDL-receptor mediated uptake or by heparin sulphate
proteoglycans (Williams and Chen 2010).
The interaction between the lipoproteins and the receptors and lipases are facilitated by the protein composition of the lipoproteins. For example apoCIII is an
inhibitor of lipoprotein lipase (Havel et al. 1973) and the apoCIII content on VLDL
particles are inversely related to the turnover of the particles (Chan et al. 2006;
Taskinen et al. 2011).

8.4

Dyslipidaemia is a Cardinal Feature of the Metabolic
Syndrome

In type 2 diabetes, dyslipidemia is an important and common modifiable risk factor
for coronary heart disease (CHD) (Turner et al. 1998). Several studies have recognised the complex nature of diabetic dyslipidemia that is a cluster of potentially
atherogenic lipid and lipoprotein abnormalities (Taskinen 2003); increased plasma
triglycerides and low concentrations of HDL-cholesterol (Adiels et al. 2006a), accumulation of sdLDL and excessive postprandial lipaemia. Interestingly, the different
components of the diabetic dyslipidaemia are not isolated abnormalities but are
metabolically closely linked to each other (Taskinen 2005) (Fig. 8.3).
Patients with a diabetic dyslipidemia have a significant increased risk of developing cardiovascular disease (CVD). Furthermore, the prognosis for CVD is much
worse in the presence of type 2 diabetes. Therefore, lipid management of diabetic
dyslipidaemia is of immense importance.

8.4.1

Elucidation of the Mechanism for Diabetic Dyslipidemia
Requires Studies with Stable Isotopes

In order to prevent and treat diabetic dyslipidemia it is necessary to characterize
the disorder to fully understand its cause. The most common way to do this is by
measuring plasma lipid or apolipoprotein concentrations. However, abnormal concentrations of lipids and apolipoproteins can result from changes in the production,
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Fig. 8.3 The dysregulation of apoB and apoAI metabolism in subjects with the metabolic syndrome.
ApoB-100 is the major structural protein of, VLDL, IDL and LDL. It is a large protein that is required
for the assembly and secretion of apoB-containing lipoproteins. It is also a ligand for LDL receptormediated endocytosis of LDL and, possibly, VLDL and IDL. Subjects with the metabolic syndrome
have significantly increased production (+ 45 % for VLDL, solid line) and reduced catabolism of
apoB100 (− 18 %, − 54 % and − 37 % for VLDL, IDL and LDL respectively, dashed lines). This
results in an increase concentration of VLDL, IDL and LDL particles. ApoAI is the major structural
protein associated with HDL particles. It is important in the activation of enzymes involved in the
maturation of HDL particles. In addition, a low HDL-cholesterol concentration is observed in these
subjects. This is primarily due to hypercatabolism of its major structural protein apoAI (+ 48 %,
dashed line) which is somewhat compensated by increased production (+ 25 %, solid line). The
figure is based on studies by Watts and co-workers. (Riches et al. 1998; Chan et al. 2002; Watts
et al. 2003)

conversion or catabolism of lipoprotein particles. Therefore, although static measurements and functional assays are important techniques, it is necessary to study the true
unit of function (the integrated metabolic pathway) to understand the complexity of
lipoprotein metabolism (Chan et al. 2004b; Chan et al. 2004a; Adiels et al. 2008).
In contrast to static measurements, kinetic experiments are of great importance in
lipid research because they further the understanding of lipid metabolism in vivo and
help to explain the pathophysiology of lipid disorders in humans (Chan et al. 2004b;
Chan et al. 2004a; Adiels et al. 2008). At present, due to species specificity, no valid
animal model can efficiently replace human studies to explore lipid metabolism, and
the use of radioactive tracers in such studies is restricted. Therefore, stable-isotope
tracer kinetic studies have become an important tool of translational research to
achieve a quantitative understanding of the dynamics of metabolic processes in vivo.

8.5

Principles of Tracer Methodology

To study the behavior of an endogenous molecule, the tracee, the same molecule,
but labeled (the tracer), is introduced into the system (usually via the bloodstream)
(Chan et al. 2004b; Chan et al. 2004a). This process is termed exogenous labeling.
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Endogenous labeling occurs when a labeled precursor of the molecule of interest is
used to label this molecule (e.g., infusion of a labeled amino acid to label a protein).
Ideally, the tracer can easily be detected and quantified, has the same kinetic behavior
as the tracee, and does not perturb the system.
Usually, kinetic studies are performed in a steady state, where the rates of input
and output for a given unlabeled tracee substance are equal and time invariant. Thus,
the information provided by the tracer reflects the behavior of the tracee (Barrett et al.
2006). At various times, the amount of tracer is quantified to provide a kinetic curve.
Then a mathematical model is constructed to extract all the information contained
in the kinetic curve. By fitting a model to the data, it is possible to estimate the
parameters of the model that characterize the flux of molecules between kinetically
homogeneous pools. For example, it is possible to calculate the production, conversion or catabolism of lipoprotein particles, information that cannot be obtained by
static measurements alone. Such models are usually constructed based on a priori
knowledge, building physiologically relevant models (de Graaf et al. 2009).
The term stable isotope refers to a non-radioactive isotope of a given atom. In tracer
experiments, the tracer is typically a molecule in which some atoms are replaced
by stable isotopes with low natural abundance, such as 2 H or 13 C. Stable isotopes
commonly used as metabolic tracers include: [2 H3 ]-leucine for apolipoprotein turnover; [2 H5 ]-glycerol and [13 C]-palmitic acid for VLDL–triglyceride metabolism;
[1,2−13 C]-acetate and [13 C]-palmitic acid for fatty acid metabolism, and 2 H2 O for
hepatic de novo lipogenesis.

8.6

Studies of Lipoprotein Metabolism Using
Multicompartment Models

When a stable isotope tracer is injected, it is incorporated into the molecules under investigation to the same extent as the unlabelled trace molecule (by definition the tracer
should have identical properties as the tracee). The fraction of labeled molecules can
be estimated by measuring the enrichment of the stable isotope (tracer/tracee ratio).
The tracer enables the dynamic fate of the latter to be traced through its metabolic
pathways. The movement of material in the system can be described by a set of
differential equations, thereby allowing quantitative information on the system to be
estimated.
The tracer data generated can be analyzed using several different methodologies. One approach to analyse VLDL kinetics is to inject a bolus of tracer and
determine the subsequent monoexponential slope of the decline in plasma VLDL
tracer/tracer ratio. A disadvantage of this approach is that it can underestimate the
true VLDL turnover rate because it does not account for recycling of the injected
bolus of tracer (Patterson et al. 2002). Multicompartment modeling is a superior
method to dissect the complexities of lipoprotein metabolism, and has been widely
applied to systems in which material is transferred over time between compartments
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connected in a specific structure to permit the movement of material among the
compartments.
Each compartment is assumed to represent a homogenous entity with respect to its
kinetic properties. Typically, compartments represent different types of lipoprotein
particles with are kinetically homogenous, while being distinct from other material
in the system. Different compartments may also represent lipoprotein or molecules in
different volumes (e.g., intracellular or in plasma). Usually, the model is constructed
based on prior knowledge of the system. However, often data can be described by
more than one model. Model selection may be carried out by examination of the
fit to the experimental curves, parameter identifiability and precision of parameter
estimates and by statistical tests of model results and complexity. However, the complexity of a multicompartment model is usually a compromise for what is practically
possible. A very simple model may not adequately describe the kinetic heterogeneity present within the system. A model that is too complex, on the other hand,
will not be supported by experimental data and, hence, will have little predictive
value. Furthermore, even if the development of models is based on experimental
data, several assumptions are required in order to derive the model that is to be
used.
Several studies have been conducted to analyses VLDL–triglyceride turnover
kinetics using stable isotopically labeled glycerol or palmitic acid tracers and
mathematical modeling; however, VLDL subclasses were not analyzed and VLDL–
apoB100 was not included in the models (Lemieux et al. 1999; Carpentier et al.
2002; Patterson et al. 2002). To enhance our understanding of the pathways leading
to VLDL1 and VLDL2 and of the metabolic fate of these particles, we developed
a multicompartmental mathematical model that allows the kinetics of triglycerides
and apoB100 in VLDL1 and VLDL2 to be simultaneously assessed after a bolus injection of glycerol and leucine (Adiels et al. 2005b). Tracer/tracee curves of leucine
and glycerol in VLDL1 and VLDL2 were analyzed to determine kinetic parameters
using mathematical modeling.

8.7

In vivo Studies Elucidates the Disturbed Lipid
Metabolism in Subjects with Type 2 Diabetes
and/or the Metabolic Syndrome

The model has greatly furthered our understanding of the disturbed lipoprotein
metabolism in diabetic dyslipidemia. For example, the model showed a linear correlation between the VLDL1 triglyceride and apoB100 production. Furthermore,
the composition of the VLDL1 and VLDL2 particles (triglyceride:apoB100 ratio) in
plasma suggests that a high level of total plasma triglycerides in achieved mainly
by an increased VLDL1 triglyceride pool, but this is the effect of increased number
of particles rather than increased particle size. Overall, the contributions of VLDL2
triglyceride pools to the total plasma TG triglyceride were less than that of the
VLDL1 triglyceride pools. We speculate that the VLDL2 secretion reflects baseline
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production of triglycerides whereas the VLDL1 secretion is modulated by dynamic
variations in substrate fluxes. This is consistent with studies showing that insulin
does not affect the direct production of VLDL2 apoB100 or the lipid composition of
the VLDL2 particles (Malmstrom et al. 1997).
The model also revealed a significant difference in the delay times of glycerol
and leucine (i.e., VLDL triglycerides and VLDL apoB100). After incorporation
of glycerol into triglycerides, the completed lipoprotein enters the blood system
within 21 min. In contrast, the delay time for apoB100 molecules is 33 min. These
observations are consistent with a sequential assembly model of VLDL and likely
provide the first evidence in man that triglyceride can be added to a primordial
apoB100-containing particle in the liver (Alexander et al. 1976; Boren et al. 1994).
We continued to analyse which features of type 2 diabetes and insulin resistance
correlate with VLDL1 production, and revealed strong correlations with plasma glucose (Adiels et al. 2005a). By extending our study to monitor liver, intra-abdominal
and subcutaneous fat as well as adiponectin, we showed that fasting insulin, plasma
glucose, intra-abdominal and liver fat and the homeostasis model of assessing insulin
resistance (HOMA-IR) are predictors of VLDL1 -apoB100 and VLDL1 -triglyceride
production (Adiels et al. 2006b). However, in a multiple regression analysis, only
liver fat and plasma glucose remained significant (Adiels et al. 2006b). Moreover,
the key predictors of liver fat are intra-abdominal fat, adiponectin and plasma glucose (Adiels et al. 2006b). Further studies have demonstrated that liver fat content is
closely related to triglyceride secretion in different settings and populations (Taskinen et al. 2011; Chan et al. 2010) and is a better predictor of triglyceride secretion
than intra-abdominal fat (Fabbrini et al. 2009; Magkos et al. 2010).
Non-alcoholic fatty liver disease (NAFLD) is defined as fat accumulation in the
liver that exceeds 5–10 % of liver weight in individuals who do not consume significant amounts of alcohol (Neuschwander-Tetri and Caldwell 2003). Recent data show
that NAFLD is strongly associated with type 2 diabetes, obesity and hyperlipidaemia
(Angelico et al. 2005; Clark and Diehl 2002; Youssef and McCullough 2002 ; Li et al.
2002; Marchesini et al. 2001; Marchesini et al. 2003; Bugianesi et al. 2005; Targher
et al. 2005). We tested the relationship between liver fat and VLDL1 suppression
among subjects with a broad range of liver fat content (Adiels et al. 2007). From this
study we confirmed that liver fat predicts baseline VLDL1 production (Adiels et al.
2006b), and also that liver fat is associated with a lack of VLDL1 suppression in
response to insulin. Indeed, insulin downregulates VLDL1 secretion in subjects with
low liver fat levels, but fails to suppress VLDL1 secretion in subjects with high liver
fat levels, resulting in overproduction of VLDL1 (Adiels et al. 2007). The reason for
this lack of VLDL1 suppression is not known. Insulin suppresses the non-esterified
fatty acid (NEFA) pool to a similar extent regardless of liver fat level (Adiels et al.
2007), and thus the high VLDL1 production in individuals with high levels of liver fat
must be facilitated either by using a greater portion of systemic NEFA or recruiting
other sources of triglycerides, such as from hepatic stores. The data suggest that liver
fat content in obesity may be a better marker of metabolic derangement and CVD
risk than visceral obesity per se.
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Data on clearance of VLDL particles in metabolic diseases are less conclusive.
Studies show clearance to be slightly slower (Sorensen et al. 2011) (p = 0.08),
(Adiels et al. 2005a) (NS), (Ouguerram et al. 2003) (NS) and (Duvillard et al. 2000)
(P < 0.05) in type 2 diabetes. ApoCIII has been shown to be inversely correlated to
the rate of clearance of VLDL and VLDL1 (Chan et al. 2006, Taskinen et al. 2011).
But it has also been reported a relative deficiency of apoCIII in all triglyceride-rich
lipoprotein species in type 2 diabetic subjects (Hiukka et al. 2005). Despite the
increased plasma concentrations of apoCIII in these subjects, the concentration of
apoCIII does not increase in concert with core lipids. ApoCIII also is implicated in
the hepatic clearance of VLDL remnants (Gangabadage et al. 2008), which may
play an important role.

8.8

Conclusions

Insight into lipid metabolism, in particular the causative relation between production,
uptake and conversion of triglycerides, may be gained from in vivo kinetic studies.
Such information may be pivotal for our understanding of dysregulation plasma lipids
as well as for finding means to optimally treat dyslipidaemias.
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Chapter 9

Gut Microbiota in Metabolic Syndrome
Fredrik Bäckhed

Abstract The human gut is colonized by trillions of bacteria that complement our
own human genes with 150-fold more microbial genes. Acting at the intersection
between diet and host biology the gut microbiota can be considered a metabolic organ
that affects host physiology. Here we explore evidence that supports the hypothesis
that there is a dynamic interrelationship between our diet and gut microbiota that plays
an important role in nutrition as well as modulating energy balance. Furthermore,
the gut microbiota is altered in obesity and germ-free mice have reduced adiposity
and are protected against diet-induced obesity. Accordingly, the gut microbiota may
be considered an important environmental factor that contributes to obesity and
metabolic diseases.
Keywords Gut microbiota · Metabolism · Metagenome · Obesity

9.1

Introduction

We humans are much alike and our genomes are > 99 % identical and we all have
approximately the same human cellular composition. However, despite this similarity we differ drastically in our microbial communities. The greatest variation is
between body sites (Costello et al. 2009). For example, the difference in microbial
communities between a person’s mouth and gut is comparable to the difference in
microbial communities that reside in soil and seawater. Even within a body site, the
differences between people are not subtle and the gut communities can differ by
80–90 % at the species level (Turnbaugh et al. 2009; Costello et al. 2009).
The human gut microbiota is established at birth when our sterile gut is colonized by bacteria from our mothers and the environment (Reinhardt et al. 2009,
Dominguez-Bello et al. 2010). This initial microbiota develops into a complex
ecosystem in a predictable fashion determined by internal (e.g., oxygen depletion
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and the immune system) and external (e.g., mode of birth, impact of environment,
diet, hospitalization, and application of antibiotics) factors. Whereas the initial gut
microbiota exhibits relatively low diversity the adult microbiota is composed by
> 1,000 bacterial species of which 160 are found in > 50 % of the study population
(Qin et al. 2010). The adult gut microbiota is estimated to weigh 1.5 kg, which is
similar to the liver, and the microbiome contains 150–200 times as many genes as we
have in our own human genome (Qin et al. 2010, Xu and Gordon 2003). The gut microbiota should be considered a metabolic organ that can affect our metabolism and
physiology function on the intersection between our genetics and our ingested food.
Accordingly, obesity is associated with an altered gut microbiota and germ-free mice
have reduced adiposity and resistant to diet-induced obesity (Bäckhed et al. 2004,
2007; Ley et al. 2005, 2006). However, the underlying mechanisms are just being
clarified and will require a combination of clinical and animal studies.

9.2

Microbial Extraction of Energy and Storage
in Adipose Tissue

The gut microbiota contains an impressive suite of glycosidases and lyases that are
essential for degrading otherwise non-degradable polysaccharides from the diet and
ferment them to short chain fatty acids (SCFA) (Xu et al. 2003). Interestingly, the
microbiota of obese mice exhibit increased capacity to degrade complex polysaccharides and store these extra calories in as adipose tissue (Turnbaugh et al. 2006).
Similarly, germ-free mice have reduced capacity to degrade polysaccharides and the
reduced levels of SCFA reaching the liver from portal circulation in these mice is
associated with reduced lipogenesis (Bäckhed et al. 2004). In addition to salvage
energy by fermenting carbohydrates to SCFA the gut microbiota promotes glucose
absorption from the small intestine by a yet unidentified mechanism (Bäckhed et al.
2004). The increased levels of circulating SCFA and glucose act as substrates for
de novo lipogenesis in the liver by activating the key lipogenic transcription factors
sterol regulatory element binding protein 1c (SREBP-1c) and carbohydrate element
binding protein (ChREBP). These transcription factors in turn regulate the rate limiting lipogenic enzymes fatty acid synthase and acetyl-CoA caboxylase (Bäckhed
et al. 2004). The increased lipogenesis was confirmed when we applied LC-MS
based lipidomics to investigate how the gut microbiota affects the host lipidome. We
identified ∼ 100 triglyceride species that were increased in livers of conventionally
raised mice (Velagapudi et al. 2010). Furthermore, colonization was associated with
increased hepatic VLDL production which is transported to the adipose tissue for
storage (Bäckhed and Crawford 2010).
The gut microbiota does not only promote lipogenesis and VLDL production
it also facilitate storage in adipose tissue by increasing lipoprotein lipase (LPL)
activity. In white fat, LPL is regulated posttranscriptionally by nutritional status:
fasting reduces and refeeding increases enzyme activity. Angiopoietin-like protein
(Angptl4, also known as fasting-induced adipose factor) is an important regulator
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of LPL activity (Yoshida et al. 2002). Expression analysis revealed that the gut
microbiota regulates the expression intestinal Angptl4 expression and analysis of
germ-free Angptl4-/- mice revealed that the gut microbiota increase LPL activity
by suppressing Angptl4 and that this suppression was associated with increased
adiposity (Bäckhed et al. 2004, 2007). Accordingly, the gut microbiota has profound
effects not only on energy extraction but also on energy partitioning and can thus be
considered as an environmental factor that modulates adiposity.

9.3

Microbial Modulation of Host Metabolism

The gut microbiota does not only affect energy extraction but also affect host
metabolism by other means. We found that germ-free mice are resistant to dietinduced obesity (Bäckhed et al. 2007), which suggests that the gut microbiota may
have large effects on both central and peripheral metabolism. The observation that
germ-free mice are protected from developing diet-induced obesity has recently
been confirmed by several independent laboratories (Rabot et al. 2010; Fleissner
et al. 2010; Ding et al. 2010) and some additional mechanistic insights are currently
being made. Since ‘Western’ diet and other high-fat diets do not contain complex
polysaccharides the gut microbiota promotes obesity by other means than carbohydrate fermentation and recent evidence suggested that the gut microbiota modulates
several important pathways implicated in energy metabolism (Greiner and Backhed
2011).
The lean phenotype of germ-free mice is associated with increased levels of phosphorylated AMP-activated protein kinase (AMPK), and its downstream molecular
targets involved in fatty acid oxidation (acetylCoA carboxylase; carnitinepalmitoyltransferase) in skeletal muscle and liver (Bäckhed et al. 2007). AMPK is an enzyme
that functions as a “fuel gauge”, which monitors cellular energy status (Kahn et al.
2005) and may thus be responsible for the ability of germ-free mice to increase fatty
acid oxidation in skeletal muscle (Bäckhed et al. 2007). As mentioned above the gut
microbiota suppresses the intestinal expression of Angptl4, which in addition to its
effects on regulating LPL, also is a potent regulator of fatty acid oxidation (Mandard
et al. 2006). In support of these findings we observed that germ-free mice lacking
Angptl4 lost their protection from developing diet-induced obesity (Bäckhed et al.
2007). Further phenotypic characterization revealed that genes involved in fatty acid
oxidation were controlled by Angptl4 under germ-free conditions. Notably, Angptl4
did not signal via AMPK, which suggests that germ-free mice are protected against
diet induced obesity by two complementary but independent mechanisms that result in increased fatty acid metabolism. In addition the gut microbiota may affect
expression and function of other hormones that modulate host metabolism.
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9.4 The Gut Microbiota and Obesity
The gut microbiota is altered in obesity but is there direct evidence that the gut microbiota may affect obesity? Elegant experiments revealed such link by transplanting
the gut microbiota of lean and obese mice into germ-free recipients (Turnbaugh et al.
2006). Surprisingly, the lean and obese phenotypes were transferred to the recipients
where mice transplanted with an obese microbiota gained significantly more adipose
mass. A recent study identified that Toll-like receptor 5 (Tlr5), a pattern recognition
receptor that recognizes the bacterial protein flagellin, as an important modulator
of gut microbial ecology (Vijay-Kumar et al. 2010). Strikingly, the Tlr5-deficient
mice are associated with inflammatory bowel disorder as well as obesity and the
Metabolic Syndrome (Vijay-Kumar et al. 2007, 2010). Importantly, the obesity phenotype was transferrable to germ-free mice demonstrating that the phenotype was
caused by the microbiota. Further analysis revealed that the altered gut microbiota in
Tlr5-deficient mice was associated by increased food intake thus suggesting that the
gut microbiota may affect the central nervous system. Furthermore, it is becoming
increasingly clear that the gut microbiota modulates behavioral aspects of animal
physiology. For example, the germ-free mice have increased locomotors activity and
display altered anxiety behavior (Bäckhed et al. 2007; Heijtz et al. 2011). Accordingly, the gut microbiota does not only modulate peripheral metabolism but can also
affect eating and behavioral phenotypes.

9.5 The Gut Microbiota as Modulator of Glucose Metabolism
In addition, to microbial effects on host adiposity the gut microbiota also contributes
to metabolic abnormalities by promoting low-grade metabolic inflammation (Cani
et al. 2007). Endotoxin is taken up from the gut together with chylomicrons or
alternatively through increased gut permeability (reviewed in (Caesar et al. 2010)).
Activation of TLR4 in macrophages that are recruited to the adipose tissue promotes
inflammation that reduces insulin sensitivity (Saberi et al. 2009). Germ-free mice
are exposed to very low levels of endotoxin from the diet but the levels are very
low compared to those observed in colonized mice. As expected germ-free mice
have reduced adipose inflammation and improved insulin sensitivity compared with
colonized counterparts (Bäckhed et al. 2004; 2007; Rabot et al. 2010; Reigstad
et al. 2009). Interestingly, antibiotic treatment of obese mice with antibiotics reduces
plasma endotoxin levels, adipose inflammation, adiposity, liver triglycerides, and
improves host glucose metabolism (Cani et al. 2008; Membrez et al. 2008). Taken
together these findings suggest that the gut microbiota can contribute directly to host
metabolism by affecting energy harvest from the diet and by modulating metabolic
and/or inflammatory signaling pathways.
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Systems Biology Approaches to Investigate Host
Microbial Interactions

The gut microbiota has an immense propensity to affect the metabolism of ingested
compounds such as dietary, drug, and xenobiotic components. Recent metabolomic
and lipidomic studies of germ-free and colonized mice have revealed that the gut
microbiota affects several important biotransformations that may have large effects
on host physiology (Claus et al. 2008; Velagapudi et al. 2010; Wikoff et al. 2009).
Untargeted mass spectrometry-based metabolomics of serum from germ-free and
conventionally raised mice demonstrated that a vast majority of the serum metabolites were modulated by the gut microbiota (Wikoff et al. 2009). Many of these
metabolites corresponded to increased xenobiotic metabolism in colonized mice and
included metabolites that were sulfated, glucoronidated, or conjugated to glycine
(Wikoff et al. 2009; Claus et al. 2008), which renders hydrophobic compounds water soluble. Tyrosine can be metabolized to p-cresol sulfate sulfatation by the gut
microbiota and thus germ-free mice have reduced serum levels of p-cresol sulfate
and corresponding elevated levels of tyrosine (Wikoff et al. 2009). The capacity
of the gut microbiota to perform such modifications contributes to an individual’s
capacity to perform xenobiotic metabolism as individuals with high bacterially mediated p-cresol generation have reduced with O-sulfonation of widely used analgesic
paracetamol (acetaminophen; (Clayton et al. 2009)). These findings may provide a
mechanism for why pre-dose urinary composition can be used to predict the extent
of liver damage sustained after paracetamol administration (Clayton et al. 2006).
Metabolism of other amino acids such as tryptophan is also modulated by the gut
microbiota. Serum levels of tryptophan are accordingly reduced in colonized mice
compared with germ-free counterparts (Velagapudi et al. 2010; Wikoff et al. 2009),
which can be explained by that the gut microbiota expresses tryptphanase which
converts tryptophan to indole, pyruvate, and ammonia. Further metabolism of indole
to indole-3-propionic acid is exclusively microbially mediated and thus IPA was
only detected in the serum of conventionally raised mice (Wikoff et al. 2009). IPA
is further metabolized by host enzymes in the liver to indoxyl and indoxyl sulfate.
Furthermore, serotonin is produced from tryptophan by enterochromaffin cells in the
gut and accordingly germ-free rats have increased volumes of serotonin producing
cells (Uribe et al. 1994). Taken together, microbial metabolism of amino acids may
have profound effects on host physiology.

9.7

Using Metabolomics to Identify Microbial Metabolites
in Disease

The above examples illustrate how the gut microbiota effects may affect host physiology by modulating metabolism of dietary components. Accordingly, metabolomic
investigations of urine from mice predisposed or resistant to developing nonalcoholic
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fatty liver disease revealed that susceptible mice were associated with increased microbial conversion of phosphatidylcholine to trimethylamines (TMA), which are
excreted into the urine. Mechanistically, the reduced levels of phosphatidylcholines
may promote steatosis and insulin resistance since phosphatidylcholines are required for VLDL secretion and impaired VLDL secretion could lead to triglyceride
accumulation in the liver. However, recent findings revealed that metabolism of dietary choline to TMA is associated with cardiovascular disease and plasma levels
of choline-derived metabolites are a excellent predictor of cardiovascular disease
(Wang et al. 2011). Accordingly, dysbalanced choline metabolism by altered gut
microbial structure/function may affect host metabolism and physiology.

9.8 Targeted Approaches to Determine Microbial Regulation
of Specific Classes of Metabolites
9.8.1

Bile Acids

Metabolism of bile acids is another example of mammalian-microbial co-metabolism
that may have great physiological effects (Claus et al. 2008; Martin et al. 2007; Swann
et al. 2010). The gut microbiota is important for deconjugation, dehydrogenation,
and dehydroxylation of bile acids, which results in secondary bile acids and increases
the chemical diversity of these signaling molecules (Midtvedt 1974). Accordingly,
germ-free animals have very simplified bile acids characterized by conjugated cholic
and murocholic acids, which are absorbed before they reach the distal gut (Claus
et al. 2008; Swann et al. 2010; Wostmann 1973). Bile acids have different capacity
to induce the nuclear receptor FXR and the G-coupled receptor TGR5 (Thomas
et al. 2008). Furthermore, bile acids have been shown to regulate not only their
own synthesis and enterohepatic recirculation, but also triglyceride and cholesterol
homeostasis through activation of FXR (Sinal et al. 2000). Interestingly, bile acids
reduce diet-induced obesity and prevent hyperglycaemia in rodents, which suggests
that they also have effects on energy homeostasis (Ikemoto et al. 1997; Prawitt et al.
2011; Watanabe et al. 2011).
In contrast, bile acid activation of the GPCR TGR5 in brown adipose tissue
increases energy expenditure by producing active tri-iodothyronine (T3 ), which subsequently increases metabolic rate and energy expenditure (Watanabe et al. 2006).
Accordingly, stimulation of TGR5 prevents diet-induced obesity (Thomas et al.
2009). Recent data demonstrated that TGR5 also is expressed by L-cells in the
colon and activation of TGR5 in L-cells induce secretion of the incretin GLP-1,
which promotes improved pancreas function and glucose metabolism in obese mice
(Reimann et al. 2008; Thomas et al. 2009). However, it is currently unclear whether
this protection requires TGR5 activation in brown adipose tissue or in L-cells.
The immense capacity of the gut microbiota to modulate bile acid diversity clearly
indicates that signaling through FXR and TGR5 are influenced by the gut microbiota.
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This was recently illustrated by that the gut microbiota modulated FXR-regulated
pathway transcripts in gnotobiotic rats (Swann et al. 2010) and suggests that new
pharmacological approaches targeting bile acid signaling networks must take the
person’s gut microbiota into account.

9.8.2

Short Chain Fatty Acids

Fermentation of fibers in the distal gut produces SCFAs, which has important signaling functions in the gut through the GPCRs GPR41 and GPR43. Enteroendocrine
cells express the SCFA receptor GPR41 and may thus be regulated through the fermentation capacity of the gut microbiota. There are no apparent differences in the
body composition of germ-free wildtype and Gpr41-deficient mice (Samuel et al.
2008). However, colonized Gpr41-deficient mice were leaner, which was associated with decreased expression of the hormone PYY. GPR43 was first identified
as a modulator of inflammatory responses in the gut as a chemoattractant receptor
on neutrophiles (Maslowski et al. 2009). Besides its effects on host inflammation
GPR43 has profound effects on host physiology. Bjursell et al., recently found that
Gpr43-deficient mice were resistant to diet-induced obesity (Bjursell et al. 2010).
Protection against developing diet-induced obesity was, at least in part, explained
by increased energy expenditure in Gpr43-deficient mice and the reduced fat mass
was accompanied by improved glucose tolerance. Despite no difference in adipocyte
size Gp43-/- mice contained fewer macrophages in the white adipose tissue, which
may explain the improved glucose metabolism.

9.8.3

Endocannabinoids

Anandamide (AEA) is an endogenous endocannabinoid (eCB) that is synthesized
from membrane bound phosphatidylethanolamine. AEA binds the eCB receptor
CB1 , which has profound effects on host metabolism. Genetic and pharmacological interference with the CB1 receptor protects against the development of hepatic
steatosis and diet-induced obesity (Osei-Hyiaman et al. 2005, 2008). Recent results
using several animal models demonstrated that the gut microbiota modulates AEA
levels in the colon but not in the small intestine and that the elevated levels correlated
with reduced expression of fatty acid amide hydrolase (FAAH), which degrades AEA
(Muccioli et al. 2010).
Obesity is associated with increased production of adipose derived eCB, increased
CB1 expression, and increased gut permeability (Cani et al. 2007; Di Marzo 2008).
Pharmacologic inhibition of CB1 in obese mice improved tight junction, reduced gut
permeability, leading to reduced serum endotoxin levels (Muccioli et al. 2010). Thus
it is possible that the gut microbiota controls gut permeability through modulating the
endocannabinoid system. As indicated above the gut microbiota has extensive effects
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on host adiposity, as well as on the eCB system in adipose tissue. Strikingly, prebioticmediated decreases in fat mass, reduced CB1 mRNA expression, and reduced AEA
levels were associated with increased expression of markers of adipocyte differentiation and lipogenesis suggesting a role of the gut microbiota. Importantly, these
results were phenocopied by blocking CB1 receptor signaling (Muccioli et al. 2010).
Conversely, agonists of CB1 increased adipogenesis in lean mice. Since CB1 function is associated with plasma LPS levels Muccioli et al hypothesized that LPS could
modulate eCB -induced adipogenesis. Accordingly, LPS reduced the expression of
adipogenic and lipogenic markers in adipose tissue. Furthermore, LPS completely
abolished the adipogenic effects of eCB receptor activation. Taken together, these
data suggest that the eCB system regulates adipogenesis, which is controlled by LPS.
In summary, the gut microbiota affects several important signaling systems that
contribute to controlling host metabolism these include, but are likely not limited to
the SCFA, bile acid, and eCB system.

9.9

Conclusions

The recent identification of the gut microbiota as an environmental factor that contributes to metabolic diseases has spurred research all over the world. At present
several studies have demonstrated an altered gut microbiota that is associated with
obesity. However, the results are highly variable between studies, likely in part
due to different analytical procedures, heterogeneous populations, and relatively
small study groups. Accordingly, well controlled studies are required to parse out
the relevant differences between the gut microbiota between lean and obese individuals, furthermore, the gut microbiota should also be studied in other metabolic
diseases such as diabetes and cardiovascular disease. Accordingly, systems biology
approaches to construct metabolic networks and putative functions encoded in the
microbiome, which are associated with specific metabolic phenotypes in the host
(including obesity, diabetes, and cardiovascular disease), will be of utmost importance to gain understanding in how the gut microbiota may affect host metabolism.
However, one limitation with this approach is the lack of direct mechanistic understanding. An attractive tool to investigate mechanisms is to use ‘personalized’
gnotobiotics where germ-free mice are colonized with defined microbial communities and subsequently phenotyped. In these models interventions can be tested as well
as the impact of specific macro- and micronutrients (Kau et al. 2011). The usage of
genetically manipulated mouse models, especially tissue specific, will provide further evidence for host factors involved in specific signaling pathways or biological
processes. However, to fully understand the intricate interplay between the gut microbiota, host, and metabolism we will need to integrate data from several ‘omics’
technologies such as metagenomics, transcriptomics, proteomics, and metabolomics
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Part III

Key Technologies to
Study Metabolic Syndrome

This section introduces some of the key technologies used to tackle metabolic
syndrome, and review how they have been applied using systems biology approach.

Chapter 10

Proteomics in the Systems-Level Study
of the Metabolic Syndrome
Isabel Rubio-Aliaga, Irma Silva-Zolezzi, Michael Affolter, Loı̈c Dayon,
Alexandre Panchaud and Martin Kussmann
Abstract Proteomics has come a long way from the initial qualitative analysis of
proteins present in a given sample to the large-scale characterization of proteomes,
their interactions and dynamic behaviour in time and space. Originally enabled by
breakthroughs in protein separation and visualization (by two-dimensional gels electrophoresis) and protein identiﬁcation (by mass spectrometry), the discipline now
encompasses a large body of protein and peptide separation, labelling, detection and
sequencing tools supported by stable-isotope- and label-free techniques and computational data processing for quantitative proteomics. The key functional importance
to investigate the protein complement has driven the study of proteomes in numerous
physiological and pathological conditions. Proteomics has been mainly applied in
discovering novel biomarkers of disease, evidenced by the fact that most clinical
tests today measure proteins in blood. Moreover, understanding the proteome helps
investigate health and disease states and understand the mechanisms of action of
speciﬁc molecules, e.g., nutrients or drugs. Here, we brieﬂy recapitulate proteomic
technologies and cover their evolution to today’s and future cutting-edge platforms.
Then we review and discuss proteomic applications to the study of the metabolic
syndrome.
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Proteomics, a Key Technology in Systems Biology

Proteomics is the large scale measurement of the proteome (the protein complement
of a cell, organ or even organism) at a given time and state. In systems biology,
proteomics complements genomics, transcriptomics and metabolomics, to holistically investigate biological phenomena at the molecular level. Main challenges
in proteomics are: (i) the interrogation of not only the expression of proteins, but
also their interactions, functions, modifications and structures; (ii) the large variety of proteins found in biological samples due to post-translational modifications;
and (iii) the dynamic range of the proteome, i.e., the wide concentration range of
proteins, especially in plasma. This complexity has led to the development of a
multitude of technologies for large-scale measurements of proteins. Previously, proteins had been classically studied individually or in small numbers. Advances in two
key technologies have contributed to the rapid rise of proteomics : the development
of soft ionization techniques for mass spectrometry, namely electrospray ionisation
(ESI) and matrix-assisted laser desorption/ionisation (MALDI), enabling sequencing
of proteins and peptides; and advanced liquid chromatography (LC) (Mallick and
Kuster 2010). In this first part an overview of the status, advances and perspectives
of proteomic technologies and approaches in biology is given.

10.1.1

Proteomic Concepts and Challenges

The “proteomic gold rush” in the later 1990’s and early 2000’s was mainly justified by
several findings and assets that make proteomics an essential activity in life science
research:
i. The availability of complete genomic sequences is not sufficient to derive
biological function.
ii. Proteomics complements genomics by focusing on the gene products active in
a cell, and therefore delivers information closer to the observed phenotype.
iii. Proteins are involved in all biological processes, such as trafficking, signalling,
catalysis and they have structural functions; therefore, proteins are highly
informative to understand biology.
iv. Gene expression and protein abundance do not always correlate linearly and,
therefore, the proteins have to be determined directly (Gygi et al. 1999b).
v. Even with modern bioinformatic algorithms prediction of gene products from
genomic data remains difficult; hence, verification of a gene product by
proteomic methods is important for annotation.
vi. Prediction of protein modification or localization is barely possible at the DNA
level; hence proteomics is indispensable for the elucidation of protein isoforms,
post-translational modifications and gene product localization.
vii. Protein regulation mechanisms, protein-protein interactions or protein complex
structures can be only determined at the protein level.
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Unfortunately, during the last two decades, the three hopes set on proteomics, namely
(i) a complete map of the human proteome; (ii) identification of many new clinical
biomarkers; and (iii) the development of new drug candidates, have only been partly
fulfilled. Mainly two factors have tempered these hopes:
i. The complexity of the proteome.
ii. The dynamics of the proteome.
In comparison to the human genome with approximately 25,000 genes, the proteome
has been estimated to encompass around 1 million different protein species (Jensen
2004). This divergence in quantity is due to more than 300 post-translational (e.g.,
protein lysine acetylation) and post-transcriptional modifications (e.g., phosphorylation). Moreover, proteogenomics has emerged, i.e., the identification of protein
coding genes by proteomics, suggesting that the amount of coding genes may be
higher than assumed (Ahrens et al. 2010). This complexity of the proteome is further augmented by the fact that proteins are rarely functioning as single molecules
but rather as complexes with other proteins or smaller molecules. In addition to
this complexity, proteins in biological samples display an enormous concentration
range. In human plasma, the estimated protein concentration range is 1010 –1012 ,
and represents 6–8 orders of magnitude difference in human cells (Lescuyer et al.
2007). Additionally, the hallmark of a proteome is its ability to regulate protein
expression dynamically in response to physiological, pathophysiological and environmental conditions. This complexity renders proteomics a challenging task and the
fact that protein analysis lacks the equivalent of polymerase chain reaction (PCR)
amplification does not make it simpler (Domon and Broder 2004).
Despite these challenges, remarkable progress has been achieved in the last
decades, positioning proteomics as a leading technology in life sciences research.
Depletion of abundant and/or enrichment of less prominent proteins have been combined and extensive protein and peptide pre-fractionation techniques are in place to
achieve deeper proteome coverage. In addition, current mass spectrometric (MS)
platforms can cover a wider dynamic range due to improved instrumentation that offers better sensitivity and specificity, the latter based on superior mass accuracy and
resolution (e.g., Orbitrap analyzer (Hu et al. 2005)). Finally, excellent software for
peptide sequencing and protein identification is in place (e.g., Phenyx (Colinge et al.
2003), OMSSA (Geer et al. 2004), X!Tandem (Craig and Beavis 2004) or VEMS
(Matthiesen et al. 2003; Matthiesen et al. 2004; Matthiesen et al. 2005)). The computing tools for proteomic data processing have evolved from scoring mass spectra with
regard to their fidelity for peptide sequence read out to assessing the trade-off between
false-positives (specificity) and false-negatives (sensitivity) in a data-dependent manner, eventually leading to computational data validation (PeptideProphet (Keller et al.
2002) and ProteinProphet (Nesvizhskii et al. 2003)).
Yet, we are far from looking at the totality of the plasma proteome, to mention the
clinically most relevant sample for protein biomarkers. Filling the clinical biomarker
and drug discovery pipelines has not become a reality because of the difficulty to
translate protein identifications into candidate markers and these into targets that deserve follow-up. Additionally, many of the marker/target validation technologies are
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still low-throughput and require multi-centre collaboration: in vivo validation takes
much longer than in vitro discovery (Alaiya et al. 2005). Moreover, the pay-off for
taking a protein biomarker to the bed-side test has so far been small in economic
terms (Alaiya et al. 2005). However, the fact that many if not most clinical tests today measure proteins should encourage further efforts in the use and improvement of
proteomics-based biomarker discovery strategies. Probably one of the better known
examples is the use of liver transaminases for liver cell destruction (Amacher 1998).
A few successful proteomics-derived biomarkers can be cited: (i) The 14-3-3 proteins
in cerebrospinal fluid (CSF) as markers for types of brain destruction such as those
found in Creutzfeldt-Jakob Disease (CJD) (Hsich et al. 1996); (ii) stroke biomarkers
discovered in the spinal fluid that have been clinically validated in serum (Lescuyer
et al. 2007). Recently, the Food and Drug Administration (FDA) approved the first
proteomics-discovered diagnostic test, OVA1, a panel of proteins that allows the
identification of malignant ovarian tumors preoperatively. Further technological advances allow the reliable and consistent measurement of plasma proteins in such low
concentrations as nanogram per millilitre in high-throughput matter; together with
well-established guidelines for designing clinical studies, standardized procedures
and quality assessment should improve the efficiency of clinical biomarker studies
using proteomics in the near future (Surinova et al. 2011).

10.1.2

Protein and Peptide Analysis

No general method enables the identification and quantification of all proteins in
a given sample by using one single technology, in contrast to DNA microarray
(Schena et al. 1995), where the whole gene expression profile can be obtained from
the total extracted mRNA with automated systems (Raymond et al. 2006). While
genome-wide microarrays are available (MacBeath and Schreiber 2000; Ptacek et al.
2005), proteomics laboratories have developed and tested a wide range of alternative
techniques and use an ample biochemical toolbox to achieve their goals.
The typical methodology applied in proteomics involves protein extraction from
biological samples, digestion of the proteins typically with trypsin, followed by extensive fractionation of the resulting peptides, and analysis of these in each fraction
using a mass spectrometer (Ahrens et al. 2010). There are five basic types of mass
analyzers currently used in proteomics (Aebersold and Mann 2003; Ptacek et al.
2005) : ion trap (IT), time-of-flight (TOF), quadrupole (Q), Fourier-transform ion
cyclotron resonance (FT-ICR), and Orbitrap (OT) (Hu et al. 2005; Ptacek et al. 2005).
Often, they work as stand-alone mass analyzer, but the current trend is to combine the
advantages of different analyzers in one hybrid mass spectrometer: triple-Q, Q-IT,
Q-TOF, IT-TOF, TOF-TOF, IT-FT-ICR, IT-OT or Q-OT tandem mass spectrometers are all capable of protein or peptide sequencing. IT-FT-ICRs and IT-OTs are
especially efficient when combined with fragmentation techniques such as electroncapture dissociation (ECD) or electron-transfer dissociation (ETD) (Ptacek et al.
2005; Syka et al. 2004a).
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Apart from the traditional and increasingly phased out 2D gel electrophoresis
(GE), two main concepts are currently applied to deal with proteome complexity and
dynamic range: extensive fractionation using separation techniques such as multidimensional protein identification technology (MudPIT) (Washburn et al. 2001) or
enrichment/depletion using affinity-based techniques (Righetti et al. 2005; Righetti
et al. 2006; Righetti and Boschetti 2007).
Most of LC tandem mass spectrometry (MS/MS)-based proteomic studies rely
on on-line LC-ESI systems. However, to combine features of the MALDI technique,
where peptides can be immobilized on a target plate, with the separation power of
liquid chromatography, LC-MALDI was developed in an automated off-line mode
(Zhen et al. 2004). Comparisons of LC-ESI-MS/MS and LC-MALDI-MS/MS have
revealed the complementarities between the two strategies.

10.1.3

Protein and Peptide Identification and Validation

In MS/MS a precursor ion with known mass selected from the survey scan is fragmented and provides sequence data, which enables more confident identification of
peptides. This process is described as peptide mass sequencing (PMS) as opposed
to PMF (peptide mass fingerprinting, i.e., using sets of peptide masses only). Identification of proteins using MS/MS data is nowadays performed using three different
approaches: (i) peptide sequence tag (Mann et al. 1993; Mann and Wilm 1994; Sunyaev et al. 2003; Tabb et al. 2003); (ii) cross-correlation method (Eng et al. 1994;
Hansen et al. 2001); and (iii) probability-based matching (Colinge et al. 2003; Craig
and Beavis 2004; Matthiesen et al. 2003; Matthiesen et al. 2004; Matthiesen et al.
2005; Perkins et al. 1999).
The simple case scenario in terms of identification would be to use only the mass
information of a peptide as a unique signature without the need to spend time for
MS/MS. Such approaches have already been described as the “accurate mass tag”
(AMT) approach (Conrads et al. 2000; Zubarev et al. 1996). In this technique,
instruments providing sub-ppm (0.1 ppm) mass accuracy are needed. However, even
with such accuracy, high levels of confidence in protein identifications can only
be achieved in small eukaryotic systems (e.g., yeast). Additional information such
as isoelectric point or LC elution time are needed to confidently identify a protein
without using MS/MS (Cargile and Stephenson 2004; Norbeck et al. 2005; Palmblad
et al. 2004).
Liquid chromatography combined with MS/MS is the preferred and most established method to conduct large-scale characterization of proteomes, together with
peptide mass sequencing search engines. One of the major problems of such sequence search engines is that they return false positive results. In the case of small
datasets, this can be solved by manually verifying and validating the spectrum-topeptide assignment. In the case of large datasets with tens of thousands of spectra,
such a time-consuming approach is not feasible. Two main strategies have been developed to meet this challenge: the first is based on a robust and accurate statistical
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model exemplified by PeptideProphet and ProteinProphet in the Trans-Proteomic
Pipeline (Keller et al. 2002; Nesvizhskii et al. 2003). Each spectrum-to-peptide assignment is compared with machine-learning techniques to all other assignments in
the datasets and computes for each spectrum-to-peptide assignment a probability of
being correct. The second strategy relies on database search using a target-decoy
database (Elias et al. 2005; Elias and Gygi 2007; Peng et al. 2003; Perkins et al.
1999) : first an appropriate “target” protein sequence database is generated and then,
a “decoy” database typically generated by reversing or scrambling the target protein
sequences, is created. The search is done against both the target and the composite
databases. One can estimate the total number of false positives (FPs) assuming that
no correct peptides are found in both the target and decoy entities and that incorrect
assignments from target or decoy sequences are equally likely. Neither one of the
approaches can claim to remove all false positives but both help researchers to share,
compare and publish data with a defined false discovery rate (Lisacek et al. 2006;
Matthiesen 2007).

10.1.4

Protein and Peptide Quantification

In proteomics we distinguish between relative quantification, defined as the amount
of a protein relative to another measurement of the same protein in another state
(e.g., protein expression changes after drug treatment or nutritional intervention),
and absolute quantification, which delivers the absolute amount of proteins in a
given sample.
All current discovery proteomic methods are relative methods. Absolute quantification of peptides as protein surrogates can be achieved with isotopically labelled
synthetic peptides and mass spectrometry, a method known as AQUA (Gerber et al.
2003). Yet, the availability of such standard peptides in defined amounts is a limited.
A way to partially overcome this bottleneck is the QCAT (Beynon et al. 2005) or
QconCAT (Pratt et al. 2006) technique, in which an artificial gene is used for expression, labelling and purification of a corresponding artificial protein, which represents
a concatemer of tryptic peptides representing several known proteins. However such
method requires a priori knowledge of the target proteins and the preparation of isotopically labelled synthetic peptides for each targeted protein. MS peptide detection
has a Boolean nature, and therefore, so called “proteotypic” peptides—peptides being a unique identifier and optimally representing the protein in chromatography and
MS behaviour—have to be synthesized to ensure absolute quantification at global
scale (Kuster et al. 2005; Mallick et al. 2007).
While still being widely deployed, “gel-based” quantitative proteomics has been
largely superseded by “gel-free” MS-based quantitative proteomics approaches. As
in the gel approach, where the protein staining intensity within a gel is not necessarily proportional to the amount present in the sample, in both MALDI- and ESI-MS
the relationship between the amount of protein or peptides present and the measured signal intensity is incompletely understood. Moreover, the reproducibility of
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a peptide/protein signal between different runs is limited. To improve quantification
performance of mass spectrometers different approaches have been developed:
A first solution came with the technique of stable-isotope dilution (SID). Pairs
of chemically identical molecules (in this case peptide pairs), but with different
stable-isotope composition (13 C instead of12 C, 2 H instead of1 H,18 O instead of16 O
or15 N instead of14 N) can be differentiated in a mass spectrometer owing to their mass
difference. Thus, the ratio of signal intensities should be a direct and accurate measure
of the abundance ratio between the two peptides/proteins. Three main approaches
exist today: (i) metabolic stable-isotope labelling, (ii) isotope tagging by chemical
reaction and, (iii) stable-isotope incorporation via enzyme reaction.
A well established metabolic method is stable isotope labelling with amino acids
in cell culture (SILAC) (Ong et al. 2002), in which amino acids containing stable
isotopes, like arginine with six 13 C atoms, are supplied in growth media. Several
amino acids have been used such as leucine, which labels 70 % of tryptic peptides
(Foster et al. 2003). Taking advantage of trypsin preferentially cleaving proteins at
arginine and lysine residues at the C-terminus, the incorporation of heavy lysine
and arginine combined with subsequent tryptic digestion results in stable-isotope
labelling of all peptides (Ibarrola et al. 2003). The principal advantages of metabolic
labelling over chemical labelling are the earliest possible introduction of the label into
the living cells, immediate pooling of case and control and the concomitant reduction
of parallel sample preparation bias and the absence of chemical side reactions. These
methods can be applied to cultured cells like bacteria or yeast, and also to higher
organisms by incorporating the labelled amino acids in their food. Examples include
Caeonorhabditis elegans, Drosophila melanogaster (Krijgsveld et al. 2003), plants
(Ippel et al. 2004) or even a rat by using15 N-labeled algae (Wu et al. 2004).
All isotopically labelled chemical reagents target reactive sites on a protein or
peptide and the two proteomes to be compared are labelled with the light and
heavy reagent, respectively. Isotope-coded affinity tagging (ICAT) was the first approach described in 1999 (Gygi et al. 1999a). A recent evolution of this method is
called catch-and-release (CAR) (Gartner et al. 2007). Isotope-coded protein labelling
(ICPL) (Schmidt et al. 2005), targets all amino groups at the protein level. Isobaric
tags for relative and absolute quantification (iTRAQ) (Ross et al. 2004) use the same
chemistry as ICPL (labelling at protein or peptide level) but generates a specific
reporter ion for quantification in tandem mass spectra (mass 114, 115, 116, 117)
and this with isobaric mass at MS level. Multiplexing (currently eight-plex) is an
interesting feature of this technique as it allows comparing more than two conditions.
Carboxylic groups have also been labelled using either methyl (Goodlett et al.
2001) or ethyl (Syka et al. 2004b) esterification at peptide level. Yet, both methods
use deuterium atoms and therefore bear the risk of chromatographic discrimination;
plus the mass offsets of 2 Da (methyl) and 4 Da (ethyl) pose problems of isotopic
overlap of the peptide pairs. A technique called AniBAL (Panchaud et al. 2008)
labels both amino and carboxylic groups at the protein level using two symmetrical
tags with six times13 C, thereby addressing the previously mentioned caveats.
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A clear advantage of these chemical approaches is the availability of functional
groups in proteins allowing the design of almost any kind of quantitative tag. Enrichment is also an asset, as it reduces sample complexity without losing quantitative
information. However, reactions must be specific, proceed to completion, minimize
sample handling and avoid side reactions. Despite these constraints, chemical stableisotope labelling has contributed importantly to quantitative proteome data, mainly
due to its chemical versatility and its applicability to any biological sample.
Promising “label-free” approaches have emerged in quantitative proteomics. The
peptide match score summation (PMSS) is semi-quantitative and based on the assumption that a protein score is the sum of identification scores of its peptides and
that the protein score is correlated with abundance (Allet et al. 2004). Another similar
approach relies on counting the spectra that identify a protein, the so-called spectrum
sampling (SpS) (Liu et al. 2004). Protein abundance indices (PAIs) are believed to
be more reliable as they are based on observable parameters, e.g., the number of
peptides identifying a protein that rises with increasing protein amount. As a larger
protein will statistically generate more measurable peptides than a smaller one, a
simple PAI can be derived by normalizing the number of observed peptides with the
number of observable peptides for the protein under consideration (Rappsilber et al.
2002; Sanders et al. 2002). Ishihama and colleagues have described an exponentially
modified PAI (emPAI) by observing a logarithmic relationship between the number
of peptides observed and the protein amount within a given sample (Ishihama et al.
2005).
Two proteomes can be directly compared label-free when analyzed one after the
other and in exactly the same way (Chelius and Bondarenko 2002; Lasonder et al.
2002). Software exists to extract the intensities of the same peptide observed in
two separate runs to compare and determine their relative abundance (e.g., MSight
(Palagi et al. 2005), SuperHirn (Mueller et al. 2007), MapQuant (Leptos et al. 2006),
SpecArray (Li et al. 2005) or VEMS (Matthiesen et al. 2004; Matthiesen et al. 2005;
Matthiesen 2007)). A clear advantage of such method is the absence of any label and
the applicability to any type of instrument. Clear drawbacks are multiple occasions
for quantification errors occurring during parallel sample processing, analysis and
the need for very accurate and reproducible replicate LC-MS runs.

10.1.5

Uncoupling Intact Mass Acquisition from Sequencing
and Transferring Peptide Separation from the Liquid
to the Gas Phase

Figure 10.1 summarizes contemporary techniques to (pre-)separate, mass-measure,
sequence and quantify proteomes and peptidomes. Essentially, today’s proteomics
starts with a tissue, cell or body fluid sample which is subsequently decomplexified,
typically at both biological (organelle isolation) and biochemical (protein/peptide
fractionation) level. Separation has traditionally consisted of protein-level gel-based
techniques, which are increasingly outperformed and replaced by peptide-level LC
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Fig. 10.1 Schematic overview on modern proteomics workflows including sample preparation,
protein/peptide fractionation, cell/protein/peptide-level stable-isotope labeling, and mass spectrometric (MS) data acquisition. (IEF) isoelectric focusing; (LC) liquid chromatography; MSE :
precursor-independent acquisition of intact and fragment masses; MS/MS: tandem mass spectrometry; (PAcIFIC) precursor acquisition independent from ion count; (RP) reversed phase; RP2 :
tandem reversed phase

or isoelectric focussing (IEF). Quantification is enabled by either protein staining or
protein/peptide mass labelling or without any label at all and, finally, data acquisition
has classically been done in a data-dependent acquisition (DDA) manner, i.e., by
selecting precursor peptide ions for further fragmentation.
Today’s proteomics workflows need to optimize the trade-off between effort and
yield, i.e., between throughput and resource-use on the one hand and completeness
of proteome coverage on the other. This is increasingly being achieved by: (i) maximizing sample specificity if sample amount allows for it (e.g., pure cell populations
or cell organelles); (ii) multiplexed depletion of the most abundant proteins (possibly
complemented by some biochemical enrichment); and, very importantly, (iii) transferring peptide fractionation from the liquid to the gas phase (i.e., restricting liquid
phase separation to 1D (or on-line 2D applying a pH step) LC plus gas phase fractionation (GPF)); plus, equally relevant, (iv) data-independent acquisition (DIA) of intact
and fragment peptide masses, which results in uncoupling mass determination from
sequencing (Precursor acquisition independent from ion count (PAcIFIC) (Panchaud
et al. 2009); precursor-independent acquisition of intact and fragment masses (MSE )
(Bateman et al. 2002; Geromanos et al. 2009); and the so-called swath-MS technique (Gillet et al. 2012). Approaches (iii), (iv) and (v) result in a split into smaller
mass acquisition windows plus acquisition of all intact masses and/or, independently,
all fragment masses (with a retrospective software-based reconstruction of the peptide/protein context). Such GPF (DDA) and PAcIFIC (DIA) routines have shown to
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Fig. 10.2 The continuum and trade-off of proteomic platform properties. The range spans from
highly versatile, “open” and flexible mass spectrometric approaches; via more sensitive, but also
more “closed” and restricted array-like platforms such as DNA aptamers (Brody et al. 2010; Gold
et al. 2010); to cell surface proteome-oriented technologies such as cell surface capture (Wollscheid
et al. 2009) and mass cytomics (Bendall et al. 2011)

deliver deeper proteome coverage and better reproducibility (Panchaud et al. 2009;
Panchaud et al. 2011; Scherl et al. 2008), because they alleviate the highly stochastic
nature of classical DDA MS/MS experiments and because fractionation in the mass
spectrometer is more reproducible than liquid-phase separation.

10.1.6

Proteomics Beyond Classical “Mass Spectrometry-Only”
Platforms

Mass spectrometry has developed into the key technology player in proteomics and
will most likely consolidate this role, mainly thanks to the information-richness of
mass spectra and the wide compatibility of mass spectrometers in terms of samples,
molecules, methods and point-of-analysis. However, the present and future challenges of delivering complete, accurate, time-resolved, and quantitative proteomes
of higher organisms—especially in view of the emerging complexity of genome
regulation at epigenetic and other levels—cannot be met by classical, exclusively
MS-based platforms alone, even considering the continuing impressive improvements in accuracy, reproducibility, robustness, user friendliness and throughput.
Rather, depending on the nature of the proteomic task, a set of complementary
technologies is already and will increasingly be required.
Figure 10.2 shows the continuum and trade-off of proteomic platform properties:
the range spans from highly versatile, flexible MS approaches; via more sensitive, but
also more “closed” or restricted array-like platforms such as DNA aptamers (Brody
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et al. 2010; Gold et al. 2010); to cell surface proteome-oriented technologies such
as cell surface capture (Wollscheid et al. 2009) and mass cytomics (Bendall et al.
2011).
DNA aptamers: A new aptamer-based proteomic technology for biomarker discovery has recently been described. The platform can simultaneously measure thousands
of proteins from a few millilitres of human serum or plasma. The described assay measured over 800 proteins with a median LOD of 1 pM, covered a dynamic
range from 100 fM to 1 mM, and exhibited only 5 % median coefficient of variation.
The basis of this technology is a new generation of DNA aptamers, i.e., chemically modified nucleotides with greatly expanded physicochemical diversity. The
measurement process transforms protein concentrations values into DNA aptamer
concentration signatures, with the latter being quantified on a DNA microarray,
thereby enabling a PCR-like amplification within a proteomics assay. In essence,
this method combines the structural specificity of proteomics with the detection
sensitivity of transcriptomics (Gold et al. 2010).
Cell surface capture: With the objective to phenotype cells without antibodies
in an unbiased, hypothesis-free fashion, multiplexed mass-spectrometric identification of several hundreds of N-linked glycosylation sites specifically from cell
surface–exposed glycoproteins has recently been demonstrated. This new cell
surface–capturing (CSC) technology covalently labels extracellular glycan moieties
on live cells, and can thereby detect and compare the cell surface N-glycoproteomes
of e.g., T and B cells. The method has also been shown to monitor abundance changes
of cell surface N-glycoprotein markers during T-cell activation and the controlled differentiation of embryonic stem cells into the neural lineage. Such snapshots of the
cell surface N-glycoproteins are expected to unravel N-glycoprotein panels as potential differentiation markers currently inaccessible by traditional means such as FACS
(Wollscheid et al. 2009).
Mass cytomics: Combining flow cytometry with MS, single-cell “mass cytometry”
has recently been developed and applied to examine healthy human bone marrow,
simultaneously measuring 34 parameters in single cells (binding of 31 antibodies,
viability, DNA content, and relative cell size). The resulting data set enabled the
assembly of related cell types defined by surface antigen expression, providing a
map of cell signalling responses in combination with drug inhibition. The analysis
revealed to-date unnoticed signalling responses confined to conventionally defined
cell subsets, and also more continuous phosphorylation responses across different
cell populations. Such single-cell analyses provided system-wide views of immune
signalling in healthy human hematopoiesis (Bendall et al. 2011).

10.1.7

The Human Proteome Project (HPP)

More than 20 years ago a shift from initiating a Human Proteome Project to a Human
Genome Project took place, mainly due to political changes and the rapid advances
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in molecular biology techniques (Banks et al. 2000). Yet, after the success of the Human Genome Project, the need to launch a Human Proteome Project emerged again.
Currently, approximately 30 % of the predicted genes lack experimental evidence at
the protein level and for many known proteins their localization, distribution, interaction and function is not known (Legrain et al. 2011). Therefore, in 2010 the Human
Proteome Organisation (HUPO) officially launched the Human Proteome Project
(HPP) designed to map the entire human protein set, elucidate biological/molecular
functions and advance disease diagnostics/treatments. The HPP is based on three
technological pillars: shotgun and targeted MS, monoclonal and polyclonal antibodies and an integrated knowledge base. The long-term objectives of the project are to
provide a complete map of the proteins in human cells, tissues and organs in adults
and at different developmental stages, and under various physiological and pathological conditions. Yet, as a proteome map is useful but not sufficient, the focus of
the HPP will be not only to generate but also to disseminate knowledge to enable
researchers to reliably measure the proteome of interest for their investigation (Hoofnagle et al. 2011). In parallel, in China, the Beijing Proteome Research Center has
launched another ambitious project to map the human proteome (Cyranoski 2010).
Finally, adjacent to the HPP are biology-driven projects, e.g., to study cancer, diabetes or energy metabolism pathways that will further contribute in the investigation
of the metabolic syndrome using proteomic technologies.

10.2

Proteomics in the Study of the Metabolic Syndrome

Like the other omics technologies, proteomics has been applied extensively in the
study of the metabolic syndrome. A search in Medline (Search engine OvidSP (Ovid
Technologies, Inc.), Date: October 2011) using proteom* and metabolic syndrome
or diabetes or insulin resistance or obesity as keywords, in the title or abstract delivered 520 references (excluding reviews), published mainly during the last 10 years.
Although some references included a combination of various terms, most publications have focused on diabetes (405 references) followed by obesity (152 references).
Most studies have been carried out in humans (303 references), in the model organism rat or mouse (255 references) or a combination of both (62 references). Finally,
the samples of choice in most studies were plasma or blood, followed by adipose
tissue, an organ where biopsies are not rare in obesity or diabetes studies. Main
focuses were to identify biomarkers of the metabolic syndrome or related metabolic
conditions like diabetes and to elucidate mechanisms of actions or altered pathways.
Fewer proteomic approaches have been used in combination with intervention studies or clinical trials. Early proteomic studies focused on detecting the relative protein
abundance differences between two phenotypic states. In the last years, investigations aimed also at quantifying these differences and integrating the proteomic data
with other omics technology-derived data, following a systems level approach. In
the second part of this chapter, various examples of the approaches using proteomics
in the study of the metabolic syndrome are presented.
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Proteome Analysis of Adipose Tissue

With the discovery of leptin in 1995, adipose tissue was recognized as an endocrine
organ and not only as a fat and energy depot (Halaas et al. 1995). Adipose tissue
is distributed between different depots as subcutaneous or omental fat. The roles of
the depots are different. Yet, adipose tissue is mainly responsible for the storage of
triglycerides in adipocytes and in signalling information about the amount stored for
the regulation of energy intake and expenditure.
Adipose tissue has therefore become an interesting organ for studying proteomic
patterns related to the metabolic syndrome. The Swiss 2D-PAGE database provides
2D-GE protein maps of mouse white and brown adipose tissue (Lanne et al. 2001;
Sanchez et al. 2001). Protein recovery from adipose tissue is challenging due to the
high fat content of the tissue. Addition of hydroxyethyl disulfide in the preparation of
adipose-tissue recovered proteins improves the solubilisation and isoelectric separation in 2D-GE proteomic analysis (Corton et al. 2004; Sanchez et al. 2001). Adachi
et al. further investigated the adipocyte proteome by combining high-accuracy, highsensitivity protein identification technology with subcellular fractionation of nuclei,
mitochondria, membrane and cytosol of 3T3-L1 adipocytes (Adachi et al. 2007).
Approximately 3,300 proteins were identified. Comparison with microarray data
showed that the mRNA abundance of detected versus non-detected proteins differed
by less than 2-fold and proteomics covered a large proportion of the insulin signalling
pathway.
Hydrolysis of triacylglycerols and cholesteryl esters by lipases in the adipose
tissue is a key event in energy homeostasis. Proteomic studies with fluorescent activity tags mimicking lipid substrates and 2D difference gel electrophoresis (DIGE)
combined with LC-MS/MS help understand energy homeostasis as new lipases have
been identified (Birner-Gruenberger et al. 2005). To better elucidate insulin action,
a catalogue of the tyrosine-phosphoproteome of the insulin signalling pathway was
established with 40 identified insulin-induced effectors, using high-resolution MS in
combination with phosphotyrosine immunoprecipitation and SILAC in differentiated
brown adipocytes (Kruger et al. 2008).
Other proteomic studies have focused on the identification of differentially expressed proteins between the different adipose tissue depots: 43 proteins were found
to be differentially expressed between omental and subcutaneous fat using 2D-DIGE
and LC-MS/MS (Perez-Perez et al. 2009). These proteins covered processes such
as glucose and lipid metabolism, lipid transport, protein synthesis, protein folding
and response to stress and inflammation, suggesting a high metabolic activity and
increased cell stress in omental compared to subcutaneous fat. Additionally, the interest in adipose tissue development triggered the identification of secreted proteins
during differentiation of pre-adipocytes to adipocytes (Kratchmarova et al. 2002),
and a comparative shotgun label-free analysis of the secretory proteome of human
adipose stromal vascular fraction cells during adipogenesis (Kim et al. 2010): 177
proteins were significantly upregulated during adipogenesis and 60 proteins significantly down-regulated. Members of developmental pathways like Wnt signalling
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were differentially expressed and expression changes of several proteins could be
confirmed by quantitative RT-PCR and immunoblotting.
Since leptin, many other hormones, the so-called adipokines, have been identified
to be secreted by the adipose tissue. Most show a positive correlation between their
circulation levels and the amount of adipose tissue mass. Moreover, imbalance in
some adipokine levels probably due to enlarged adipose tissue, have been correlated
with obesity, type 2 diabetes mellitus (T2DM) and cardiovascular problems (Deng
and Scherer 2010). A combination of cleavable isotope-coded affinity tags (cICAT)
and label-free quantification showed 317 proteins differentially secreted by 3T3L1 adipocytes with or without insulin treatment; 179 proteins were significantly
upregulated and 53 downregulated. Western blot analysis of the reported adipokines,
like adiponectin or resistin, confirmed the quantitative results from MS, revealing
individualized secreting patterns of these proteins by increasing insulin dose (Zhou
et al. 2009). Although the list of adipokines is already long, proteomic profiling of
media from differentiated primary human adipocytes revealed a novel adipokine,
DPP4 (dipeptidyl- peptidase 4). DDP4 is mainly known in energy metabolism as a
transmembrane glycoprotein that cleaves the incretins glucagon-like peptide-1 (GLP1) and gastric inhibitory polypeptide (GIP). These incretins are released from the
intestine after food intake and contribute to the postprandial insulin secretion. Yet,
the proteomic approach suggested that DPP4 is also released from the adipose tissue
to the circulation and their levels are positively correlated with adipose tissue mass.
Interestingly, obese individuals showed a two-fold increased secretion compared to
lean subjects (Lamers et al. 2011).

10.2.2

Proteome Analysis of Other Organs and Organelles
Relevant to the Metabolic Syndrome

Pancreatic beta cells. The pancreatic beta cell plays a key role in the maintenance
of glucose homeostasis primarily by secreting insulin after certain stimuli. As with
adipose tissue, proteomic studies using beta cells have focused on cataloguing the
proteins for a better understanding of beta cell (dys)function. 2D-LC-MS/MS analysis of human pancreatic islets revealed 3,365 proteins (Metz et al. 2006). The major
islet proteins (insulin, glucagon and somatostatin) were detected as well as various
beta cell-enriched secretory proteins, ion channels and transcription factors. Moreover, a wide range of metabolic enzymes and cellular pathway proteins was covered,
like the integrin signalling cascade, MAP kinase, NFκβ and JAK/STAT pathway.
Pancreatic islets. Other proteomic projects focused on finding new molecular targets associated with islet cell (dys)function and protection. A ground-laying study of
glucose-responsive proteins in pancreatic islets from rats separated and visualized by
2D-GE was already performed in 1992 (Collins et al. 1992). More recently, 78 proteins showed changes in their levels after glucose and 3-isobutyl-1-methylxanthine
stimulation using 2D-DIGE and MS (Suss et al. 2009). Most of these were proposed
as novel targets of rapid regulation in beta cells. Schrimpe-Rutledge et al. updated
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this with novel glucose-regulated proteins in isolated human pancreatic islets using
LC-MS/MS-based proteomics (Schrimpe-Rutledge et al. 2012) : their analysis revealed 256 differentially abundant proteins after 24 h of high-glucose exposure from
more than 4’500 identified proteins in total. Several novel glucose-regulated proteins
were elevated under high glucose, including regulators of mRNA splicing, processing and function. Many proteins found to be regulated by high-glucose stimulation
are still uncharacterized or hypothetical. Another study catalogued the proteins in the
insulin secretory granules of pancreatic beta cells by fractionating and characterizing
the rat insulin-secreting cell line INS-1E and deploying nano-LC-ESI-MS/MS. This
catalogue including 130 proteins, of them 110 newly reported to insulin secretory
granules should help understand impaired insulin secretion (Brunner et al. 2007).
Skeletal muscle. In order to elucidate molecular alterations associated with insulin
resistance in muscle tissue, human skeletal muscle biopsies from patients with T2DM
were compared to healthy controls with 2D-GE and eight proteins were suggested
as potential markers of T2DM in fasting state in muscle. The observed changes
in protein expression indicated elevated cellular stress, and perturbations in ATP
(re)synthesis and mitochondrial metabolism (Hojlund et al. 2003). In a later study,
15 proteins were found differentially expressed between muscle tissues of lean, obese
and type 2 diabetes subjects. An overall decreased mitochondrial protein abundance
was observed, together with altered cytoskeletal structure, chaperone function and
proteasome subunits, indicating changes in muscle structure, protein degradation and
folding (Hwang et al. 2010). Quantitative interaction proteomics based on SILAC
technology and whole cell lysate from the differentiated murine muscle cell line
C2C12 has recently added new insights into the insulin signalling pathway: it revealed
the phosphotyrosine interactome of the insulin receptor family and its substrates
IRS-1 and IRS-2 (Hanke and Mann 2009).
Kidney. Expanding from evident energy metabolism-related tissues like islets
or muscle, renal cortical proteome analysis of db/db mice using 2D-GE combined
with MALDI-TOF, MALDI-TOF/TOF, and LC-MS/MS yielded 278 proteins whose
expression levels were significantly increased or decreased more than two-fold by
diabetes. Pathway analysis indicated that PPAR-α was the most common node of
interaction for the numerous enzymes whose expression levels were influenced by
diabetes (Tilton et al. 2007).
Mitochondria are membrane-enclosed cell organelles that generate most of the
biochemical energy ATP required in eukaryotic cells. Mitochondria are also involved in biological roles like cell growth and death. Energy metabolism-linked
pathologies like diabetes or obesity have been associated with mitochondrial dysfunction (Wallace 1999). Currently, the most complete mitochondrial protein catalogue
comprises over 1,000 proteins and seems to cover 85 % of the predicted-to-becomplete mitochondrial proteome (Calvo and Mootha 2010). In a further study,
1,091 mitochondrial proteins, 228 phosphoproteins, and 355 hydroxyproteins were
identified in the mitochondrial proteome (Deng et al. 2010). In addition, proteins
involved in beta-oxidation, the tricarboxylic acid cycle, oxidative phosphorylation,
and other bio-energetic processes were up-regulated in T2DM. Increased oxidative
stress was evidenced by altered post-translational modifications, like more abundant
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hydroxylated proteins with progressing diabetes. Finally, the necessity to integrate
transcriptomic and proteomic data was confirmed as many alterations could not be
identified by either proteomics or genomics approaches alone.

10.2.3

Potential Biomarkers of Metabolic Syndrome and Related
Pathologies

Discovering novel biomarkers by proteomics is one of the most challenging but also
most promising applications of proteomic technologies and numerous studies focussed on finding new biomarkers for metabolic syndrome and related pathologies.
For example, early biomarkers of diabetes should facilitate interventions designed to
prevent diabetes, or delay its onset, or slow down its progression. Also, diabetic patients would greatly benefit from biomarkers for disease monitoring and therapeutic
success.
Using a label-free quantitative shotgun strategy, 1,377 human serum proteins
were detected in a first approach. Then, so-termed “localized statistics of protein
abundance distribution” (LSPAD) revealed 68 proteins significantly over-represented
in diabetic sera compared to control sera of human volunteers. Pathway analysis
showed an over-representation of the complement system pathway. In addition, an
upstream activator of the complement pathway, ficolin-3, was confirmed to be overrepresented in the serum of an additional cohort of type 2 diabetic patients. Therefore,
ficolin-related complement activation is a candidate biomarker in diabetes (Li et al.
2008).
In diabetic patients, the need for a non-invasive diagnostic method is of great interest to circumvent the repeated needle prick. Therefore, several efforts in detecting
urinary or salivary biomarkers have been published. Analysis of whole saliva from
control and type-2 diabetic individuals by 2D-LC-MS/MS and label-free quantification, identified 65 proteins with greater than 2-fold difference in abundance between
control and type-2 diabetes samples. Independent validation of a subset of potential
biomarkers by immunodetection confirmed their differential expression. Interestingly, a trend of increase in their abundance with progression from the pre-diabetic
to the diabetic state was observed (Rao et al. 2009).
A model for monitoring proteome alterations with T2DM disease progression is
to study those changes over time in the urinary proteome of a streptozotocin-induced
rat model of diabetes that occur during the initial response to the hyperglycaemic
state. 2D-LC-MS/MS and label-free quantification were executed on urine samples
obtained at different time points from treated and control rats (Schlatzer et al. 2009) :
differences in urinary protein abundance occurred in this animal model before observable pathophysiological changes appeared and include increased pro-alpha collagen,
which is regulated by circulating levels of insulin and/or glucose. Collagen fragments
have been suggested as earlier biomarkers for diabetes-induced renal damage with
respect to the currently used urinary albumin. Subjects with diabetic nephropathy
were identified after profiling their urinary proteome by capillary electrophoresis MS
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(Alkhalaf et al. 2010). In a previous study, urinary protein abundance was investigated
in patients with selected glomerular diseases: focal segmental glomerulosclerosis,
lupus nephritis, membranous nephropathy, or diabetic nephropathy (Varghese et al.
2007). Twenty-one 2D-GE protein spots were found significant for the differentiation of the diseases; 11 proteins were identified by MS indicating that diseases
causing nephrotic syndrome change glomerular protein permeability. These proteins
are candidate biomarkers but need validation in further studies.

10.2.4

Proteomics in the Elucidation of Mechanisms
in Metabolic Syndrome

Most mechanistic proteomic studies on the metabolic syndrome have been performed
in rat or mouse models, such as the leptin-deficient mouse (Lep-/- ). This choice of
model also applies to many other pathological and physiological conditions, because
of tissue availability and the possibility to further genetically modify the organism.
Angiopoietin-like protein 4 (ANGPTL4) has been suggested as an adipokine in
energy metabolism, through unknown mechanisms though. Therefore, livers of db/db
mice were treated with or without ANGPTL4 and analyzed by 2D-DIGE followed
by MALDI-TOF and LC-MS/MS (Wang et al. 2007). This study suggested that the
adipokine ANGPTL4 might elicit its metabolic effects through modulating mitochondrial function and methionine metabolic cycles in the liver tissue. In another
study, 2D-GE followed by MALDI-TOF of an immortalized rat mesangial cell line
suggested that the Akt/GSK-3beta pathway and the adapter protein 14-3-3zeta may
play an important role in IGF-1 signalling and survival of mesangial cells in diabetic
nephropathy (Singh et al. 2007). Combining 2D-GE with MALDI-TOF/TOF-MS,
ubiquitin and ubiquitin carboxyl-terminal esterase L1 (UCHL-1) in the hypothalamus
were suggested to influence the genesis of diet-resistant or diet-induced obesity in
rats by interfering with the integrated signalling network that control energy balance
and feeding (Wang et al. 2011b).
Proteomics has recently given mechanistic insights into endoplasmic reticulum
(ER) stress in obesity. Fu et al. performed 1D nano-LC MS/MS proteomics in the
livers of Lep-/- mice and their wild-type littermates (Fu et al. 2011) : from a total of 2,021 proteins identified, 120 were significantly regulated in obese hepatic
ER samples. The up-regulated proteins were mainly involved in lipid metabolism
where as the down-regulated were implicated in protein synthesis and transport, indicating a hepatic ER function shift from protein to lipid synthesis and metabolism.
Further lipidomic analysis, biochemical and genetic experiments identified and confirmed a lipid-driven calcium transport, which—together with ER stress— provided
a framework to understand liver pathogenesis in obesity.
Proteomics has been deployed not only to reveal mechanisms of action in
metabolic syndrome and its pathogenesis, but also to investigate pathways in the
consequences of these pathogeneses, like diabetes-induced renal injury. Starkey et al.
labelled the protein fractions isolated from the renal cortex of control and db/db mice
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with18 O- and16 O-water (Starkey et al. 2010). Tryptic peptides were first separated by
2D-LC, further by nano-LC, and then identified and quantified by MS. This analysis
revealed that retinoic acid metabolism in the diabetic kidney may be dysregulated.
A further proteomic study showed that increased 3-hydroxy-3-methylglutaryl-CoA
(HMG-CoA) synthase 2 (HMGCS2) abundance leads to excess ketogenic activity in
diabetic kidneys (Zhang et al. 2011).

10.2.5

Proteomics in Human Intervention Studies Within
the Scope of Metabolic Syndrome

Proteomics has also been applied to understand the mechanisms underlying nutritional or pharmacological interventions in metabolic syndrome and related
pathologies.
One widely used anti-diabetic drug, rosiglitazone, is an insulin sensitizer metabolite known to act on peroxisome proliferator-activated receptor alpha (PPAR-α). This
drug has anti-diabetic benefits but it has also been observed to augment the risk of
cardiovascular disease in some patients. In the last decade, several intervention studies have investigated the underlying mechanisms of action to better understand both
desired and undesired effects of the drug and to find alternative targets. Some of
these studies have applied proteomics : in one of these, 122 proteins spots separated by 2D-GE were found differentially expressed in obese healthy subjects before
and two weeks after rosiglitazone treatment (Ahmed et al. 2010). Major changes
were observed in cytoskeletal rearrangement, insulin and calcium signaling, and inflammatory and redox signals that up-regulate GLUT4 granule trafficking in human
adipose tissue. In another study, control and Lep-/- mice were treated with rosiglitazone and proteomic changes were monitored in liver plus white and brown adipose
tissue by 2D-GE-MS/MS (Sanchez et al. 2003) : here, 34 proteins were found differently expressed between lean control and obese leptin deficient mice. Eleven proteins
were significantly modulated after treatment in the obese, but not in the lean mice.
These proteins may reveal new drug targets in insulin resistance. Another PPARα agonist (Wy 14,643) has earlier been shown to up-regulate 16 liver proteins in
leptin-deficient mice as elucidated by a 2D-GE-MS/MS approach (Edvardsson et al.
1999).
By using 2D-LC, MALDI-TOF/TOF and ESI-TOF analysis, the levels of transthyretin, AMBP, haptoglobin precursor were found to be down-regulated, while albumin, zinc alpha 2 glycoprotein, RBP4 and E cadherin were observed up-regulated
in the urine of diabetic patients as compared to controls (Riaz et al. 2011). Treatment with thiamine decreased albumin by 34 % in urine samples of diabetic patients
compared to controls and placebo-treated diabetic patients, while the other urinary
protein markers did not show any significant change after the therapy.
Proteome changes were also monitored when applying a low-calorie diet in a
clinical obesity study: the expression of 6 adipocyte proteins was found significantly changed in eight overweight/obese subjects who underwent an intervention of
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5 weeks of a very low-calorie diet followed by 3 weeks of a normal diet; these changes
suggested a reduced intracellular scaffolding of GLUT4, an increased uptake of fatty
acids, an improved inflammatory profile of the adipose tissue and a change in fat
droplet organization (Bouwman et al. 2009).

10.2.6

(Prote) omics-Driven Obesity Research Networks

During the European 5th Framework Programme (started in 2001) a project applied
omics technology in the study of obesity, NuGenOb: Nutrition, Genes and Obesity.
The main objectives of this consortium were to (i) identify and characterise novel
nutrient-sensitive candidate genes for obesity; (ii) analyse differential gene expression in adipose tissue in relation to the acute intake of a high-fat meal and of a
long term hypocaloric diet with either a high or a low fat content; (iii) assess the
effects of functional variants of the candidate genes on physiological responses in
obese subjects to a high-fat test meal; and (iv) identify predictors of changes in body
weight and composition during dietary intervention, including changes in fat intake.
Single nucleotide polymorphisms and transcriptomics analysis in parallel to classical anthropometric and biochemical parameters were measured. Targeted proteomic
analysis showed that moderate caloric restriction but not macronutrient composition
influences the production and secretion of adipose tissue-derived proteins during a
hypocaloric diet (Arvidsson et al. 2004).
Not only targeted but also hypothesis-free discovery proteomics were applied in
a project within the 6th European Framework Programme, namely DiOGenes: Diet,
Obesity and Genes. This European, multicentre, randomized, controlled dietary intervention study showed that a diet rich in protein and with a low glycaemic index
is slightly more efficient in maintaining weight (after intended weight loss) than a
high-protein/high glycaemic index diet or a low-protein diet with either low or high
glycaemic index (Larsen et al. 2010). Classical biochemical, anthropometrical and
omics measurements were applied to investigate the mechanisms behind, identify
biomarkers and/or asses the physiological/biological consequences of the intervention. Targeted proteomic analysis was applied to validate and identify biomarkers
of successful weight maintenance (Wang et al. 2011a; Wang et al. 2012), whereas
proteomic analysis searched for the mechanisms accompanying weight maintenance
(Rubio-Aliaga et al. 2011).
The EU FP7 “beta-JuDO” project (http://ec.europa.eu/research/health/medicalresearch/diabetes-and-obesity/projects/beta-judo_en.html) aims at studying hyperlipidemia in young obese individuals and is based on the study of lipotoxicity
on human islets in culture, but also on a cohort of 3,000 patients. Also within
the 7th European Framework Programme the obesity-related omics technology
project FLORINASH, (http://ec.europa.eu/research/health/medical-research/severechronic-diseases/projects/florinash_en.html) has started in 2010, studying the role of
the intestinal microflora in non-alcoholic fatty liver disease (NAFLD). In accordance
with the evolution of systems biology in the last decade, advanced systems-level
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omics metrics (leveraging proteomic, metabolomic, trancriptomic and metagenomic platforms) combined with bioinformatic and chemometric modelling of the
phenotypes will be applied.
Important for the present scope and context, the Human Proteome Organisation
(HUPO, see 10.1.7) has recently announced several biology/disease-driven human
proteome projects (HPPs), among which the one on diabetes has started with a
recently established consortium (http://cms.unige.ch/medecine/hdpp.info/node/1).
The plan is to leverage this international constellation of expertise to generate
systems-level insights into diabetes-associated cellular changes by gathering multivariate data sets over time from specialised cells and organs of healthy and
diabetes-affected individuals.

10.3

Future Perspectives

Novel approaches in study design, technological advances, standardization of applied
methodologies, comprehensive cataloguing of the human proteome and the integration with other omics technologies (genomics, transcriptomics, metabolomics and
epigenomics), will facilitate proteomic progress in the delivery of novel biomarkers,
the understanding of mechanisms of action and/or the delivery of new drug targets in
the context of metabolic syndrome and other common complex traits and diseases.
These expectations are nourished by the following recent developments or
emerging trends:
i. Ultra-high resolution and -mass accuracy mass spectrometers.
ii. Workflows combining efficient reduction of sample complexity and deep and
broad proteome coverage with reasonable effort and high throughput.
iii. Robust bioinformatics for efficient data processing, assessment, validation,
visualization and interpretation.
iv. Expanding beyond classical discovery/targeted mass spectrometry and embracing new and complementary proteomic technologies such as DNA aptamer
assays and cell surface capture.
All the above relates to technology improvements. Moreover and at least equally important, the design of systems biology studies may need to be improved considering
the following aspects:
i. A key to healthy energy metabolism and to to avoiding/delaying the onset of
metabolic syndrome is maintenance or (re-)establishment or of metabolic flexibility and elasticity. Therefore, repeated observations of the very same study
subject over time and under (repeated) exposure to a safe metabolic challenge,
should enable to capture the moment of “derailing from healthy trajectory”, i.e.,
the early biomarker signature.
ii. These repeated observations need to be systems-based, technology-rooted but
not technology-driven: truly integrated measurements from all possible angles
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[(epi-)genomics, transcriptomics, proteomics, lipidomics, metabonomics] are
required.
iii. Each study subject should serve, when possible, as its own case and control, to
better address the influence of genomic individuality.
iv. Interesting or extreme phenotypes observed within the range of responses to
challenges can be mechanistically investigated and hypothesis should be tested
in human clinical studies.
v. Ideally, such metabolic studies should not only sample the host, but also its gut
residing microbiome, because of its impact on host health and metabolism.
Taken together, these improvements will in our opinion facilitate a time-resolved
systems view of a complex chronic disease such as the metabolic syndrome.
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Chapter 11

Metabolomics in the Systems-Level Study
of the Metabolic Syndrome
Tuulia Hyötyläinen

Abstract Metabolic syndrome (MetS) is a combination of medical disorders, including abnormalities in insulin, glucose and lipid metabolism, hypertension and
abdominal obesity, causing several metabolic complications. Metabolomics has been
increasingly employed for investigating obesity and obesity-related diseases in recent
years. Because metabolome is dependent on the physiological, environmental, and
genetic status of an organism, metabolomics can help to understand the biochemical
networks that underlie metabolic homeostasis in obesity. The ongoing development
of mass spectrometry (MS) and chromatography has enabled more comprehensive
coverage of the metabolome. Many obesity-related metabolites have already been
identiﬁed by metabolomics and demonstrated to be disturbed signiﬁcantly in both
animal models and in humans. This chapter describes the methodology used in
metabolomics and summarizes the current knowledge about the effect of obesity and
MetS on metabolic pathways.
Keywords Metabolomics · Chromatography · Mass spectrometry · NMR ·
Metabolic syndrome

11.1

Introduction

Metabolomics involves the comprehensive characterization of the small molecule
metabolites (MW < 1500 amu) found in an organism. The metabolites include a
large variety of compounds, including nucleotides, amino acids, bile acids, steroids,
fatty acids, carbohydrates, hormones and lipids, among others. The metabolome is
closely tied to the genotype of an organism, and is affected by the environmental
factors such as lifestyle, diet and gut microbiota (Holmes et al 2011; Vrieze et al 2010;
Wikoffa et al. 2009). Therefore, metabolomics offers a unique opportunity to look
at genotype-phenotype as well as genotype-envirotype relationships. The levels of
metabolite indicate the status of the organism’s physiology, for example, metabolites
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such as citrate, lactate, and glucose can reflect situations such as apoptotic alterations,
hypoxia and oxidative stress.
The advances in metabolomics have been driven by the development of analytical
technologies, in combination with advances in mathematical and statistical modeling
for the data mining and data interpretation. In spite of the novel developments,
currently there is no single metabolomics platform that allows for the comprehensive
analysis of full metabolome. The metabolic analyzes are challenging because the high
number of metabolites, the large concentration range, over eight orders of magnitude,
and chemical diversity of metabolites. No single analytical method can cover analysis
of all the metabolites. It should also be noted that not only is the chemical analysis
difficult enough, but the mathematical modeling needed to make useful deductions
is often even more challenging, owing to the colossal amount of data produced
by the novel analytical methodologies. In metabolomics the appropriate design of
the work protocol is essential, including all the steps from study design to sampling,
selection of both the analytical techniques, data preprocessing and statistical tools, to
identification of candidate biomarkers, and finally, to the elucidation of the biological
meaning of the findings.
In recent years, metabolomics has been increasingly employed for investigating obesity and obesity-related diseases. Metabolomics can help to understand
the biochemical networks that underlie metabolic homeostasis in obesity. Indeed,
many obesity-related metabolites have already been identified by metabolomics and
demonstrated to be disturbed significantly in both animal models and humans.

11.2

Selection of the Analytical Tools

The analytical workflow covers all steps from sampling, storage, sample preparation, analysis and data preprocessing. Two types of approaches are used in the
metabolomics, namely targeted selective analysis and more comprehensive, nontargeted profiling methods (Fig. 11.1). In the targeted analysis, only a limited number
of preselected metabolites are analyzed with an optimized, selective and typically
quantitative analytical protocol. This approach allows very sensitive and robust determination of the metabolites, and is suitable for the hypothesis driven approach where
the key metabolic pathways are already known. However, the targeted approach gives
relatively limited information of the total metabolic system. In the non-targeted approaches, for hypothesis generating studies, the endogenous metabolites of potential
interest are not selected a priori, and the aim is to cover as many metabolites as possible. The non-targeted, global methods are typically only semi-quantitative, however,
and it is not possible to optimize the methodology for all individual compounds.
The quality control is an essential step in metabolomics particularly when large
sample sets are analyzed, and the methodological variation must be corrected.
Typically, a suitable set of internal standards are used for normalization of the
methodological variation. Moreover, the performance of the method must be followed by using sufficient amount of standard samples, blank samples and control
samples. The best control sample is to take an aliquot of each sample of the batch and
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Fig. 11.1 The work flow for sample preparation for metabolomics. GPC gel permeation chromatography, LLE liquid-liquid extraction, LPME liquid phase micro extraction, MAE microwave
assisted extraction, PP protein precipitation, SAE sonication assisted extraction, SBSE stir-bar
sorptive extraction, SLE solid-liquid extraction, SPE solid phase extraction, SPME solid-phase
micro extraction

pool them together, when possible. In addition, a batch sample for controlling of the
long-time variation should be analyzed within each sample set. In routine analyzes
the number of quality control samples should be ca. 5 % of the total sample amount
(1:20 samples) but in more complex analyzes, quality control samples should be
analyzed even more frequently (1:5 to 1:10 samples). The randomization of both
sample preparation and analysis order is also important.

11.2.1

Sampling and Sample Preparation

In metabolomics, the sample type may be gaseous, such as breath samples, liquid such
as urine, saliva, blood, serum, plasma, CSF, or (semi)soli such as cells, and tissue
biopsies. With biological samples particularly, the sampling, storage and sample
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preparation are in crucial role because unsuitable protocols can lead to biased results
due to conversion or degradation of metabolites (Álvarez-Sánchez et al. 2010a).
The most common types of samples in metabolic studies are blood-derived
serum and plasma because blood metabolic profile reflects systemic changes in the
metabolome. In addition, blood samples require relatively non-invasive sampling. It
should be noted, however, that the metabolic profiles of serum and plasma are not
identical because of the preparation of serum and plasma are quite different. Also, in
plasma samples, the anticoagulant used for the plasma collection has also an effect to
the metabolic composition. For example, citric acid which is an important metabolite of the TCA cycle, is present in higher concentrations in EDTA plasma than in
serum, most probably due to complex formation between citric acid and Ca2+ and
Mg2+ ions in serum during sample preparation, leading to precipitation in serum
(Gronwald et al. 2008). Also, the overall protein content in serum is lower than in
plasma which is a benefit in the analysis of metabolites because of the reduced matrix effects in e.g. LC-MS determinations. For the analysis of lipids, the serum and
EDTA or citrate plasma give very similar results, however, for the determination of
carboxylic acids and amino acids, it is best to use serum instead of plasma.
Also the temperature during the sampling and sample preprocessing may be crucial for specific metabolites, particularly for unstable compounds such as eicosanoids.
Deactivation of metabolism, i.e. quenching, is essential part of the procedure. It is
particularly critical in the analysis of cells and tissues when the goal is to elucidate
the metabolic profile inside (endometabolome) and outside (exometabolome) the cell
(Álvarez-Sánchez et al. 2010b). Deactivation can be done by very rapid freezing of
the sample, by changing the pH, or by adding a mixture of enzyme inhibitors and/or
antioxidants to the sample.
In the sample pretreatment, the goal is to isolate the analytes of interest from the
matrix, and to improve the selectivity, detectability, reliability, accuracy and repeatability of the analysis. The sample preparation includes several steps, depending on
the sample type (Fig. 11.1). The sample preparation is in most cases necessary due to
the complexity of the samples. It should be emphasized that sample preparation is the
major cause of errors in the analytical results because typically, multistep and often
manual procedures are required in this stage. The lack of homogeneous standard protocols for sample preparation also introduces a barrier to comparing results among
laboratories and to reproducing metabolomics experiments. In most cases, extraction is needed before the analysis, except in cases where analysis is to be performed
directly on the tissue, as is the case with matrix-assisted laser desorption/ionization
(MALDI) imaging (Trim et al. 2008; Pól et al. 2011) or desorption electrospray
ionization (DESI) (Wu et al. 2009). For tissue samples, homogenization is required
before the extraction. Homogenization can be done using cryogenic homogenizator
or more conventionally, using ball mills. The advantage of the cryogenic homogenizator is that the samples are deep frozen during the homogenization, minimizing
alteration of the sample during this step.
It should also be noted that in the sample preparation stage, different approaches
are needed for targeted analysis and for global profiling. For targeted analyzes,
highly selective sample pretreatment is beneficial while non-selective methodology
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that is not biased towards any certain groups of metabolites is needed for global
profiling (Hyötyläinen 2012; Hyötyläinen 2010; Álvarez-Sánchez et al. 2010b). For
extraction, the most common methods are liquid extraction with suitable organic
solvents, or solid-phase extraction for liquid samples. In many cases, simple protein
precipitation with methanol or acetonitrile is sufficient. For targeted methods, the
extraction conditions can be carefully adjusted, and often the crude sample extract,
e.g. after liquid extraction, is purified using solid-phase extraction to selectively
remove disturbing matrix compounds such as phospholipids. For global profiling,
simple solvent extraction is typically used, such as Folch extraction for lipids and
other hydrophobic metabolites while methanol or acetonitrile is often used for more
polar metabolites. In the profiling, it is difficult to find optimal conditions for all
types of analytes, so some compromised has to be done in the selection of conditions
(Álvarez-Sánchez et al. 2010b; Hyötyläinen 2012; Theodoridis et al. 2012).
Novel approaches in this field utilize techniques such as cryogenic homogenization of tissues, solid-phase extraction with novel formats and automated at-line
sample pretreatment systems can help to minimize the challenges in the sample
preparation step.

11.2.2 Analytical Methodologies
At present, the methodologies used in metabolomics for final separation and identification are based mainly on mass spectrometry (MS), often combined with
chromatographic methods, such as liquid chromatography (LC) and gas chromatography (GC). Also NMR is used to some extent. Capillary electrophoretic techniques
(CE) have also been utilized in some metabolic studies, however, they have not gained
wide popularity, mainly because of the less repeatable migration times hinders the
use of CE in any large scale analyses.
Although MS detection alone can be used for metabolomics, using high-resolution
chromatographic separation prior to MS detection, which can be achieved with HPLC
or GC, or even more preferable, UHPLC or GCxGC, is better suited to global profiling of the metabolome. Optimized chromatographic separation improves peak shape
and sensitivity of the detection, thus dramatically decreasing signal variability in
the MS detection. Moreover, the separation of components by the chromatography
prior to their detection minimizes matrix effects, such as ion suppression, charge
competition, and other possible interactions between matrix components. Moreover,
isobaric components can be analyzed, as long as they can be separated by the chromatographic step. With MS alone, it is not possible to analyze isobaric compounds
they have identical elemental compositions and therefore identical m/z ratios.
11.2.2.1

MS Analyzers

Several types of MS systems are used in metabolomics, and the selection of the instrument depends on the application (Dettmer et al. 2007). If the goal is to determine
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Table 11.1 Comparison of the MS instruments in terms of accuracy, resolution and scanning speed.
(modified from http://www.chromedia.org)
Analyzer

Mass range
(m/z,
*10−3 )

Resolution
(m/z)

Resolving
power, FWHM
(*10−3 )

Mass
accuracy
(ppm)

Scan rate
(Hz)

Single quadrupole
QqQ
Ion trap
Linear ion trap
Orbitrap
TOF
QTOF
IM-TOF
Double focusing
magnetic sector
FTICR

3
3
4–20
4–20
6
20–40
10–40
20–100
5–15

0.1–0.7
0.1–0.7
0.1–0.7
0.1–0.7
–
–
–
–
–

–
–
–
–
50–100
15–20
15–25
20–40
30–80

< 100
< 100
50–200
50–200
0.5–1
2–5
3–5
0.5–1
1–5

0.5–20
0.5–4
5–10
1–4
0.5–2
20
20
30
0.1–0.5

5–15

–

100–1500

0.1–1

0.3–1

elemental composition of specific metabolites, high-resolution, accurate mass determination (HRAM), typically together with tandem mass measurements for structural
characterization, is required. For targeted, qualitative analyzes, low-resolution mass
spectrometers such as quadrupole MS are typically used; as triple quadrupole systems
for LC-MS, and single quadruple systems for GC-MS.
In LC-MS combinations, as well as in shotgun MS, the use of hybrid quadrupole
mass spectrometer-time-of-flight MS (Q-TOF) and Fourier-trap-MS (FTMS) instruments, both the cyclotron and the Orbitrap type, allow for accurate mass
measurements and, subsequently, the identification of metabolites. Desired detector
characteristics include high resolution (greater than 10,000) and accurate mass (less
than 5 ppm) in full-scan mode. Table 11.1 compares the critical features of the different MS systems. TOF technologies typically offer higher scanning speed (more than
20 Hz) and achieve the required mass accuracy with internal calibration standards.
Orbitrap and FT-ICR mass spectrometers offer excellent measurement accuracy with
external calibration and a wide resolution range. Particularly the FT-Orbitrap-MS has
been gaining popularity in combination with LC separation because it a high-speed,
high ion-transmission instrument, due to shorter accumulation times. The maximum
resolving power and mass accuracy are lower than those for FT-ICR-MS but clearly
higher than for QTOFMS. The novel tandem MS system combining ion mobility
with TOFMS enable even the separation of isobaric compounds.
Targeted analyses, using LC for the separation are typically done using triplequadrupole (QqQ) mass spectrometer, owing to its high duty cycle and a large
dynamic range in MS/MS mode. The QqQ system utilizes collision-induced dissociation while monitoring unique precursor to product ion transitions, affording
superior sensitivity, precision, and accuracy, especially for simultaneous analysis
of multiple analytes (selected reaction monitoring, multiple reaction monitoring). It
should be noted, however, that novel HRAM MS systems are now achieving sensitivity comparable to that of QqQ instruments while providing full-scan MS data

11

Metabolomics in the Systems-Level Study of the Metabolic Syndrome

219

on all analytes, which will certainly increase their utility for quantitative assays. An
especially attractive feature of the HRAM approach is that, unlike multiple reaction
monitoring experiments, data are collected over a preselected wide mass range, and
the ability to measure unexpected analytes is preserved. In GC-MS, the quadrupole
MS is still the most common instrument, but also TOFMS and other accurate mass
instruments are gaining popularity.
Shotgun MS. The shotgun methods uses direct infusion of sample extracts into the
mass spectrometer (Schwudke et al. 2007) and in principle, any type of (ionizable)
compound can be analyzed. Typically, high-resolution mass spectrometers are used
in the shot-gun approach. The shotgun approach is a relatively simple and rapid way
to profile crude extracts of the biological samples. The major complication in this
methodology is the ion suppression and compounds present in trace amount are often
not detected due to the suppression phenomena (Moco et al. 2007). Moreover, because the composition of the samples can vary substantially, the ion suppression can
change from sample to sample, and thus the quantitative results for global profiling
is not very reliable. With labeled standards, quantitative results can be obtained for
those, rather limited number of compounds that the standards are available. To avoid
ion suppression, more careful sample pre-treatment, using e.g. fractionation can be
applied, however, then the main advantage of the shotgun approach, i.e. simplicity
and speed are then lost. Thus, the applicability of shot-gun MS in the search of novel,
previously unknown biomarkers is relatively restricted. However, the shot-gun MS
is a viable tool for clinical practices for a group of identified biomarkers, particularly
when combined with suitable, very selective sample preparation method.
LC–MS. In metabolomics, LC-MS based methodologies have several advantages
and this technique has been widely used for both for targeted and non-targeted analyses, using various types of mass spectrometers, from a simple single quadrupole to
hybrid instruments and to high-resolution Orbitrap instruments (Nygren et al. 2011;
Theodoridis et al. 2012). The sensitivity in LC-MS is typically high, and identification
of novel compounds in possible. The novel fast LC methodologies, utilizing very high
pressures, elevated temperatures and novel column materials allow high-through-put
analyses.
GC–MS. GC is suitable for the targeted analysis of sufficiently volatile compounds, such as fatty acids, small polar compounds, such as carboxylic acids, sugars,
amino acids and sterols. The latter require derivatization before the analysis, complicating the sample preparation. This has been considered as the main bottleneck
in the metabolomic analyses and reason why many of the GC-based methodologies
are currently done by LC-MS. However, the GC-based methods have several advantages over the LC-MS based approaches. The main advantage is the availability
of huge commercial spectral libraries for the identification of unknown metabolites.
An additional advantage of all GC based methods is the repeatable characteristics of
retention, particularly when nonpolar stationary phases are used. This makes it possible to use universal retention indexes which are highly useful in the identification
of unknown compounds, in combination with mass spectral detection. Moreover, the
quantitation is more reliable, because the matrix effects in GC-MS are not an issue.
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The most commonly used derivatization methods are trimethylsilylation and tertbutyldimethylsilylation. In addition, keto-(oxo-) groups are usually oximated in order
to improve their GC properties and prevent enolization reactions which can introduce multiple reaction products. The derivatization can be done in automatic fashion
even in the injector systems of the modern GC instruments, thus simplifying the
procedure.
Recently, two-dimensional gas chromatography combined with time-of-flight MS
(GCxGC-TOFMS) has been gaining popularity in the metabolomics as it is one
of the most powerful analytical tools for the separation of organic compounds in
complex samples, and particularly suitable for the non-targeted profiling, allowing
the separation of several hundreds of compounds in a single analysis (Castillo et al.
2011; Hyötyläinene et al. 2012; Dettmer et al. 2007).

11.2.2.2

NMR

NMR (1 H-NMR is a fast and robust method, it is non-invasive and non-destructive
and the analytical costs per-sample are low (although the instruments are very expensive) (Malet-Martinoa et al. 2011). NMR has the theoretical possibility to detect and
structurally elucidate any molecule containing hydrogen and also being very quantitative in its nature. However, the main disadvantage of NMR is the inherent lack of
sensitivity, typical detection limits being in the range milli- to high micromolar. In
addition, due to the large number of metabolites, the one-dimensional spectra gets
very dense with spectral information resulting in more abundant metabolites masking
signal of less abundant ones. The complexity of the data, together with the limited
sensitivity, limit quantitative profiling to less than100 metabolites in most biological
samples by current methods. For NMR, minimal sample preparation is required for
urine and other low-molecular-weight metabolite-containing fluids, whereas blood,
plasma, and serum require extraction or NMR-weighted techniques to separate polar
and lipophilic metabolites (Aranibar et al. 2006).

11.2.2.3

Identification of Metabolites

The identification of unknown metabolites is a very challenging task. If authentic
standards are available, a metabolite can be identified unambiguously by directly
comparing its mass, retention time and fragmentation spectrum with those of the
standards. However, this is not always possible, and in any case, the metabolite has
to be first tentatively identified before standards can be applied.
In GC(xGC)-EI-MS, comprehensive commercial libraries are available
(NIST/EPA/NIH (Babushok et al. 2007), Fiehnlib (Kind et al. 2009) and Golm
(Kopka et al. 2005) based on electron ionization using high internal energy (70 eV).
The NIST library, for example, have a mass spectra for 192 108 compounds. In GCbased applications it is also possible to utilize retention indexes in the identification,
together with the spectra, making the identification much more reliable. It should
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also be noted that a large amount of compounds still cannot be identified as they
are not found in the spectral libraries. However, even for unknown compounds, due
to the reliable fragmentation patterns in GC(xGC)-EI-MS, group level identification
can typically be made, making the classification of the functional group(s) of the
metabolites possible (Hummel et al. 2010). The elemental composition of a compound can be determined by GC equipped with chemical ionization (CI) and accurate
mass detector (Kumari et al. 2011). With electron impact ionization, the molecular
ion often is not detected due to the extensive fragmentation, making the identification of unknown compounds more challenging. With GC-CI-MS, the molecular ion
can usually be detected; however, the mass spectral libraries for GC-CI-MS are not
as extensive as for GC-EI-MS. The best approach to identify unknown compounds
is to analyse the samples with both GC-EI-MS and GC-CI-MS, thus combine the
fragment information and accurate mass determination of the molecular ion.
In LC-MS and shotgun-MS, the lack of comprehensive mass-spectral libraries
is a major limitation in the identification of unknown compounds. Some spectral libraries are available, including the Human Metabolome Database (HMDB)
(http://www.hmdb.ca), the METLIN Metabolite Database (http://metlin.scripps.edu)
(Smith et al. 2005) and the MassBank (http://www.massbank.jp) (Horai et al. 2010).
Unfortunately, construction of universal spectral databases forAPI-MS is challenging
due to the poor reproducibility and high interinstrument variability of fragmentation
patterns. In the interpretation of the mass spectra from both shotgun MS and LCMS studies, first step is to ensure that the signal of interest really corresponds to a
monoisotopic ion and not to a natural isotopologue ion or an adduct ion (Xu et al.
2010; Ralf et al. 2011). Elemental compositions can be deduced from accurate
mass measurements and used for further database queries. To aid the identification, a number of chemical databases containing huge amount of chemical structures
to aid in structural elucidation after fragmentation of the metabolite are available
(e.g. ChemSpider, http://www.chemspider.com, http://msbi.ipb-halle.de/MetFrag)
(Wolf et al. 2010). Also several in-silico software packages for the prediction of
in-silico spectra for compounds are available (Neumann et al. 2010; Schymanski
et al. 2009).

11.2.3

Data Analysis Tools

The correct choice of the mathematical tools is essential for efficient data mining and
correct information of the data. It is challenging to link the huge amount of metabolic
information obtained with the current methodologies with available clinical and genetic data. The work flow in data analysis compromises of signal processing, data
normalization, transformation, and assessment followed by application of statistical methods for comparison of groups and the construction of predictive models
(Katajamaa et al. 2007; Sumner et al. 2008).
Often, data on hundreds of metabolites is obtained in the modern metabolic analyzes. However, in practise the models using information of hundreds of metabolites
are not realistic. For robust models, the number of significant variables should be less
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than ca. 25, derived from a limited number of metabolic markers (3-10 compounds).
With a larger number of variables/metabolites, there is a high risk of over fitting of
the data. Therefore, the first step of the statistical analysis is typically data reduction, using e.g. pattern recognition processes; either in unsupervised or supervised
manner. In unsupervised data analysis, the data analysis is conducted without any
preconceptions or preselection, i.e. without biasing the results by the introduction
of prior information of the samples. The unsupervised methods include hierarchical
cluster analysis and principal component analysis, and they are good in identification
of patterns of the data. In the supervised approach, such as principal component regression and neural networks, each sample or metabolite is first associated to already
known class, and this prior information is then used in generation of the clusters of
patterns (Lee et al. 2008). For the discovery of predefined metabolic pathways or
altered biological networks several methods are available (Aggio et al. 2010; Xia and
Wishart 2010; Kankainen et al. 2011). In addition, new computational approaches
have been recently developed for analysing high-dimensional datasets and elucidate
the genotype to phenotype relationship using metabolic constraint-based modelling
(CBM) approach (Duarte et al. 2007; Jerby et al. 2010; Trawick and Schilling 2006;
Shlomi et al. 2009; Lanpher et al. 2006). In these methods, thermodynamic and stoichiometric constraints are given to enable the genome-scale analysis and prediction
of metabolic phenotypes under diverse physiological and genetic conditions (Duarte
et al. 2007; Jerby et al. 2010).

11.2.4

Comparison of Different Methodologies for Metabolomics

The key features of the analytical techniques utilized in metabolomics are shown in
Table 11.2. In Human serum Metabolome study, five different metabolic profiling
methods were used to experimentally characterize as much of the known serum
metabolome as possible using 1) NMR; 2) GC-MS; 3) lipid mediators by LC-ESIMS/MS; 4) lipidomics profiling via TLC/GC-FID-MS; and 5) direct infusion MS/MS
(N. Psychogios et al. 2011). Using these five platforms, a total of 3564 distinct
metabolites including several exogenous compounds could be identified from the
serum. The study showed clear differences in the ability of the platforms to identify
and quantify metabolites: NMR spectroscopy was able to identify and quantify 49
compounds, GC-MS was able to identify 90 and quantify 33 compounds, targeted
ESI-MS/MS identified and quantified 96 compounds, TLC/GC-FID-MS identified
and quantified 3381 compounds while direct infusion MS/MS identified and quantified 139 compounds. Some metabolites could be detected with several platforms,
and for example, comparison of amino acid concentrations as measured by NMR,
GC-MS and DFI MS/MS showed that the quantitative results are in relatively good
agreement. The study showed that of the known, quantifiable serum metabolome
(4229 known and probable metabolites; 665 literature derived metabolites and

a
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metabolites,
identification of
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MS
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compounds
cannot be
identified, ion
suppression is a
major problem

5–100 μl
50–100/day
Moderate
Nanomolar

60–500 μl
ca 10 min/sample
good
Millimolar—high
micromolar
Low
High-very high
Good spectral
libraries, may
require high
sample volumes

UPLC-MS
Profiling
Moderate

shot-gun-MS

Profiling + targeted Targeted
simple
Simple-moderate

For biofluids, such as urine, serum/plasma

Cost/sample
Instrument cost
Comments

Approach
Sample
preparation
Sample amount a
Sample throughput
Reproducability
Sensitivity

NMR

5–100 μl
20–80/day
Good
Nanomolarpicomolar
Medium
Moderate-high
Suitable for wide
range of
metabolites

Targeted
Tedious

UPLC-MS

5–100 μl
20–80/day
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Nanomolarpicomolar
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small
metabolites
(MW < 700),
polar
compounds
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derivatization,
huge spectral
libraries
available,
retention
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verification of
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Targeted
Tedious

GC-MS

Table 11.2 A comparison of the key features of the metabolomics methods. (modified from Hyötyläinen 2012)

5–100 μl
20–30/day
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metabolites (MW < 700)
polar compounds require
derivatization, huge
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clean spectra’s due to very
high separation efficiency,
retention indexes can be
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identification

Profiling + targeted
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GCxGC-TOFMS
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3564 experimentally derived or predicted), NMR was able to measure ∼1.2 %
(49/4229) of the human serum metabolome, GC-MS was able to measure 2.13 %
(90/4229), ESI-MS/MS was able to measure 2.3 % (96/4229), TLC/GC-FID-MS
(general lipidomics) was able to measure 79.9 % (3381/4229) while direct infusion
MS/MS was able to measure 3.3 % (139/4229) of the serum metabolome. It should be
noted that the study included only known metabolites. With more advance methodologies, such as global profiling with GCxGC-TOFMS, typically 1200 metabolites
can be detected from human serum samples, of these however, only 10–30 % can
be identified. Also, global profiling of lipids with UHPLC-QTOFMS typically allows detection of ca. 600 lipids in human serum, and of these, ca. 150 lipids can be
identified.

11.3

Metabolic Profile in Metabolic Syndrome

Metabolic Syndrome (MetS) is a combination of medical disorders, including abnormalities in insulin, glucose and lipid metabolism, hypertension and abdominal obesity, causing several metabolic complications, such as type 2 diabetes, non-alcoholic
fatty liver disease (NALFD) and coronary heart diseases (CHD). Abdominal adiposity and insulin resistance appear to be at the core of the pathophysiology of the MetS
and its individual components. Insulin, on the other hand, has an effect on several
key functions, such as amino acid uptake, protein synthesis, proteolysis, adipose
tissue triglyceride lipolysis, lipoprotein lipase activity, very low density lipoprotein
(VLDL) triglyceride secretion, muscle and adipose tissue glucose uptake, muscle
and liver glycogen synthesis, and endogenous glucose production. Adipose tissue
and liver are the two key organs associated with obesity, metabolic syndrome and
diabetes risk (Fig. 11.2) (Cohen et al. 2011; Kotronen and Yki-Jarvinen 2008).
Current research indicates that the capacity of adipose tissue to safely store fat
may be more vital than the actual amount of fat an individual has. In the case of
excess calory intake, the extra energy is stored as fat, preferably in the adipocytes
(Pietiläinen et al. 2011). However, the adipocytes do not have an unlimited capacity
to store extra fat, and when their capacity is exceeded, the fat starts to accumulate
in skeletal muscles, in liver and in other organs, leading to potentially toxic effects
in peripheral tissues via the excessive accumulation of reactive lipid species. Particularly, the fat accumulation in skeletal muscle and in liver is associated with insulin
resistance which in turn causes major changes in glucose and lipid metabolism.
Insulin affects on amino acid uptake, protein synthesis, proteolysis, adipose tissue triglyceride lipolysis, lipoprotein lipase activity, very low density lipoprotein
(VLDL) triglyceride secretion, muscle and adipose tissue glucose uptake, muscle
and liver glycogen synthesis, and endogenous glucose production. Thus, metabolic
analyses covering intermediates of these pathways can be utilized for in depth studies
of the obesity associated diseases.
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Fig. 11.2 Fatty acid composition of adipose tissue in acquired obesity. a Selected fatty acid relative
amounts in twin pairs discordant for BMI. Lines connect the pairs of twins. b Schematic representation of fatty acid compositional changes when comparing heavy and lean obesity-discordant
twins. Significant changes (p<0.05; pairwise t test) are color-coded. The activities of specific fatty
acid elongation or desaturation steps are estimated by appropriate fatty acid concentration ratios.
From Pietiläinen et al. 2011

11.3.1

Glucose Metabolism and Tricarboxylic Acid Cycle

Glucose metabolism and energy metabolism has been found to be severely altered
in obesity in both animal and human studies. Elevated levels of lactate, a glucose
precursor, has been observed both in blood of obese mice and Zucker rats (Serkova
et al. 2006; Duggan et al. 2011) and in several human studies (Newgard et al. 2009;
Felig et al. 1974). The concentration of lactate in blood is predominately determined
by the balance of rate of lactate production in skeletal muscle, the erythrocytes,
brain and adipose tissue, relative to the removal of lactate by other tissues and
urinary excretion. It has been shown that subcutaneous fat is a significant source
of lactate, and this could explain the higher blood lactate levels of obese subjects,
due to increased release of lactate by the excess adipose tissue (Jansson et al. 1994).
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However, obese subjects have also shown to have significantly higher net uptake
of lactate, as well as glycerol, alanine and free fatty acids by liver (Felig et al.
1974). It has been suggested that elevated levels of lactate in obese subjects is due
to upregulated anaerobic glycolysis, in comparison with lean subjects. The current
results thus indicate perturbation of hepatic glucose production and lipid synthesis.
Also pyruvate, the endpoint of glycolysis, has been found out to be upregulated in
obese subjects (Felig et al. 1974). Under aerobic conditions, pyruvate enters the
TCA cycle via acetyl coenzyme A to produce energy via formation of citrate, and
other TCA cycle metabolites. The concentration of citrate is regulated by insulin,
glucose levels, fatty acid utilization, cholesterol synthesis, liver clearance and renal
excretion. Higher levels of citrate has been observed in high fat feed obese animals
with insulin resistance (Li et al. 2008).

11.3.2

Lipid Metabolism

Lipids are a diverse group of compounds with multiple key biological functions:
they function as energy storage sources, they participate in signaling pathways and
constitute the cellular structural building blocks in both cell and organelle membranes
(Orešič et al. 2008; Fahy et al. 2011).
Obesity is linked with increased basal lipolysis in adipose tissue, and elevated
circulating FFAs. In blood, elevated levels of FFAs or cholesterol in blood have been
used already for a long time as indicators of disease risk, as their alteration is related to
some cardiovascular diseases, such as coronary heart disease, diabetes, and hypertension (Orvall et al. 1996; Laaksonen et al. 2002; Green et al. 2002). Traditionally, FAs
secreted from adipocytes have been considered to function entirely as energy sources
for other tissues of the body. However, it has been shown that FAs function also as
endocrine factors that regulate metabolic function in target tissues and the obesityassociated insulin resistance may be explained by competition between increased
FFAs and glucose for oxidative metabolism in insulin-responsive cells (Randle et al.
1963). Later studies have implied that glucose uptake rather than intracellular glucose metabolism is the rate-limiting step for FA-induced insulin resistance (Shulman
2000). Also the serum FFA composition, especially the proportion of saturated FAs
has been observed to correlate positively with the development of obesity and diabetes
(Wang et al. 2003). Diabetic subjects has been shown to have elevated levels of longchain free fatty acids, such as oleic, palmitoleic and palmitic acids, and decreased
levels of arachnidonic acid than non-diabetic subjects (Fiehn et al. 2010). Also the
concentrations of blood TGs is affected in obesity due to tissue resistance to insulin
mediated glucose uptake, which in turn accelerates the very low density lipoprotein
(VLDL), TG production rate and leads to endogenous hypertriglyceridemia (Reaven
et al. 1967; Barter and Nestel 1973; Kissebah et al. 1976).
Applying global lipid profiling, combined with targeted FA analysis to plasma
samples from obese individuals has shown that fatty liver overproduces triglycerides
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with lower carbon number and double bond content (Westerbacka et al. 2010), indicative of increased de novo hepatic lipogenesis (Kotronen et al. 2009a). Further
analysis of lipid profiles in lipoprotein particles showed that these lipids are also enriched in VLDL particles of insulin resistant subjects (Kotronen et al. 2009b). Recent
research also implicates increased mitochondrial pathways and gluconeogenesis in
NAFLD (Sunny et al. 2011). Induction of lipid oxidation is required for the endergonic steps of gluconeogenesis and ureagenesis, pathways that are partially localized
in liver mitochondria and constitutively upregulated during insulin resistance (Sunny
et al. 2011). Thus, unlike skeletal muscle, the insulin-resistant and fatty liver may
activate oxidative metabolism (Iozzo et al. 2010; Sanyal et al. 2001). A prevalent
model for development of diet-induced insulin resistance confirms these findings,
stating that when mitochondrial fatty acid oxidation is inadequate to deal with the
large load of dietary fat, the result is the accumulation of lipid-derived metabolites
such as diacylglycerols (DAGs) and ceramides that can activate stress kinases to
interfere with insulin action (Savage et al. 2007; Holland et al. 2008).
Recently, identification of numerous lipid and protein signals secreted from white
adipose tissue has led to its recognition as a major endocrine organ (Rondinone
2006; Trayhurn and Bing 2006). In an animal study, male transgenic apolipoprotein
E3 Leiden (ApoE3Leiden) mice were studied during high-fat feeding (Caesar et al.
2010). This animal study combined time-resolved microarray analyzes of mesenteric, subcutaneous-, and epididymal adipose tissue (EWAT) with histology and targeted
lipidomics. The results showed upregulated levels of linoleic acid and alpha-linolenic
acid in EWAT in comparison with other depots. The authors hypothesized that this
could be due to the androgen receptor, which expression was higher in EWAT than in
other tissues, causing depot-dependent differences in de novo lipogenesis rate. The
authors therefore suggested that dietary essential FAs are accumulated in EWAT as
a result of sex-steroid mediated suppression of lipogenesis, providing an adaptive
strategy to provide precursors for epididymal PUFA synthesis (Caesar et al. 2010).
The same mouse model has been used also in another study, reporting that specific
plasma free fatty acids (C16:1, C16:0, C18:1, C18:0 and C18:2, C22:6) as well as
their ratio can be used to predict future glucose intolerance in these ApoELeiden
mice (Wopereis et al. 2012).
In a recent human study, young and healthy obesity-discordant MZ twins were
studied, allowing to focus on the effects of obesity independent of genetic factors
(Pietiläinen et al. 2011). In this study, the lipid composition of adipose tissue was
studied. The study subjects were monozygotic twin pairs, the other twin being obese,
and the other lean. The results showed multiple changes in membrane phospholipids
composition in obese, but still healthy co-twins. The changes in phospholipids were
highly selective, showing both functional group as well as fatty acid specificity
(Fig. 11.3). Despite that the obese co-twins had a lower dietary polyunsaturated fatty
acid intake, they had increased levels of palmitoleic and arachidonic acids in their
adipose tissue, including upregulated levels of ethanolamine plasmalogens containing arachidonic acid. In comparison to non-obese co-twins, the obese co-twins had
increased levels of lysophosphatidylcholines, which are lipids found in proinflammatory (Yang et al. 2005) and proatherogenic conditions, as well as decreased levels of
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ether phospholipids, which are known to exert antioxidative properties (Engelmann
2004). These lipid changes were associated with insulin resistance. The results of
the next part of the study, using molecular dynamics simulations of lipid bilayers,
suggested that the observed lipid remodeling maintains the biophysical properties of
lipid membranes, at the price, however, of increasing their vulnerability to inflammation (Pietiläinen et al. 2011). Next, a separate group of morbidly obese subjects was
studied. Interestingly, in morbidly obese subjects, the levels of these plasmalogens
containing arachidonic acid in the adipose tissue was distinctly decreased, on contrary
to the results obtained for obese, but still metabolically healthy subjects. These results were further supported by in vitro adipocyte confirmatory model. The study also
showed that that the lipid network regulating the observed remodeling may be responsive to genetic modulation. The authors therefore suggested that by a new generation
of therapies directed at several targets in the lipid metabolism pathways, it may be possible to correct these abnormalities as proper management of obesity, and favorably
modify the risk, course and outcome of diabetes and cardiovascular diseases. This
study allowed to identify adaptive mechanisms that may lay behind the characteristic remodeling of the AT lipidome in response to positive-energy-balance-induced
adipose tissue expansion during the evolution of obesity (Pietiläinen et al. 2011).

11.3.3 Amino Acid Metabolism
Amino acids have been in several studies to display a significant obesity associated
variations. It has been reported already decades ago several amino acids, including
branched chain amino acids (BCAAs), are elevated in the blood of obese, insulinresistant, or type 2 diabetic subjects relative to healthy controls (Felig and Wahren
1971). BCAAs have an important role in protein synthesis as well as in glucose
metabolism and oxidation and they can also regulate leptin secretion from fat and
food intake. A more recent study suggests that obesity induces increased catabolism
of BCAA and correlated with insulin resistance even in obese subject that are healthy,
although more insulin resistant than the lean controls. Five amino acids, namely three
BCAAs (isoleucine, leucine, valine) and two aromatic amino acids (tyrosine and
phenylalanine) have been shown to have highly significant associations with future
diabetes in a two large, longitudinal studies (Wang et al. 2011). Moreover, a combination of three amino acids predicted future diabetes. The change in concentration
of these five amino acids during oral glucose tolerance test was not associated with
incident diabetes, suggesting that concentrations after OGTT did not add predictive
information to the baseline concentrations. Results of amino acid supplementation,
both in a high-fat diet animal study and as an infusion of a AA mix in a human study
(Tremblay et al. 2005) showed that the AA supplementation decreased the insulin
sensitivity, thus indicating that these metabolites are not merely by-products of the
disease process, but contribute to development of metabolic dysfunction.
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Fig. 11.3 The obesity associated metabolic pathway

11.3.4

Metabolites Related to Mitochondrial Dysfunction
and Oxidative Stress

Mitochondrial functions include regulation of several key pathways related to energy homeostasis, including biogenesis, thermogenesis, and glucose and fatty acid
metabolism, and obesity has shown to alter these functions which in turn may lead
to obesity-related pathologies. Excess dietary intake can lead to significant mitochondrial dysfunction, in part due to the harmful effects of highly reactive molecular
species (ROS) which can cause oxidative stress to the system. The oxidative stress
is defined as a persistent imbalance between the production of ROS and antioxidant
defenses of the organism.
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Particularly, defects in mitochondrial oxidative metabolism of fatty acids have
been linked to diet-induced obesity and the development of insulin resistance in
adipose tissue and skeletal muscle (Kusunoki and Kanatani 2006; Maassen et al.
2007). Insulin resistance may arise from defects in these mitochondrial functions,
which in turn lead to increases in intracellular FA metabolites (fatty acyl-CoA and
diacylglyerol) that disrupt insulin signaling in the muscle as well as the liver (Qatanani
and Lazar 2007).
Obesity has shown to cause systemic oxidative stress to the organism. The oxidative stress has been shown to correlate with fat accumulation in humans and mice
(Halliwell 1995; Rosen et al. 2001; Evans et al. 2002). Studies have shown that
ROS are upregulated already in prediabetic stage, which is suggested to be due to
obesity-related elevations of FAs that cause oxidative stress due to increased mitochondrial uncoupling and β oxidation, leading to the increased production of ROS
(Wojtczak and Schonfeld 1993; Carlsson et al. 1999; Rao and Reddy 2001). This
hypothesis has been supported by studies that show that infusion of FAs into healthy
subjects causes increased oxidative stress and insulin resistance that is reversed by
infusion with antioxidants such as glutathione (Paolisso et al. 1992). In addition,
there is a significant inverse correlation between the fasting plasma FFA concentration and ratio of reduced/oxidized glutathione in T2D patients (Palisso et al. 1996).
In vitro studies have shown that ROS and oxidative stress lead also to the activation
of multiple serine/threonine kinase signaling cascades (Kyriakis and Avruch 1996;
Evans et al. 2003). These activated kinases can act on a number of potential targets
in the insulin signaling pathway, including the insulin receptor and the family of
IRS proteins. However, the molecular mechanisms by which oxidative stress leads
to insulin resistance are not yet fully clarified. Also the decrease in mitochondrial
function associated with obesity and insulin resistance is not totally clear, as it has
been shown that functional mitochondria are needed for an FA-induced increase in
ROS (Evans et al. 2002). It has been suggested that an increase in ROS due to FA
oxidation may occur early during the development of insulin resistance and prior to
mitochondrial dysfunction (Quatatni et al. 2007). At a later stage of developing insulin resistance, ROS might lead to a decrease in mitochondrial function that on turn
can lead to the accumulation of fat in the muscle and liver, exacerbating the insulin
resistance phenotype. Thus, the recent studies support the hypothesis that oxidative
stress is a causative factor in the development of insulin resistance (Fridlyand and
Philipson 2006; Houstis and Rosen 2006).

11.3.5

Metabolic Biomarkers of MetS

Early biomarkers for MetS and related diseases have been searched intensively. Current studies indicate several different metabolites characteristic for T2DM. Glucose,
2-hydroxyisobutyric acid (α-HB), linoleic acid, palmitic acid and phosphate have
been indicated to be potential biomarkers in some studies (Li et al. 2009). Particularly, serum α-HB has been considered as an early marker for both insulin resistance
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and impaired glucose regulation (Gall et al. 2010). Association between α-HB levels
and HOMA-IR has also been observed in specific lipoprotein fraction, namely in
VLDL fraction (Hyötyläinen et al. 2012). Upregulation of several intermediates of
pentose-phosphate pathway, such as xylose, has also been observed in other recent
studies in diabetic subjects (Fiehn et al. 2010).

11.4

Conclusions

Metabolomics is a valuable tool for a detailed study of the pathophysiological
mechanisms in obesity and the mechanisms in obesity-related diseases. The novel
analytical tools allow detailed characterization of the metabolic profiles in biofluids
and tissues. Moreover, integration of the metabolic data with clinical, genomic and
transcriptomics data facilitates the development of metabolic models to understand
the alterations of metabolism during obesity and related diseases. Several of the core
metabolic pathways have been already been defined, however, a detailed knowledge
of the metabolic pathways is still missing. Evaluation of the metabolic pathways
across multiple tissues is crucial for understanding the compensatory mechanisms
that operate at organismal level to maintain energy homeostasis. Detailed understanding of metabolic pathways may help in developing new generation of therapies
for proper management of obesity.
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Chapter 12

Fluxomics
Marta Cascante, Adrián Benito, Igor Marín de Mas, Josep J. Centelles,
Anibal Miranda and Pedro de Atauri

Abstract Metabolic processes are dynamic, ﬁnely regulated and interconnected. In
order to characterize metabolic networks and their functional operation, quantitative
knowledge of intracellular ﬂuxes is required. Whereas metabolite concentrations
can be directly estimated, the set of molecular ﬂuxes through each reaction within
a metabolic network can only be estimated indirectly. Isotope labelling experiments
with 13 C-labelled tracers, using nuclear magnetic resonance or mass spectrometry,
are emerging as powerful strategies used to measure ﬂuxes in complex interconnected metabolic networks. In this chapter, we review these methods together with
the computational resources for ﬂux analysis. Current challenges and limitations in
ﬂuxomics applied to Metabolic Syndrome are discussed.
Keywords Fluxomics · Fluxome ·
Isotopic steady state
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Methods in Fluxomics: an Overview

As stated in the previous chapter, the term metabolome refers to the collection of all
metabolites in a biological entity (cell, tissue, organ or organism), these metabolites
being the end products of gene expression, mRNA synthesis and protein activity
(Kuchel 2010; Dudley et al. 2010; Oresic 2009). In brief, the metabolome of an
organism is the result of the in vivo activity of gene products and is closely tied
to its physiology and environment (what the organism eats or breathes). Accordingly, metabolomics has been deﬁned as the measurement of the composition of
low-molecular-weight molecules in biological samples. However, knowledge of the
complete set of metabolites is not enough to predict the phenotype of a cell as it gives
only an instantaneous ‘snapshot’ of the physiology of that cell (Castro-Perez et al.
2011; Lorkowski 2011).
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The distinct metabolic processes involved in metabolite production and degradation are dynamic, finely regulated and interconnected. Therefore, in order to
comprehensively characterize metabolic networks and their functional operation
(metabolite turnover), quantitative knowledge of intracellular metabolic fluxes is required. Fluxomics is the field of ‘omics’ research dealing with the dynamic changes
in metabolites over time, i.e. the quantitative analysis of fluxes through metabolic
pathways (Cascante and Marin 2008; Paul Lee et al. 2010). Fluxomics involves
the quantitative monitoring of the operation of the whole metabolic network by
methods of flux analysis, providing a global perspective on integrated regulation at
the transcriptional, translational and metabolic levels (Cascante and Marin 2008;
Bothwell and Griffin 2011). Molecular fluxes through metabolic networks (the fluxome) reflect the integration of genetic and metabolic regulation and determine the
cellular phenotype (Sauer 2004). Thus, whereas transcriptomics, proteomics and
metabolomics provide a measure of metabolic network capacities and thermodynamic driving forces, fluxomics provides a measure of the flux through each reaction
in the network, which can be considered a direct measure of the metabolic phenotype
(Krömer et al. 2009).
Whereas metabolite concentrations can be directly estimated using the methods
described in Chap. 11, the set of molecular fluxes through each reaction within a
metabolic network can only be estimated indirectly. Thus, measurement over time of
metabolites in the extracellular media that enter or exit the cell permits estimation of
the fluxes in uptake and secretion. The balance of these input and output fluxes, within
a stoichiometric model of the reaction network, gives the overall quantitative flux
distribution. However, quantifying fluxes by simple flux balancing is only possible for
simple metabolic pathways, e.g. biosynthetic linear pathways (Zamboni and Sauer
2005), due to futile cycles and a high degree of interconnection between metabolic
pathways.
The quantification of fluxes through complex interconnected networks has only
been possible with the use of labelled metabolites that can enter and be metabolized
inside the cell, e.g. 13 C-labelled metabolites. Nowadays, isotope labelling experiments are emerging as very powerful strategies used to measure fluxes in metabolic
networks (for a review see (Cascante and Marin 2008; Paul Lee et al. 2010; Metallo
et al. 2009; Krömer et al. 2009; Matsuoka and Shimizu 2010; Selivanov et al. 2010)).
The isotopes used in such experiments can be radioactive (3 H, 32 P and 14 C) or
nonradioactive stable isotopes (2 H, 15 N and most commonly 13 C). Experiments using
either radioactive, or preferably stable isotopes, have been extensively performed at
the level of cell culture as well as at the level of tissues, organs and whole organisms
(Lane et al. 2011). The specific conversion of substrates into products through each
metabolic pathway imprints different characteristic label patterns in intermediate
metabolites and products. This increases the capacity of stoichiometric flux balancing
to trace the flux in more complex non-linear pathways.
Metabolomics and fluxomics can accurately and comprehensively depict both the
steady physiological state of a cell or organism and their dynamic responses to genetic
and environmental modulation. Thus, fluxomics offers a unique opportunity to look
at relationships between genotype and phenotype and how these are influenced by
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the environment and the overall state of the organism, including the influence of
nutrition and disease.
An increasing number of papers are providing a detailed description of the fluxes
throughout metabolic pathways at the cellular level. These descriptions are based on
the combination of experimental techniques, using 13 C substrates, and computational
approaches, providing a detailed picture of the metabolic pathways. Below, a description is provided of the principles on which the analysis of metabolic pathways in
mammalian cells is based. An overview of the computational approaches is given, beginning with methods based on biochemical and biophysical constraints, followed by
an explanation of the coupling of computational methods and stable-isotope assisted
experiments.

12.2

Flux Analysis Using Biochemical and Biophysical
Constraints

Various computational approaches have been used to estimate the flux distribution
in metabolic pathways. Early attempts to model metabolism in cells began with rate
equations of individual enzymes in each metabolic pathway, which constrain the
metabolic behaviour. This type of model (kinetic model) has been constructed not
only for unicellular organisms such as Escherichia coli and yeast, but also for highly
complex cells such as hepatocytes (e.g. (Rodriguez-Prados et al. 2009; Curto et al.
1995; Teusink et al. 2000; Raftos et al. 2010; Curien et al. 2009; Nikerel et al. 2009;
Maher et al. 2003)).
The regulation of enzyme activity by metabolites that can act as inhibitors or
activators of the enzyme is taken into account in these kinetic models. The principal
difficulty when constructing this type of quantitative flux model of metabolic networks in a particular cell, tissue or organism is the availability of rate equations and
reliable values for the required kinetic parameters (e.g. Km , Ki , Vmax etc.). Another
critical step is to decide the boundaries of the models, e.g. metabolites assumed to
be constant (de Atauri et al. 2000).
In modern systems biology it is widely accepted that detailed kinetic models are
not always necessary, as many specific questions such as which enzymes should be
modified to successfully alter the flux, or metabolite concentration, in pathways of
clinical relevance, can be tackled by techniques such as Metabolic Control Analysis
(Heinrich and Schuster 1996; Stephanopoulos et al. 1998; Cascante et al. 2002;
Moreno-Sanchez et al. 2008; Bruggeman et al. 2008).
Moreover, the fact that biological information is typically incomplete led to the
development of constraint-based modelling approaches for analysing flux distribution in metabolic networks (for a review see (Llaneras and Pico 2008; Ruppin et al.
2010; Orth et al. 2010)), which do not include rate equations for enzymes. In practice, these approaches enable the steady state distribution of metabolic fluxes to be
estimated based on the addition of successive constraints. In this context, flux balances around metabolites are constraints describing the network topology and the
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associated stoichiometry for each reaction step. Additional constraints can include
experimental data, e.g. measurements of substrate uptakes, production rates, thermodynamics of reactions, etc. All these constraints are limiting the solution space of
flux distributions, where a solution of flux distribution is such a complete assignation
of flux values of the reaction steps that all the constraints are satisfied. The set of all
possible solutions is the solution space of flux distributions. The solution is provided
by solving problems of maximization (or minimization), e.g. maximizing fluxes of
essential cell components, such as biomass or ATP, which should have a selective
advantage (Schuster et al. 2008; Feist and Palsson 2010; Orth et al. 2010). These
maximizations are applied to compute optimal flux distributions, which can be nonunique. The minimum and maximum flux for each reaction in the network can be
analysed while satisfying some state of the network, e.g. 90 % of maximal biomass
production (Mahadevan and Schilling 2003; Gudmundsson and Thiele 2010). The
idea underlying these approaches is to describe a metabolic network by a set of constraints that characterize its possible metabolic behaviour and permit calculation of
the metabolic flux states that would be exhibited under different assumptions.

12.3
12.3.1

Flux Analysis Using Labelled Substrates
Experimental Approaches for Stable Isotope-Assisted
Fluxomics

Uncertainty regarding intracellular fluxes comes in large part from the degrees of
freedom associated with complex metabolic networks that involve ramifications, bifurcations and cycles. The use of stable isotope-labelled substrate provides a direct
means of estimating flux distributions, which can be combined to satisfy the above
discussed constraints. The distribution of atoms from a labelled substrate (tracer) allows the quantitative determination of the substrate–product relationship (Cascante
and Marin 2008; Paul Lee et al. 2010; Metallo et al. 2009; Krömer et al. 2009;
Matsuoka and Shimizu 2010; Selivanov et al. 2010). The propagation of the label
from labelled substrates to different metabolic products is analysed in order to estimate the relative contribution of the internal fluxes involved in the complex metabolic
networks.
Figure 12.1 illustrates the use of label propagation. The propagation after one turn
of the Krebs cycle is represented, with 13 C coming from [1,2–13 C2 ]D-glucose. Here,
a hypothetically labelled molecule of pyruvate and its transformation to acetyl-CoA
for lipid production is represented. In this example, carbons from lipids synthesized
de novo are labelled with 13 C, enabling estimation of glucose contribution for lipid
synthesis (Boren et al. 2003). After more turns of the cycle the picture regarding
labelled and non-labelled carbons becomes more complex. In this example all reactions affecting label propagation also affect the concentration of intermediaries.
However, some reactions produce changes in label distribution but not in chemical
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Fig. 12.1 Label propagation. Scheme of the carbon skeleton of Krebs cycle intermediates, where
each carbon is represented by a circle. The non-labelled (white circles) and labelled (gray circles)
carbons come from a labelled substrate (in this case [1,2–13 C2 ]D-glucose) after only one turn of
the cycle. Reactions with discontinuous arrows were not considered

balance (Selivanov et al. 2005). These ‘invisible reactions’ can be followed using
labelled metabolites. Figure 12.2 illustrates invisible reactions involved in the mechanism of transketolase. The example focuses on the case of ribose-5-phosphate and
sedoheptulose-7-phosphate (discontinuous circle), where there is an ‘invisible’ cycle
between them that does not affect concentrations but does affect label distribution
(discontinuous arrows).
Selection of the appropriate labelled substrates and products is a major challenge
that is determined by the intracellular fluxes to be quantified, and strongly influences the quality of the estimated fluxes (Metallo et al. 2009). Depending on the
fluxes under study, a wide range of tracers exists. Among them, stable-isotope labelled substrates such as 13 C-glucose or 13 C-glutamine are the most widely used.
Traditionally, 13 C tracers have been employed in the study of microbial metabolism,
where microorganisms are generally fed with single carbon source. The issue of
tracer choice is more complex in mammalian cell systems, which are cultured with
multiple carbon sources and are grown in complex media containing all amino acids
and often additional compounds such as nucleotides or lipids. Researchers have used
a variety of tracers in order to study particular metabolic pathways, including labelled
glucose, glutamine, acetate and atypical substrates such as propionate (RodriguezPrados et al. 2010; Gaglio et al. 2011; Collins et al. 2011; Burgess et al. 2007).
For instance, [1,2–13 C2 ]-glucose provides information on glycolysis, pentose phosphate pathway, pyruvate oxidation versus carboxylation (Marin et al. 2003; Vizan
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Fig. 12.2 Invisible reactions involving transketolase. Transketolase reversibly catalyzes the transfer
of a glycoaldehyde from ketoses to aldoses by a ping-pong mechanism: transketolase (E) reacts
with a ketose (x5p, s7p or f6p) to form an enzyme-glycoaldehyde form (EG) and liberates an aldose
(g3p, r5p or e4p, respectively). Then, the reaction cycle is completed when EG covalently links
the glycoladehyde with another aldose, thus producing a new ketose and E. Binding the same type
of aldose as the previously released, results in returning to the initial state: no concentrations are
changed. However, if this bound aldose differs in the isotopomer composition, such a reaction cycle
can change the isotopomer distribution of the media without changing the total metabolite concentrations. Such a reaction will be called ‘invisible reaction’, e.g. s7p + r5p ↔ r5p + s7p. Metabolites:
e4p, erythrose-4-phosphate; f6p, fructose-6-phosphate; g3p, glyceraldehyde-3-phosphate; r5p,
ribose-5-phosphate; s7p, sedoheptulose-7-phosphate; x5p, xylulose-5-phosphate

et al. 2009) and de novo synthesis of lipids (Fig. 12.1) (Boren et al. 2003). Specific products can be selected to determine the ratios of specific intracellular fluxes.
Thus, 13 C propagation from [1,2–13 C2 ]-glucose to lactate is analysed to determine
the approximate ratio of fluxes through the pentose-phosphate pathway with respect
to the carbon flow descending through glycolysis, whereas 13 C propagation from
[1,2–13 C2 ]-glucose to RNA ribose is analysed to determine the approximate ratio
of fluxes through the oxidative and non-oxidative pentose-phosphate pathway. In
addition, 13 C propagation from [1,2–13 C2 ]-glucose to glutamate is analysed to estimate the approximate relative contributions of pyruvate carboxylase and pyruvate
dehydrogenase to the Krebs cycle (Marin et al. 2003). However, labelled glucose
often fails when assessing fluxes in the Krebs cycle, since most 13 C atoms can be excreted in the form of lactate and alanine. In this case, labelled glutamine can be used
to better resolve the activity of the Krebs cycle.
In the context of 13 C labelling, isotopologue refers to isomers with a specific
number of 13 C substitutions and isotopomer (‘isotope isomers’) to isomers with
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13

C substitution in a specific carbon position1 , which can be determined via various analytical platforms. Alternatively, such isomers can be referred to as mass
isotopomer and positional isotopomer, respectively (Paul Lee et al. 2010). Thus,
isotopologues account for those reaction products with zero, one, two, etc. 13 C
substitutions, which are denoted as m0, m1, m2, etc. respectively. For a specific
metabolite, the number of possible isotopomers, 2n , depends on the number, n,
of carbons for each metabolite. For instance, for lactate, with three carbons, there
are 23 = 8 isotopomers. A lactate compound denoted as m2 contains three possible
isotopomers:13 C1 –13 C2 –12 C3 ,13 C1 –12 C2 –13 C3 and 12 C1 –13 C2 –13 C3 .
The detection and quantification of isotopomers and isotopologues is a challenging issue. There are currently two main methods of detecting and measuring
isotopomer/isotopologue distributions: nuclear magnetic resonance (NMR) and
mass spectrometry (MS) (Lane et al. 2009; Wiechert 2001; Li et al. 2011). The
NMR technique is able to distinguish isotopomers by the magnetic properties of the
atom nucleus, and provides information of positional labelling. However, it requires
a large amount of sample, long analysis times and expensive equipment. On the other
hand MS is widely accessible, more affordable and provides high sensitivity in the
detection of isotopologues (‘mass’ isotopomers).
MS distinguishes between isotopologues by differences of mass, thus allowing
13
C-labelled compounds to be distinguished from unlabelled compounds containing
12
C, as the former are heavier than the latter. However, a major limitation of this
method compared with the NMR method is that only isotopologues can be distinguished unless tandem MS analysis is used, which potentially increases the amount
of labelling data (Choi and Antoniewicz 2011). Coupled to MS, various chromatographic separations can be used, such as liquid (LC) (Henry et al. 2011) or gas
chromatography (GC) (Selivanov et al. 2010; Hiller et al. 2010). A high resolution is achieved by GC-MS, although samples must be chemically derivatized to
form volatile compounds before fractionation by GC and ionization by electron impact or chemical ionization. Afterwards, the resulting ions are detected using their
mass-to-charge ratio (m/z), and as the ions usually have a single charge, the m/z
value is equivalent to the molecular weight of the fragment in mass units. For LCMS no derivatization is required. Nevertheless, isotopologue analysis by LC-MS is
infrequent.

12.3.2

Flux Analysis Under Isotopic and Non-Isotopic
Steady State

The relative abundance of labelled product (isotopomers and isotopologues) depends
on the labelled status of the substrates (e.g. labelled glucose) and the flux distribution
1

For a more general definition of isotopologue and isotopomer we refer the reader to (IUPAC
Compendium of Chemical Terminology—the Gold Book 2011)
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throughout the metabolic network. Thus, by proposing an appropriate metabolic network, at fixed relative abundances of the isotopic forms of labelled substrates, one
or more flux distributions throughout the assumed networks are expected that will fit
the measured distribution of labelled products, also satisfying the biochemical and
biophysical constraints associated with the metabolic network. Other experimental
measures, such as measured inputs or outputs, can also be fitted or fixed as constraints to be satisfied. However, additional factors must be considered (Wiechert
2001). Among them, we highlight the natural abundance of 13 C, and in particular,
the fact that both the steady state of concentration and fluxes and the isotopic enrichments of all metabolite pools undergo a transient phase before the steady state of
isotopomer distribution is finally reached (isotopic steady state). Thus, the duration
of the experiment and the size of the metabolic pools are fundamental factors when
determining the strategy to be applied to solve fluxes based on labelled measurements (Deshpande et al. 2009; Selivanov et al. 2010; Wiechert 2001). Larger pools
experience a longer transient phase, which may be even longer than the duration
of the experiment, especially when the metabolites belong to pools corresponding
to macromolecular biomass constituents, such as proteins or RNA, large pools of
internal metabolites, such as glycogen, or pools of intermediates of central carbohydrate metabolism that are secreted to or exchanged with the culture medium, such as
lactate and other amino acids or lipids. Although intracellular metabolites may reach
the isotopic steady state within minutes, the existence of these stores delays the time
required to establish the isotopic steady state (Selivanov et al. 2010).
When metabolic and isotopic steady state is required, cells need to be incubated
with the tracer for a sufficiently long period to obtain complete isotope incorporation,
which can take a long time in mammalian systems. Thus, it is crucial to study the
metabolic and isotopic behaviour prior to deducing any physiological conclusions
from a tracer-assisted experiment (Deshpande et al. 2009). Under isotopic steady
state, isotopomer and isotopologue abundances can be predicted from the balances
around isotopomers, which are analogous to the flux balances around metabolites,
but also taking into account label transitions (Antoniewicz et al. 2006; Antoniewicz
et al. 2007). These balances describe the dependency of isotopomer abundances on
fluxes and isotopomer abundances of other metabolites. The goal is to find the set
of fluxes that minimizes the difference between observed and simulated isotopomer
measurements (Antoniewicz et al. 2006).
Alternatively, under (isotopic) non steady state, time-series of isotopic labelling
can be measured to compute fluxes during dynamic phases. This kind of analysis
is useful when internal stores such as glycogen, amino acids, lipids etc. delay the
(isotopic) steady state of the internal and external metabolites. Estimation of fluxes
during dynamic phases requires alternative mathematical approaches (Noh et al.
2006; Baxter et al. 2007; Selivanov et al. 2010). In simulations using detailed kinetic models, comparison with experimental time courses of such ‘slow’ variables
provides additional restrictions that help to evaluate the fluxes. Taking into account
the thermodynamic relationships between kinetic and equilibrium constants restricts
the domain of estimated fluxes, as illustrated in the detailed modelling of the kinetic
mechanisms of transaldolase and transketolase (Selivanov et al. 2005).
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In summary, the tools for the theoretical analysis of both isotopic steady and nonsteady state have been developed in conjunction with the experimental techniques
of stable isotope tracing. There are many examples of application to the study of
metabolism in different organisms, such as fungi (Jouhten et al. 2009) and yeast
(Jouhten et al. 2008; Aboka et al. 2009), as well as mammalian cells in normal and
disease states, as shown in man (Fan et al. 2009), in primary cultures (Amaral et al.
2010), and in cultured cancer cells (Selivanov et al. 2010).

12.4

Computational Resources for Flux Analysis

Several strategies for metabolic flux estimation have been described in this chapter.
In order to obtain such estimates in a complex and dynamic system such as the
cell metabolism, the use of specialized software is required. To this end a large
number of computational resources are available for analysis associated with fluxes
and 13 C labelling. Examples of the algorithms and software used for flux analysis
from carbon-labelled experiments are ‘13C-FLUX’ (Wiechert et al. 2001), ‘Fiatflux’
(Zamboni et al. 2005), ‘OpenFLUX’ (Quek et al. 2009), FIA (Srour et al. 2011) and
‘Isodyn’ (Selivanov et al. 2004, Selivanov et al. 2005; Selivanov et al. 2006).
In order to illustrate how modelling is used to analyse flux based on 13 C tracer
data, the software Isodyn will be discussed in more depth. Isodyn (from ‘isotopomer
dynamics’), which was developed in C + + , represents a simulation environment
for the dynamics of metabolite labelling by 13 C isotopes in metabolic reactions of
living cells. Isodyn simulates 13 C isotopomer distribution in the same way as classical
kinetic models simulate the time-course of metabolite concentrations.
Figure 12.3 provides a detailed flow chart description of Isodyn. The program
is organized into separated modules for simulations of kinetic of metabolite concentrations, isotopomer concentrations and statistical analysis. A first module is a
classical kinetic model of metabolic pathways represented by a system of ordinary
differential equations (ODE). Numerical solution of this ODE system gives the time
course of evolution of metabolite concentrations and fluxes. If metabolic steady
state is simulated, the basic kinetic simulation lasts until the metabolic steady state is
reached. Kinetic model is linked, through total metabolite concentration and fluxes,
with a module that computes the distribution of 13 C isotopomers. The program automatically constructs hundreds of ODEs describing the evolution of all isotopomers
in the system. The simulation of isotopomer distribution starts after simulating the
evolution of metabolic fluxes and concentrations in accordance with the scheme of
metabolic pathways and a set of parameters and initial concentrations, implemented
in the kinetic model. The isotopomer distributions are fitted by modifying the values
of model parameters using a modified Simulated Annealing algorithm (Kirkpatrick
et al. 1983). The goodness of fit is evaluated by χ2 (square of difference between
the measured data and the predicted values, normalized by standard deviation σ of
the measurement) and numbers of degrees of freedom, as described in (Press et al.
2002). The χ2 values obtained for the best fit identify the acceptability of the model
and the reliability of the evaluated fluxes.
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Simulations

1
2
3
4

5

Initial parameters
and variables
Kinetic model

Isotopomer dynamics

Change
same
parameter

Calculated isotopomer/
isotopologue distributions
S1, S2,...

χ² =Σi((Si,calculated - Si,measured)/σi)²

6

Change
other
parameter

7

If χ²min > χ²new
If χ²min < χ²new

Measured isotopomer/
isotopologue distributions from MS/RMN
S1±σ1, S2±σ2,...

Experimental data

Statistic analysis
Fig. 12.3 Isodyn flow chart. Steps: 1) Starts with an initial set of model parameters; 2) Metabolite
concentrations and fluxes are determined by dynamic simulation; 3) In order to simulate isotopomer
dynamics, metabolite concentrations are used as initial values for unlabeled isotopomers (labeled
internal isotopomers initially have zero concentrations) and fluxes are used to define the sum of
reaction rates for all isotopomers; 4) Simulation of isotopomer dynamics provides isotopomer distributions (Si being a particular isotopomer/isotopologue); 5) The χ2 (see main text) is determined;
6) The value of a randomly chosen parameter is modified to decrease χ2 , the process from step
2 to 5 is repeated, and the new χ2 is compared with the previous one (the process is repeated by
changing the value of the same parameter while the new χ2 remains lower than the minimum,
previously obtained); and 7) A new model parameter is randomly selected and step 6 is repeated
for this parameter

12.5

Current Challenges and Limitations in Fluxomics Applied
to Metabolic Syndrome

Metabolic Syndrome (MetS), being a multifactorial disorder, brings about an array
of alterations in metabolite concentrations that occur in tissues and cells that are
distant from those containing the primary lesions. One of the main challenges for
fluxomics is to be able to map all human metabolic network fluxes, including compartmentalization and crosstalk between organs. The achievement of this objective
will require:
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1) Collecting sufficient information from biofluids (blood, urine, breath, saliva. . . .)
from tissue biopsies and/or from cell lines established from patient tissues.
2) A view of metabolism and metabolic fluxes with the focus not only on maps of
the metabolic stoichiometric reaction networks catalyzed by enzymes, but also
on the supramolecular organization of the metabolism. This overall view of the
metabolism needs to include interactions between different cell components and
new modes of metabolic regulation (i.e. interactions with structural elements,
interfering RNAs, etc. (Kuchel 2010)).
It is expected that recent advances in transcriptomics, proteomics, metabolomics and
fluxomics with reference to MetS will, in future, provide sufficient information from
a patient to enable early diagnosis, prognosis, prediction of treatment efficiency and
follow-up of response to treatment.
Since MetS requires a complete and simultaneous understanding of several organs
at the same time, in vivo approaches are required to fully understand this disease.
Current approaches to in vivo fluxomics rely on the study of the systemic circulation
of metabolites, and usually involve estimation of the rates of hepatic glucose production and clearance (Vaitheesvaran et al. 2010a), rates of lipolysis through glycerol
production (Vaitheesvaran et al. 2010b), and general pathway utilization after glucose administration (Xu et al. 2002). More accurate results have been obtained by
combining techniques such as GC-MS and NMR after infusion with 13 C-labelled
metabolites of perfused rat hearts (Li et al. 2011), or applied to the study of the
metabolism and clearance of xenobiotics (Zhang et al. 2009; Gu et al. 2010).
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Chapter 13

In vitro Colon Model to Study Metabolic
Syndrome
Anna-Marja Aura

Abstract Metabolic syndrome (MetS) is a metabolic disorder, tightly linked to obesity, and predisposing to cardiovascular disease and type-2 diabetes mellitus (T2D).
There is already some knowledge related to intake of diet rich in phytochemicals and
improved biological effects e.g. adipose tissue function or biomarkers of improved
insulin sensitivity. This chapter aims to describe the connection between plant food
and beverage intake and circulating metabolites by using the in vitro colon model. The
in vitro colon model coupled with metabolomic systems biology is applied to connect
food components, over-expressed in vitro metabolite proﬁles and corresponding in
vivo metabolite proﬁles. When the diet relation has been made, the same metabolites
are identiﬁed from the human body ﬂuids. The traditional end-points related to health
and disease can be connected with the biomarkers of intake of the same volunteers.
Finally, novel biomarkers of health status can be sought using novel lipidomic and
proteomic techniques, which has potential to answer to the urgent need for early
biomarkers of disease and improved health.
Keywords Metabolic syndrome · Colonic metabolism and in vitro digestion models ·
Flavanols and proanthocyanins · Hydroxycinnamic acids · Anthocyanins

13.1

Introduction

Metabolic Syndrome (MetS) is a metabolic disorder, tightly linked to obesity, and
predisposing to cardiovascular disease and type-2 diabetes mellitus (T2D). MetS is
characterized by central obesity, insulin resistance, dysglycemia, dyslipidemia and
hypertension (Eckel et al. 2005; Möller and Kaufman 2005). MetS is also connected
with adipose tissue metabolism, skeletal muscles, liver steatotosis and systemic
oxidative stress. MetS associated inﬂammation is indicated as elevated levels of
C-reactive protein and levels of pro-inﬂammatory cytokines in obese people and
genetically modiﬁed obese (ob/ob) mice (Visser et al. 1999; Zahorska-Markiewicz
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et al. 2000; Dube et al. 2008). MetS patients exhibit activation of biochemical
pathways leading to systemic oxidative stress, which regulates expression of genes
governing lipid and glucose metabolism (Grattagliano et al. 2008).
MetS patients are a good target group for linking plant food intake and improvement of health status, because they have already biomarkers related to unbalanced
health status, however, those biomarkers are still reversible, if the factors affecting
regulation of the balance are corrected. There is already some knowledge related
to dietary fibre, plant food or beverage intake and improved biological effects in
MetS, e.g. adipose tissue function as biomarker of improved insulin sensitivity. This
chapter aims to describe the connection between plant food and beverage intake and
metabolism, the in vitro colon model as a tool for filling in the gap between the
intake and its circulating metabolites, and finally to describe research on colonic
metabolism of those compounds from the diet which have shown a relation to MetS
or its end-points. The chapter will conclude with prospects and considerations related
to this work.

13.2

Dietary Fibre Components and Health

Different types of dietary fibre (DF) have been reported to take part in the control of
body weight, glucose and lipid homeostasis, insulin sensitivity and in the regulation
of many inflammation markers involved in the pathogenesis of MetS (Galisteo et al.
2008; Ma et al. 2008; Priebe et al. 2010). American Dietetic Association (ADA) has
taken a position that the intake of DF, coming from variety of plant foods, has beneficial effect on risk factors for developing several chronic diseases, including MetS and
T2D (ADA 2008). The novel definition of DF in the European Commission directive
29th Oct 2008 (2008/100/EC) includes non-digestible and non-absorbable carbohydrate polymers, oligomers and monomers and phytochemicals such as phenolic
compounds and sterols.
Meta-analysis (14 cohorts with 48 000 individuals in European descent) was performed on interaction of the dietary whole grain intake with fasting glucose- and
insulin levels: greater whole grain intake was associated with lower fasting glucose
and insulin levels and it was related to relevant genetic logi independent of demographic, other dietary or life style factors (Nettleton et al. 2010). Cereal fibre intake
and effects in improved lipid, glucose and energy metabolism has been reviewed
recently, indicating also qualitative factors related to physicochemical properties
(e.g. solubility, viscosity, fermentability), fibre extract molecular weight, particle
size and microstructural features (Smith and Tucker 2011; de Mello et al. 2011).
A stronger protective role association was shown for insoluble fibre than for soluble fibre, suggesting that other characteristics than fermentability of carbohydrates
to short-chain fatty acids is associated with DF intake and reduced risk of diabetes
(Weickert and Pfeiffer 2008). A diet rich in fatty fish, bilberries and wholegrain products was associated with improved markers of endothelial function and inflammation
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in overweight and obese individuals at high risk of developing diabetes. The study
was conducted as a randomised controlled diet (de Mello et al. 2011).
Table 13.1 shows that intake of whole grain and DF associated polyphenolic
components has exerted systemic effects in vivo on biomarkers of MetS in humans
and animals, including adipose tissue function and glucose and insulin metabolism.
Table 13.1 also displays some in vitro mechanistic studies related to the effects of
DF associated phenolic compounds on the glucose and insulin metabolism.
Furthermore, ellagitannins exhibited strong activities in both stimulating insulinlike glucose uptake and inhibition of 3T3-L1-adipocyte differentiation in vitro (Bai
et al. 2008). It should be noted that not only such solid phenolic sources as DF
matrices, but also tea consumption resulted in improvement of biomarkers related
to insulin sensitivity (Stote and Baer 2008). Green tea epigallocatechin gallate was
shown to direct the lipid accumulation to the cytosol of hepatocyte cell model (McARH7777), decreasing apoB-100 very low density lipoprotein secretion thus affecting
its assembly (Li et al. 2006). Also citrus flavonoids affected lipid metabolism in
HepG2 cells by suppressing ApoB secretion (Lin et al. 2011). This evidence suggests
that diet rich in DF and or phenolic compounds can be associated with reduction of
MetS-related biomarkers. Verzelloni et al. (2011) demonstrated that ellagitannin
colonic metabolites (urolithins and pyrogallol) were effective in vitro antiglycative
agents, whereas chlorogenic acid-derived metabolites (dihydrocaffeic or –ferulic
acids or feruloylglycine) were neuroprotective in vitro, suggesting to be counteractive
in diabetic complications i.e. protein glycation and neurodegeneration. The question
remains to be answered how components which are enclosed in the DF matrix or
large in size can regulate pathways active in reduction of MetS. The studies exposing
the cell lines to dietary phenolics as is do not take into account the situation where
polyphenols are converted to their intestinal metabolites. From this perspective it is
more likely that the tissues in the body are rather subjected to the intestinal metabolites
of food components than to those originally present in the food.
DF is by definition non-digestible and is thus subjected to colonic microbial interaction. Colonic microbiota degrades the DF complex, forms short-chain fatty
acids (SCFA) from carbohydrates, releases phytochemicals from the plant matrix
and transforms them to chemically different forms such as phenolic acids and lactones (Selma et al. 2009; Aura 2008). Microbial metabolites can form a link to
food exposure, because they are abundant in circulation after exposure (Lafay and
Gil-Izquierdo 2008). The studies have verified the connection between plant foods
and beverages and pure phenolic compounds as precursors of colonic metabolites,
which furthermore have also been identified in the plasma and urine of humans after
consumption of the precursors, having a long residence time in the body (Kuijsten
et al. 2005; Sawai et al. 1987; Seeram et al. 2006). This has led to a hypothesis
that the health promotion can be mediated by colon derived metabolites as signal
molecules alone or in synergy with the plant food components. Therefore identification of the plant food- and beverage-derived microbial metabolites is needed by
studying colonic metabolism alone and excluding the host metabolism in the liver
or intestinal epithelia.

Human intervention with healthy
Finnish subjects
Human intervention with persons
with mild metabolic syndrome

Human intervention with
hypertensive patients

Long-term animal trial on C57BL/6J
mice

Diabetic obese mouse model
Diabetic mouse model

High-polyphenol dark chocolate

Tea (-)-Epigallo-catechin-3-gallate
(EGCG)

Cacao liquor proanthocyanidins
Proanthocyanidin polymer or
oligomer preparations from
persimmon peel
Short-chain fructo-oligosaccharides

In vivo rat pancreas and in vitro rat
pancreatic cells

Hydroxycinnamic acids
p-methoxycinnamic acid and
ferulic acid
Ellagitannin rich raspberry and
strawberry extracts
Anthocyanins and anthocyanidins

In vitro inhibition of α-amylase and
α-glucosidase tests
In vitro rodent pancreatic β-cells for
testing insulin secretion
Anthocyanins from muscadine grapes In vitro inhibition of α-amylase and
lipase activities
Polyphenols from leaves of
LDL-deficient mice
molokheia (Corchorus
olitorius L.)

Streptozotozin-induced diabetic rats
and tissue cell-lines in vitro

Proanthocyanidins

Obese and lean dogs

Study design

Component

Whole-meal rye bread and bread
with whole kernels
Rye-pasta diet vs. white wheat
bread—oat-potato diet

(Juntunen et al. 2003)

References

(McDougall et al.
2005)
(Jayaprakasam et al.
2005)
(You et al. 2011)

(Adisakwattana et al.
2008)

(Respondek et al.
2008)
(Pinent et al. 2006)

Reduced body weight, liver weight and hepatic triglycerides by (Wang et al. 2011)
reduction of oxidative stress and increased β-oxidation in the
liver

Delphinidin, cyanidin and pelargonidin glycosides increased
insulin secretion
Lower digestibility of starch and fat

Synergistic inhibition of starch digestion

Adipose tissue transcriptome showed modulated genes in fatty
acid and glucose metabolism
Postulated mechanism: direct effect on glucose uptake in
adipose tissue and muscle: insulin—signalling pathways
involving PI3K and p38 MAPK activation and GLUT-4
translocation
Regulated blood glucose level by stimulating insulin secretion
from pancreatic β-cells.

Early insulin secretion enhanced, gene expression modulated in (Laaksonen et al.
subcutaneous abdominal adipose tissue; modulated
2005; Kallio et al.
inflammatory status
2007; Kallio et al.
2008)
Blood pressure reduced and insulin sensitivity increased in
(Grassi et al. 2008)
glucose intolerant, hypertensive animals after 15 days of
consumption
ECGC inhibits obesity, metabolic syndrome markers and
(Bose et al. 2008)
fatty-liver disease in high-fat-fed mice during 16 week
dietary regime
Prevents elevation of blood glucose levels
(Tomaru et al. 2007)
Especially oligomers affected inflammatory reactions and
(Lee et al. 2008)
ameliorated hyper-lipidaemia and hyper-glycaemia

Lower insulin response, but not a lower glucose response

Effect

Table 13.1 Effects of dietary fibre and its components on metabolic syndrome (MetS) biomarkers
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Colon Models

In vitro models have traditionally been used to study fermentation characteristics
of DF components both carbohydrates as precursors of SCFAs, especially propionic and butyric acids (Barry et al. 1995; Rumney and Rowland 1992; Tabernero
et al. 2011). In vitro colon models include continuous, semi-continuous or batch
culture systems, which maintain colonic microbiota, usually obtained from human
faeces, under strictly anaerobic conditions. The methods differ from each other in
the structure of the fermentor, substrate-to-inoculum ratios, media, operating conditions and sampling (Rumney and Rowland 1992; Edwards et al. 1996). Media have
varied from a simple mineral salt solution to a complex medium containing vitamins,
hemin, SCFA, yeast extract and trypticase, a reducing agent and different buffers.
The cultures have been static or several mixing methods have been used: regular
swirling, a shaking water bath and periodic mixing (Edwards et al. 1996).
Different types of colon models can be used for different purposes. Batch models
due to its small scale are suitable for the studies of microbial metabolism of DF,
resistant starch and isolated phenolic compounds, as examples (Barry et al. 1995;
Edwards et al. 1996; Deprez et al. 2000; Aura et al. 2002; Aura et al. 2005b). A European interlaboratory study was performed for testing a simple reproducible batch
system for DF fermentation (Barry et al. 1995). The inoculum was composed of fresh
human faeces mixed with a carbonate-phosphate-buffer complex supplemented with
trace elements and urea. Five different carbohydrate sources were compared in five
laboratories on three occasions to determine pH, residual non-starch polysaccharides
and SCFA production during fermentation. Interlaboratory differences could be reduced either by adding less substrate during incubations or using a dense inoculum.
The optimal amount of carbohydrates was 10 g/l in a faecal suspension of 167 g/l.
There was also a close correspondence between the in vitro data and an in vivo rat experiment using supplemented diets with the same sources of DF (Barry et al. 1995).
This batch model has been further applied to various isolated phenolic compounds
and foods containing them in search for the food-related metabolites.
In the batch models nutrients are consumed and products are accumulated causing
altered cultural conditions during the incubation, which may result in a distorted
interpretation of microbial metabolism in batch cultures at later time points. This can
be avoided by detecting the metabolites profiles at several time points to elucidate the
metabolite dynamics and excluding artefacts occurring late during the incubation.
However, continuous and semi-continuous systems have additional benefits because
they do not accumulate the metabolites and their more dilute microbiota adapts to
the substrates with more nutritive media, than applied in batch models (Barry et al.
1995). Thus continuous systems are also suitable for the study of the ecosystem
and bacteriology (Miller and Wolin 1981; Allison et al. 1989; Bearne et al. 1990;
Campbell et al. 1992).
A single-stage continuous system cannot reproduce the heterogeneity of physiological conditions and nutrient availabilities that occur at different parts of colon,
which is achieved in multi-stage chemostats (Allison et al. 1989). To correct this
problem, a two-stage continuous system was first developed by Bearne et al. (1990).
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Furthermore, a three-stage continuous culture system was investigated in terms of
carbohydrate metabolism and amino acid metabolism. Carbohydrate breakdown and
SCFA production occurred mainly in the first reactor, whereas amino acid fermentation producing branch-chain fatty acids occurred mainly in the reactors 2 and
3. Thus the reactions in the three reactors corresponded to reactions occurring in
the ascending, transverse and descending colon in vivo, respectively (Macfarlane
et al. 1998). Molly and co-workers took this development even further when they
presented a 5-step multi-chamber reactor as a simulation of the human intestinal
microbial ecosystem. This so called SHIME model comprises of two vessels simulating duodenum and jejunum, and ileum, respectively, and the 3rd, 4th and 5th
corresponding caecum and ascending colon, transverse colon and descending colon,
respectively (Molly et al. 1993).
The latest development of a continuous, anaerobic colon model is a validated computer controlled in vitro system, comprising of TNO Intestinal Models 1 and 2 (TIM-1
and TIM-2), simulating the upper intestine and colon, respectively (Tabernero et al.
2011; Venema et al. 2004). When the substrate is passed from one compartment
to another through the model, temperature, pH, peristaltic movements, absorption
of water and fermentation products are continuously monitored and controlled. The
model has been applied with high density complex microbiota. The model has been
used for fermentation of DF and phenolic compounds, formation of ammonia, investigation of probiotic bacteria and bioconversion of glucosinolates (Venema et al.
2004).
Identification of food-specific intestinal metabolites is impossible without ruling
out the metabolism from the tissues in the human body. An anaerobic in vitro colon
model by Barry et al. (1995) was adopted and modified for the purpose of release
and conversion of dietary phytochemicals. The time course and extent of microbial
metabolite formation can be measured from complex food mixtures after enzymatic
digestion in vitro (Aura et al. 1999) or from isolated compounds with tailor-made approaches without enzymatic digestion. The model is performed in strictly anaerobic
conditions at human body temperature and by using pooled human faeces from several healthy donors to provide diverse microbiota and reproducible data. The model
has already been applied to study metabolism of the DF complex of cereals (Aura
et al. 2005a; Aura et al. 2006), fruits (Bazzocco et al. 2008; Aura et al. 2012) and
various isolated phenolic compounds (Aura et al. 2002; Aura et al. 2005b; Pealvo
et al. 2005) and it has been coupled with metabolomics platform based on dataprocessing from mass-spectrometry (Aura et al. 2012; Aura et al. 2008) for search
of phenolic compound-related metabolites. Thus in vitro colon model coupled with
metabolomic systems biological tools is applied to connect food components, overexpressed in vitro metabolite profiles and corresponding in vivo metabolite profiles.
When the diet relation is made by using the in vitro model and the same metabolites
are identified from the human body fluids, the traditional end-points related to health
and disease can be connected with these biomarkers of intake and compliance. There
is an urgent need for early biomarkers of disease and for biomarkers designating the
improvement of health status. The role of in vitro colon model in the research related
to MetS is displayed in Fig. 13.1.
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Fig. 13.1 Colon model in studies of Metabolic Syndrome (MetS). Colon model helps the identification of food-related metabolites by indicating compliance biomarkers of the food intake. Biomarkers
of MetS include biomarkers involved in glucose and insulin, liver fatty acid, adipose tissue and skeletal muscle metabolism. Mechanistic studies are performed for finding the regulated pathways in the
cell assays under influence of the metabolite extracts from the same foods as has been included in
the diet of the clinical trial. Mechanistic studies reveal the pathway regulation patterns and explain
potential novel biomarkers, which can be investigated from human body fluids and tissues with
metabolomic and lipidomic approaches. Finally, biomarkers of compliance, traditional and novel
biomarkers of MetS are combined to understand the causal relationships between diet and health

13.4

Impact of Microbiota in Health

Colonic microbiota consists of 1000 phylogenetic types of microorganisms constituting an ecologically dynamic community, which is closely related to human
physiology (Rajilic-Stojanovic et al. 2007). Microbiota is involved in maturation
and proliferation of intestinal cells, help in maintenance of the homeostasis with
pro-inflammatory and anti-inflammatory responses, relating to MetS (Hattori and
Taylor 2009). Changes in microbiota is also associated with induced inflammation
by lipopolysaccharides from the gut in connection with high-fat diet, which induces
MetS and insulin resistance (Cani et al. 2007; Cani et al. 2008). Furthermore, modulation of the microbiota by prebiotics has been linked to improvement of glucose
homeostasis, leptin sensitivity and enteroendocrine cell activity in obese and diabetic mice (Everard et al. 2011). It has also been reported that colonic microbial
activity influences the fatty acid composition in liver and adipose tissue and reduces
proinflammatory cytokines (Wall et al. 2009).
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The microbiota can be associated with the formation of the food related microbial
metabolites, with the circulating human metabolome during the dietary interventions,
and with the biological responses in the human body (Turnbaugh and Gordon 2008;
Wishart 2008). However, there is a challenge from the large individual differences
which are expected in food-derived microbial metabolite profiles, because human
microbial composition and their conversion capacity vary between subjects. The in
vitro colon model facilitates finding biomarkers of exposure and establishing the
causal relationships between the food intakes and circulating metabolites in vivo,
because the activities of liver and intestinal epithelia are excluded and reduces the
diversity of the detected metabolites.

13.5

Bioavailability of Phenolic Compounds

In order to understand how dietary phytochemicals enter the colon, a short description of their bioavailability is needed. Phenolic compounds serve as biomarkers of
exposure to plant food and beverage phytochemicals. Dietary intake of phenolic
compounds from different fruit and vegetable sources differs between individuals
depending on their habitual diets but the average has been estimated at about 1 g/day
(Scalbert and Williamson 2000). Mediterranean diet, rich in fruits and vegetables,
and Nordic diet rich in rye and berries, contain complex set of monomeric and
polymeric phenolic compounds which are converted to specific microbial metabolites (Aura 2008). Bioaccessibility in vitro and bioavailability in vivo of phenolic
compounds are dependent on the resilience and nature of the food and beverage matrices to digestion in the upper intestine, the degradation and release properties of
the matrix in the colon and structures of the phenolic compounds. The degradation
and release properties of the food and beverage matrices also determines in which
stage and to what extent components are accessible for the colonic microbiota and
its conversion activities, and finally, what is the composition of metabolite pool in
the blood circulation.
When flavonoids and related phenolic compounds are consumed in the diet, they
are released from the matrix after mastication. The stomach reduces food particle
size, which further enhances the release of phenolic compounds (Scalbert et al. 2002).
Phenolic acids can be absorbed in the free form in the stomach (Zhao et al. 2004;
Lafay et al. 2006). Flavonoid glycosides can be deglycosylated in the mouth by microbiota or by oral epithelial cells (Walle et al. 2005). Aglycones can also be formed
in the small intestine by the action of membrane–bound lactase phloridzin hydrolase
and they are absorbed passively through the epithelium or flavonoids can be transported through the epithelium as glycosides by sugar transporters. In the epithelial
cells, cytosolic β-glucosidase hydrolyses the glycosides and aglycones are formed after absorption (Day et al. 2000; Nemeth et al. 2003). Generally, absorption is affected
by the structure of phenolic compounds (glycosylation, molecular weight and esterification). Once absorbed, aglycones and phenolic acids undergo conjugation in the
ileal epithelium or in the liver (Scalbert et al. 2002). A part of the hepatic metabolites
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(methylated, sulfated or glucuronidated conjugates) (Donovan et al. 1999; Felgines
et al. 2003; Natsume et al. 2003) is returned to the lumen via bile (Roberts et al. 2002)
and re-absorbed after deconjugation by the luminal bacteria from the colon (enterohepatic re-circulation). Subsequently, luminal non-absorbed or re-cycled phenolic
compounds and those still bound into the food matrix enter the colon.
In the colon, cleavage of the glycosyl or glucuronosyl moiety from the phenolic
backbone is catalysed by microbial enzymes resulting in the transient appearance of
aglycones prior to further catabolism by the microbiota (Aura et al. 2002; Rechner
et al. 2004; Hein et al. 2008). Deconjugation is catalysed by fecal microbial enzymes
(α-rhamnosidase, β-glucosidase and β-glucuronidase), the specific activities of which
reflect the in vitro deconjugation rates of phenolic compounds. Many flavonoid aglycones undergo C-ring-fission, as a result of which hydroxylated aromatic compounds
are formed from the A-ring and phenolic acids from the B-ring. (Aura et al. 2002;
Aura et al. 2005a; Rechner et al. 2004). In contrast to deconjugation, sulfate conjugation of phenolic hydroxyl groups is catalysed by arylsulfotransferases originating
from human intestinal bacteria. This enzyme activity has been detected in human
and rat faeces (Kim and Kobashi 1986a; Kim et al. 1986b). Furthermore, lactones
can be formed from ellagic acid and plant lignans (Heinonen et al. 2001; Cerda et al.
2004; Cerda et al. 2005).
Pharmacokinetic studies show that microbial metabolites have up to a 24–48 h residence time in the bloodstream after a single dose of their parent compounds (Kuijsten
et al. 2005; Sawai et al. 1987; Gross et al. 1996; Nesbitt et al. 1999; Juntunen et al.
2000; Kilkkinen et al. 2003). After formation, complex microbial metabolites such
as lactones are absorbed from the colon and are again substrates for liver metabolism,
resulting in the production of glucuronidated, methylated, glycinated and sulfated
derivatives (Adlercreutz et al. 1995; Lampe 2003). These microbial and hepatic
metabolites undergo entero-hepatic re-circulation, which contributes to the low diurnal variation of the metabolite concentrations in the blood (Bach Knudsen et al.
2003). Finally, lactone forms are excreted via urine as hepatic conjugates (Seeram
et al. 2006; Adlercreutz et al. 1995), and microbial phenolic acid metabolites mainly
in a free form (Sawai et al. 1987). This may also indicate that the free phenolic acids
are better accessible to peripheral tissues such as skeletal muscle and adipose tissue,
when their molecular size is not increased by conjugation.
The daily flux of water through the colonic epithelium is estimated to be over
one litre calculated from the daily volumes of the chyme entering the caecum
(∼ 1500 mL) and that of the fecal excretion (∼ 200 mL) (Guyton and Hall 1996).
As the metabolites described above and their hepatic conjugates are found in plasma
and urine, therefore they circulate through the body and may exhibit both local and
systemic effects. Phenolic metabolite levels in urine are at the micro-molar range
(Gross et al. 1996; Knust et al. 2006), whereas plasma levels range from low to high
nano-molar concentrations (Sawai et al. 1987; Kilkkinen et al. 2001; Kern et al.
2003; Johnsen et al. 2004; Kuijsten et al. 2006). In peripheral tissues the concentrations of anthocyanidin glucuronides have been shown to be at range of 0.01–0.50
nano-moles per kilogram fresh weight of brain tissues (Milbury and Kalt 2010).
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Personal differences in the enzymatic conversion activities, intestinal diseases
or medication cause qualitative and quantitative variation of the metabolite profiles
in vivo, which is applicable to colon model, as well. High individual variation
in the extent of metabolism is a reflection of the inter- and intra-individually
variable colonic microbiota (Cerda et al. 2005; Lampe 2003; Kilkkinen et al.
2002). When a pooled inoculum from several donors is applied to a colon model,
the repeatability of the responses can be enhanced. As a consequence, the results
from different experiments have appeared to be qualitatively similar and having
smaller standard deviations than those observed from corresponding animal trials
or human experiments. Furthermore, the control is from the same origin and thus
comparison between the control (no food added) and the food (food with microbiota)
shows the over-expression of the metabolites, which is useful especially when a
non-targeted analytical approach is applied (Aura et al. 2012; Aura et al. 2008).
Use of proton nuclear magnetic resonance 1 H-NMR, gas chromatography coupled
to mass spectrometry (GC-MS), two-dimensional GC coupled to time-of-flight
MS (GC × GCTOFMS) and liquid chromatography coupled to MS (LC-MS)
methods enable a metabolomic approach to profiling of the colonic conversions.
Furthermore, these techniques can be applied to samples derived from colon models
and urine and faecal water from human intervention studies (Aura et al. 2008;
Grün et al. 2008; Jacobs et al. 2008; Pettersson et al. 2008; Hanhineva et al. 2012;
Aura et al. 2012).
The complex microbial community provides a high metabolic potential and interaction with the host via the colonic epithelium. The individual metabolite profiles
show considerable inter- and intra-individual differences. The quantitative metabolite
concentrations are more variable than the qualitative metabolite compositions among
subjects, suggesting that different colonic communities share general metabolic
activities, which convert food components to specific metabolite profiles (Jacobs
et al. 2009). The identification of the phenolic microbial metabolites reveals that
a rather large number of different dietary phenolic precursors (flavonoids, phenolic acids and proanthocyanidins) are converted to the same microbial phenolic acid
metabolites which comprise the predominant metabolites as far as we know today. The next chapter will elucidate the formation of microbial metabolism more in
detail.

13.6

Identification of the Metabolites from the Key Foods
Associated with MetS

As mentioned in the Table 13.1 key phenolic groups concerned in terms of possible
interaction with biochemical pathways associated with MetS are proantocyanidins,
monomeric flavanols and hydroxycinnamic acids, all sharing phenylpropionic and
phenylvaleric acids as primary microbial metabolites. Anthocyanins have also been
considered as possible affective phenolic compound.
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Monomeric Flavanols and Proanthocyanidins

Flavan-3-ols can be divided into monomers such as (+)-catechin and (–)-epicatechin
and their galloylated derivatives which are in high amounts in green tea, and dimeric,
oligomeric and polymeric proanthocyanidins, which are abundant in cocoa, apples,
grapes and, as a consequence, beverages thereof such as cider and wine. Metabolites
from monomeric, dimeric and polymeric flavan-3-ols are collated in Table 13.2.
Hydroxyphenylvaleric acids were shown to be formed from (+)-catechin by the
in vitro action of rabbit intestinal microbiota (Scheline 1970). When two different
batches of human microbiota was used in the in vitro incubations, stereoisomerism
did not have a marked effect on the conversion of (+)-catechin and (–)-epicatechin,
but the site of ring-fission was dependent on the microbiota. (+)-Catechin and
(–)-epicatechin were transformed either to hydroxyphenylpropionic or hydroxyphenylvaleric acid derivatives in two separate experiments using pools of microbiota
obtained from different donors of the faecal inocula (Aura et al. 2008; Meselhy et al.
1997). (–)-Epicatechin, (–)-epigallocatechin and their 3-O-gallates were catabolised
extensively by human faecal suspensions, whereas gallates resisted degradation
by a rat caecal suspension, suggesting species differences in catabolic activity of
the two microbiota (Meselhy et al. 1997). In a recent study (–)-epicatechin-3-Ogallate incubated in vitro with rat caecal microbiota was converted to trihydroxyor dihydroxyphenyl-trihydroxypropanol, and dihydroxyphenylhydroxyvaleric acid
(Table 13.2) (Takagaki and Nanjo 2010). A series of catechin isomers and their
gallates were incubated in pig caecal microbiota and all had a similar qualitative
metabolite profile, including phenylpropionic acids, phenylacetic acids, benzoic
acids and phloroglucinol (vant’t Slot and Humpf 2009).
The first in vivo study identified 11 metabolites in human urine after (+)catechin intake. The major components were hydroxyphenylpropionic acid and
hydroxyphenyl- γ-valerolactone (Table 13.2) (Das 1971). In a pharmacokinetic study
of tea catechins, ring-fission catabolites appeared in significant amounts after 3 h
and peaked in plasma at 8–15 h after consumption (Lee et al. 2002). Ring-fission
metabolites from tea polyphenols were excreted in urine as di- and trihydroxylated derivatives of phenyl-γ-valerolactone and they accounted for 1.5–16 % of the
ingested catechins (Meng et al. 2002).
A substantial proportion of ingested green tea flavan-3-ols passes through the
small intestine to the large intestine (Stalmach et al. 2009). Roowi et al. (2010)
showed that a minimum of 40 % of the intake of flavan-3-ols from green tea is
converted to phenolic acid metabolites in the colon, whereas about 8 % is excreted
as flavan-3-ol methyl, glucuronide and sulfate metabolites, the metabolites which
reflect the small intestine absorption. Furthermore, colonic metabolites undergo
hepatic metabolism, since urinary metabolites comprise of hydroxybenzoic acid,
hippuric acid and methoxylated-hydroxyphenylacetic acid, which do not accumulate in the faecal suspensions. In contrast, dihydroxyphenyl-γ-valerolactone and
dihydroxyphenyl-γ-valeric acid, which were major (–)-epicatechin metabolites in
faecal suspensions, were not excreted in urine (Table 13.2) (Roowi et al. 2010).

In vitro human colon model with two different faecal
pools as a source of microbiota

In vitro model rat caecal microbiota

In vivo study on human urine

Human faecal suspension from an in vivo study
Urinary hepatic microbial metabolites

In vitro human colon model

Flavan-3-ol monomers
(+)-Catechin
(−)-Epicatechin

(−) Epicatechin-3-O-gallate

(+)-Catechin

Green tea flavan-3-ols
(−)-Epicatechin

Grape seed
proanthocyanidin dimers
B1-B4 and two
unidentified
[14C]-Proanthocyanidin
polymer

In vitro human colon model

Study design

Component

2-(4 -hydroxyphnyl)acetic acid,
5-(3 -hydroxyphenyl)valeric acid,
3-phenylpropionic acid,
3-(3 -hydroxyphenyl)propionic acid,
3-(4 -hydroxyphenyl)propionic acid

(Deprez et al. 2000)

2-(3 -hydroxyphenyl)acetic acid,

(Roowi et al. 2010)

(Das 1971)

(Takagaki and Nanjo
2010)

(Appeldoorn et al.
2009)

(Aura et al. 2008)

References

3-(3 ,4 -dihydroxyphenyl)propionic acid
3-(3 -hydroxyphenyl)propionic acid
5-(3 ,4 -dihydroxyphenyl)-γ-valeric acid
3-(3 ,4 -dihydroxyphenyl)propionic acid
3-(3 -hydroxyphenyl)propionic acid
5-(3 ,4 -dihydroxyphenyl)-γ-valeric acid
5-(3 -hydroxyphenyl)-γ-valeric acid
1-(3 ,4 ,5 -trihydroxyphenyl)-3-(2 ,4 ,6 trihydroxy)propan-2-ol
1-(dihydroxyphenyl-3-(2 ,4 ,6 trihydroxy)propan-2-ol
5-(3 ,5 -dihydroxyphenyl)-4-hydroxyvaleric
acid
3-(3 -hydroxyphenyl)propionic acid
5-(3 -hydroxyphenyl)-γ-valerolactone
5-(3 ,4 -dihydroxyphenyl)-γ-valerolactone
5-(3 ,4 -dihydroxyphenyl)-γ-valeric acid
4-hydroxybenzoic acid, hippuric acid,
3 -methoxy-4 -hydroxyphenylacetic acid
3 ,4 -dihydroxyphenylacetic acid,
5-(3 ,4 -dihydroxyphenyl)-γ-valerolactone

Metabolites

Table 13.2 Identified metabolites from flavan-3-ols, hydroxycinnamic acids and anthocyanins
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Cranberry phenolic acids

Chlorogenic acid

Ferulic acid dimers with a
8-O-4–linkage
Ferulic acid dimers with a
5–5-linkage

Hydroxycinnamic acids
Phenolic acids from whole grain
wheat: a matrix bound ferulic
acid
Phenolic acids from whole
grain wheat bread: ferulic acid,
sinapic acid, coumaric acid
Caffeic acid and its esters,
chlorogenic acid and caftaric
acid
Caffeic acid

Component

Table 13.2 (continued)

In vivo rat plasma and
urine
In vivo human urine
In vivo rat urine

In vitro human colon
model
In vitro human colon
model
In vitro human colon
model

In vitro human colon
model
Human intervention
with a single dose and
collection of plasma
and urine
In vitro human colon
model

Study design

Methylated, sulfated and glucuronidated, conjugates of
hydroxyphenylacetic acid and hydroxyphenylpropionic acid

monomeric ferulic acid
3-(3 ,4 -dihydroxyphenyl)propionic acid
2-(3 ,4 -dihydroxyphenyl)acetic acid
3-phenylpropionic acid
3-(4 -hydroxy-3 -methoxyphenyl)pyruvic acid,
3-(3 ,4 -dihydroxyphenyl)lactic acid, benzoic acid
dimeric products demethylated to caffeic acid, dimeric
products with reduced double bonds to dihydroderivatives
(propionic acid side chain) and a combination of the two
conversions
Hippuric acid

4-ethylcatechol

3-(3 -hydroxyphenyl)propionic acid,
3-phenylpropionic acid
Ferulic acid, sinapic acid, coumaric acid
3,4-dimethoxybenzoic acid
3-(3 -hydroxyphenyl)propionic acid
3-phenylpropionic acid
3-(3 -hydroxyphenyl)propionic acid
benzoic acid

Metabolites

(Prior et al. 2010)

(Gonthier et al.
2003b)

(Braune et al. 2009)

(Peppercorn and
Goldman 1971)

(Gonthier et al.
2006)

(Mateo Anson et al.
2009; Mateo
Anson et al. 2011)

References
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Cyanidin-O-glucosides
Delphinidin-, petunidin-, peonidinand malvidin-3-O-glucosides
from Cabernet Sauvignon grapes

Anthocyanins
Cyanidin B ring
Malvidin B-ring
Peonidin B-ring
Pelargonidin B-ring
Anthocyanin A-ring

Component

Table 13.2 (continued)

In vivo human urine and faeces
In vitro model with pig
microbiota

In vitro human colon model

Study design
3,4-dihydroxybenzoic acid (protocatechuic acid)
3,5-dimethoxy-4-hydroxybenzoic acid
(syringic acid)
3-methoxy-4-hydroxybenzoic acid (vanillic acid)
4-hydroxybenzoic acid
2 ,4 , 6 -trihydroxyphenylacetaldehyde,
benzaldehyde,
3-methoxy-4-hydroxybenzoic acid,
2,4,6-trihydroxybenzaldehyde,
2,4,6-trihydroxybenzoic acid, gallic acid
3,4-dihydroxybenzoic acid (protocatechuic acid)
3-O-methylgallic acid,
3,4-dimethoxybenzoic acid,
2,4,6-trihydroxybenzaldehyde

Metabolites

(Vitaglione et al. 2007)
(Forrester et al. 2008)

(Aura et al. 2005b; Keppler
and Humpf 2005;
Fleschhut et al. 2006)

References
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Van’t Slot and co-workers found that flavan-3-ols dimers, but not trimers, were
degraded by pig caecal microbiota in vitro (Slot van’t et al. 2010). When a mixture of proanthocyanidin dimers was incubated with human colonic microbiota,
the main metabolites were dihydroxylated phenylacetic acid and corresponding γvalerolactone (Table 13.2) (Appeldoorn et al. 2009). In the reproducible application
of the in vitro model the metabolism of dimers was slower than that of monomers
(Aura et al. 2008).
Stoupi et al. (2010a) also showed that orally administered 14 C-labelled dimer B2
appeared to blood of male rats only to a low extent (8–11 %). Because only 63 % of
the label was excreted via urine within 4 days after administration, a long residence
time of metabolites in the body was shown prior to the final excretion. Despite the
similarities of microbial metabolite profiles of (–)-epicatechin and proanthocyanidin
B2 (ten common metabolites), five unique metabolites of the dimer B2 were produced
by human faecal microbiota (Stoupi et al. 2010b). These were dimeric intermediates,
where the C-ring was cleaved either in the upper or in the lower unit (Stoupi et al.
2010c).
Deprez et al. (2000) found that only 9–22 % of the label from [14 C]-proanthocyanidin was incorporated into the metabolite pool after in vitro fermentation with
human colonic microbiota. The metabolites that were produced in this study included
several derivatives of phenylvaleric, phenylpropionic, phenylacetic and benzoic
acids with different patterns of hydroxylation (Table 13.2). The total yields of
metabolites were shown to decrease significantly with an increased polymerization
(Bazzocco et al. 2008; Gonthier et al. 2003a; Rios et al. 2003). Phenylcarboxylic acid
metabolites derived from monomeric or dimeric catechins are also formed from their
analogues in apples or cider, cocoa, almonds and grapes or red wine, (Bazzocco et al.
2008; Aura et al. 2012; Urpi-Sarda et al. 2009a; Urpi-Sarda et al. 2009b). Llorach
et al. (2009) detected 27 metabolites using metabolomic profiling of urine samples
after cocoa intake. These metabolites included alkaloid derivatives and polyphenol
metabolites, as well as processing-derived products such as diketopiperazines.
Further evidence linking a high degree of flavan-3-ol polymerization with reduced rates of degradation was obtained by Bazzocco and Aura with colleagues
(Bazzocco et al. 2008; Aura et al. 2012). Bazzocco and colleagues showed that
Marie Ménard apples and cider proanthocyanidins, with a respective average degree
of polymerisation 8.2 and 2.2, were broken down more extensively and yielded higher
metabolite concentrations than Averolles apples and cider with an average degree of
polymerisation 71.2 and 7.4, respectively. In grape products, the highest amounts of
metabolites were obtained with red wine with the lowest degree of polymerization.
Isolated proanthocyanidin fractions from Marie Ménard and Averolles apples, and
Syrah grapes surprisingly showed significantly lower short-chain fatty acid formation from the carbohydrates in the samples than faecal control (Aura et al. 2012).
The suppression occurred only in the absence of fruit pericarp or beverage matrix
and was dose-dependent, which was tested using Syrah proanthocyanidin fraction
(Bazzocco et al. 2008; Aura et al. 2012). Polymeric flavan-3-ols have a tendency
to bind to proteins, causing astringency and inhibition of enzymes. The binding increases with the degree of polymerisation due to high number of interacting hydroxyl
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groups (Scalbert 1991). This may well contribute to the lower number of metabolites
and to the reduced metabolism of the polymeric proanthocyanidins.

13.6.2

Hydroxycinnamic Acids

Phenolic acids are present in a number of foods with especially high amounts occurring in whole grains, berries and wine. The most abundant phenolic acid in cereals
is ferulic acid. Since a high proportion of the ferulic acid in cereals is bound to
polysaccharides by ester bonds, its bioavailability requires the presence of degradative esterases from intestinal tissues and microbiota (Kroon et al. 1997; Plumb et al.
1999; Andreasen et al. 2001a; Andreasen et al. 2001b; Rondini et al. 2004). In
addition, Andreasen and co-workers (Andreasen et al. 2001a) have demonstrated
the release of sinapic acid and p-coumaric acid from rye and wheat bran by human colonic esterases (Andreasen et al. 2001b). Hydrolysis by intestinal esterases is
probably the major route for release of soluble, conjugated hydroxycinnamic acids
in vivo. Such free phenolic acids can then be absorbed across the gastrointestinal
barrier and enter the peripherial circulation of mammals (Andreasen et al. 2001a).
Metabolites derived from hydroxycinnamic acids are collated in Table 13.2.
When eight post-menopausal women consumed rye bread, daily urinary excretion of ferulic acid was 47 % of daily intake (Harder et al. 2004). Only a half of
the analysable ferulic acid was apparent, which can be explained partly by its matrix bound nature, by a slow release but also by further metabolism to structurally
different compounds. An experiment was performed using wholegrain wheat breads
fortified with either bioprocessed (by enzymatic and yeast fermentation) or native
wheat bran. Bioaccessibility in the upper intestine and colonic conversions were
studied in human in vitro gastrointestinal models TIM-1 and TIM-2 described in
section 13.3. The bioaccessibility of ferulic acid, p-coumaric acid and sinapic acid
was increased 5-fold, if the bran in the bread had undergone bioprocessing. Since
the contents of p-coumaric acid and sinapic acid were low and their release was
mainly in the TIM-1 model simulating the upper intestine, the microbial conversion
products were better connected to matrix bound ferulic acid (Mateo Anson et al.
2009). The major colonic metabolites in the TIM-2 model from the wheat bran fortified breads were 3-(3 -hydroxyphenyl)propionic acid and 3-phenylpropionic acid
(Table 13.2) independent of the bioprocessing, however, the release and conversion
were enhanced by enzymatic and yeast fermentation processes of the wheat bran
(Mateo Anson et al. 2011). A similar pattern was observed when 300 g of the same
breads were digested by eight healthy volunteers, after which plasma and urine samples were collected for 24 h after intake. In addition to ferulic, sinapic and coumaric
acids, 3,4-dimethoxybenzoic acid was detected as an early metabolite from the whole
grain breads. Bioavailability of the phenolic acids was increased 2–3-fold by bioprocessing and the same phenylpropionic acid metabolites (Table 13.2) were detected as
major metabolites presumably from the matrix-bound phenolics entering the colon
(Mateo Anson et al. 2011).
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Dry fractionation using micronization and electrostatic separation of rye and
wheat brans resulted in aleurone fractions of the cereal grains. The formation of
3-(3 -hydroxyphenyl)propionic acid was enhanced compared with the native brans
in an in vitro colon model using human faecal inoculum as a source of microbiota
(Nordlund et al. 2012). The impact of dry fractionation on bioaccessibility of phenolic acids had been shown earlier (Hemery et al. 2010). Reduced particle size after dry
fractionation and enzymatic digestion was concluded to have contributed to the release and conversion of ferulic acid from rye and wheat aleurone fractions (Nordlund
et al. 2012).
Additional conversions of hydroxycinnamic acids can be observed in vitro. Formation of hydroxyphenylpropionic acid and small amounts of benzoic acid (Table 13.2)
occurred when caffeic acid and its esters, chlorogenic acid and caftaric acid, were
used as substrates in an in vitro human colon model (Gonthier et al. 2006). The sidechain shortening of phenylpropionic acid occurs via β-oxidation. Caffeic acid can
also be decarboxylated and reduced to 4-ethylcatechol by human fecal microbiota
(Table 13.2) (Peppercorn and Goldman 1971).
Ferulic acid dimers are another form of released phenolic acids from cereal matrices (Andreasen et al. 2000). Two ferulic acid moieties can be bound to each other via
either an 8-O-4– or a 5-5–linkage. Dehydrodiferulic acid 8-O-4- and 5-5-derivatives,
were incubated with human fecal microbiota. The 8-O-4-derivative was shown
to degrade transiently to monomeric ferulic acid. In contrast, the 5-5-diferulate
derivative was subjected only to demethylation and/or side-chain reduction. The
metabolites from ferulic acid dimers are shown in Table 13.2 (Braune et al. 2009).
In vivo studies support the in vitro findings. Feeding studies with chlorogenic
acid (5-O-caffeoylquinic acid) revealed the appearance of hydroxylated cinnamic
acids, benzoic acid and hippuric acid in plasma and urine of rats. Hippuric acid is
formed by glycination of benzoic acid in the liver (Gonthier et al. 2003b). In humans
half of the ingested chlorogenic acid was excreted in urine as hippuric acid (Olthof
et al. 2003), while 57 % of the ingested chlorogenic acid was detected in rat plasma
and urine as microbial metabolites (Gonthier et al. 2003a). Prior and colleagues
studied excretion of metabolites in rats after ingestion of concentrated cranberry
powder taking into consideration the colonic conversions and further conjugations
of these metabolites. Hydroxyphenylacetic and hydroxyphenylpropionic acids were
excreted in urine as methylated, sulfated and glucuronidated conjugates with a degree
of conjugation ranging from 65 to 100 % depending on the phenolic acid. Only the
degree of conjugation of 3-(4 -hydroxyphenyl)propionic acid was enhanced with the
increased dose of the cranberry powder (Prior et al. 2010).

13.6.3 Anthocyanins
Anthocyanins have a labile flavylium cation structure and their microbial metabolism
has been investigated only recently. Due to their instability, the detection of anthocyanins from human samples has been challenging. The total amount of anthocyanins
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in 24 h urine is very low, < 0.2 % of the ingested dose. Usually the parent anthocyanins predominate in urine, but methylated and glucuronidated derivatives have
also been detected (Vitaglione et al. 2007).
The microbial metabolism of anthocyanin glycosides includes deconjugation and
ring-fission as described above for flavonols (Aura et al. 2005b; Keppler and Humpf
2005; Fleschhut et al. 2006). The metabolites rising from different anthocyanin
structures reflect the substitution pattern of the B-ring of their precursors, whereas
the metabolites suggested to be formed from the A ring are more common to all
anthocyanins (Table 13.2) (Keppler and Humpf 2005; Fleschhut et al. 2006). Furthermore, an unidentified derivative of the anthocyanin aglycone with a molecular
weight 85 mass units higher than that of the corresponding aglycone was detected
for anthocyanidins originating from malvidin-, peonidin-, petunidin-, delphinidinand cyanidin-3-O-glucosides (Aura et al. 2005b). The major in vivo metabolite of
cyanidin-O-glucosides, 3,4-dihydroxybenzoic acid, is excreted in 24-h urine and
faeces in amounts corresponding to 73 % of the ingested anthocyanin (Vitaglione
et al. 2007). Thus, results in vitro and in vivo are in agreement.
Compounds similar to colonic anthocyanin metabolites can be formed at neutral
pH. Glycosidic anthocyanins exist in equilibrium between the flavylium cation (red
coloured and abundant at low pH), blue quinoidal bases and the carbinol and chalcone
pseudobases (non-coloured), the three latter compounds being more abundant at
pH 7 (Clifford 2000). Anthocyanidins can form a reactive α-diketone, which can
readily decompose to phenolic acids and the corresponding aldehydes (Keppler and
Humpf 2005). However, under the mildly acidic conditions predominating in the
in vitro colon model, phenolic acids were not detected, unless active microbiota
were present (Aura et al. 2005b). This suggests that both microbial and spontaneous
decomposition of anthocyanins can occur in the intestinal environment.
Nurmi and co-workers (Nurmi et al. 2009) followed urinary excretion of phenolic acids after ingestion of a bilberry-lingonberry purée for a 48-h-period. Early
excretion of 3,4-dihydroxybenzoic acid was observed, together with caffeic acid,
p-coumaric acid and ferulic acid. Low level excretion of isoferulic acid and dehydroisoferulic acid was also detected. 3 -Methoxy-4 -hydroxyphenylacetic acid
(homovanillic acid) and 3-methoxy-4-hydroxybenzoic acid (vanillic acid) were the
most abundant metabolites, peaking after 6 h. 3-(3 ,4 -Dihydroxyphenyl) propionic
and the corresponding acetic acid appeared 12 h after intake and at the same time
their monohydroxylated 3 -derivatives maintained steady profiles (Nurmi et al. 2009).
The metabolic pattern of bilberry-lingonberry purée appears to reflect the presence
of bilberry anthocyanins and lignonberry phenolic acids and flavonols.
A berry mixture containing bilberries, lingonberries, blackcurrants and chokeberries, was ingested in a placebo controlled human intervention. Phenol intake was
837 mg/day, and quercetin, p-coumaric acid, 3 -hydroxyphenylacetic acid, caffeic
acid, 3,4-dihydroxybenzoic acid, 3-methoxy-4-hydroxybenzoic acid, 3 -methoxy4 -hydroxyphenylacetic acid and 3-(3 -hydroxyphenyl)propionic acid increased significantly in the plasma of the berry group compared to that of the control group.
The urinary excretion of quercetin, p-coumaric acid and 3 -hydroxyphenylacetic acid
was increased likewise in the berry group (Koli et al. 2010).
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Forrester and Waterhouse (Forrester and Waterhouse 2008) carried out an in
vitro study incubating an extract of Cabernet Sauvignon grapes with pig microbiota. Delphinidin-, petunidin-, peonidin- and malvidin-3-O-glucosides disappeared
within 6 h and three major metabolites (3-methoxygallic acid, 3,4-dimethoxybenzoic
acid and 2,4,6-trihydroxybenzaldehyde accumulated (Table 13.2). The microbial
metabolites from pigs, therefore, resemble those of humans.
Anthocyanin bioavailability has also been investigated in Sprague-Dawley rats
after ingestion of wild bilberries. Benzoic acid was the main metabolite in the liver
and brain tissues after 4- and 8- week- supplementation (Bò et al. 2010). In addition,
anthocyanins and their glucuronides were detected in pig brain tissues after administration of a 2 % blueberry diet. The levels were low (ranging 0.01–0.50 nmol\kg
fresh weight) but indicative of passage through the blood-brain barrier (Milbury and
Kalt 2010). These studies suggest that phenolic compounds and their metabolites
may enter the peripheral tissues and potentially be bioactive at these sites.

13.7

Prospects and Considerations of Colon Model in Relation
to MetS

In vitro colon models have been used for dietary fibre research for years. Choice
of a suitable model for different applications should be considered carefully. Multicompartmentalized colon models are excellent tools for studying effect of substrates
on changes of the composition of microbiota, whereas simple batch models are not
applicable in microbial ecological research due to the stability and high density
of the microbial inoculation with faeces. However, batch models are suitable for
studying metabolic profiles, because the microbiota is not changing. If the strict
anaerobiosis is maintained throughout the processing of the faecal suspension, the
interaction between food and the microbiota is genuine. Metabolic comparisons
between substrate incubations with the microbiota and the faecal control without
substrates give relevant responses: the over-expressed metabolites from the food
describing the food-related intestinal metabolome, appearing in the circulation and
excreted in urine, when the same foods are eaten.
Metabolomics is an explorative technology, which is still under development.
In its untargeted forms, it enables complex metabolic patterns and pathways to be
profiled and explored in a reproducible manner. The identification of the metabolite
profile from the colon model includes data alignment, statistics and visualization as
heat maps displaying fold-changes of metabolites against the control without food
or the food without microbiota. The biggest challenge is in the identification of the
over-expressed components. Using combination of targeted approach, group specific
identification and several databases, the identification of profiles of food metabolites
can be achieved. If the compounds cannot be given specific names, the mass spectra
can still be used for finding the same biomarkers of intake from human body fluids
as biomarkers of intake and compliance. The role of the colon model is in building
the connection between specific metabolites and the authentic food.
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Metabolomic analysis has revealed the diversity of components in foods as a
discriminative or informative fingerprint (Cevallos-Cevallos et al. 2009), but when
this diversity is objected to microbial metabolism, the metabolites are shared with
many plant foods and the number of designated metabolites is reduced and points
out rather a polyphenol-rich diet than a single food item. Furthermore, when the
number of metabolites can be reduced by selecting only over-expressed metabolites
for finding them from the human body it is much easier to find correlations between
the diet and the possible affected biomarkers or pathways related to MetS.
Correlation between diet and a health response without causality is not adequate.
Causality requires mechanistic approach using in vitro cell and in vivo animal models. In order to take into account the circulating metabolites the purified microbial
metabolite extracts from a food or a diet can be used in the cell based assays using isolated food extracts without metabolism as a control. Precise purification techniques
have to be applied to ensure that the extracts contain only food-related metabolites.
The use of controls ensures that the effects in the cell lines are not caused by media,
microbial non-food components or other artefacts. The effect could also be verified
in the target tissue in animal models, possessing the same metabolites from the same
diet. In addition, the metabolite transport across the body and reaching the site of
action could be performed by analysis of plasma and urine in humans and if possible, by tissue biopsies. Finally, improvement of the clinical outcome in subjects with
MetS is the most important biomarker of the successful positive effect related to the
diet. Only then the effect of a diet on MetS is established.
Phenolic metabolites have been shown to correlate with particular food intake,
which has been proven to affect MetS biomarkers. Heterogenic symptoms in MetS
give a challenge for finding correlations using traditional statistical methods. Novel
data processing techniques may offer personalized approaches and new angles
to characterize the responses. Nevertheless, the great challenges are apparent in
all aspects of systems biological nutritional research. For this reason the combination of different techniques are needed. As a consequence only with genuine
multidisciplinary collaboration between scientists these challenges can be overcome.
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Part IV

Modeling Metabolic Syndrome

This section introduces some of the key modeling strategies and models needed to
study metabolic syndrome, with examples of applications.

Chapter 14

Genome-Scale Modeling of Tissue
and Cancer Metabolism
Livnat Jerby and Eytan Ruppin

Abstract The emergence of ‘omics’ technologies has enabled global reconstruction
of cellular metabolic networks. While detailed kinetic modeling of these networks
remain challenging due to a lack of kinetic, network analysis based on appropriate
constraints such as the steady-state condition (constraint-based analysis) is already
feasible. Here the methods for the reconstruction of metabolic networks are reviewed
along with recent developments in the ﬁeld, including the modeling techniques such
as ﬂux balance analysis and elementary ﬂux modes.
Keywords Constraint based modeling · Human metabolic model · Metabolic
networks

14.1

Introduction

Classically, metabolism, as other ﬁelds in biology, has been studied in a reductionist
manner, by focusing on a small set of reactions often referred to as a metabolic pathway. Although much of our knowledge of metabolism has been discovered this way,
this paradigm cannot account for the numerous interactions and emerging propertied characterizing metabolism. Furthermore, technological developments have
produced a ﬂood of genomic, transcriptomic and other high-throughput data that
cannot be interpreted and integrated via the classical methods. The insufﬁciency of
the reductionist approach, on the one hand, and the growing availability of large-scale
data, on the other hand, created the increasingly pressing need for computational,
mathematical methods to study metabolism in a systematic fashion.
By and large, the in-silico models of metabolism base upon a representation
of metabolism as a network, in which an edge denotes a reaction and a node
denotes a metabolite. Some properties can be inferred based on the topology
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of the network per se. Mathematical modeling of cellular metabolism has been
traditionally performed via kinetic modeling techniques that are composed by a
set of differential equations, describing the change in the metabolites concentration
over time (Garfinkel and Hess 1964). These models can provide an informative
dynamic description of metabolism, though as they require detailed information
on kinetic constants and on enzyme and metabolite levels, the lack of accurate
cellular information currently limits the scope of the methodology to small-scale
systems, as the human red blood cell (Jamshidi et al. 2001; Joshi and Palsson 1989;
Lee and Palsson 1991; Mulquiney and Kuchel 1999). An alternative computational
approach, constraint-based modeling (CBM), bypasses these hurdles as it does not
depend on such detailed information. CBM assumes a metabolic steady-state under
which feasible flux distributions satisfy a stoichiometric mass-balance requirement,
thermodynamic constraints, and constraints on enzymes’ capacities that are based
on experimental observations of flux rates. By imposing the set of these governing
cellular constraints the requirement for kinetic information is relaxed.
The modeling paradigm of CBM has been extensively applied with considerable
success to study microbial physiology (Edwards et al. 2001; Durot et al. 2009;
Shlomi et al. 2005; Feist and Palsson 2008; Oberhardt et al. 2009; AbuOun et al. 2009;
Kumar and Maranas 2009). Though still less developed, genome-scale modeling of
human metabolism is constantly progressing (Goodacre et al. 2004); earlier work
has focused on characterizing distinct human metabolic pathways (Kanehisa and
Goto 2000; Romero et al. 2004), and modeling specific cell types and organelles
(Wiback and Palsson 2002; Vo et al. 2004; Chatziioannou et al. 2003). In 2007, two
generic genome-scale human metabolic models were presented based on an extensive
evaluation of genomic and bibliomic data (Ma et al. 2007; Duarte et al. 2007).
The generic human metabolic models (Ma et al. 2007; Duarte et al. 2007) consist
of a collection of biochemical reactions that take place in different tissues and celltypes, depending on physiological conditions. The potential clinical utility of the
generic model has been previously demonstrated by its ability to identify functionally
related sets of reactions that are causally related to hemolytic anemia, and potential
drug targets for treating hypercholesterolemia (Duarte et al. 2007). The utility of this
generic human metabolic model was further demonstrated in predicting metabolic
biomarkers whose concentration is altered due to genomic mutations in IEMs (Shlomi
et al. 2009).
Nonetheless, the different tissues and cell-types of the human body vary in their
metabolic phenotypes (Mathews et al. 2000; Berg et al. 2002). Therefore, a generic
model is not sufficient to recapitulate human metabolism, as it should be modeled in
a tissue-specific manner. Here we present two complementary computational methods that address this challenge: the first, the integrative Metabolic Analysis Tool
(iMAT) (Shlomi et al. 2008), describes a tissue-specific metabolic phenotype, and
the latter, the Model Building Algorithm (MBA), reconstructs tissue-specific models.
To describe a tissue-specific metabolic phenotype iMAT integrates a generic model
with tissue-specific gene and protein expression data (Shlomi et al. 2008). It was
applied to predict a variety of metabolic behaviors of different human tissues, including the brain, liver, and kidney. The predicted metabolic behavior characterizes,
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for each tissue, a single, normal physiological condition under which the expression
data that is used as input was measured. MBA reconstructs tissue-specific metabolic
models by utilizing a variety of different tissue-specific molecular data sources:
literature-based knowledge, transcriptomic, proteomic, metabolomic, and phenotypic data. MBA was applied to generate the first genome-scale metabolic model of
the liver, a compartmentalized model of the plant Arabidopsis thaliana, as well as
the first genome-scale model of cancer metabolism. Lastly we describe two studies of cancer metabolism, where genome-scale metabolic modeling was applied to
guide experimental work, leading to the discovery of metabolic phenomena and to
the identification of selective drug targets.

14.2 The Underlying Framework: Constraint-Based
Modeling (CBM)
The metabolic network is described by the stoichiometric matrix S, formed from the
stoichiometric coefficients of the reactions that comprise the network. Each column
in the matrix denotes a metabolic reaction, and each row denotes a metabolite. The
entries in the matrix are stoichiometric coefficients. Meaning, every row describes
the reactions in which the metabolite participates, and thus embodies the interconnection between the different reactions. The dynamic behavior of the network can be
described by the flux rate of the metabolic reactions. The network flux vector consists of the flux rates of each reaction in the network. By utilizing the stoichiometric
matrix one can transform the network flux vector into a vector of the time derivatives
of all the metabolites’ concentrations (Fig. 14.1).
In other words, the stoichiometric matrix S is a linear transformation from a flux
vector
ν = (ν1 , ν2 , . . . , νn )

(14.1)

to a vector of time derivatives of the concentration vector
x = (x1 , x2 , . . . , xm )

(14.2)

as
d
x
(14.3)
dt
The flux vector is composed of a dynamic component and a steady-state component:
Sν =

ν = νdyn + νss

(14.4)

By definition at steady-state the concentration of the different intracellular metabolites remains constant, meaning, there is no accumulation or depletion of metabolites.
Hence, the rate of each metabolite production is equal to its consumption rate. The
steady state component satisfies
d
Sνss = x = 0
(14.5)
dt
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Fig. 14.1 The formulation and conceptual basis of CBM. a A schematic illustration of a (toy
example) metabolic network. Nodes represent metabolites and edges represent reactions. b The
network is represented by its stoichiometric matrix S; Columns represents reactions and rows
represent metabolites. Matrix S transforms the reactions’ flux vector v into a vector that contains the
time derivatives of all the metabolites’ concentrations. c Without constraints, the flux distribution
of the network may lie at any point in the space. When mass-balance constraints (imposed by
the stoichiometric matrix) and capacity constraints (imposed by the lower and upper bounds) are
applied, they define a convex solution space. Only flux distributions within this subspace are valid,
while points that lay outside of it are excluded by the constraints. d By maximizing an objective
function, a narrow-range optimal flux distribution that lies on the edge of the solution space can be
identified

Thus, vss is in the null space of S.
In order to infer the metabolic phenotype at steady state one needs to explore
the null space of the stoichiometric matrix, that is, the feasible solutions that satisfy
the steady-state constraints. However, the null space, also referred to as the solution
space, consists of feasible solutions that are irrelevant in the biological context. By
imposing additional constraints one can filter out these inappropriate solutions, and to
reduce the space of solutions (Fig. 14.1). Such constraints include linear constraints
that limit the upper and lower rate of reactions in the network, in the form of:
νmin ≤ ν ≤ νmax

(14.6)

Thermodynamic constraints determine the reversibility of reactions by setting the
lower bound of irreversible reactions to zero. On the other hand, enzymatic rate
constraints impose a limit on the maximal bound νmax according to prior knowledge
on the enzymatic capacity. The metabolic network is an open system in which certain
metabolites can be secreted or absorbed from the extracellular environment by a set
of reactions entitled exchange reaction. By imposing constraints on the upper and
lower bounds of these reactions CBM accounts for the availability of metabolites in
the extra-cellular surrounding (the medium) and for the prior knowledge regarding
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secreted metabolites. As the rate of exchange reactions is relatively easier to measure
experimentally, it can be integrated by employing Quadratic Programming (QP)
to find a flux distribution with a minimum Euclidian distance from a set of the
experimentally measured fluxes.
CBM analysis is intimately tied to the mathematical field of optimization. Therefore, in addition to the constraints that govern cellular metabolism, CBM can
also account for the optimization criteria that determine the metabolic phenotype
(Fig. 14.1d). This is achieved by including a mathematical objective quantified by
a scalar function of the unknown flux rates Z = F (ν1 , ν2 , . . . , νn ). The function
F, termed the objective function, further limits the solution space, as only solutions that optimize it are considered. Although the objective function plays a crucial
role in CBM, it is not as theoretically sound as physiochemical constraints. It is
mostly considered as a working hypothesis, serving as a powerful tool for quantitative predictions, which should be validated experimentally. Surprisingly, certain
simple objective functions have been shown to successfully predict diverse biological
phenotypic characteristics.
In the realm of microorganisms, the most widely used CBM method is Flux Balance Analysis (FBA) (Kauffman et al. 2003; Varma and Palsson 1994) that assumes
the metabolism of a microorganism is evolutionary adopted to maximize growth.
To incorporate this assumption in the formulation of the problem a reaction termed
biomass reaction is added to the model. This reaction consumes biosynthetic precursors in an appropriate ratio to produce the biomass of the in-silico growing organism
(Varma and Palsson 1993). Remarkably, FBA has been shown to accurately predict an
impressive array of phenotypes observed in microorganisms. These include growth
rates (Edwards et al. 2001), uptake rates, by-product secretion (Varma and Palsson
1993), the outcomes of adaptive evolution (Fong and Palsson 2004; Ibarra et al.
2002), gene expression levels (Famili et al. 2003), metabolic flux rates (Segre et al.
2002; Shlomi et al. 2005; Wiback et al. 2004), and knockout lethality (Edwards and
Palsson 2000).
When going beyond the realm of microorganisms to that of multi-cellular organisms the definition of the objective function becomes somewhat vague. The biomass
maximization hypothesis as utilized in FBA can be considered relevant in certain
circumstances, for example, when modeling metabolism during embryonic development, during maturation and growth or in some pathological phenotypes as tissue
regeneration, wound healing, and cancer. However, this assumption is not apt to
capture the metabolic behavior of most multi-cellular organisms. In multi-tissue
organisms additional hurdles are encountered as different tissues apparently have
different objective functions that are dynamically changing in an interactive manner
according to physiological condition and needs of the entire body. Meaning, although
the organism as a whole strives to maintain homeostasis, the role of each one of its
tissues varies and is subject to diverse regulatory signals, as hormonal signals for
instance.
Nonetheless, the objective function can be utilized as a tool to quantify the capacity
of the biological hardware, let it be a microorganism or a multi-cellular tissue, to
carry out a metabolic function at different conditions. By applying the CBM method
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Flux Variability Analysis (FVA) (Mahadevan and Schilling 2003) one can determine
the feasible range of each reaction independently within the solution space. FVA is
performed by formulating a LP problem that minimizes or maximizes the flux through
the reaction of interest. Alternatively, the convex polytope of the solution space can
be extensively explored using random Monte Carlo sampling (Schellenberger and
Palsson 2009) to obtain distributions of the steady-state flux levels for each reaction
in the metabolic network. Despite the computational complexity of this approach it
is sometimes preferred over FVA as it gives additional insight into the shape of the
high-dimensional solution space.

14.3

Network-based Prediction of Human
Tissue-Specific Metabolism

iMAT is a tool for the prediction of human tissue-specific metabolic behavior via
the integration of a genome-scale metabolic network with tissue-specific gene expression and protein abundance data (Shlomi et al. 2008). The metabolic phenotype
is highly affected by the gene expression and protein abundance levels (Levine et al.
2006; Yanai et al. 2005). It has been reported that there is a strong correlation
between gene expression and measured (Daran-Lapujade et al. 2004; Fong and
Palsson 2004) as well as predicted (Akesson et al. 2004; Bilu et al. 2006; Famili
et al. 2003; Schuster et al. 2002) metabolic fluxes in micro-organisms. Nonetheless,
due to various cellular regulatory mechanisms and enzyme kinetics, the correlation
is not complete. To account for these mechanisms, iMAT treats the expression levels,
not as the final determiners of metabolic activity, but as cues for the likelihood of the
corresponding reactions to carry a metabolic flux. Network integration is then used
to accumulate these cues into a global, consistent metabolic behavior, which reflects
the outcome of putative post-transcriptional regulatory effects (Fig. 14.2). Relying
on enzyme expression data to infer tissue-specific metabolic flux activity using iMAT
eliminates the need for a priori knowledge of tissue-specific objective functions
and metabolites exchanged between the tissue and biofluids. Rather, the method
provides predictions regarding tissue-specific metabolite uptake and secretion.
To examine iMAT’s ability to correctly predict metabolic behavior based on gene
expression data, it was first applied to predict the metabolic state of the yeast S.
cerevisiae under conditions for which reliable data is readily available for validation. Then, the method was applied to the genome-scale human metabolic network
model of (Duarte et al. 2007), integrated with tissue-specific enzyme expression data
to predict tissue-specific metabolic behavior of ten human tissues. Specifically, for
each tissue, a unique view of metabolic activity was obtained. The tissue-specific activity predictions were validated in two ways. First, a comprehensive comparison to
known large-scale information on tissue-specificity of genes, reactions and metabolites obtained from various databases was performed. Second, the tissue-specificity of
metabolic disease causing genes was studied, demonstrating the method can capture
the metabolic behavior of different tissues under normal and disrupted physiological
conditions.
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Fig. 14.2 Predicting flux-activity states based on a metabolic model and gene-expression measurements. Circular nodes represent metabolites, whereas diamond nodes represent enzymes. White,
red and green represent normal, significantly low and significantly high expression of the enzymeencoding genes, respectively. Solid edges represent metabolic reactions. Broken edges associate
enzymes with the reactions they catalyze. Purple and black arrows denote active and inactive
reactions, respectively, according to the predicted steady-state flux distribution. Enzyme E7 is
predicted to be post-transcriptionally upregulated and E5 is predicted to be post-transcriptionally
downregulated. The figure is adapted from Shlomi et al. (Shlomi et al. 2008)

14.3.1

Integrative Metabolic Analysis Tool (iMAT)

Given a generic metabolic model and two sets of genes, that consist of highly and
lowly expressed genes, iMAT initially infers the expression state of each metabolic
reaction according to Gene-Protein-Reaction (GRP) associations. By doing so, two
sets of reactions are assembled: RH and RL that consist of highly and lowly expressed
reactions, respectively.
The next step involves formulating a mixed integer linear programming (MILP)
problem. The solution to this problem is a steady-state flux distribution satisfying
stoichiometric and thermodynamic constraints, while maximizing the number of
reactions whose activity is consistent with their expression state (Eq. (14.7)):

 +
 
max
(xi )
(14.7)
yi + y−
i +
i∈ RH

i∈RL

s.t
S·ν =0

(14.8)

νmin ≤ ν ≤ νmax

(14.9)
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νi + νi+ (νmin,i − ε) ≥ νmin,i : i ∈ RH

(14.10)

νi + νi− (νmax,i + ε) ≤ νmax,i : i ∈ RH

(14.11)

(1 − xi )νmin,i ≤ νi ≤ (1 − xi )νmax,i : i ∈ RL

(14.12)

Where ν is the flux vector and S is a m × n stoichiometric matrix, in which m is the
number of metabolites and n is the number of reactions. The mass balance constraint
is enforced in Eq. (14.8). Thermodynamic constraints that restrict flow direction are
imposed in Eq. (14.9), by setting νmin and νmax as lower and upper bounds on flux
values, respectively. For each highly expressed reaction, the Boolean variables y +
and y − represent whether the reaction is active (in either direction, thus either y + or
y − is assigned the value 1) or inactive (when both y + and y − are 0). For each lowly
expressed reaction, the Boolean variable x represents whether the reaction is inactive
(when x is 1) or active (when x is 0). Specifically, a highly expressed reaction is
considered to be active if it carries a flux with an absolute value greater than a positive
threshold ε(Eqs. (14.10) and (14.11)). Alternatively, a lowly expressed reaction is
considered to be inactive if it does not carry a flux that is greater than 0 in either
direction (Eq. (14.12)). The optimization maximizes the number of reactions whose
activity is similar to their expression state.
A solution found by the MILP solver to the problem formulated above is guaranteed to be optimal, meaning, to maximize the similarity to expression. On the other
hand, the solution may not be unique as a space of alternative optimal solutions may
exist. In this case, the space of optimal solutions represents alternative steady-state
flux distributions attaining the same similarity with the expression data. To account
for these alternative solutions, the optimal similarity to the expression is calculated.
Then, the model is constrained to attain this optimal similarity, which reduces the solution space significantly. Then the optimal solution space is traversed by employing
Flux Variability Analysis (FVA) (Mahadevan and Schilling 2003). FVA obtains for
each reaction its minimal and maximal attainable flux, subject to the aforementioned
constraints. A reaction is considered to be confidently active if its absolute flux is
above some active threshold. Alternatively a reaction is considered to be confidently
inactive if its minimal and maximal flux values are 0. Due to solver inaccuracies a
small ε around 0 is permitted. The activity state of a reaction whose minimal and
maximal flux predications as calculated by FVA do not sustain either condition is
considered to be undetermined (unconfident). In summary, for some of the reactions
the flux activity state can be uniquely determined to be active or inactive, while for
others, the activity state cannot be uniquely determined because of potential alternative flux distributions with the same overall similarity to the expression data, mostly
due to isozymes or alternative pathways. For each metabolic reaction iMAT determines its activity state as described above. Notably, because expression levels are
not enforced as exclusive determinants of metabolic flux, the flux activity states of
reactions may deviate from their expression states. Hence, genes are considered to
be post-transcriptionally up-or-down regulated based on a difference between their
measured expression level and the predicted flux activity state of their associated
reactions.
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Computational Reconstruction of Specific
Metabolic Models

MBA is a computational method for reconstructing functional metabolic network
models of human tissues based on a variety of different tissue-specific molecular
data sources, rather than predicting a single metabolic state of a tissue as done by
iMAT (Jerby et al. 2010). The obtained models can be used to explore the metabolic
state of a tissue under various genetic and physiological conditions through standard
CBM methods, without requiring additional context-specific molecular data. More
specifically, by exploiting the metabolic model one could simulate and study the
effects of genetic perturbations or drug applications in a straightforward manner.
MBA is based on heuristically pruning the generic human metabolic model to derive a sub-model that is as consistent as possible with the pertaining tissue-specific
molecular data sources. Applying MBA to generate the first genome-scale metabolic
model of the liver, the resulting model is shown to be consistent with a variety of
hepatic data sources, and to successfully permit the simulation of various metabolic
states under different physiological conditions, in a manner superior to that obtained
using the generic model.

14.4.1

The Model Building Algorithm (MBA)

MBA derives a tissue-specific metabolic model from a generic model based on network integration with various molecular data sources. First, based on tissue-specific
data core reactions are identified. These reactions are included in the generic model,
and should be included in the tissue-specific model. Core reactions that have a high
vs. moderate probability to be carried out in the tissue are differentiated. The core
is therefore divided into two sets, CH and CM , for high and moderate likelihood
reactions, respectively. By and large the CH set includes human curated tissue specific pathways and the CM set includes reactions testified by molecular data. Both
the CH and the CM are subsets of the generic model. The input to the algorithm is
a generic model that is composed of a union of reactions that may exist in different,
individual tissues and the core, tissue-specific reactions (Fig. 14.3). The core by
itself is not a consistent model, as it includes many reactions that cannot carry flux.
These reactions are termed dead-end reactions. The goal is then to derive the most
parsimonious tissue-specific consistent model, which includes all the tissue-specific
high probability reactions (CH ), a maximal number of moderate probability reactions (CM ), and a limited set of additional reactions from the generic model that is
required for gap filling. The latter enable the activation of all core reactions, resulting
in a fully viable and consistent tissue-specific model. This is done by searching for a
minimal set of reactions that should be added to obtain a consistent model, where for
each reaction there is a feasible flux distribution in which it is active. Aiming to find
the most parsimonious model on one hand, and maximizing the number of moderate
probability reactions included in the model on the other hand, induces a tradeoff. It
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Fig. 14.3 MBA model reconstruction. MBA is given a generic model and tissue-specific core
reactions sets (CH and CM ) as input. It reconstructs a tissue model, containing all the CH reactions,
as many CM reactions, and a minimal set of other generic model reactions that are required for
overall model consistency

is tuned via a parameter that weighs both optimization criteria to obtain a score that
evaluates the quality of a model. Sensitivity analysis was preformed to examine the
reliance of the resulting model on this optimization parameter, showing that MBA’s
performance is fairly robust and does not hinge upon a choice of a narrow range of
optimization parameter values.
To find an optimal model with a maximal score, a greedy heuristic search is employed. Starting form a generic consistent model non-core reactions are iteratively
pruned from it, in a random order, while maintaining its consistency. In each pruning
step, a reaction is removed only if its removal does not prevent the activation of reactions in CH , and increases the model’s score. Since the reactions’ scanning order may
affect the resulting model, the algorithm is executed with different, random pruning
orders (1000 in our implementation) to construct multiple candidate models. Each
reaction is then assigned a confidence score that is computed as the sum of candidate
models in which it is included. To construct the final tissue model, reactions, ordered
by their scores, are iteratively added to CH , until a final, minimal and consistent
model is obtained.

14.4.2

Generating Tissue and Cancer Metabolic Models

14.4.2.1

Genome-scale Metabolic Model of the Human Liver

MBA can serve for the rapid development of an array of metabolic models of a variety of human tissues. It provides a computational platform to probe the metabolism
of tissues as the kidney, heart and brain on a genomic scale. MBA was applied to automatically generate the first genome-scale metabolic model of the liver (Jerby et al.
2010). The starting point was the generic human metabolic model of (Duarte et al.
2007), accounting for 2766 metabolites, 3742 reactions, 1905 genes, and 100
metabolic pathways. The essential core, CH , was a collection of metabolic pathways that are known to be active in the liver based on the literature (Bock et al. 1991;
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Baynes and Dominiczak 2004; Gropper and Smith 2008; Chisari and Fausto 2001). It
consists of 37 intact metabolic pathways that are involved in central metabolism, carbohydrate, lipid, and amino acids metabolism as well as specific hepatic metabolism
as drug metabolism, and bile acid biosynthesis. These pathways involve in sum 779
reactions and 873 metabolites. The more permissive core, CM , consists of a set of 304
reactions, and 484 metabolites. It was assembled from tissue-specific data sources,
including metabolomics (Wishart et al. 2007) transcriptomic (Yanai et al. 2005;
Shmueli et al. 2003), proteomic (He 2005; Yan and Sadee 2000; Saier et al. 2006),
and phenotypic data (McKusick 2007) of the liver. Each reaction was included in
CM only if it was supported by at least two of the data sources listed above or if it was
necessary for the inclusion of a liver metabolite that appeared in the metabolomics
data (Wishart et al. 2007). The total core hence comprises of 1083 reactions and
1187 metabolites.
The resulting liver model obtained via MBA consists of 1827 reactions and 1360
metabolites. Out of the reactions in the derived liver model that are not included
in either reaction cores, 50 % are transport reactions that transfer metabolites across
compartments. Most of these reactions are not associated with genes in the model and
hence could not be included in the core reaction sets. Notably, despite the heuristic
nature of the MBA algorithm, the participation of many of the reactions in the
resulting liver model is consistently predicted across the different random reaction
elimination orders. For 70.65 % of the non CH reactions the algorithm provides
completely unanimous predictions, that is, the reaction is either present in all models
or absent in all of them.
The model was verified using standard cross-validation procedures, and through
its ability to carry out hepatic metabolic functions. The model’s flux predictions
correlate with flux measurements across a variety of hormonal and dietary conditions,
and improve upon the predictive performance obtained using the original, generic
human model (prediction accuracy of 0.67 versus 0.46). Finally, the model better
predicts biomarker changes in genetic metabolic disorders than the generic human
model (accuracy of 0.67 versus 0.59).
14.4.2.2

Plant Metabolism: Multi-Tissue Metabolic Model of Arabidopsis

MBA is not restricted to the modeling of human tissues. It can be used to generate
tissue models for any organism for which a generic model exists. Indeed, MBA has
been applied to construct an array of tissue-specific metabolic models of the plant
Arabidopsis thaliana. In this work a generic compartmentalized model of Arabidopsis was integrated with tissue-specific protein expression data (Schmid et al. 2005)
from various tissues, including leaves, flowers, roots, siliques, seeds, and cell cultures. The reconstructed tissue models are fully functional and are amenable for CBM
analysis, and significantly extend upon previous model reconstruction attempts. The
models were validated by the prediction of measured fluxes in metabolically engineered seed strains. They were then utilized for the computational design of genetic
manipulations that could potentially increase vitamin E production, a significant
nutrient for human health.
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Cancer Metabolism: From a General to a Type-Specific Model

Aberrant metabolism is one of the main driving forces in the initiation and development of cancer (Hanahan and Weinberg 2011; Ward and Thompson 2012). During
carcinogenesis, selective pressures lead to diverse metabolic alterations, imposed by
multiple molecular mechanisms (Cairns et al. 2011; Tamada et al. 2012; Miller et al.
2012). These metabolic adaptations enable cancer cells not only to proliferate and
cope with high energetic demands, but also to avoid apoptosis, evade the immune
system and control the rate of mutagenesis (Prendergast 2011; Sotgia et al. 2011;
Cairns et al. 2011). Characterizing the unique metabolic dependencies of different cancer cells can potentially pave the way towards the development of selective
treatments and diagnostic tools (Vander Heiden 2011; Meijer et al. 2012). To this
end MBA was applied to construct the first genome scale metabolic model of cancer (Folger et al. 2011). The utility of the model was demonstrated by its ability
to predict cytostatic drug targets, of which 40 % are targeted by known, approved
or experimental anticancer drugs. Furthermore, the model was applied to identify
combinations of synthetic lethal drug targets, whose synergy was validated using
available drug efficacy and gene expression measurements across the NCI-60 cancer cell line collection. Finally, potential selective treatments for specific cancers
that depend on cancer type-specific downregulation of gene expression and somatic
mutations were compiled.
A type-specific model generates more accurate drug-target predictions for a specific type of cancer. Accordingly, MBA was applied to construct a specific metabolic
model of Hereditary Leiomyomatosis and Renal-Cell Cancer (HLRCC) (Frezza et al.
2011). HLRCC is caused by a germline mutation in the gene encoding Fumarate
Hydratase (FH), followed by a somatic mutation in its second allele. By analyzing
the specific metabolic model of the FH-deficient cells, the survival mechanism that
enables the cells to operate the mitochondrial electron transport-chain despite the mutation was unraveled. According to the computational predictions the FH-deficient
cells produce NADH, the driving force of the electron transport-chain, by activating
a linear metabolic pathway beginning with glutamine uptake and ending with bilirubin excretion (Fig. 14.4). This pathway, through the biosynthesis and degradation
of heme, permits FH-deficient cells a partial mitochondrial NADH production, as it
prevents the lethal accumulation of TCA cycle metabolites. In agreement, according to the model, numerous synthetic lethal pairs of FH are located along the heme
biosynthesis pathway (Fig. 14.4). These synthetic lethal predictions have been confirmed experimentally in-vitro, showing that targeting a key enzyme on this pathway
(HMOX) renders only the FH-deficient cells non-viable, selectively sparing wildtype cells. This provides a new potential target for treating HLRCC patients by a
drug that is potentially selective, with minimal side-effects on healthy renal cells.
However, these studies, as many others, were based on data from cancer cell lines,
which might fail to depict the metabolism of the cancer in-vivo. To provide a system
level view of cancer metabolism in-vivo a new method, termed Metabolic Phenotypic
Analysis (MPA) was developed and applied to study breast cancer metabolism based
on data of clinical samples.

Genome-Scale Modeling of Tissue and Cancer Metabolism

Fig. 14.4 Study of renal cancer metabolism via an MBA-reconstructed model. The scheme depicts the metabolic flux rearrangement observed in FH-deficient
cells, based on model-driven predictions and experimental validations (Frezza et al. 2011). Blue arrows indicate FH synthetic lethal metabolic reactions
predicted by the metabolic model; red arrows indicate genes and reactions found to be upregulated in FH-deficient cells. The scheme also shows the truncation
of the TCA cycle observed in FH-deficient cells. Fumarate and succinate are significantly accumulated (in red). The flux through the first part of the TCA cycle
is reduced in FH-deficient cells due to decreased pyruvate entry and absence of recycling of metabolites through the TCA cycle. Glutamine uptake and
glycolytic production of lactate (in green) are induced in FH-deficient cells. Figure 14.4 adopted from Jerby et al. (Jerby and Ruppin 2012)
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Metabolic Phenotypic Analysis (MPA)

Previous methods for incorporating contextual gene expression or protein abundance
measurements within a generic CBM metabolic model have focused on describing
the metabolic state by restricting the model to obtain an optimal fit to the data
(Shlomi et al. 2008; Akesson et al. 2004; Zur et al. 2010; Becker and Palsson 2008;
Jensen and Papin 2011). These approaches have shown much value in providing
context-dependent metabolic descriptions. However, by requiring an optimal fit they
have ignored the ability of cells to adaptively reinstate lost functions by inducing
even small changes in their overall gene expression. This, in turn, can potentially lead
to false predictions of reaction-inactivity, and mask observed differences between
metabolic states. In contradistinction, given a gene expression or protein abundance
signature of a sample, MPA provides a genome-scale view of its metabolism by
considering solutions that may deviate to some extent from the optimal fit – this
yields an estimation of the adaptive potential of the sample to carry out an array
of metabolic processes in a given context. In the model, a metabolic process is
defined by its medium (that is, which metabolites can be secreted or absorbed by
the cell), and its end-reaction. Based on a curated, literature-based definition of
metabolic processes (Gille et al. 2010), each sample-process pair is assigned an MPA
score: First, the consistency of the sample molecular signature (mRNA expression,
proteomics, as defined in (Shlomi et al. 2008)) with the metabolic state of the model
is computed, when requiring the activation of the given process in its medium. Then,
this consistency score is divided by the optimal consistency that can be obtained
between the signature and the model under the same medium, without this additional
activation constraint. The result is the final MPA score for this sample-process pair. It
quantifies the extent of adaptive significant flux changes that are required to carry out
the process examined, given the observed molecular signature. A high MPA score
(close to 1) denotes that a given process can be carried out in a given context with
minimal adaptive flux or transcriptional changes and is hence more likely to occur,
while a low MPA score (close to 0) denotes the opposite.
MPA was applied to conduct the first genome-scale study of breast cancer
metabolism based on the gene expression of a large cohort of clinical samples
(Jerby et al. 2012). It was validated by examining its ability to capture known differences across three human tissues (muscle, liver, and adipose tissue), approximate the
lipid production capacity of breast tumors, and bridge the gap between gene expression and protein abundance by identifying post-transcriptionally regulated metabolic
reactions. MPA correctly predicted cell lines’ growth rates, and revealed a subtypeindependent “go or grow” dichotomy in breast cancer, where proliferation decreases
as the tumor becomes metastatic (Fig. 14.5a). This phenomenon was computationally
predicted and validated experimentally in-vitro. A stoichiometric tradeoff between
proliferation and the capacity to detoxify reaction oxygen species was found, linking
the slow proliferation to the growing need of the tumor to counteract oxidative stress
(Fig. 14.5b, c). The utility of MPA for diagnosis was demonstrated in two ways.
First it was shown to improve breast cancer prognosis prediction. Then its potency
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Fig. 14.5 Breast cancer metabolic progression. a The average measured (blue bars) and MPApredicted (red plot) growth rates of the different breast cancer cell lines, ordered according to their
stage. b The differences between the central metabolism of early- and late-stage tumors according
to MPA. The MPA scores of the reactions colored in azure (pink) are significantly higher in early
(late) stage tumors. c A pathway-level description of the differences between the metabolic states
of early- and late-stage tumors, as suggested by MPA. In azure (pink) are processes that are more
active in early (late) stage tumors. Figure 14.5 is adopted from Jerby et al. (Jerby et al. 2012)

for biomarker identification was validated by comparing its prediction to experimental data; employing it a set of novel biomarkers for metastatic breast cancer was
compiled. This study demonstrates how metabolic modeling can, with complementing experimental work, pave the way for a system-level understanding of cancer
metabolism that is vital for its diagnosis and treatment.
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Chapter 15

Modeling of Lipid Membranes and Lipoproteins
Artturi Koivuniemi and Ilpo Vattulainen

Abstract Metabolic states that precede diseases such as the Metabolic Syndrome
are associated with abnormal conditions, such as dyslipidemia, reﬂected in circulation as elevated levels of triglycerides and low levels of high-density lipoproteins.
Yet, the underlying molecular phenomena associated with these conditions are not
understood. This is quite unfortunate, since understanding the interplay of lipids and
proteins in the context of normal and abnormal metabolite proﬁles would promote
development of novel ways to guide dysfunctional metabolic proﬁles towards normal ones. Here we discuss how molecular simulations can be used to shed light on
these issues by modelling the structure, dynamics, and function of biological systems comprised of lipids and proteins. By considering recent simulation studies of
lipid membranes, membrane proteins, and lipoproteins we highlight the added value
brought out by simulations in unravelling how nano-scale phenomena take place
in complex lipid-protein systems. The examples shown here also demonstrate the
signiﬁcant added value of bridging molecular simulations with experiments, and in
a biomedical context with clinical studies.
Keywords Coarse-grained modelling · Computer simulation · Lipid membrane ·
Lipoprotein · Molecular dynamics simulation

15.1

Introduction

Without doubt, the research of complex biological systems is mainly based on
experiments. Thanks to methodological development, there is now an exceptionally broad arsenal of different experimental techniques by which one is able to
I. Vattulainen ()
Department of Physics, Tampere University of Technology,
PO Box 692, 33101 Tampere, Finland
MEMPHYS—Centre for Biomembrane Physics,
University of Southern Denmark, Odense, Denmark
e-mail: ilpo.vattulainen@tut.ﬁ
A. Koivuniemi
VTT Technical Research Centre of Finland, PO Box 1000, 02044, Espoo, Finland
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characterize properties of living cellular systems, thereby gaining insight into the
principles and mechanisms that govern the function of living matter. However, as
any means, also experimental techniques have limitations. One of them is related to
the fact that a great deal of processes take place on a molecular level where individual molecules in cells interact with one another, giving rise to a wide variety of
phenomena and molecular-scale functions, such as formation of lipid-protein complexes, recognition, and modulation of protein conformation through lipid-protein
interactions. As these transient molecular processes take place over scales of the
order of nano/microseconds and nanometers, it is not a simple feat to gauge them
experimentally. Even the state-of-the-art of super-resolution microscopy techniques
applied to soft biological systems is currently limited by a spatial resolution of about
5–20 nm (Donnert et al. 2006). This is one of the main reasons why molecular computer simulations (Vattulainen and Rog 2011; Ayton and Voth 2009) have recently
received more and more attention as they can make a difference to considerations of
molecular phenomena in living matter.
In principle, there is no limit for the scope of phenomena that can be gauged
by computer simulations. There are appropriate techniques for studies of enzyme
action, proton diffusion, diffusion of lipids and proteins, ligand-receptor binding,
endocytosis, lipid transport managed by lipoproteins, and a large variety of other
phenomena in the molecular world of lipids, proteins, and carbohydrates. The fact
that there are suitable computational methods to consider even the finest details
such as chemical reactions, where one has to deal with electronic properties, and
specific atom-scale binding events between ligands and molecular receptors, renders
computer simulations the method of choice for elucidating nano-scale phenomena in
biological systems. In essence, one can gain a great deal of added value by bridging
simulations and modelling to experiments.
In this chapter, we discuss the principles of computer simulations. We focus on
atomistic and coarse-grained molecular dynamics simulation techniques as they can
provide not only structural but also dynamic information for any complex biological system. Here, the emphasis of discussion is on lipids (Mouritsen 2005). The
applications that we present focus on lipid membranes where lipids interact with
proteins, and lipoproteins where we also see lipids interacting with proteins. Relevance of molecular simulations to life sciences and clinical biomedicine is also
briefly discussed.

15.2

Main Principles of Molecular Simulations and Their
Limitations

Molecular simulations are often the method of choice, if detailed insight is needed
to understand the principles, which govern the behaviour of molecular systems.
Before any simulations can be started, however, one has to decide what is the most
appropriate technique to be used. The answer depends on the research topic, which
one would like to clarify.

15

Modeling of Lipid Membranes and Lipoproteins

301

For processes where one has to account for electronic degrees of freedom, the
method of choice is definitely quantum mechanics (QM). This is the case for diffusion of protons, action of lipases (enzymes) on lipids, and other chemical processes
(Kamerlin et al. 2011). Meanwhile, if the process one would like to understand is
not chemical but instead a physical one, then a classical atomistic description often
suffices very well. Diffusion of water molecules across lipid membranes, binding
of lipases on a lipid substrate, and formation of ordered cholesterol-rich domains in
membranes are exemplary processes about this situation (Murtola et al. 2009). The
downside of classical atomistic simulations lies in the scales that are feasible to be
considered, since currently the state-of-the-art of atomistic simulations is roughly a
system of about one million atoms simulated over a millisecond (Shaw et al. 2010).
This is of course much more than the picosecond time scale in systems of a few tens
of atoms in QM simulations, but the scales of atomistic studies are yet rather modest.
To overcome this issue, one can coarse grain the molecular description further by
lumping several atoms to a single bead, thus decreasing the computational cost and
gaining a speed up that is usually about 103 –106 (Marrink et al. 2004, 2007; Murtola 2009; Ayton and Voth 2009 ) compared to atomistic simulations. Simulations of
coarse-grained (CG) models have become common place recently, allowing considerations of large-scale phenomena such as fusion of liposomes, release of osmotic
pressure inside liposomes through gating of mechanosensitive channels, and effects
of peoples’ living habits on lipoprotein structure (Murtola et al. 2009; Louhivuori
et al. 2010; Yetukuri et al. 2010 ). The scales that can be studied with CG models are
also rather extensive, and while they depend on the level of coarse graining in a given
model, they usually cover times up to seconds and length scales up to millimetres.
Here we focus on atomistic and CG molecular dynamics (MD) simulations since
they are the most commonly used simulation techniques applied to lipid systems. In
both cases, there are three corner stones on which the simulation of any system is
based. First, the simulation project starts from construction of the initial configuration
for a given system, such as an aqueous environment with a high density lipoprotein
(HDL) comprised of lipids and proteins. Second, most importantly, one has to derive
a description for all intra- and intermolecular interactions. This description known as
a force field is the heart of the model since the force field determines the properties
of the system. Finally, to find out how HDL evolves in time, its time evolution
is determined by solving Newton’s equations of motion for particle positions and
velocities, as they are integrated a sufficient number of times using interatomic
forces computed from the force field.
The force field is the core of MD simulations, thus let us consider it more detail.
Other important aspects of MD simulations such as integration of Newton’s equations
of motion, constraints, thermodynamic ensembles, periodic boundary conditions and
treatment of long-range interactions in a principally infinite system are discussed
elsewhere in detail (Frenkel and Smit 2001; Gromacs 2010).
Consider interactions described in Fig. 15.1. There are three terms describing
bonded interactions in terms of bonding between two particles, bending between
three particles bonded to each other, and dihedral (torsional) terms as a four-body
interaction, while the remaining two terms reflect non-bonded interactions that here
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Fig. 15.1 Typical description of potential function terms (bonding, bending (angle), torsion angle,
Coulomb, and van der Waals) often used in classical molecular dynamics simulations. The parameters associated with these terms are d for bond length, d0 describing its equilibrium value, and θ
being angle in three-body interaction with θ0 representing its equilibrium value. Further, ϕ is torsion
angle, ϕ0 being 0 or 180 degrees, and n represents phase. Kb , Ka , and Kt are force constants of
related interactions, qi and qj denote partial charges of particles, which are not covalently bonded,
and ε is dielectric constant. Finally, rij is distance between a pair of interacting atoms, and A and B
are constants, which depend on the chemical nature of interacting atoms. (Adapted from Vattulainen
and Rog 2011)

correspond to electrostatic and Lennard-Jones (van der Waals) interactions. The set
of these interactions together with their parameter values constitute the force field.
In principle, the description shown in Fig. 15.1 is an example of a force field, which
can be used for atomistic as well as CG models, though the number and the details
of the terms as well as their parameter values are often quite different in different
force fields. In atomistic simulations, typical force fields used for biomolecular
systems are Amber, Charmm, OPLS, and GROMOS (van Gunsteren et al. 2006).
The parameters used in these atomistic force fields are physically easy to understand,
since they describe, e.g., interatomic distances, or interactions such as Coulombic
forces that are intuitively clear to interpret.
In CG simulations, the interpretation of force field parameters is more complicated since due to the CG nature of a molecular description, the parameters also
contain an entropic component. Therefore in CG models the force field describes
the free energy (sometimes called the effective interaction) rather than the internal
energy of the system. Two schemes often used to derive the effective interaction
for a CG system are based on matching either forces (Yanting et al. 2009) or structural properties (Murtola et al. 2009) between the coarse-grained and the underlying
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atomistic systems. Another technique that has also gained considerable attention is to
consider the thermodynamic free energy of a CG particle to partition in a water-like
or oil-like environment, and to parameterize the coarse-grained model in this spirit.
The MARTINI model (Marrink et al. 2004, 2007; Monticelli et al. 2008; Lopez et al.
2009) based on this idea has been very successful in simulations of lipid and protein
systems.
While computer simulations using MD have been carried out since the 1950’s,
there has been continuous improvement in the field. More efficient and accurate
algorithms and their implementations have been developed, and a lot of attention has
been paid to develop techniques for massively parallel simulations. Several publicdomain MD packages have been published, GROMACS (Hess et al. 2008) and
NAMD (Phillips et al. 2005) being perhaps the most popular simulation packages
used these days in biomolecular sciences. For more discussion on the methodology
of molecular simulations (see, e.g., refs. Frenkel and Smit 2001; Gromacs 2010).

15.3

Simulations of Lipid Membranes with Membrane Proteins

Biological membranes are mainly composed of lipids and membrane associated
proteins that interact with one another. The fact that proteins are involved in cell
functions has been known for a long time, but the idea of lipids being also involved
in many functions is more recent. It has become apparent that the role of lipids is
important, e.g., in recognition and signaling, and very importantly also in modulating
membrane protein function (Lingwood and Simons 2010).
The diversity of lipids in biological membranes is enormous: biological membranes are composed of thousands of chemically distinct lipids, and the lipid
composition varies quite substantially between tissues and cell organelles, reflecting
their different roles in cellular functions (Yeagle 2005). Despite considerable research, the reasons for this complexity are still far from being understood. What we
know is that different lipids affect membrane fluidity and other physical properties
quite differently, and properties such as membrane elasticity can in turn affect the
function of membrane proteins such as mechanosensitive channels. Meanwhile it has
also been realized that lipids can modulate membrane protein and membrane receptor functions in a specific manner, sphingomyelin and cholesterol being just a couple
of recently found examples (Contreras et al. 2012; Lingwood and Simons 2010).
As there are lipids targeting specific proteins, and considering the large number of
different membrane proteins, this is one plausible reason for the diversity of lipids
in cells. Another possibility is the need to ensure stable and robust conditions for
membrane proteins to carry out their functions even if, e.g., membrane composition
and pH changed locally. Without lipid diversity such small local perturbations could
lead to the disruption and malfunctioning of the membrane (Simons and Sampaio
2011).
The variety of lipids and their concentration changes are relevant also in the
Metabolic Syndrome (MetS). As the composition of membranes changes, it also
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influences lipid-protein interactions and physical properties of lipid membranes,
which in turn modulate the activity of membrane-associated proteins. It is interesting to note that roughly a third of the human genome codes membrane-associated
proteins and, still, very little is known about how lipids and proteins play together.
This is to a major extent due to the low number of atomic-scale structures that have
been determined for integral membrane proteins. This is currently the greatest challenge to foster the understanding of functions associated with biological membranes.
As new membrane protein structures are published, what we gain is not only insight
of protein structures but also their dynamics in varying pools of lipids interacting with
the proteins. These considerations that bridge experiments with molecular simulations can reveal when biological membranes are dysfunctional and lead to diseases,
as revealed by pathological symptoms. Combining, e.g., temporal lipidomic analyses with lipid membrane simulations can therefore provide a novel way to better
understand mechanistic processes that underlie certain diseases, eventually leading
to discoveries of new biomarkers or novel ways to design preventive therapies.
Here we discuss some examples, which show how molecular dynamics simulations can be used to study the properties of lipid membranes with and without
membrane proteins.

15.3.1

Simulations of Lipid Membranes

As cell membranes are extremely diverse regarding their lipid composition, the
number of different interactions between lipids is staggering and the local domain
structure in cell membranes can be very complex. How the structural and dynamical
properties of biological membranes arise from the structural details of individual
lipids? How the functional groups of different lipids interact in lipid bilayers, and
which of these interactions drive the formation of biologically relevant patches or
nano-sized domains in cell membranes? These are some of the topical questions that
are very hard or even impossible to clarify with the current arsenal of experimental
methods. This is one of the reasons for the growing popularity of lipid bilayer simulations since, unlike any other technique, they can provide a detailed view of lipid
behavior in complex lipid membranes.
Regarding specific interactions between lipids, one good example where atomistic
simulations have provided valuable insight is the interaction between sphingomyelin
(SM) and cholesterol molecules (Aittoniemi et al. 2007). They are both important in
the formation of lipid rafts known as nano-scale membrane domains, which together
with membrane proteins form units with specific functions (Lingwood and Simons
2010). Simulations suggest that the transient hydrogen bonding patterns of SM result
in a tilted head group configuration that can shield cholesterol from water molecules
(see Fig. 15.2). The tilting of SM head group was shown to increase when cholesterol
approaches SM to stand next to it, the driving force being hydrophobic shielding
together with the charge pair interaction between them. This mechanism, which in
part reflects the so-called umbrella model, complements the previously proposed
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Fig. 15.2 Simulation snapshots representing typical SM
orientations (left) without,
and (right) with cholesterol.
Note the tilting of the SM
head group when cholesterol
is next to SM. Other lipids in
a membrane and water are not
shown for clarity’s sake.
(Adapted from Aittoniemi
et al. 2007)

view that SM and cholesterol like each other due to direct hydrogen bonding only.
What likely also plays some role is the fact that cholesterol often prefers saturated
lipids instead of unsaturated ones, the interaction in this case being largely entropic.
Glycolipids are the most complex lipid type due to the carbohydrate units in their
head groups. In glycolipids, every detail matters. It has been shown through atomistic
simulations that single-component lipid bilayers comprised of either glucose- or
galactose-based glycerolipids have quite different membrane properties (Rog et al.
2005), fluidity being the primary example since almost all physical properties of
membrane are affected by it. Yet, these two sugar head groups are identical except for
their stereochemistry. The challenge is to unravel the complex interaction patterns
of glycolipids, and atomistic simulations are definitely the method of choice for
this quest. In the case of galactosylceramide (GalCer), it was recently shown by
Hall et al. that cholesterol molecules form direct hydrogen bonds with the sugar
head group of GalCer, resulting again in a tilted head group orientation of GalCer
(Hall et al. 2010, 2011). This orientation shields cholesterol molecules from water,
suggesting a plausible reason why glycosphingolipids are present in cholesterol-rich
lipid rafts. Intriguingly, the same phenomenon has been identified in interactions of
cholesterol with GM1, which is one of the glycolipids acting as membrane receptors.
A combination of experiments and atom-scale simulations revealed how cholesterol
can inhibit the receptor function of GM1 by enforcing GM1 to tilt its complex head
group towards the membrane plane, thus rendering it inaccessible for the ligands
nearby (Lingwood et al. 2011). In a biological context, the observed cholesterolinduced head group tilting plays a role in erythrocyte blood group presentation and
glycolipid receptor function during the activation of sperm fertility (Lingwood et al.
2011).
Simulations of coarse-grained model systems have also improved our understanding of membranes quite considerably. Regarding lipid rafts, CG models have
provided insight into the formation of nano-scale domains in membranes composed
of saturated and polyunsaturated lipids together with cholesterol (see Fig. 15.3; Risselada and Marrink 2008). Risselada et al. showed how saturated and unsaturated
phosphatidylcholines with cholesterol self-assemble spontaneously into coexistence
of liquid-ordered and liquid-disordered domains. The findings matched experimental
data and emphasized the role of saturated acyl chains in the formation of raft-like
domains, since cholesterol prefers saturated over polyunsaturated lipid chains due
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Fig. 15.3 Formation of liquid-ordered domains in ternary lipid mixtures based on CG molecular
simulations. a Color coding used in describing the different lipids is as follows: Green describes
saturated lipids, red polyunsaturated lipids, and gray is used for cholesterol where the hydroxyl
group is shown in white. b Time evolution of phase segregation observed in a planar membrane
where the starting structure at time t = 0 is a random mixture and the final structure at t = 20 μs
shows the coexistence of liquid-ordered and liquid-disordered domains. c A liposome with a size of
about 20 nm showing phase segregation for the same lipid mixture. d and e Several periodic images
(2 × 2) merged together to show typical patters in terms of stripes and circular domains. The scale
bar shown in panel A corresponds to 5 nm. (Adapted from Risselada and Marrink 2008. Copyright
(2008) National Academy of Sciences, U.S.A.)

to stronger van der Waals interactions. Together with an earlier atomistic simulation study (Niemelä et al. 2007), the two pioneering works are the cornerstone of
lipid raft simulations, the future aim being to complement these cases with similar
considerations in the presence of membrane proteins.
Lipid simulations have also been coupled to clinical studies. Lipidomic analyses
of adipose tissue in twin pairs with acquired obesity indicated changes in plasma
membrane lipid composition, in particular increased levels of plasmalogen, which
is the most abundant ether lipid, and decreasing levels of shorter and more saturated
phospholipids (Pietiläinen et al. 2011). In this case, atomistic molecular dynamics
simulations provided insightful information (Fig. 15.4) of how plasma membrane
thickness and fluidity changed, when the amount of arachidonic acid increased and
phosphatidylcholine (PC) head group was replaced by phosphatidylethanolamine
(PE). Simulations revealed that the simultaneous increase in levels of polyunsaturated
acyl chains and PE head groups does not alter membrane properties like area per
lipid and fluidity. Meanwhile, the addition of a vinyl ether bond was observed to
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Fig. 15.4 Atomistic molecular dynamics simulations of different lipid membrane systems. Six
single-lipid component systems were studied, representing major groups of lipids found to be
differentially regulated in acquired obesity (see panel A). Two lipid mixes, corresponding to observed
concentration changes of most abundant lipids (see panel B), were also studied to represent lipid
membrane composition in heavy and lean weight-discordant twins. a Structures of two PUFAcontaining PCs included in the simulations, one plasmalogen and one ester-bonded. b Average area
per lipid of the eight simulated bilayer systems, indicating the packing or fluidity of the bilayer
(smaller area means decreased fluidity). c The molecular order parameter (Smol ) profiles along
selected unsaturated acyl chains. Segment number means the carbon position starting from the
ester-vinyl linkage and ending at the methyl group in the end of the chain. d Snapshots from the
end of four simulations, with the lipids ordered from top to bottom according to decreased fluidity.
(Reproduced with permission Pietiläinen et al. 2011)
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change the ordering of lipid acyl chains considerably, although the area per lipid was
not registered to decrease significantly. The ordering effect of the ether bond was
especially profound in acyl chain carbons 2–8. Interestingly, it seems that adipocyte
cells are able to adapt to changing fatty acid composition during their expansion
by generating vinyl-ether bond plasmalogens with arachidonic acids to maintain the
desired membrane properties. Intriguingly, it was further showed that in morbidly
obese subjects the proportion of ether lipids containing polyunsaturated fatty acids
(PUFAs) was markedly lower, indicating that the mechanism of lipid remodeling
observed in healthy obese subjects did not exist. Regarding membrane properties, it
is good to mention that adding more double bonds and replacing the PC head group
with PE increases the negative curvature of a lipid membrane substantially (Fuller
and Rand 2001). Adding ether bonds probably amplifies this effect. If these lipids
are markedly increased in planar lipid membranes, membrane frustration is expected
to emerge since highly negative spontaneous curvature in a monolayer prefers more
negatively curved surfaces. Spontaneous curvature changes have been suggested to
play a significant role, e.g., in vesicle fusion events that are important in vesicular
trafficking (Chernomordik and Kozlov 2008). Nonetheless, this example highlights
the added value of bridging clinical studies, lipidomics, and simulations to better
understand cellular processes on a molecular level.
The above examples show how molecular simulations can be used to study different lipid membrane properties including specific lipid-lipid interactions, lipid
membrane phase behavior and lateral pressure profile, all of which can play an
important role in the functions of cellular membranes. These examples also demonstrate how fruitful the combination of lipidomics and computational simulations can
be, providing detailed insight into the understanding of how changes in biophysical
properties of bilayers may result in abnormal metabolic states like in the MetS.

15.3.2

Membrane Lipids Interacting with Proteins and Receptors

One of the greatest challenges at the moment is to understand how lipids modulate
or even control membrane protein and receptor function. In basic terms one can
consider this problem from three perspectives:
• How lipids interact with and modulate membrane proteins and receptors via
specific interactions?
• How lipids modulate membrane protein aggregation and complex formation in
a manner, where specific lipid-lipid and lipid-protein interactions are important,
but generic physical effects such as hydrophobic mismatch also play an important
role?
• How the function or conformational state of membrane proteins is affected by
membrane-mediated interactions via the lateral pressure profile?
Here we briefly consider recent computational studies as examples that highlight
each of these cases.
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Specific interactions Can membrane protein and receptor activity be modulated
by direct/specific interactions? This idea has been considered quite plausible, since
crystallized membrane protein structures often contain lipids as an integral part of
the complex (Palsdottir and Hunte 2004; Adamian et al. 2009 ). Recent studies have
strongly supported this view. A beautiful example is the work by Contreras et al. (Contreras et al. 2012), who considered a sphingolipid binding protein (the transmembrane
domain of the COPI machinery protein p24) interacting with sphingomyelin (SM).
In experiments they found a marked specificity of p24 for sphingomyelin, and SM
18 in particular. Atomistic simulations reported in the same study confirmed the
specificity of SM 18: the lifetime of the SM-p24 complex was the largest with fatty
acid C18, the lifetimes with fatty acids of different length being five times shorter.
The binding mechanism observed in simulations suggests that it is not only the head
group which interacts strongly with the protein, but the role of hydrocarbon chains is
also important, as they both interact favorably with the protein’s SM binding pocket.
More generally speaking, direct lipid interactions can also be important for the
proper folding of proteins, and lipid molecules may be an important part of the
active site in enzymes. The importance of specific lipid-protein interactions in enzyme function has been realized in X-ray structures of many proteins that contain
lipid-binding cavities, for example phosphatidylethanolamine in the photosynthetic
reaction centre of T. tepidum (Nogi et al. 2000). As for membrane receptors, another
very recent example is the study by Lingwood et al., who found cholesterol to modulate membrane receptor conformation and function by specific interactions with
the receptor’s head group (Lingwood et al. 2011). In the absence of cholesterol, the
receptor was visible to its ligand, while in the presence of cholesterol the receptor
head group tilted downwards towards cholesterol, rendering itself inaccessible.
Hydrophobic mismatch Integral membrane proteins have a transmembrane domain which is mainly hydrophobic, avoiding contact with water and preferring
oil-like environment provided by the lipid hydrocarbon chains. The hydrophobic
thickness of transmembrane domains depends on the protein in question, and it is
not obvious that it would match the hydrophobic thickness of a membrane which
embraces the protein. When the hydrophobic thicknesses of the protein and the
membrane do not match, one talks about hydrophobic mismatch.
Positive mismatch refers to proteins whose hydrophobic thickness is thicker than
that of the membrane, while negative mismatch corresponds to the opposite case.
Obviously, in both cases the mismatch can be expected to affect protein-protein
interactions mediated by the membrane and also affect the orientation of a single
protein. The topic is broad and extensive discussions of it can be found elsewhere
(Jensen et al. 2004; Marsh 2008). Let us here provide just a couple of recent highlights
of lipid-protein simulations that have shed light on the consequences of hydrophobic
mismatch.
Kaiser et al. combined experiments with atomistic simulations to consider lipid
reorganization around integral membrane peptides whose hydrophobic mismatch was
varied systematically from negative to positive (Kaiser et al. 2011). The results were
quite exciting. It was observed that the organization of lipids around a peptide depends
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on mismatch, and the strongest effects on protein-induced membrane deformation
were observed with negative mismatch. The role of cholesterol was found to be
especially important as it controlled the organization of lipids in the peptides’vicinity,
in practice controlling elastic stress which emerges from the mismatch. The results
indicated how the cholesterol-induced adaptation at the peptide-membrane interface
translate into a sorting potential and promote selective lateral segregation of peptides
and lipids according to their hydrophobic length.
Ramadurai et al. considered consequences of hydrophobic mismatch from a different perspective (Ramadurai et al. 2010). Their main interest was to better understand
how the mismatch affects protein diffusion in the membrane plane. They found that
hydrophobic mismatch has a pronounced effect on the lateral diffusion of membrane
peptides, and this effect was considerably stronger compared to the effect of lipid
head composition. Moving on, when attention is paid to protein-rich conditions, the
role of protein-protein interactions becomes a matter of great interest. Parton et al.
elucidated this aspect and observed that when the degree of hydrophobic mismatch
was varied, the simulations displayed levels of protein aggregation ranging from
negligible to extensive (Parton et al. 2011). Protein aggregation was shown to be
influenced by, e.g., orientation of the protein, which depends on mismatch.
While a lot has been done, not much is really understood about the hydrophobic
mismatch in realistic conditions, corresponding to a protein-rich (crowded) environment in membranes with a realistic many-component lipid composition. Most of the
exciting topics still remain to be explored.
Lateral pressure profile and 3-dimensional pressure field inside a membrane
Some membrane protein classes such as mechanosensitive channels are known to
be sensitive to membrane elasticity and lateral stress along the membrane plane
(Lundbak et al. 2010; Ollila et al. 2009). In this spirit, lateral pressure profiles of cell
membranes have been suggested to play a role in the activity of membrane proteins
(Cantor 1999; Ollila and Vattulainen 2010).
The lateral pressure profile of a lipid membrane describes how pressure inside
a membrane is distributed (see Fig. 15.5). The depth-dependent distribution of lateral stress has been shown in several atomistic simulations (Ollila and Vattulainen
2010), and while it is an extremely difficult quantity to gauge by experiments, some
measurements have provided evidence that the pressure profile has the same indicated by simulations. Many studies have shown that there are extremely abrupt and
strong variations in the stress inside a membrane, a typical gradient being a change
in pressure of 1,000 bar over a distance of 0.2 nm. This corresponds to a gradient of
5 × 1012 bar/m. It is quite easy to understand that if the pressure (force) exerted on
a membrane protein changes so drastically, it may have an effect on protein conformation and activation too. By molecular dynamics simulations, it has been shown
that polyunsaturation of phospholipid membranes changes the pressure profile (see
Fig. 5; Ollila et al. 2007) and even more pronounced changes occur when sterols are
introduced to the membranes (Ollila et al. 2009). In addition to lipid composition,
small metabolites solvated into lipid membranes are also able to change the lateral
pressure profiles (Terama et al. 2008). This is especially interesting in the case of
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Fig. 15.5 Schematic presentation for lateral pressure profiles of single-component lipid bilayers
composed of DPPC, POPC, PLPC, PAPC, or PDPC lipids having zero, one, two, four, or six
double bonds, respectively. The pressure is shown as a function of z, which is the normal coordinate
along membrane normal direction, the case z = 0 corresponding to the membrane center. The water
phase resides for | z | > 2 nm. Statistical errors are presented for one leaflet of the POPC system.
Error bars in the other leaflet and in other systems are similar. (Adapted from Ollila et al. 2007)

anesthetics, where the interaction mechanism of small molecules with biological
systems is not understood (Cantor 1997; Terama et al. 2008).
Atomistic simulations have shown that changes in lateral pressure can indeed
play a role in membrane protein activation. Changes in molecular composition of a
membrane change also the pressure profile of the membrane, which in turn couples
to changes in protein conformation (Ollila and Vattulainen 2010). The contribution
of the pressure profile to protein activation can be significant, even tens of percent
of the total free energy barrier for activation (Ollila and Vattulainen 2010), and this
contribution is due to membrane-mediated interactions. Summarizing, it is apparent
that in order to understand the role of the lipids in membrane protein function, one
cannot neglect the role of generic interactions mediated by membranes.

15.4

Lipoprotein Simulations

Cardiovascular diseases associated with the MetS are the main cause of death in
Western countries. It is believed that cardiovascular diseases are partially caused by
high concentration of low density lipoprotein (LDL, ‘bad’ cholesterol) particles in
circulation. Somehow LDL particles end up into the arterial intima, which is followed
by a complex cascade of events leading to the formation of arterial plaques, the hallmark of atherogenesis. This gives rise to the narrowing of arteries, rupture, clotting,
and potential death. Meanwhile, HDL particles (often called “good” cholesterol) are
aggregates of lipids and proteins that mainly transport cholesterol and its esters as
well as other lipid molecules between tissues in circulation, essentially transporting
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cholesterol back to the liver for excretion and re-utilization. HDL therefore plays an
important role in reverse cholesterol transport, and clinical studies suggest that a low
level of HDL in circulation correlates with increased risk of atherosclerosis.
One important question is how the metabolic processes related to shuttling of
lipoprotein particles are associated with their molecular composition? Also, are
there biophysical properties of lipoprotein particles that could be used to predict
individuals’ risk of being exposed to cardiovascular diseases?
To date there has been a tremendous effort to elucidate the structure of lipoproteins and to reveal its impact to lipoprotein functionality. This development has been
a rocky road due to the lack of experimental methods able to characterize the properties of extremely small and heterogeneous particles. Therefore, to complement
experiments, computational approaches have been used to unravel the structure and
dynamics of lipoprotein particles, thus giving insight to their structure-function relationship. In this section, we highlight the recent progress in molecular simulations
of lipoprotein particles.

15.4.1

Distribution of Lipids in HDL Particles

HDL particles have been studies in quite a few simulations (Koivuniemi and
Vattulainen 2012). While the majority of these considerations has assessed the conformational properties of apoA-I in discoidal HDL particles, some attention has also
been paid to spherical HDL to study the effect of lipid and protein composition on
the distribution of lipids in HDLs (Koivuniemi and Vattulainen 2012). Recently, the
idea of how the lipid composition differs between individuals with low and high
HDL levels has also been explored (Yetukuri et al. 2010; see Fig. 15.6).
A low level of high density lipoprotein is a significant risk factor for cardiovascular disease. What molecular properties drive the low concentration of HDL?
Does lipidomics of HDL have predictive power when combined with biophysical
information, such as the distribution of lipids and surface tension of HDL. Yetukuri
et al. clarified related questions by studying the lipidomics of individuals with low
or high HDL levels (Yetukuri et al. 2010). The average lipidomic profiles of these
two groups, determined from clinical studies, were used in molecular dynamics simulations to consider how variations in molecular composition change the structural
properties of HDL. Experiments showed that the particle size of HDL was smaller
in the low-HDL group compared to the high-HDL group. Simulations supported
this finding and also showed that in the low-HDL group the amount of triglycerides
(TGs) at the surface of HDL particles increased, suggesting that the lipid distribution
in low-HDL individuals could promote the increased catabolism of HDL particles.
Interestingly it was also noted that free (unesterified) cholesterol accumulated next
to apoA-I proteins. One plausible explanation for this observation is that cholesterol
molecules prefer to stand next to apoA-I because of the high curvature of HDL: the
highly curved surface would expose hydrophobic cholesterol molecules more to the
polar phase than in planar bilayers.
In another study, lipidomics and molecular dynamics simulations were combined
to study the effect of drug treatment on lipid and protein composition of HDL particles
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Fig. 15.6 Coarse-grained simulations of HDL particles reconstituted based on lipidomics data. a
Snapshots from the end of high- and low-HDL simulations (8 CEs). Apo-AIs are colored with red and
green, cholesterol molecules are yellow, and all other lipids are gray. Water phase was removed from
the snapshots for clarity. The snapshot in the middle demonstrates how the cholesterol molecules are
localized next to and under apoA-Is in high HDL-C simulation. b The number of contacts between
apoA-Is and different lipid beads in each simulation (error bars indicate ± standard deviation). The
number of contacts was not normalized with the number of different lipid constituents. c Radial
distribution function for TG molecules g(r) with respect to the center of mass (COM) of HDL.
When surface lipid concentration decreases, more TGs are able to penetrate the surface monolayer,
which is noticed as formation of higher plateaus near 3.5 nm. The number of contacts between TG
and water beads (per TG) in different simulations is shown in the inset. (Adapted from Yetukuri
et al. 2010)

(Yetukuri et al. 2011). In this case, simulations demonstrated that the amount of
triglycerides and cholesteryl esters (CEs) at the surface layer depends on the amount
of apolipoproteins (Apos) at the surface. Especially, the novel role of apoA-II in
HDL particle remodeling was demonstrated by the finding that the higher amount of
apoA-II in HDL decreased the amount of core lipids at the surface of lipoparticles,
thus changing core lipid metabolism in circulation.

15.4.2

Structure and Dynamics of LDL Particles

LDL particles are much larger than HDL (diameter varying between 21–25 nm), thus
LDL particles are also computationally more demanding to simulate. In addition,
apoB-100 that is the protein part of LDL is extremely complex. Its structure has not
been solved despite years of substantial research aimed to elucidate the conformations
and structural details of apoB-100 around LDL. Consequently the exact mechanism
of how LDL particles interact with, e.g., the LDL-receptor is not known. Furthermore,
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Fig. 15.7 LDL particle
structure. a Lipids. Red beads
show the location of glycerol
(PC, lysoPC), hydroxyl
(CHOL), and ester (CO, TO)
groups. b Full LDL from the
final structure. Lipids shown
in similar colors as in panel
A, without red highlights, and
PC and lysoPC colored blue.
ApoB-100 shown in tan, with
the lipovitellin domain (first
1000 residues) pointing up. c
Same as panel B, except that
lipids are shown as
transparent spheres. d LDL
simulated without the protein,
cut through the middle. Note
how the core penetrates to the
surface. e Same as panel B,
except that the lipid part has
been cut through the middle.
The core penetrates to the
lipid surface under the
protein. f Close-up image of
the surface from panel B.
(Adapted from Murtola et al.
2011)

an important aspect in lipoprotein metabolism is the activation of apoB-100 during
the conversion of VLDL particles to smaller LDL particles.
Starting almost from scratch, Murtola et al. constructed a model for apoB-100
by using bioinformatics tools to define the model structure for different domains of
apoB-100, after which it was placed around a pre-equilibrated lipid droplet. This
system was then simulated to study the interactions between lipids and apoB-100
(Murtola et al. 2011).
The results (Fig. 15.7) highlighted the importance of lipids in understanding LDL
function. Not only the surface lipids but also the core lipids were fund to play an
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important role in LDL, as interactions between lipids and apoB-100 drive core lipids
to the surface. As suggested by Segrest et al., core lipids and especially cholesteryl
esters like to gather under the amphiphilic beta-sheet structures. This observation
may be biologically significant in the transportation of core lipids by carrier proteins
such as the cholesteryl ester transfer protein, which mediates the heteroexchange of
cholesteryl esters and triglycerides between apoB-100 containing lipoproteins and
HDL. The rather loose packing at the surface and the observed fast diffusion at the
LDL surface compared to the core would promote this for lipids close to the surface
layer.
Simulation results also showed that the distribution of lipids in LDL cannot be
defined in terms of strict and well-defined layers, such as those for core and surface lipids, as usually have been suggested. Instead, the lipid regions are loosely
defined. Yet, one can conclude that phospholipids are located at the surface, neutral
lipids (triglycerides and cholesteryl esters) are almost entirely in the core, and finally
cholesterol molecules reside close to the lipid-water interface between phospholipids and the core region. Regarding the enzymatic processes related to core lipid
metabolism, the amount of core lipids at the surface of LDL may play an important
role in lipoprotein metabolism. In general, the lipid composition governed by lipid
distribution could play a major role in the function of LDL and likely varies between
individuals with different diet and living habits. However, it is very difficult to associate this core lipid distribution to certain lipid type, or just to the ratio of core and
surface lipids, as there are many factors that are compensating each other. Thus, it is
very hard to clarify experimentally how much the core lipid distribution matters in
lipoprotein metabolism. One way to clarify this issue would be to construct in silico
models for different LDL species using lipidomics data from different individuals
and link this structural information, e.g., to the different symptoms of MetS.
The above-discussed results provide a solid foundation to design follow-up simulations for elucidation of LDL functions. The models can be used to find, e.g.,
how enzymatic modifications and lipid oxidation due to free radicals change the
molecular interactions in LDL particles, as these processes are known to promote
the development of cardiovascular diseases.

15.5

Conclusions

Molecular simulations have become a technique which can provide experiments
with substantial added value. First, the constantly developing computer resources
and simulation technologies render consideration of realistic systems possible over
time and length scales that are comparable to those studied in experiments. Second,
the increasing scales imply that simulations can rapidly broaden their profile to new,
more challenging phenomena and processes, using a broad arsenal of quantummechanical, atomistic, as well as coarse-grained molecular models. The greatest
impact emerges from cases where these atomistic or semi-atomistic approaches are
used to complement experiments, with an objective to clarify the mechanisms of
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exciting biomolecular processes, find the principles that govern those, and in general
explain why the processes in question take place as they do. What is more, molecular
simulations no longer just repeat what has been observed in experiments, but instead
they also predict novel phenomena to be tested by experiments. Summarizing, the
greatest impact in lipid research will be gained by combining experiments with
simulations and theory, focusing their efforts together to unlock the most important
questions in life sciences. As this strategy has recently been used more and more
in the field, we are confident that also the research of lipid-related syndromes and
diseases will benefit from this progress at an increasing pace.
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Chapter 16

Computational Statistics Approaches to Study
Metabolic Syndrome
Ilkka Huopaniemi and Samuel Kaski

Abstract In this chapter, we review a set of key research problems and methods in
analysing ‘omics’ data, gene expression, proteomics, metabolomics, and lipidomics.
We start with the common systems biology approach to study metabolic syndrome,
as well as any other disease, namely comparative case-control setting. The setting is
usually an over-simpliﬁcation, since there are other covariates that affect the concentrations of molecules, for instance drug treatments, gender, body mass index (BMI),
and time in time-series experiments. Given these covariates, the setting becomes a
multi-way experimental design. When multiple data sources are available, such as
several ‘omics’ types, multiple tissues or multiple species, each forms a different data
space with different molecules or variables, bringing in the problem of data integration. We start by giving a brief tutorial on the commonly used basic univariate and
multivariate statistical approaches applicable if the problem is simpliﬁed by stratifying to a case-control design. We then focus on the multi-way setups of the Analysis
of Variance (ANOVA) type, and in particular their main difﬁculty for ‘omics’ data:
the large number of variables compared to the small number of observations. We
introduce a recent family of Bayesian methods that is able to deal with multi-way,
multi-source data sets and to translate biomarkers between multiple species. The
approach is able to handle small sample-size combined with high dimensionality,
and it allows a rigorous estimation of uncertainty of the results.
Keywords ANOVA · Data integration · Multi-way experimental design · Omics data
· Statistical analysis
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Introduction

The common systems biology approach for studying diseases is a comparative casecontrol setting: two populations of samples are compared in order to infer what is different between them. In the case of metabolic syndrome, the cases can be for example
patients with a diagnosed Type 2 diabetes and controls are healthy individuals. The
high-throughput measurement techniques—metabolomics (lipidomics), proteomics,
and gene expression—have become a standard tool for such analyses, and they all
result in similar concentration-type, continuous-valued, high-dimensional data.
The motivation of such case-control settings is to discover potential biomarkers for
disease and to find out physiological changes caused by the disease. If the samples in
the case population have a statistically significantly higher (lower) concentration of a
certain molecule, this is called an up (down)-regulation and is considered a potential
biomarker for disease. Such a biomarker can then end up as a diagnostic marker for
the disease after a careful clinical validation. A more advanced example is having
patients who later developed into Type 1 diabetes as cases and patients who remained
healthy as controls (Orešič et al. 2008), implying that differences between cases
and controls are potential early biomarkers for Type 1 diabetes. A third example is
studying treatment-response in omics data by having drug-treated patients as cases
and placebo-treated patients as controls. In each of the three examples, various
standard statistical tools can be used for the statistical testing of the significance of
the up or down regulations.
The omics data have made it possible to profile a large number of molecules
(variables) in search of the biomarkers, but they have also brought a serious, fundamental statistical difficulty to the core of the data analysis (Benjamini and Hochberg
1995; West 2003): whereas the number of variables (molecules) p is large, the
number of samples (patients) n is often small due to economical and ethical reasons
or simply because of a small number of patients available. The scientific community
is currently in the process of searching for feasible computational approaches to deal
with the ‘small n, large p’-conditions, conditions where the assumptions into which
a century of work in traditional multivariate statistics have leaned, do not hold.
The ‘small n, large p’ problem permeates all omics data analyses. We will next introduce two other key problems that must be addressed in serious biomedical studies:
multi-way experimental designs, stemming from there usually being multiple other
covariates in the experimental design in addition to the case-control; and data
integration, that is, analysis of measurements of multiple types. A common approach
in systems biology has been to stratify the analysis according to the additional covariates and to analyze each data source separately. The different statistical problems
that arise in studying a disease based on omics data are summarized in Fig. 16.1.
In Sect. 16.2, we will give a brief tutorial to the commonly used basic univariate
and multivariate methods applicable to (stratified) single-source, case-control settings, and when the task is simply to find groups of similarly behaving molecules.
The emphasis is on discussing the implications of the main challenge of analyzing omics data: small number of samples (patients) and large number of variables
(molecules).
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Fig. 16.1 Illustration of the four data analysis tasks in this chapter. a Case-control design, but with
large dimensionality (variables) compared to number of samples (rows). b Multi-way experimental
design. c Multi-way, multi-source design with paired samples. d Multiple data sources without
paired samples (translation). The images represent data matrices, where rows are samples and
columns are variables. The illustration represents the experimental design of each task, composed
of a combination of covariates (disease, treatment) and integration of multiple data sources
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In Sect. 16.3, we discuss modeling omics data under a multi-way experimental
design as multi-way Analysis of Variance (ANOVA)-type modeling (and General
Linear Models); the task here is to model the effects of all the covariates and their
interactions. The experimental design may also be a time-series setting and the
time-point can also be seen as a covariate.
Finally, in Sect. 16.4 we will discuss a state-of-the-art Bayesian approach for analyzing multi-way, multi-source data. The advantage of the Bayesian approach is that
one can build a single unified model for the whole problem involving multiple covariates and multiple data sources. In a Bayesian model, rigorous uncertainty estimates
are inherently obtained, which is crucial when the number of samples is small. We
will also discuss an extension of the Bayesian approach and a recent non-Bayesian
approach for translating biomarkers between model organisms and human studies.

16.1.1

Multi-way Experimental Design

The conceptualization of an experiment as a comparison of case and control populations is in many cases an oversimplification for two reasons: (1) in biomedical
experiments there are usually confounding effects that might bias the results unless
dealt with properly, and (2) in many experiments it is interesting to actually find the
effects of multiple covariates in the data, and additionally the effects of their interactions, which are usually the most interesting effects. A covariate here is simply a
variable that annotates a sample. Each sample (patient) is associated with one or multiple covariates, such as disease status or treatment, and the usual task of statistical
analysis is to find the effect of the covariate(s) in the data.
In human disease studies, covariates such as gender, age, BMI, drug treatment,
or race can have large effects on concentrations of metabolites or other measured
molecules. Although the diseased-healthy comparison is here the most interesting
question, disease status is only one of the relevant covariates. The other covariates
may act as confounding factors, biasing the associations to the disease effect, unless
they are dealt with properly. A basic approach is to stratify the data into smaller
sets, for instance comparing healthy and diseased males and females in different age
groups separately. Stratification has the side effect that it leads to an even smaller
number of samples in each sub-population, worsening the ‘ small n large p problem’
and, additionally, interpretation of the results of the multiple separate analyses is
more tedious. It would be advantageous to formulate the data analysis problem as
a multi-way experimental design, where the effects of all the covariates and their
interactions in the data can be estimated jointly.
On the other hand, in many experiments the covariates are not seen as confounding
but the main research question is to study the effects of many relevant covariates and
their interactions. One of the most common biomedical experiment types is study
of the effects of various interventions or other factors such as drug, diet, oncogene,
knock-out, or the effects of gender and age, as additional risk factors for disease.
Treatment groups and other relevant descriptors are therefore a common covariate in
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experimental designs. For instance, in multi-way experiments on diseased-healthy,
drug intervention (such as Huopaniemi et al. 2010a), a direct drug effect may be
interpreted as a drug side effect, and the interaction of drug and disease is actually
the interesting effect, indicating whether the drug cures the disease. As another
example, patients of different genders have been shown to have different omics
profiles (Nikkilä et al. 2008; Mostertz et al. 2010), and the interaction effect of
disease and gender may be interesting for determining whether different genders
have differential disease effects or differential responses to drugs.
In summary, many clinical or biomedical settings can be formulated as multi-way
experimental designs, where observations (samples or individuals) are divided into
populations of measurements according to multiple covariates.

16.1.2

Measuring and Integrating Multiple Data Sources

There is a growing trend in biomedical research to measure multiple omics data
sources from each individual, for the very good reason that the different sources are
biologically complementary and the prices of the measurements are becoming tolerable. Other cases where multi-source omics data are measured are measurements from
multiple tissues in the same individual, and measurements from both model organisms and men. In the latter case the goal is to translate biomarkers between humans
and model organisms, and data sources come from different individuals. In each
case, (at least partly) different molecules are measured in the different data sources,
which results in an interesting statistical challenge since the data spaces are different.
Multiple data sources from each individual There are two types of applications
for multi-tissue experiments: (1) The practical application of predicting the state of a
disease tissue from another, more easily collectable tissue, such as blood plasma. The
relevant research question then is whether there are shared disease-related effects
between blood and disease tissue molecules, and it would be of great diagnostic
and scientific interest to be able to map target tissue molecules to blood plasma
molecules in the hope that their disease-dependent associations would be preserved
in the mapping. (2) More generally, it is informative to search for disease-related
changes in multiple tissues, to obtain a more holistic view of the physiological or
biological state of the individual.
From the statistics point of view, the task in analyzing both multi-tissue measurements and multiple omics types is integration of data from multiple sources
with paired samples and different variable spaces. Pairing here means that multiple
sources have been measured from the same patient. Different omics types (mRNA,
proteins, metabolites) clearly have different variables and we also assume that different tissues in general have different variables even if the omics type is the same;
there might be partially same chemical molecules, but these might have different
roles in different tissues.
Although each data source can be (and unfortunately usually is) analyzed with
a reductionist approach, that is, separate analysis by standard statistical tools, such
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analyses miss many of the multivariate effects while producing a huge number of
partial results. Interpretation of such results gets tedious when the number of sources
and covariates grows. It would be desirable to complement the toolbox with more
powerful methods.
Translating biomarkers between humans and model organisms Other organisms
are often used in biomedical research as disease models, and drug effects are also
often tested on model organisms in pre-clinical phases before proceeding to human
clinical studies. A further need for model organisms is that since biopsies are usually
difficult or impossible to obtain from humans, multi-tissue studies are mostly limited
to model organisms.
A particularly relevant research question is whether disease- and treatment-related
findings done in a model organism actually have a correspondence in human clinical
studies (Salek et al. 2007; Seo et al. 2007; Sysi-Aho et al. 2011). As different species
do not in general have fully the same lipids or proteins, for example, and chemically
similar biomolecules may have different roles in different species, a new statistical
modeling problem emerges: how to translate findings made in a model organism
into human clinical studies, and how to map a disease-related human metabolome
to a mouse metabolome (Sysi-Aho et al. 2011), for instance. Such an analysis can
be also used to evaluate the validity of a model organism as a model for the disease
(Damian et al. 2007). From the statistics point of view, the data analysis problem
here is integrating multiple data sources without paired samples.

16.2

Basic Tools Commonly Used in the Exploratory Statistical
Analysis of Omics Data

In this chapter, we review briefly tools that can be used when the underlying multiway (and multi-source) experimental design has been simplified by stratification
to a case-control or unsupervised setting in one data source. Most omics data are
simply continuous-valued multivariate data, and hence many of the widely known
classical tools are applicable after suitable pre-processing. The data typically are
relative or absolute concentrations of molecules (usually in log-scale), collected
into a data matrix where rows are samples (patients) and columns are variables
(molecules). Each sample is annotated by a covariate, such as class label disease or
healthy, according to the experimental design. Here we concentrate on exploratory
analysis, which aims at hypothesis generation based on the data, for instance at
finding potential biomarkers.
Statistical analysis can be done either one variable at time (univariate analysis)
or taking into account their relationships (multivariate analysis). Another division
of methods is into supervised methods or unsupervised methods. Supervised methods are usable for predicting values of covariates, and applicable to diagnostics or
analyzing what is different between the case and control populations. Unsupervised
methods do not take the covariate information into account, but they can be used, for
example, to discover unknown subgroups of patients or groups of similarly behaving
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molecules. We first describe the nature of omics data from the point of view of statistics. We then review the most commonly used methods, including univariate statistical tests, unsupervised multivariate methods such as PCA and clustering, and supervised multivariate methods: classification, regression and testing of known groups.

16.2.1

Data and Statistical Challenges

In many respects omics data are just standard continuous-valued data, but what is
special is the ubiquitousness of the ‘small n, large p’-condition, where n is the number of samples and p the number of variables. The condition causes several problems
for data analysis. First, it is difficult to interpret high-dimensional data by visual inspection and hence dimensionality reduction is necessary. Second, univariate testing
evokes the multiple testing problem of inflating significance thresholds. Third, most
multivariate methods run into technical problems, such as overfitting or singularity
of the covariance matrix.
Another problem in omics data are that they are often multicollinear, meaning
that there are groups of highly correlated variables (genes, proteins, or metabolites)
because of the existence of biochemical networks and pathways regulated similarly.
The highly correlated groups of variables result in redundancy of information and,
therefore, multicollinearity is a problem for some standard methods. On the other
hand, searching for the correlated groups of variables is biologically interesting.
Some methods can deal with multicollinear data, and some methods can even take
advantage of it.

16.2.2

Univariate Analysis

An univariate statistical test is the basic tool for answering whether two populations,
case and control, differ. The Student t-test, one-way Analysis of Variance (ANOVA),
and Wilcoxon rank sum test are the most common such tests.
In technical terms, a statistical test tests whether the null hypothesis holds; the
simplest null hypothesis is that there is no difference between the means of the one
variable in the two populations. The statistical test gives a p-value, which indicates
the probability to observe a difference equal to or larger than the actually observed
value, under the null distribution where there is no difference and data are drawn
from the same population at random. If the p-value is smaller than the a priori defined
threshold of 0.05, the null hypothesis is rejected and there is said to be a statistically
significant difference.
Univariate statistical tests and p-values are a widely accepted means to measure
the statistical significance of the difference of a variable between two populations,
and they are the basic approach for detecting potential single-variable biomarkers for
disease. A common threshold is p = 0.05, but tighter thresholds, such as p = 0.01,
0.005 or 0.001 are also used to decrease the chance of detecting false positives,
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erroneously rejected null hypotheses, where there was a difference between the
variables by chance. If one has to test only one or a few variables, univariate tests
are a well-working approach.
The testing of statistical significance is often accompanied by a study of ‘fold
change’, the actual magnitude of the difference in the variable values between the
two populations. Using these two measures together (McCarthy and Smyth 2009)
is a more reliable approach for detecting biomarkers, since a statistically significant
difference between two populations may not be biologically meaningful if the actual
fold change is very small.
Unfortunately, omics data are very high-dimensional (the number of molecules
is large), which implies big statistical problems for the univariate approach of testing each variable at time. The reason is the problem of multiple testing: setting a
threshold, say p = 0.05, for rejecting a null hypothesis means a probability of 5 %
of finding a false positive in each single test, and hence testing, say, 10,000 variables from gene expression data results in approximately 500 false positives. This
is obviously unacceptable in biomedical data analysis. This problem is commonly
alleviated by modifying the p-value to account for the number of statistical tests.
False Discovery Rate (FDR) (Benjamini and Hochberg 1995) is the most common
multiple testing correction used. Bonferroni correction is an older method, that is
too conservative (makes the threshold too low to find markers in practice) when the
dimensionality is high.
Another problem is that univariate analysis of high-dimensional data unfortunately only results in long lists of p-values and the similarity between variables
(genes, proteins or metabolites functioning together) is not modeled in any way. The
need for multivariate modeling, and need for dimensionality reduction stemming
from multicollinearity in omics data, are widely acknowledged. The most common
measure of similarity between two variables is correlation, usually measured by
Pearson correlation.

16.2.3

Clustering

Clustering is a basic statistical tool for partitioning objects to a set of groups of
similar objects. One can cluster either samples or variables depending on the data
analysis question. Since multicollinearity of omics data is a known fact, clustering
the variables (genes, proteins and metabolites) is a standard way of finding similarly
behaving clusters of biological molecules and reducing redundancy of information in
the data. The most commonly used clustering tools are hierarchical clustering (Ward
1963) and K-means clustering, and Pearson correlations and Euclidean distance are
common choices for similarity or distance measures.
Clustering of the patients can be relevant as well. For example, in a population
of patients with a metabolic syndrome, such a clustering can be used to detect subtypes of metabolic syndrome. The groups of patients can further be related to clinical
variables. An example method for clustering patients from an omics experiment is
(Damian et al. 2007).

16

Computational Statistics Approaches to Study Metabolic Syndrome

16.2.4

327

Unsupervised Component Models: PCA

Principal Component Analysis (PCA) is the most commonly used dimensionality
reduction method. It enables detecting similarly behaving groups of variables in
the multicollinear omics data, and also enables visualization of the relatedness of
samples (patients). PCA is very often used as the first basic analysis, since it does
not require using the covariates but it serves as ‘the first look at the data’. PCA can
also be used in the ‘small n, large p’-conditions and it greatly reduces the redundant
information in multicollinear omics data.
PCA projects the original high-dimensional data onto a few principal components.
A principal component is a single score computed for each sample (patient), forming
one axis and compressing a large number of correlated variables. It is common
to plot a two-dimensional representation of the scores of the two most important
principal components to illustrate how different samples (patients) are related. Such
a plot could reveal for example that patients with a high blood pressure are closer to
patients with a diagnosed type 2 diabetes than to healthy patients with normal blood
pressure. Note that PCA is unsupervised, meaning that the covariate information
(healthy, diseased) is not used in constructing the principal components, but can be
used later to interpret the visualization.
PCA is useful if there is a large number of correlated variables (redundant information), such as in omics data. PCA forms a loading matrix that relates variables
to the principal components and the loading matrix can be directly used to assess
which variables are correlated.
There are two problems in using PCA. First, since PCA is unsupervised, the association of data to covariates is not taken into account when forming the components,
and hence there is no guarantee that it will find biologically relevant variation in the
data. For example, if PCA cannot separate diabetic and healthy patients it does not
necessarily mean that there is no difference between them. Second, when grouping
variables standard PCA will result in each component having a non-zero loading for
all of the original variables. This makes interpretation of the components somewhat
difficult when there is a large number of variables. This problem has been a motivation for developing sparse approaches, where most loadings are set to zero, and only
the most significant loadings are retained.

16.2.5

Supervised Models

Supervised modeling means predicting the value of one variable given other variables.
The variable to be predicted can here be one of the covariates; classification then refers
to modeling the association of (omics) data to discrete covariates (class labels), such
as (healthy, disease) or (treated, untreated). Regression differs from classification
in that the variable to be predicted is continuous-valued; below we will focus on
classification and refer the reader to statistics textbooks for specifics of regression.
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Supervised classification methods can be (and are often) used for multivariate
modeling of the association of variables to a discrete covariate. The idea is to train
a classifier model that maximally separates (at the simplest) two populations of data
points (classes) and can predict the class label of a new sample with an unknown
class label.
Classification accuracy is a measure of how well the classifier can predict the class
labels of new test samples, and it is a widely accepted measure of the association
of data and the covariate. The accuracy is measured by dividing the samples in the
data set with known class labels into a training set and test set. The training set
is used to build the classifier, which is then used to predict the class labels of the
test samples, and the proportion of successes determines the classification accuracy.
Many classifiers are interpretable in the sense that it is straightforward to report
which variables influence the discrimination between the classes the most.
Some classifiers do dimensionality reduction by forming supervised latent factors
when learning the classifier from data. The idea is the same as in PCA scores, but
the latent factors have been constructed taking the association with the covariate into
account. This latent factor-space is used for the classification task, but the components
can also be studied for interpretations. Partial Least Squares Discriminant Analysis
(PLS-DA) (Wold et al. 1984) and its advanced version Orthogonal Projection in
Latent Structures OPLS (Trygg and Wold 2002) are among the most commonly
used classifiers for omics data, since they can form such latent factors in ‘small
n, large p’—conditions and can deal with multicollinear data. Linear discriminant
Analysis (LDA) is a similar classical method, but it is based on inverting a data
covariance matrix which becomes singular in the ‘small n, large p’-conditions. Hence
a regularization scheme, such as in (Tai and Pan 2007), is needed to use LDA on
omics data.
Variable selection is another approach for dimensionality reduction for classifiers,
and it also enhances interpretability by highlighting the most significant separating
variables. Variable selection is a good approach to search for a small set of significant
variables. If the separation between the classes is due to a correlated group of variables
(redundant information), variable selection may not work well in the sense that the
selected variables may not be stable. Any of the redundant variables is almost equally
good explanation, and different variables may get selected in different trials.
Some of the most popular classifiers for omics data using variable selection
are Decision Trees and their extension Random Forest (Breiman 2001), as well
as LASSO (Tibshirani 1996). Support Vector Machines (SVM) (Vapnik 1995) and
K-Nearest Neighbors (KNN) (Tan et al. 2006), on the other hand, are examples of
well-performing classifiers where interpretation may be harder.
Using classifiers for biomarker discovery Interpretable classifiers have become
a popular method for biomarker discovery, since the standard tool of univariate
statistical testing is not a satisfactory approach for high-dimensional data, and there
are no widely used multivariate statistical tests for high-dimensional data. Classifiers
enable multivariate modeling of the variables contributing to the differences between
case and control classes. The justification for using them for biomarker discovery
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is that variables that have predictive value for a class label (case, control), can be
assumed to be biologically relevant. There are, however, several problems in this
approach, of which the reader should be aware of.
First, it is important to realize that in classification, the task is to find a sufficient
distinction between different classes, which can be achieved by finding only a few,
most strongly discriminative variables. When classification is combined with variable
selection or assumptions of sparsity, the goal is explicitly to find a minimal set of
variables. Then all the relevant variables are not necessarily found.
Second, overfitting is a serious problem for supervised multivariate methods,
especially when the number of samples is small and dimensionality high. Overfitting means that a supervised method searches for a maximal separation between
the classes in the learning data set, but when there is a large number of variables
and small number of samples, the model can fit to whatever variables it can find,
which can be simply noise. Serious care to guard against overfitting has to be taken.
Resampling methods, such as cross-validation, bootstrapping (Efron 1979), or permutation testing, are a commonly used tool to estimate the uncertainty of the results
and therefore guarding against overfitting. Resampling means that one divides the
data into training data and test data multiple (∼ 1,000–10,000) times. This is done
randomly in bootstrapping, and deterministically in cross-validation. In permutation
testing, the classifier is compared to multiple models that are obtained by permuting
the class labels randomly; the random classifiers form a null distribution from which
the real classifier needs to distinguish itself. The idea underlying these uncertainty
estimation methods is to accept only such discriminative variables that are consistently found after these validation steps, which helps considerably against overfitting.
Also, classification accuracy needs to be evaluated by resampling to get a reliable
estimate.
When using classifiers that form a supervised latent factor space, such as PLS-DA
and OPLS, one has to very cautious (Westerhuis et al. 2008) if considering to use the
latent factors for further analysis, such as visualization or doing further statistical
testing on them. If the same data which were used for estimating the latent factor
space are visualized or represented in the resulting latent factor space, the class
separability will seem over-optimistic; testing classifiers on learning data will give
too optimistic results, drastically so in ‘small n, large p’—conditions.

16.2.6

Testing Known Groups

Another commonly used multivariate approach which could perhaps be considered
supervised, is testing the joint differential expression of a priori known sets of
variables. This means simply that one defines known groups of, say, genes that are
known to belong to the same pathway, and tests whether the genes in this group are
differentially expressed. The standard methods are Gene Set Enrichment Analysis
(GSEA) (Subramanian et al. 2005) and Gene Set Analysis (Efron and Tibshirani
2007), and the concept has also been extended for metabolomics data (Kankainen
et al. 2011). In an advanced extension (Wang et al. 2008), multi-way experimental
designs were taken into account.
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The disadvantages of testing known sets are that the a priori defined sets may
not capture the interesting biological effects; a correlated cluster may also be only a
subset from a gene set (Wu et al. 2009), or composed of subsets from several gene
sets. An additional, exploratory drawback is that by testing known sets, no new and
potentially interesting sets can be found.

16.2.7

Summary

As a summary, whereas unsupervised methods are at a risk of not retaining biologically relevant covariate-related variation when forming latent factors, supervised
methods model the most strongly separating direction in the data and are at a risk of
overfitting—especially for small sample-sizes which are typical to omics data.
Another important question that we do not discuss further is model complexity
selection. When using any component model, supervised or unsupervised, the choice
of how many components are chosen is crucial, yet this is in fact a very difficult,
fundamental question and subject to considerable research effort. To point some
keywords, searching a cutoff for the number of components according to a percentage
of variance explained, is the classical approach for the model complexity selection of
unsupervised methods. In classifiers, classification accuracy is often chosen as such
a measure: when adding components does not improve classification accuracy, the
optimal number of components has been found. More advanced measures include
predictive likelihood, Akaike information criterion (AIC), and Bayesian Information
Criterion (BIC) and their more recent variants.

16.3

Modeling Data Under a Multi-way Experimental Design

Most of the current omics studies have inherently a multi-way experimental design
where, in addition to the case-control comparison, there are additional covariates.
Examples include drug treatments, age, gender, BMI, and time in a time-series
setting. These additional covariates can be either confounding factors, or it can be
interesting to explore the effects of all the covariates and their interactions in the data.
In this chapter, we discuss ANOVA-type analysis, which is the standard approach
for analyzing data from multi-way experimental designs. We begin by discussing
the univariate multi-way ANOVA, and its multivariate generalization MANOVA. We
then explain how these are special cases of the framework of General Linear Models,
which is followed by a discussion on Linear Mixed Models. We then discuss the
problem of ANOVA and MANOVA in the case of ‘small n, large p’, and proposed
solutions that combine a PCA dimensionality reduction and further (M)ANOVA
modeling.

16

Computational Statistics Approaches to Study Metabolic Syndrome

331

16.3.1 ANOVA and MANOVA
The univariate Analysis of Variance (ANOVA) (Fisher 1918) was the first and is
currently the most widely known method for the task of modeling the effects of
multiple covariates and their interactions in populations of measurements. Multiway ANOVA is an extension of the one-way ANOVA and Student t-test. The central
assumption of multi-way modeling is an additive generative model for explaining
the observed covariate-related variation in the data. In the case of two covariates, the
equation is
xj |(a,b) = μ + αa + βb + (αβ)ab + ε

(16.1)

Here xj is the observed data point for sample j, a and b (a = 0 . . . A and b =
0 . . . B) are the two independent covariates, such as disease and treatment, and the
main effects αa and βb and the interaction effect (αβ)ab model the variation from
the baseline level (grand mean) μ. Despite the confusing notation, the interaction
effect (αβ)ab is just another term: the interaction effect of disease and treatment, for
example. The ε is a noise term.
Whereas a one-way ANOVA or t-test would only solve the statistical significance
of one term, αa , the result of two-way ANOVA is the statistical significance (p-value)
of all the terms αa , βb , and the interaction effect (αβ)ab simultaneously. Using a t-test
in the case of a multi-way design results in comparing all the pairwise combinations,
which results in tedious interpretation of the results.
If αa or βb can only have dichotomous values, such as healthy/diseased or
male/female, they are called binary covariates. A covariate can also have multiple
levels, such as multiple time points or multiple drug treatments.
There can be an arbitrary number of covariates and therefore main effects, but
when the number of covariates grows, the number of interactions grows exponentially. Interpreting the results then becomes tedious and massively more data are
needed to estimate the effects reliably.
Multivariate ANOVA (MANOVA) is a multivariate generalization of ANOVA.
The MANOVA model is the same as the ANOVA model in Eq. (16.1), except that
all the terms are vectors, whereas in the univariate ANOVA-model they are scalars.
A Bayesian formulation of ANOVA was presented in (Gelman et al. 2003).

16.3.2

General Linear Model

ANOVA and MANOVA are special cases of the General Linear Model (GLM),
which is a general term for the generative model
X = DB + noise

(16.2)

Where X is the data matrix, D is a design matrix of known covariates, and B are the
regression coefficients. The statistical significance of the elements of B can be used as
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a measure of which covariates in D explain the data in X. GLM is applicable to both
univariate and multivariate data and for discrete and continuous-valued covariates.
ANOVA is the special case of GLM in the case of discrete covariates and univariate
data; in MANOVA the data are multivariate. In the case of a mixture of discrete and
continuous covariates, the corresponding methods are called Analysis of Covariance
(ANCOVA) and Multivariate Analysis of Covariance (MANCOVA). The Student
t-test, F-test and linear regression are also special cases of GLM. Generalized Linear
Model is a generalization of GLM that additionally includes non-linear relationships
between data and covariates, such as the logistic function in logistic regression. A
century of work in classical statistics has been dedicated to studying the properties
of GLM in its various forms. The work has mostly assumed univariate or lowdimensional data and large number of samples, whereas in omics data the opposite
case holds: high dimensionality and small number of samples.

16.3.3

Linear Mixed Models and Time-series Modeling

Whereas the standard (M)ANOVA-type linear model consists of standard fixed effects, such as diseases, treatments and time-points, Linear Mixed Models (LMM)
extend (M)ANOVA-type analysis such that it can also include random effects. The
fixed effects refer to effects such as treatments, that have been chosen to the experimental design and are relevant regarding the chosen research question. Random
effects are uninteresting effects that ‘model out’ uninteresting but real effects in the
data, such as repetitions on an individual (Wolfinger et al. 2001), gene-specific effects in a clustering model (Celeux et al. 2005; Ng et al. 2006), or confounding
factors due to a population structure (Listgarten et al. 2010). The equation for linear
mixed models is often written as
X = DB + VU + noise

(16.3)

which extends the fixed effects model with the inclusion of random effects V. The
U are the regression coefficients from random effects to the data. Whereas the fixed
effect design matrix D indeed consists of fixed zeros and ones that relate known
covariates to the samples, the random effects V are assumed to have been sampled
from a Gaussian distribution, and they have to be learned as well.
LMM’s have been a popular choice for modeling time-series omics data. In
ANOVA-type or LMM-modeling of time-series data, the time-point is usually the
fixed effect. A particularly interesting, multivariate application of LMM:s, is clustering genes in time-series omics data (Celeux et al. 2005; Ng et al. 2006). In this
approach, cluster-specific time-course is the interesting fixed effect, and the genespecific variation from the time-course, gene belonging to the cluster, is a random
effect. This is also a model-based clustering approach, where the cluster-specific
time-course becomes the ‘model’. The random effects are used here to model out
uninteresting gene-specific time-effects, which helps in forming the clusters.
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Beyond the possibilities ofANOVA-type modeling, time-series modeling of omics
data is a big field of research of its own (Bar-Joseph 2004), where the central research
question is how to optimally take the time-series nature of data into account and
predict future time-points.
As an example, one recent approach (Sysi-Aho et al. 2011) tackled the fact that individuals develop to different age-related metabolic states at an individual pace, and
age may not be a relevant descriptor per se to find common metabolic development
states. Hidden Markov Models were used to align time-series omics data into unobserved latent metabolic states. Such an abstraction of underlying metabolic states can
help to deal with additional technical constraints of (1) missing time points that are
common in clinical follow-up studies, and (2) humans and mice have very different
life spans, yet the time-series results from multiple species have to be compared or
integrated.

16.3.4

Problems of ANOVA and MANOVA

The general challenges of univariate statistical tests for high-dimensional data also
hold for multi-way ANOVA. The problem of multiple testing can be alleviated with
multiple testing corrections, such as FDR, and there are also more advanced test
statistics developed for multi-way experimental designs (Smyth 2004; McCarthy
and Smyth 2009). Access to the information of correlated clusters can be sought by
clustering the variables before the analysis, or by grouping the variables according
to the p-values obtained from the univariate statistical tests.
MANOVA is the multivariate generalization of ANOVA and defines a formal
multivariate statistical test for testing the effects of covariates on populations of
measurements, taking correlations between the variables into account. MANOVA
was originally designed for low-dimensional data and in n > p conditions. Unfortunately, in ‘small n, large p’ conditions, ubiquitous in omics data, the covariance
(correlation) matrix becomes singular and MANOVA cannot be used. In addition,
MANOVA tests the difference between two populations in terms of all the variables
simultaneously, and therefore only gives the statistical significance of the overall
effect. This result is not sufficiently informative for high-dimensional data, and the
highly relevant information of which variables were up/down-regulated has to be
deduced by other methods, such as univariate tests. Furthermore, as ANOVA and
MANOVA only give the statistical significance of the effect, the direction, up or
down, has to be deduced by other means.
The univariate ANOVA and multivariate MANOVA are two extremes for how
to solve the multi-way modeling problem, both of them facing both technical and
interpretational problems due to the ‘small n, large p’- conditions. Few efforts have
been presented for multivariate multi-way modeling, essentially solving the general
linear model in ‘small n, large p’ conditions. It is obvious that a compromise between
testing a single variable (ANOVA) and all the variables simultaneously (MANOVA)
needs to be sought, and the common modeling choice is a dimensionality reduction
into low-dimensional latent factor (principal component) space, where the statistical
testing is done.

334

16.3.5

I. Huopaniemi and S. Kaski

Multivariate Many-step Approaches

To our knowledge, no methods for multivariate multi-way modeling of highdimensional data with a single model exist in classical statistical literature. One
working solution is a many-step approach, PCA-based dimensionality reduction is
done first, and the effects of covariates are then studied with statistical tests in the
reduced-dimensional principal component space. Examples are ANOVA on the PCA
scores (Bratchell 1989), 50-50 MANOVA (Langsrud 2002) where a MANOVA test is
done on the PCA scores, and ANOVA-Simultaneous Component Analysis (ASCA)
(Smilde et al. 2005).

16.3.6

Multi-class Classification

A multi-way experimental design can in principle be naively considered as a multiclass classification problem, where each combination of covariates, such as ‘diseased
treated’, is considered as an individual class. Even standard classifiers, such as PLSDA and LDA, can be used in this sense. An example of converting a data analysis
problem with a multi-way, multi-source design into a series of multi-class PLS-DA
classifiers, each data source at a time, was presented in (Webb-Robertson et al. 2009).
In this approach, one naturally loses the information that samples with ‘treatment
1 in early time-point’ and samples with ‘treatment 1 in late time-point’ are related
due to both having ‘treatment 1’. Multi-class classification cannot be used easily
to estimate the statistical significance of the effects of multiple covariates and their
interactions.

16.4

Bayesian Multi-way, Multi-source Modeling

We have recently developed Bayesian models for omics data with a multi-way, multisource design. We start this Chapter by introducing briefly the advantages of using
Bayesian models and present our approach for multivariate multi-way modeling in
the single-source case. We then continue with a short overview of existing approaches
to integrating multiple data sources, followed by our Bayesian approach for multiway, multi-source data that directly tackles the question of how to take the multi-way
experimental design into account. Finally, we present an extension of the Bayesian
model to the case of translating biomarkers between multiple species.

16.4.1

Bayesian Modeling

The Bayesian modeling paradigm is an increasingly popular method of choice in
statistical analysis. The main advantage of using full Bayesian inference is that a
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joint probability distribution for all the model parameters is defined, which can be
used directly as a rigorous uncertainty estimate of the results in form of confidence
intervals. Using Bayesian statistics is especially advantageous when the number of
available data samples is small, since a principled uncertainty estimation is crucial
in such conditions.
Another advantage of Bayesian modeling is that it allows a principled way
of combining several modeling contributions, models or components, into a unified hierarchical model. The uncertainty estimation for the whole model is done
jointly, and uncertainty estimates propagate appropriately across the model. This is
a main improvement over many-step approaches such as PCA + MANOVA. In our
case, we need to combine proper dimensionality reduction, multi-way ANOVA-type
modeling, and multi-source integration.

16.4.2

Bayesian Multivariate Multi-way Modeling

Our approach to Bayesian multivariate multi-way modeling, introduced in
(Huopaniemi et al. 2009; Huopaniemi 2012), is the following: We take advantage
of the known fact that there are groups of correlated variables in omics data, and
use clusteredness of data as a main assumption which leads to implicit dimensionality reduction. This enables to overcome both the ‘small n, large p’ problem and
multicollinearity. We essentially state that effects of covariates should be modeled
on groups of variables, instead of single variables. We then use a Factor Analysis
(FA)-type approach (similar to PCA) where each latent factor models one cluster of
variables. The effects of multiple covariates and their interactions are modeled on
the latent factors, each factor representing a group of correlated variables. This is
done according to the following generative model:


xlat
j (a,b) ∼ N αa + βb + (αβ)ab , I
xj = N(μ + Vxlat
j , )

(16.4)

Here, xjlat is a low-dimensional latent factor for individual j, V is a projection matrix
that projects the latent-space variation into the actual observed data space, and  is
diagonal noise.
This is intuitively analogous to doing an ANOVA or MANOVA analysis on the
PCA scores; the added benefit is that the full Bayesian inference allows us to propagate uncertainties between the model parts, resulting in uncertainty estimates that
take all sources of uncertainty into account. The technical details of the model are
discussed in (Huopaniemi et al. 2009). In Fig. 16.2, an example of results is presented, obtained from a lipidomic data set with a two-way setting: healthy/diabetic,
male/female. This method was also applied on another multi-way lipidomic data set
in (Yetukuri et al. 2011), where the effects of Fenofibrate and placebo where studied
on patients with Type 2 diabetes from the FIELD study.
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Fig. 16.2 An example of the results from applying the Bayesian multi-way model on a lipidomic
dataset with a diseased/healthy, male/female setting. Cluster 3 was down-regulated as a result of
disease, and for lipids in clusters 1 and 4, females had a higher concentration. No significant
gender-dependent disease effects were found. For each cluster of correlated variables, the statistical
significance of the effects of disease, gender, and their interaction is estimated by the posterior
distribution being above (below) zero with 95 % confidence indicates an up (down)-regulation.
(Reprinted with kind permission from Springer: Huopaniemi et al. 2009 Fig. 4)

Another, related Bayesian approach that uses sparse components in the context
of multi-way designs is Bayesian sparse latent factor regression models (West 2003;
Carvalho et al. 2008). The work includes a Bayesian approach for the multiple
testing problem of univariate multi-way ANOVA-models, together with means
of how to supervise latent factors to be predictive of multiple classification or
regression problems.

16.4.3

Basic Approaches for Multi-source Data

The standard approach for dealing with omics data coming from multiple tissues
or multiple omics types is to analyze each data source separately. As a step towards
proper data integration, a few supervised (one-way) and unsupervised approaches
have been developed. The unsupervised approaches, such as sparse Canonical
Correlation Analysis (CCA) (Parkhomenko et al. 2007) and O2-PLS (Trygg and
Wold 2003; Rantalainen et al. 2006) attempt to answer what is shared between the
data sources. Another approach (Sysi-Aho et al. 2007; Le Cao et al. 2009; Monni
and Tadesse 2009) is regression from one data source to one variable in the other
data source at time; as an example, one can do regression by PLS from all the protein
concentrations to predict the concentration of each lipid, one at a time. The disadvantage of unsupervised approaches is that they do not take covariates into account
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in any way. The basic supervised (one-way) approach is to teach a classifier in each
data source separately and combine the results, and such integration has been shown
to improve classification accuracy over a single data source (Webb-Robertson et al.
2009; Le Cao et al. 2010). In the case of a multi-way design, one has to either stratify
the analysis to a (one-way) case-control setting, or predict each covariate at time.

16.4.4

The Bayesian Multi-way, Multi-source Model

We have recently introduced a data integration model for multi-source omics data
that tackles directly multi-way experimental designs (Huopaniemi et al. 2010a). The
model extends our Bayesian single-source model, having the same dimensionality
reduction component, based on clusters of correlated variables. The multiple data
sources can be integrated by a CCA-type shared latent variable, which allows a
decomposition of the covariate-related variation into shared- and source-specific
effects. For example, in Huopaniemi et al. (2010a) we applied the method on a
lipidomic lung cancer/healthy, treated/untreated design, where measurements were
taken from multiple tissues. We found a shared cancer effect and a shared treatment
effect between plasma and lung tissues. We therefore concluded that there was a
disease- and treatment-related connection between the tissues.

16.4.5

Translating Biomarkers Between Species

We have also studied the task of translating biomarkers between human studies and
model organisms from experiments that have a multi-way experimental design. We
have, in particular, concentrated on the case where different species have different
variables, and in other words there is no a priori known matching between human
and mouse lipidomes, for example.
Previous works on cross-species modeling of omics data (Seo et al. 2007; Lu et al.
2009; Le and Bar-Joseph 2010) have focused on gene expression, where matching
between the genes in multiple species is mostly known on the basis of similarity of
the DNA sequence (orthologous genes). In the case of lipidomics, for example, the
task is to actually find such a matching between the molecules of multiple species
from the omics data in a disease context. We have approached this problem with
a CCA-type model (Sysi-Aho et al. 2011; Tripathi et al. 2011) and as a Bayesian
multi-way, multi-source modeling approach (Huopaniemi et al. 2010b; Suvitaival
et al. 2011). The latter approach was developed for the case of a similar multi-way
experimental design in both species, such as a longitudinal follow-up study (SysiAho et al. 2011) of patients who later developed into type 1 diabetes, and patients
who remained healthy. Again, the definition of integrating the data sources, in other
words translation, is a similar response to multiple covariates and their interactions
in the two data sources (species) that can be modeled by shared latent effects. The
advantages of this approach are that there is a clear interpretation of what defines a
translation, and a joint uncertainty estimation of the whole model.
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Conclusions

We have discussed the statistical analysis of omics data, which is often a main
difficulty in the systems biology approach to study metabolic syndrome, as well as
any other disease. In such a setting, one usually faces the question of having highdimensional, small sample-size data with a multi-way experimental setting, in which
there are confounding factors and other interesting covariates, such as interventions,
in addition to the diseased-healthy comparison. The data may additionally come from
different data sources, such as multiple omics types, multiple tissues or multiple
species, each source having different variables. Due to methodological difficulties,
the data analysis is unfortunately often done with a reductionist approach: stratifying
the analysis and analyzing each data source separately.
There is a great need of novel statistical tools for proper data integration and dealing with multi-way experimental designs. Developing such methods is currently an
active research topic in the machine learning and statistics communities, in addition
to the question of how to deal with the problem of high-dimensionality and small
sample-size.
We have recently introduced a family of Bayesian methods for modeling multiway, multi-source omics data. The advantages of the Bayesian approach is that
one can build a unified hierarchical model that can deal with the data integration,
multi-way modeling and dimensionality reduction jointly. A rigorous uncertainty
estimation for the whole model is directly obtained, which is crucial with small
sample-sizes.
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M-R, Vattulainen I, Jauhiainen M, Orešič M (2011) High density lipoprotein structural changes
and drug response in lipidomic profiles following the long-term fenofibrate therapy in the
FIELD substudy. PLoS One 6:e23589

Chapter 17

Towards Modeling of Metabolic Syndrome:
Tissue Crosstalk in Lipid Spillover
Sergey Smirnov, Eugeny Metelkin, Nail Gizzatkulov,
Oleg Stepanov and Oleg Demin
Abstract In this chapter we propose a framework for development of the mathematical model of Metabolic Syndrome. The cornerstone of the model is “adipose
tissue expandability hypothesis”, which treats long-term increase in FAs concentration in blood and their subsequent accumulation in muscle and liver as a main
cause of decrease in insulin sensitivity and, consequently, MetS development. The
key biological facts underlying the construction of MetS model have been collected
and analyzed and the main requirements of the model have been formulated. To take
these facts into account and meet the requirements formulated, we have developed
a novel algorithm enabling us to combine kinetic models, which describe changes
in metabolite (lipoproteins) concentrations due to biochemical transformations in
blood and tissues, with the mathematical model of the molecular movement in blood
ﬂow.
Keywords Lipid metabolism · Lipid spillover · Kinetic modeling · Very low density
lipoprotein

17.1

Introduction

Metabolic syndrome (MetS) develops through a long and complex process, which
is associated with several organs and tissues. Several experimental data values characterizing various aspects of MetS have been simulated and collected. However,
mathematical models describing the development of MetS, and for example, its progression to type 2 diabetes (T2D), have not yet been developed. To a large extent,
this is due to the inherent complexity of the processes and regulatory mechanisms
related to MetS. To correctly describe the development of MetS, a mathematical
model needs to account for the crosstalk between different organs and tissues at
various levels such as physiological and biochemical levels.
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One of the main factors in MetS development is a decrease in tissue sensitivity to
insulin (Albu et al. 2010; Felber and Golay 2002; Golay et al. 1984; He et al. 2010;
Lin et al. 2009; Muscelli et al. 2008; Pastucha et al. 2010; Pigeon et al. 2009). We
use this fact as a basis for our MetS model. However, to construct such a model we
first need to identify an experimentally confirmed mechanism that would allow us to
establish the relationship between obesity and a decrease in insulin sensitivity (Czech
et al. 2010; Katz et al. 2000; Prentki and Madiraju 2011; Stannard and Johnson 2004;
Wu et al. 2010).
The aim herein is to outline a framework for further development of the mathematical model describing the occurrence of MetS and its progression to T2D within
the conceptual framework of the adipose tissue expandability hypothesis (AEH)
(Chap. 1.1). For this purpose, first, we developed a model to describe lipid spillover,
which is the non-homogeneous concentration of fatty acids (FA) and lipoproteins
in the circulatory system. To account for the space-time distribution of FAs and
lipoproteins, we developed a new approach that allows us to combine models describing intra- and extra- cellular processes of biomolecules and lipoprotein particle
transformation, where the models describe the transport of blood, molecules, and
lipoproteins in the circulatory system.

17.2

Modeling Framework: Description of the Biological
System and Model Requirements

Based on AEH, the development of MetS can be associated with obesity and it
consists of the following events.
In the first stage of the development of obesity, we assume that the expandability
of the adipose tissue is high. This means that excess FAs can be stored in adipose
tissue. The term “excess FA” refers to all FAs that originate in consumed food or are
produced from glucose in the liver but have not been utilized in energy production.
As obesity develops (i.e., patient weight increases), the expandability of adipose
tissue decreases. If the energy supply resulting from food intake continues to be
higher than the energy consumption required to sustain the organism, then the rate of
influx of FAs starts to exceed the rate of FA storage in adipose tissue. This causes the
concentration of FAs in the blood to increase and FAs to accumulate in certain tissues
such as those of the muscle and liver. Accumulation of FAs in these tissues results in a
decrease in their sensitivity to insulin. Muscle cells can utilize both glucose and FAs
to produce the energy required to maintain intracellular processes and performance.
This means that an increase in FA concentration may result in a decrease in glucose
consumption, and as a consequence, a decline in the insulin-dependent transport of
glucose in muscles.
Thus, to develop a model that satisfactorily describes MetS on the basis of AEH,
we need to account for the following aspects of the disease (Armoni et al. 2007; Bajaj
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et al. 2002; Everett-Grueter et al. 2006; Hirasawa et al. 2005; Kelley and Mandarino
2000; Kim et al. 2007; Lewis et al. 2002; Schnell et al. 2007; Staehr et al. 2003):
(i)
(ii)
(iii)
(iv)

transformation of glucose in the organism
lipid spillover
energy balance in the organism
tissue crosstalk underlying the interconnections between (i), (ii), and (iii).

Transformation of glucose in an organism. Glucose entering the organism through
food can either be utilized to produce energy or it can be stored as glycogen in
liver and muscle tissues and as FAs in adipose tissue. If glucose uptake exceeds
glucose utilization for energy production over a long period, then all excess glucose
is transformed into FAs, which are then stored in adipose tissue. The alternative
method of glucose storage (as glycogen) cannot compete with the process of glucose
transformation into FAs since the glycogen storage capacity of liver and muscle
tissues is extremely low. This means that the ability to accumulate excess glucose in
the form of glycogen is quickly weakened.
If the rate of glucose uptake exceeds the sum of the rates of (i) glucose consumption
to produce energy and (ii) glucose transformation into FAs, then the glucose level
in blood increases until it is balanced with the glucose clearance in urine. If the
dominance of glucose intake over total glucose consumption occurs over a long
period, then the glucose level in blood remains considerably high all the time. This
is the main symptom of MetS (or T2D). In conclusion, we can state that MetS (or
T2D) is a long-lasting state of an organism when the glucose intake rate permanently
exceeds the total rate of its consumption to produce energy, resulting in the storage
of glucose as FAs in adipose tissue.
Lipid spillover. Chap. 2.6 describes in detail the processes involved in FA transformation, transport, and homeostasis. Based on this description, we conclude that
the fate of FAs entering the organism is highly similar to that of glucose. FAs can
either be utilized to produce energy or be stored in adipose tissue. If the rate of FA
uptake exceeds the sum of the rates of (i) FA consumption to produce energy and
(ii) FA storage in adipose tissue, then the FA level in blood increases, i.e., excess FAs
are observed. In accordance with AEH, excessive amounts of FAs in the organism
are responsible for the development and progression of MetS.
In the version of the model presented below, we neglect many aspects of lipid
spillover that are described in Chap. 2.6. For example, we do not distinguish between
VLDL1 and VLDL2 and we do not take into account that there are other lipoproteins
involved in lipid spillover, such as IDL and HDL.
Requirements for development of MetS model. Based on the description of the
biological system presented above, we can prepare a list of requirements for the
development of the MetS model, as follows:
• The model should reproduce the transport of glucose and FAs between different
organs and tissues through biological fluids (tissue crosstalk).
• The model should reproduce glucose and FA dynamics for different diet and food
intake regimens.
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• The model should reproduce the dynamics of the glucose and FA exchange that is
dependent on the energy balance (difference between the energy from consumed
food and that utilized to meet energy needs) in the organism.
• The model should describe changes in the glucose and FA blood concentration
levels resulting from the passage of blood through a selected organ/tissue (or part
of the organ/tissue).

17.3

Model Development

As we have indicated in previous sections (see also Chap. 2.6), the main items
considered in the MetS development model are the glucose and the FAs attached
to various carriers. This means that the model development can be subdivided into
three stages:
• development of the lipid spillover model
• development of the glucose homeostasis model
• merging of the lipid spillover and glucose homeostasis models
In this section, we describe the development of the lipid spillover model. Development of the glucose homeostasis model is not presented in this chapter. In accordance
with the description in Chap. 2.6, there are several organs/tissues actively involved in
lipid spillover. These are the liver, gastrointestinal tract, blood, muscles, and adipose
tissue. Underlying lipid spillover is the intensive crosstalk between organs and tissues. The term “tissue crosstalk” refers to the mechanism by which one organ/tissue
can influence the operation of another organ/tissue via excretion and transport of
active components that can be absorbed and metabolized by the target organ/tissue.
Tissue crosstalk is necessary for the cooperation between tissues, which results in
homeostasis of glucose and FAs in an organism. The following types of crosstalk are
involved in lipid spillover: liver-adipose, liver-muscle, and adipose-muscle.
To be able to describe tissue crosstalk and meet all the requirements discussed
above, the MetS model should consider the complete organism as a set of compartments that exchange biological fluids (e.g., blood and lymph) and consist of
biological entities (e.g., lipoproteins, molecules, and cells).
To build the compartmental structure, we define a “route” as a set of compartments
that are sequentially located. Each route corresponds to a set of blood vessels located
in an organ or part of an organ and describes the blood flow through the organ without
branching or merging into the bloodstream.
A route is characterized by the following basic features:
• blood flow velocity along the route (i.e., the volume of the blood passing through
the route per unit time)
• total volume of blood in a route (i.e., the sum of blood volumes in all compartments
of the route at any given time)
• diameter of the blood vessels along the route
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Fig. 17.1 Schematic of routes taken in lipid spillover model (physiological module). The circulatory
system routes in the lipid spillover model are represented in this schematic. The number above each
arrow indicates the volume of blood traveling through the routes per second (i.e., per cardiac beat).
The following information is indicated in the rectangles: (i) name of the route, (ii) number of
compartments included in the route (C), and (iii) residence time of the blood portion in the route (T)

On the basis of these characteristics, we can calculate the residence time of the blood
in the compartments of a route. The residence time is equal to the ratio of the total
volume of blood in the route and the blood flow velocity along the route.
The number of compartments in a route should be selected such that it is possible to
reproduce both the anatomical location of various organs/tissues in an organism and
their linkage via the circulatory system. Further, there should be a sufficient number
of compartments to enable a detailed description of the space-time distribution of the
biological entities (lipoproteins, molecules, or cells) along the route. Moreover, the
number of compartments should be kept as low as possible to reduce the complexity of
the model. To meet these requirements, we selected a compartment volume such that
the blood residence time of the compartment was equal to one second. Therefore, the
number of compartments in a route is equal to the blood residence time of the route,
expressed in seconds. However, since the residence time and total blood volume
differ for each route, the number of compartments and their volumes also differ.
Splitting the circulatory system into a set of routes is based on a specific biological
task, and therefore, it changes for each model. The route schematic for the lipid
spillover model is given in Fig. 17.1. A detailed description of the routes is presented
in Table 17.1.
To model biochemical reactions that occur in either biological fluids (blood or
lymph) or various organs/tissues interconnected via the circulatory system, we developed the step-by-step algorithm (SBSA). Within the framework of this algorithm,
movement of blood along the route is combined with changes in concentrations
of transported biological entities (molecules and lipoproteins), which is a result of
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Table 17.1 Routes and compartment structure of model
Route

Model #

Number of
compartments

Compartment
volume (ml)

Transient
time (sec)

Total blood volume
in route (ml)

Right heart
Lung
Left heart
Big arteries
Brain
Myocard
Kidneys
Liver
Intestine
Adipose
Muscles
Other
Big veins

No model a
No model a
No model a
No model a
No model a
Model 3
No model a
Model 4
No model a
Model 2
Model 3
No model a
Model 1

3
10
3
7
5
6
2
17
6
56
102
58
12

80
80
80
80
11.2
3.8
18
22.5
16
8.4
11
5.1
80

2.7
9
2.7
6.3
4.5
5.4
1.8
15.3
5.4
50.4
91.8
52.2
10.8

240
800
240
560
56
22.8
36
382.5
96
470.4
1122
295.8
960

a

“No model” means that only transfer of molecules with blood flow without any chemical
transformation occur in these organs. Therefore, any kinetic model was not defined for these organs

chemical reactions and interactions at the walls of the blood vessels, in the following
manner:
• Blood movement along a route is divided into discrete steps. The duration of each
step corresponds to the blood residence time in a compartment.
• For the duration of a single step, blood is considered an immovable fluid. Changes
in concentrations of biological entities in the selected compartment result from
biochemical reactions and interactions at cells of only the vessel wall.
• At the end of a single step, the content of the i-th compartment is transported
infinitely fast to the (i + 1)-th compartment. This is continued in subsequent steps.
Physical implementation of SBSA In this subsection, we focus on a system that
can be represented by a network of interconnected compartments with fluid flowing
through them. In this system, there are molecules (or particles), which can (1) react
with each other in accordance with stoichiometry and reaction rates, (2) interact
with immovable parts of the system (for example, the compartment walls), and (3)
be transferred from one compartment to another with the fluid.
As a model of fluid flow, we consider an incompressible fluid that fills the complete
volume of the compartments and has a laminar flow. Each point in the fluid flows at the
same rate. The equation describing changes in metabolite (particle) concentrations
in compartment s can be written as
∂Cs
∂Cs
= Ns vs + us
+ rs
∂x
∂t

(17.1)

Here, Cs is the vector of metabolite concentrations, rs is the flow rate through the
compartment s (if there is no flow in a compartment, then r = 0), Ns is the stoichiometric matrix, νs is the vector of reaction rates, us is the vector of the influxes of
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molecules/particles from outside (for example, drug administration), t is time, and
x is the variable describing the transfer along the compartment(s) resulted from the
flowing fluid. The boundary condition describing the junction between compartments
can be written as
rs


∂Cj
∂Cs
(0, t) =
rj
(xmax, j , t)
j
∂x
∂x

(17.2)

where index j corresponds to all compartments that supply the flowing fluid to
compartment s. This boundary condition imposes the law of conservation of
molecules/particles at the border between each compartment. The law of conservation
of flowing fluid is given by

rs =
rj
j

Thus, the mathematical model (described by Eqs. 1 and 2) represents a set of advection equations interconnected with boundary conditions describing the continuity of
the flowing fluid and the topology of the linked compartments.
To solve the system numerically, we have (1) assumed that the characteristic time
for chemical reactions is much less than that of fluid transfer and (2) used an upwind
differencing scheme for the construction of finite difference equations on the basis
of differential equations (1 and 2).
We subdivide each compartment into smaller parts, allowing us to neglect the
concentration gradient of volume x = Vf where Vf is the fixed volume of the
sub-compartment. Using the selected difference scheme, we obtain
Cf − Cf −1
∂Cs
≈
Vf
∂x

(17.3)

Where f is the index of the current sub-compartment of compartment s. Taking into
account Eq. 1 and the boundary condition (Eq. 2), we arrive at
 Ci
dCf
Cf
+
ri + Nf vf + uf
= −rf
i
Vi
dt
Vf

(17.4)

where Cf is the function/variable, which depends on time only and index i
corresponds to all compartments that supply the flowing fluid to compartment f.
The value of Cf for each iteration of k is calculated in two stages: (1) we solve
the system of equations without taking into account the contribution of fluid transfer
and (2) we introduce corrections, which describe the contribution of the flowing fluid
to changes in the concentrations of molecules/particles as well as the contributions
from external sources.
The first stage describes the system without any influxes from other compartments:
dCf
= Nf vf + uf
dt

(17.5)
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Cf (0) = Cf , k

(17.6)

These equations describe the chemical transformation of molecules/particles in the
system but do not account for the contribution of their transfer with flowing fluid
from one compartment to another. Concentrations of molecules/particles calculated
in the previous iterations are taken as initial conditions. These equations give us the
following solution at any small time period (T ):
C f , k+1 = C f (T )
The second stage is to correct the solution derived in the first stage for the contribution
of the flowing fluid:


C f , k+1  C k+1i
Cf , k+1 − C f , k+1
= −rf
+
ri
i
T
Vf
Vi

(17.7)

Hence,


Cf , k+1 = C f , k+1 − rf



 C i, k+1
C f , k+1
T +
ri
T
i
Vf
Vf

(17.8)

Mathematical implementation of SBSA As a mathematical object, the complete system can be represented as a series of compartments interconnected by
edges. The compartments are split into routes that correspond to different organs
(see Table 17.1). The edges are described by numeric characteristics that describe
the movement between compartments in terms of a table of interconnections. The
biological processes in each compartment are described by a kinetic model. Different
compartments can be associated with the same or a different kinetic model.
The movement of blood and biological entities located in a specific portion of the
blood is described in a pulse manner with a period equal to T. It is assumed that the
movement of the blood between neighboring compartments happens instantaneously
at the end of the time period. This allows us to separate the solution of the system
into two independent stages. The first stage includes the solution of the kinetic model
in each compartment without taking into account the contributions to metabolite
concentrations resulting from the movement of the blood. The second stage calculates
corrections to metabolite concentrations resulting from the movement of the blood.
Here, we describe the calculation in detail for the first step (t0 , t0 + T). At the
beginning of the step (i.e., when t = t0 ), we know all the metabolite concentrations
in all compartments of the system Cf ,0 i , where Cf ,0 i is the concentration of the i-th
metabolite in compartment f at t = t0 . These data are supplied from the previous step
in the calculation. Then, we show that within the framework of SBSA, it is possible
to calculate the metabolite concentrations Cf ,1 i at t1 = t0 + T. In the first stage
of the calculations, we solve all kinetic models numerically in all compartments
during the time interval [t0 , t0 + T]. As a result, we have intermediate values of
the metabolite concentrations Cf ,1 i at t = t1 . In the second stage of the calculations,
these intermediate concentrations Cf ,1 i are corrected to account for the movement
of the blood and biological entities between compartments (see Eq. 8). From these
calculations, we now have the required values of the metabolite concentrations Cf ,1 i .
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Table 17.2 Description of variables of model 1
Variable

Description

Timer

Auxiliary variable represents time in special
0
function that reproduce the dynamics of dietary
fat in small intestine
Auxiliary variable, that describes the increase of
0
dietary fat in small intestine
Auxiliary variable, that describes the decrease of
1
dietary fat in small intestine
Dose of dietary fat, expressed as concentration in 100
intestine lumen at time point zero
Concentration of free fatty acids in cytosole of
0
enterocytes
Concentration of Chylomicrons in blood
0
Concentration of VLDLs in blood
0
Concentration of VLDL remnants in blood
0
Concentration of Chylomicron remnants in blood
0
Concentration of free fatty acids in blood
0

F1
F2
Dietary_Fat
FA_ent
ChM
VLDL
VLDL_rem
ChM_rem
FA_flow

Initial Value
(at time point
zero)

Units

sec

Dimentionless
Dimentionless
μM
μM
μM
μM
μM
μM
μM

Kinetic models describing biochemical transformations of metabolites/particles
The SBSA model consists of (i) basic (physiological) and (ii) kinetic modules. The
physiological module is responsible for the description of the movement of biological fluids and the transfer of biological entities between various organs/tissues. The
mathematical apparatus of the module is given by Eqs. (7) and (8). The kinetic module is responsible for the description of biochemical processes in each organ/tissue.
The mathematical apparatus of the module is given by Eqs. (5) and (6). As explained in the “Mathematical implementation of SBSA” subsection, all biological
processes in each compartment are described by a kinetic model (see Table 17.1).
Different compartments can be associated with the same or different kinetic models.
Therefore, the number of different kinetic models included in the kinetic module is determined by the number of different organs/tissues included in the construction of the
SBSA-based model. In this section, we describe the different kinetic models
associated with the SBSA model of lipid spillover. These are
Model 1: Formation of chylomicrons (ChMs) and their influx in vena cava from
the lymphoid system through the thoracic duct.
Model 2: Hydrolysis of TGs of ChMs and VLDLs in adipose tissue and the
release/uptake of fatty acids from/in the tissue.
Model 3: Hydrolysis of TGs of ChMs and VLDLs in muscle and the release/uptake
of fatty acid from/in the tissue.
Model 4: Uptake of free FAs and FAs released from ChMs and VLDL remnants
and VLDL formation in the liver.
Below, we describe the kinetic models in further detail.
Model 1 describes ChMs formation from the fat of food in enterocytes and the
release of the ChMs into the blood via the lymphatic system (thoracic duct). Model
1 includes 10 variables (see detailed description in Table 17.2), whose dynamics are
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Table 17.3 Description of rate laws of model 1
Reaction

Rate Law

Comments

R1: = timer;

V(1) = k_time;

Auxiliary reaction for agreement
between the times of dietary fat
dynamics and the internal time of
model
R2: = f1;
If timer > f1_lim then V (2) = k_f1
V(2) describes the increase of
else V (2) = 0
auxiliary variable f1
R3: = f2;
If timer >; f 2_lim then V (3) = k_f2 V(3) describes the increase of
else V(3) = 0
auxiliary variable f2
R4:Dietary_Fat = V(4) = k_df_fa*Dietary_Fat*f2*f12 / Fatty acids absorption, the part of
formula in bold reproduces the
(Km_f1 + f12 );
FA_ent;
dietary fat dynamics in small
intestine
R5:FA_ent = ;
V(5) = k_fa_cm*FA_ent;
Fatty acids inclusion in chylomicrons
R6: = ChM;
V(6) = k_fa_cm*FA_ent/N_fa_cm; Chylomicron production
R7:VLDL = ;
V(7) = k_vldl_deg*VLDL;
VLDLs degradation in blood
R8:VLDL_rem = ; V(8) = k_vldlr_deg*VLDL_rem;
VLDL remnants degradation in blood
R9:ChM = ;
V(9) = k_cm_deg*ChM;
Chylomicrons degradation in blood
R10:ChM_rem = ; V(10) = k_cmr_deg*ChM_rem;
Chylomicron remnants degradation in
blood
R11:FA_flow = ;
V[11] = k_fafl_deg*FA_flow;
Free Fatty Acids degradation in blood

described by the following ODE system:
dtimer/dt = V[1]
df1/dt = V[2]
df2/dt = V[3]
dDietary_Fat/dt = −V [4]
dFA_ent/dt = V[4] − V[5]
dChM/dt = V[6] − V[9]

(17.9)

dVLDL/dt = −V[7]
dVLDL_rem/dt = −V[8]
dChM_rem/dt = −V[10]
dFA_flow/dt = −V[11],
The right-hand sides of the system described by Eq. (9) are given by the rate laws
listed in Table 17.3. The values of the rate law parameters are listed in Table 17.4.
Model 2 describes FA exchange in capillaries of adipose tissue. Model 2 includes
10 variables (see detailed description in Table 17.5), whose dynamics are described
by the following ODE system:
dFA_flow/dt = −V[1]
dFA_exch/dt = V[1] − V[2] + V[3] + V[7] + V[9]
dFA_stor/dt = V[2] − V[3]
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Table 17.4 Description of parameters of model 1
Parameter

Description

k_time

Auxiliary coefficient of agreement between the times of
dietary fat dynamics and the internal time of model
Auxiliary coefficient of rate of increase of dietary fat in
small intestine after fat load
Time after fat load, when the f1 variable stops to
increase
Auxiliary coefficient of rate of decrease of dietary fat in
small intestine after fat load
Time after fat load, when the f2 variable stops to
increase
Rate constant of fatty acids absorptions from small
intestine to enterocytes
Concentration of fatty acids in intestine lumen, that
causes half-maximal rate of absorption (EC50)
Number of fatty acids molecules in one chylomicrons

k_f1
f1_lim
k_f2
f2_lim
k_df_fa
Km_f1
N_fa_cm

Value
1

Dimensionless

1

Dimensionless

60
1
7200

Rate constant of fatty acids inclusion in chylonicrons
(chylomicrons production)
k_vldl_deg Rate constant of VLDLs degradation in blood
k_vldlr_deg Rate constant of VLDL remnants degradation in blood
k_cm_deg
Rate constant of Chylomicrons degradation in blood
k_cmr_deg Rate constant of Chylomicron remnants degradation in
blood
k_fafl_deg Rate constant of Free Fatty Acids degradation in blood

sec
Dimensionless
sec

1

1/sec

1

mM

10000

k_fa_cm

Units

1

Molecules/
particle
1/sec

0
0
0
0

1/sec
1/sec
1/sec
1/sec

0

1/sec

Table 17.5 Description of variables of model 2
Variable

Description

Initial Value
(at time point
zero)

Units

FA_flow
FA_exch
FA_stor
ChM
BS

Concentration of free fatty acids in blood
Concentration of free fatty acids in proteoglycan matrix
Concentration of stored fatty acids in adipocytes
Concentration of Chylomicrons in blood
Concentration of binding sites on endothelium for VLDLs
and Chylomicrons
Concentration of VLDLs in blood
Concentration of Chylomicron remnants in blood
Concentration of VLDL remnants in blood

0
0
0
0
5

μM
μM
μM
μM
μM

0
0
0

μM
μM
μM

VLDL
ChM_rem
VLDL_rem

dChM/dt = −V[4]
dBS/dt = −V[4] − V[5] + V[6] + V[8]
dChM_BS/dt = V[4] − V[6]
dVLDL/dt = −V[5]
dVLDL_BS/dt = V[5] − V[8]
dChM_rem/dt = V[6]
dVLDL_rem/dt = V[8],

(17.10)
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Table 17.6 Description of rate laws of model 2
Reaction

Rate law

Comments

R1:FA_flow =
FA_exch;

V(1) = k_fa_tr_fl_ex*FA_flowk_fa_tr_ex_fl*FA_exch;

R2:FA_exch =
FA_stor;
R3:FA_stor =
FA_exch;

V(2) = k_fa_uptake*FA_exch;

Free fatty acids exchange between
blood plasma and proteoglycan
matrix
Free fatty acids uptake by adipoytes

R4:ChM + BS =
ChM_BS;
R5:VLDL + BS =
VLDL_BS;
R6:ChM_BS =
BS + ChM_rem;

V(4) = k_cm_bs*ChM*BS;

R7: = FA_exch;

V(7) = k_cm_hyd*ChM_BS*
LPL*(N_fa_cm-N_fa_cmr);

R8:VLDL_BS =
BS + VLDL_rem;

V(8) = k_vldl_hyd*VLDL_BS*
LPL;

R9: = FA_exch;

V(9) = k_vldl_hyd*VLDL_BS*
LPL*(N_fa_vldl-N_fa_vldlr);

If FA_stor > FA_stor_lim then
V (3) = k_fa_release else
V (3) = k_fa_release*FA_stor/
FA_stor_lim

V(5) = k_vldl_bs*VLDL*BS;
V(6) = k_cm_hyd*ChM_BS*
LPL;

Rate of fatty acids mobilisation from
adipocytes is not depend on concentration of stored fatty acids (first
order reaction) if this concentration
is under lower limit (FA_stor_lim).
Otherwise, this rate is limited with
lack of stored fatty acids
Chylomicrons binding to their binding
sites on endothelium
VLDLs binding to their binding sites
on endothelium
Triglyceride hydrolysis by lipoprotein
lipase (LPL) and Chylomicron
remnants formation
Triglyceride hydrolysis by lipoprotein
lipase (LPL) and fatty acids release
from Chylomicrons
Triglyceride hydrolysis by lipoprotein
lipase (LPL) and VLDL remnants
formation
Triglyceride hydrolysis by lipoprotein
lipase (LPL) and fatty acids release
from VLDL

The right-hand sides of the system described by Eq. (10) are given by rate laws listed
in Table 17.6. The values of the rate law parameters are listed in Table 17.7.
Model 3 describes FA exchange in capillaries of muscles. Model 3 includes 10
variables (see detailed description in Table 17.8) whose dynamics are described by
the following ODE system:
dFA_flow/dt = −V[1]
dFA_exch/dt = V[1] − V[2] + V[3] + V[7] + V[9]
dFA_stor/dt = V[2] − V[3]
dChM/dt = −V[4]
dBS/dt = −V[4] − V[5] + V[6] + V[8]
dChM_BS/dt = V[4] − V[6]
dVLDL/dt = −V[5]
dVLDL_BS/dt = V[5] − V[8]
dChM_rem/dt = V[6]
dVLDL_rem/dt = V[8],

(17.11)
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Table 17.7 Description of parameters of model 2
Parameters

Description

Value

Units

k_fa_tr_fl_ex

Rate constant of free fatty acids transport from
1
blood plasma to proteoglycan matrix
Rate constant of free fatty acids transport from
1
proteoglycan matrix to blood plasma
Rate constant of free fatty acids absorption from
1
proteoglycan matrix by adipocytes
Rate constant of free fatty acids release from
0
adipocytes to proteoglycan matrix
Minimal concentration of stored free fatty acids in
1
adipocytes that not limited fatty acids release
Rate constant of Chylomicrons binding to their
1
binding sites on endothelium
Rate constant of Chylomicrons binding to their
1
binding sites on endothelium
Rate constant of triglyceride hydrolysis by
1
lipoprotein lipase (LPL) and fatty acids release
from Chylomicrons
Rate constant of triglyceride hydrolysis by
1
lipoprotein lipase (LPL) and fatty acids release
from Chylomicrons
Lipoprotein lipase (LPL) concentration
10
Number of fatty acids molecules in one
10000
chylomicron
Number of fatty acids molecules in one
100
chylomicron remnant
Number of fatty acids molecules in one VLDL
5000
Number of fatty acids molecules in one VLDL
100
remnant

1/sec

k_fa_tr_ex_fl
k_fa_uptake
k_fa_release
FA_stor_lim
k_cm_bs
k_vldl_bs
k_cm_hyd

k_vldl_hyd

LPL
N_fa_cm
N_fa_cmr
N_fa_vldl
N_fa_vldlr

1/sec
1/sec
1/sec
μM
1/sec
1/sec
1/sec

1/sec
μM
Molecules/particle
Molecules/particle
Molecules/particle
Molecules/particle

Table 17.8 Description of variables of model 3
Variable

Description

Initial Value
(at time point
zero)

Units

FA_flow
FA_exch
FA_stor
ChM
BS

Concentration of free fatty acids in blood
Concentration of free fatty acids in proteoglycan matrix
Concentration of stored fatty acids in muscle cells
Concentration of Chylomicrons in blood
Concentration of binding sites on endothelium for
VLDLs and Chylomicrons
Concentration of VLDLs in blood
Concentration of Chylomicron remnants in blood
Concentration of VLDL remnants in blood

0
0
0
0
5

μM
μM
μM
μM
μM

0
0
0

μM
μM
μM

VLDL
ChM_rem
VLDL_rem

The right-hand sides of the system described by Eq. (11) are given by rate laws listed
in Table 17.9. Values of the rate law parameters are listed in Table 17.10.
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Table 17.9 Description of rate laws of model 3
Reaction

Rate law

Comments

R1:FA_flow =
FA_exch;

V(1) = k_fa_tr_fl_ex*FA_flowk_fa_tr_ex_fl*FA_exch;

R2:FA_exch =
FA_stor;
R3:FA_stor = ;

V(2) = k_fa_uptake*FA_exch;

Free fatty acids exchange between
blood plasma and proteoglycan
matrix
Free fatty acids uptake by adipoytes

R4:ChM + BS =
ChM_BS;
R5:VLDL + BS =
VLDL_BS;
R6:ChM_BS =
BS + ChM_rem;

V(4) = k_cm_bs*ChM*BS;

R7: = FA_exch;

V(7) = k_cm_hyd*ChM_BS*
LPL*(N_fa_cm-N_fa_cmr);

R8:VLDL_BS =
BS + VLDL_rem;

V(8) = k_vldl_hyd*VLDL_BS*
LPL;

R9: = FA_exch;

V(9) = k_vldl_hyd*VLDL_BS*
LPL*(N_fa_vldl-N_fa_vldlr);

V(3) = k_energy_exp*FA_stor

V(5) = k_vldl_bs*VLDL*BS;
V(6) = k_cm_hyd*ChM_BS*
LPL;

Free fatty acids usage for energy
production
Chylomicrons binding to their binding
sites on endothelium
VLDLs binding to their binding sites
on endothelium
Triglyceride hydrolysis by lipoprotein
lipase (LPL) and Chylomicron
remnants formation
Triglyceride hydrolysis by lipoprotein
lipase (LPL) and fatty acids release
from Chylomicrons
Triglyceride hydrolysis by lipoprotein
lipase (LPL) and VLDL remnants
formation
Triglyceride hydrolysis by lipoprotein
lipase (LPL) and fatty acids release
from VLDL

Table 17.10 Description of parameters of model 3
Parameters

Description

Value

Units

k_fa_tr_fl_ex

Rate constant of free fatty acids transport from
blood plasma to proteoglycan matrix
Rate constant of free fatty acids transport from
proteoglycan matrix to blood plasma
Rate constant of free fatty acids absorption from
proteoglycan matrix by adipocytes
Rate constant of free fatty acids usage for energy
production
Rate constant of Chylomicrons binding to their
binding sites on endothelium
Rate constant of Chylomicrons binding to their
binding sites on endothelium
Rate constant of triglyceride hydrolysis by
lipoprotein lipase (LPL) and fatty acids release
from Chylomicrons
Rate constant of triglyceride hydrolysis by
lipoprotein lipase (LPL) and fatty acids release
from Chylomicrons
Lipoprotein lipase (LPL) concentration
Number of fatty acids molecules in one
chylomicron
Number of fatty acids molecules in one
chylomicron remnant
Number of fatty acids molecules in one VLDL
Number of fatty acids molecules in one VLDL
remnant

1

1/sec

1

1/sec

1

1/sec

0

1/sec

1

1/sec

1

1/sec

1

1/sec

1

1/sec

10
10000

μM
Molecules/particle

100

Molecules/particle

5000
100

Molecules/particle
Molecules/particle

k_fa_tr_ex_fl
k_fa_uptake
k_energy_exp
k_cm_bs
k_vldl_bs
k_cm_hyd

k_vldl_hyd

LPL
N_fa_cm
N_fa_cmr
N_fa_vldl
N_fa_vldlr
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Table 17.11 Description of variables of model 4
Variables

Description

Initial Value
(at time point
zero)

Units

ChM_rem

Concentration of Chylomicron remnants in blood,
expressed as concentration of included fatty acids
Concentration of free fatty acids in hepatocytes
Concentration of VLDL remnants in blood, expressed as
concentration of included fatty acids
Concentration of free fatty acids in blood
Concentration of VLDLs in blood, expressed as
concentration of included fatty acids
Concentration of Chylomicrons in blood, expressed as
concentration of included fatty acids

0

μM

0
0

μM
μM

0
0

μM
μM

0

μM

FA_liv
VLDL_rem
FA_flow
VLDL
ChM

Table 17.12 Description of rate laws of model 4
Reaction

Rate laws

Comments

R1:ChM_rem = ;

V(1) = k_cmr_upt*ChM_rem;

R2: = FA_liv;

V(2) = k_cmr_upt*ChM_rem*
N_fa_cmr;
V(3) = k_vldlr_upt*VLDL_rem;

Chylomicron remnants uptake by
hepatocytes
Uptake of free fatty acids from
Chylomicron remnants
VLDL remnants uptake by
hepatocytes
Uptake of free fatty acids from
VLDL remnants
Free fatty acids uptake by
hepatocytes
Free fatty acids usage for energy
production (beta-oxidation)
Fatty acids inclusion in VLDLs
VLDL production

R3:VLDL_rem = ;
R4: = FA_liv;
R5:FA_flow = FA_liv;

V(4) = k_vldlr_upt*VLDL_rem*
N_fa_vldlr;
V(5) = k_fa_upt*FA_flow;

R6:FA_liv = ;

V(6) = k_fa_energy*FA_liv;

R7:FA_liv = ;
R8: = VLDL;

V(7) = k_fa_vldl_syn*FA_liv;
V(8) = k_fa_vldl_syn*FA_liv/
N_fa_vldl;
V(9) = k_cm_deg*ChM;

R9:ChM = ;

Chylomicrons degradation in blood

Model 4 describes FA exchange in liver tissue. Model 4 includes 6 variables (see
detailed description in Table 17.11) whose dynamics are described by the following
ODE system:
dChM_rem/dt = −V[1]
dFA_liv/dt = V[2] + V[4] + V[5] − V[6] − V[7]
dVLDL_rem/dt = −V[2]
dFA_flow/dt = −V[5]

(17.12)

dVLDL/dt = V[7]
dChM/dt = −V[9],
The right-hand sides of the system described by Eq. (12) are given by rate laws listed
in Table 17.12. Values of rate law parameters are listed in Table 17.13.
Each of the models of the kinetic module has been associated with compartments
of the physiological module (see Table 17.1).
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Table 17.13 Description of parameters of model 4
Parameters

Description

k_cmr_upt

Rate constant of Chylomicron remnants uptake by
hepatocytes
N_fa_cmr
Number of fatty acids molecules in one
chylomicron remnant
k_vldlr_upt
Rate constant of VLDL remnants uptake by
hepatocytes
N_fa_vldlr
Number of fatty acids molecules in one VLDL
remnant
k_fa_upt
Rate constant of free fatty acids uptake by
hepatocytes
k_fa_energy
Rate constant of free fatty acids usage for energy
production (beta-oxidation)
k_fa_vldl_syn Rate constant of VLDL production
N_fa_vldl
Number of fatty acids molecules in one VLDL
k_cm_deg
Rate constant of Chylomicrons degradation in
blood

17.4

Value

Units

1

1/sec

100
1
100

Molecules/particle
1/sec
Molecules/particle

1

1/sec

0.1

1/sec

1
5000
0

1/sec
Molecules/particle
1/sec

Outcome of the Model

Comparison of SBSA with CAT/ACAT algorithm In this section, we compare two
different algorithms used to describe the movement of biological entities with blood
flow through blood vessels. These are the CAT/ACAT algorithm (Huang et al. 2009)
and the SBSA presented in this chapter.
The CAT/ACAT algorithm was initially developed to describe the absorption
and transit of non-degradable and highly soluble drugs in the gastrointestinal tract
(Agoram et al. 2001; Grass 1997). The process of a drug passing through the small
intestine is considered as a flow through a series of segments. Each segment can be
described as a single compartment with linear transfer kinetics. Each compartment
can have different volumes and flow-rates, but they all have the same transit rate
constant. CAT/ACAT (or similar) algorithms have been implemented in various
software packages (simulations-plus.com 2012; system-biology.com 2012).
SBSA was developed to describe fast processes that occur in the bloodstream
(or other flowing biological fluids). The term “fast process” refers to processes that
result in a change in the concentration of some metabolite (or any other biological
entity) located in blood with a characteristic time less than the turnover time of the
circulatory system. An example of a fast process is the exchange of oxygen and
carbon dioxide between erythrocytes and tissues in the bloodstream. The blood in
arterioles is oxygen-rich and the blood in venules is saturated with carbon dioxide.
This means that the O2 /CO2 ratio decreases significantly from the beginning of the
capillaries to their ends. This spatial distribution of the O2 /CO2 ratio is provided
by fast O2 /CO2 exchange in capillaries. SBSA was developed for the purpose of
describing the spatially non-homogeneous distribution of biological entities.
To compare the SBSA and CAT/ACAT algorithm we selected a model describing the movement of a portion of blood through a tissue. Blood transports
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non-homogeneously distributed biological entities. We assumed that within the
framework of the model, during the movement, the biological entity could interact with the tissue. Chylomicrons (ChM) are considered to be biological entities
transported within the bloodstream. Adipose tissue was selected as a tissue through
which ChMs are transported. In accordance with description in sub-section “Lipid
spillover” of the section “Modeling framework – description of biological system
and model requirements,” ChMs circulating in blood are able to attach to endothelial
cells that pave the capillaries of adipose tissue. To account for the process in our
model, we assumed that the rate of attachment of ChMs to the cells is described in
accordance with the irreversible mass action law with a corresponding binding rate
constant (k_cm_bs):
v_sorption = k_cm_bs*[ChM]*[BS],
where BS is the concentration of binding sites for ChMs or VLDLs located on the
surface of the endothelium wall.
The value of the rate constant (k_cm_bs = 0.008 s−1 ) was selected so as to provide
a 20 % attachment of ChMs to the endothelial cells paving the capillaries of adipose
tissue during a single passage through the part of adipose tissue considered in the
model. This is in line with experimental results of measurements of arterio-venous
differences in ChM concentration across subcutaneous adipose tissue and skeletal
muscle in vivo (Evans et al. 1999).
The initial distribution of ChMs (i.e., dependence of ChM concentration on spatial
coordinate or compartment number) was selected in the following way. Dependence
of ChM concentration is bell-shaped for the first 16 compartments of the model and
equal to zero for all other compartments.
On the basis of the model, we determine the answers to the following questions:
• Does the shape of the spatial distribution change over time?
• How does the ChM concentration change in blood? Is this change fully determined
by the value of k_cm_bs?
We answered these questions by applying the SBSA and CAT/ACAT algorithm to
the model described above. This means that the movement of the portion of blood
through the vessel and the distribution of the concentration of ChMs at each moment
of time was modeled and simulated in accordance with these algorithms. To simulate
the dependence of ChM concentration on time and compartment number (spatial
coordinate) within the framework of the SBSA, we applied the model described in the
“Model development” section. To compare the results obtained from the framework
of the SBSA-based model with those obtained from the CAT/ACAT algorithm, we
simulated the passage of ChMs through the “adipose” route in the SBSA-based
model. In accordance with the data given in Table 17.1 and Fig. 17.1, this route
includes 56 compartments.
To simulate the dependence of ChM concentration on time and compartment
number within the framework of the CAT/ACAT algorithm, we applied the model
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described below:
dChM1 /dt = −k_transport ∗ [ChM1 ],


dChMi /dt = k_transport ∗ ChMi−1 − k_transport ∗ [ChMi ], i = 2, . . . 12


dChMi/dt = k_transport ∗ ChMi−1 − k_transport ∗ [ChMi ]
− k_cm_bs ∗ [ChMi ], i = 13, . . . 44,


dChMi /dt = k_transport ∗ ChMi−1 − k_transport ∗ [ChMi ], i = 45, . . . , 55
dChM56 /dt = k_transport ∗ [ChM55 ],
where k_transport is the rate constant of ChM transport from the upstream compartment to the downstream one. It is worth noting that values of the parameters
responsible for the transport of ChMs between compartments, within the framework
of the CAT/ACAT model, were selected so as to provide an exact match of the time
of passage of ChMs through the adipose tissue in the CAT/ACAT model with the
time of blood flow passage through adipose tissue within the framework of the SBSA
model (which is equal to 56 s):
k_transport = 1s−1
Simulation results obtained within the framework of the SBSA and CAT/ACAT
algorithm are shown in Figs. 17.2 and 17.3. The following differences between
simulations were identified:
(1) Despite the decrease in the maximal value of ChM concentration with the compartment number, the shape of the time profile of ChM concentration calculated
in various compartments did not change in the SBSA-based model (Fig. 17.2a).
On the contrary, we observed a broadening of the time profile in the CAT/ACAT
algorithm-based model (Fig. 17.2b). In fact, ChMs were distributed among 40
compartments at t = 30 s, although they were initially distributed among only
17 compartments (Fig. 17.3).
(2) The value of ChM concentration at the peak of the time dynamics decreased
by 20 % with an increase in compartment number in the SBSA-based model
(Fig. 17.2a). In the CAT/ACAT algorithm-based mode (Fig. 17.2b), we observed
a more significant decrease (more than two times the initial level of ChMs) in
the concentration.
In accordance with clause (2), we can state that the decrease in ChM concentration
resulting from the single passage of the selected portion of blood through adipose
tissue, calculated within the framework of the CAT/ACAT algorithm, is significantly
more than that calculated on the basis of the SBSA. To understand the nature of the
significant differences in simulation results produced by the CAT/ACAT and SBSAbased models, we simulated the spatial-temporal distribution of ChM concentration
under the condition of absence of ability of ChMs to attach to the endothelial cells,
i.e., we assumed the value of k_cm_bs = 0. Evidently, under these conditions, the
concentration of ChMs during the movement with blood flow cannot decrease since
there is no process for ChM consumption in the model. The results shown in Fig. 17.4a

17 Towards Modeling of Metabolic Syndrome

359

25
Compartment 1

Chylomicron concentraon (nM)

Compartment 15

20

Compartment 30
Compartment 45

15

10

5

0
0

a

10

20

30

40

50

60

70

80

90

100

Time (sec)
16

Chylomicron concentraon (nM)

14

Compartment 1

Compartment 15

Compartment 30

Compartment 45

12
10
8

6
4
2
0

b

0

10

20

30

40

50

60

70

80

90

100

Time (sec)

Fig. 17.2 Simulations of time courses of ChM concentration for various compartments of the
“Adipose” route. Simulations were performed to compare models developed within the framework
of the SBSA (a) with those of the CAT/ACAT algorithm (b). All initial values and parameters were
identical for both versions of the model. In both the models, the “Adipose” route was considered.
The route consisted of 56 compartments. At the t = 0, a bell-shaped distribution of ChMs was
observed in 12 upstream compartments located immediately before the start of the “Adipose”
route. In both CAT/ACAT and SBSA-based models, the initial concentration of ChMs in any of
the 56 compartments of the “Adipose” route was zero. Time courses for ChM concentration were
calculated in the 1st , 10th , 20th , 30th , 40th , and 50th compartments of the “Adipose” route. The
kinetic parameter responsible for binding ChMs to the vessel wall cells was equal to 0.08 s−1
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Fig. 17.3 Simulations of spatial distribution of ChM concentration along the “Adipose” route.
Simulations were performed to compare models developed within the framework of the SBSA (a)
with those of the CAT/ACAT algorithm (b). All initial values and parameters were identical for both
versions of the model. In both models, the “Adipose” route was considered. The route consisted
of 56 compartments. At t = 0, a bell-shaped distribution of ChMs was observed in the first 17
compartments of the “Adipose” route. The maximum concentration of ChMs was equal to 20 nM.
The peak of the initial distribution corresponded to the 9th compartment. The spatial distribution of
ChM concentration along the “Adipose” route was simulated for an initial time t = 0 (solid curve)
and t = 30 s (dashed curve). We assumed that the kinetic parameter responsible for the binding of
ChMs to the vessel wall cells was equal to 0.08 s−1
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Fig. 17.4 Time course simulations of ChM concentration for various compartments of the “Adipose”
route. Simulations were performed to compare models developed within the framework of the SBSA
(a) with those of the CAT/ACAT algorithm (b). All initial values and parameters were identical
for both versions of the model. In both the models, the “Adipose” route was considered. The
route consisted of 56 compartments. At t = 0, a bell-shaped distribution of ChMs was observed
in the 12 upstream compartments located immediately before the start of the “Adipose” route.
In both CAT/ACAT and SBSA-based models, the initial concentration of ChMs in any of the
56 compartments of the “Adipose” route was zero. Time courses for ChM concentration were
calculated in the 1st, 10th, 20th, 30th, 40th, and 50th compartments of the “Adipose” route. The
kinetic parameter responsible for binding ChMs to the vessel wall cells was 0
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demonstrate that simulations obtained within the framework of the SBSA-based
model are in line with the conclusion. In fact, there is no decrease in the peak
value of the time series of ChM concentration calculated for various compartments
and the shape of the time profile does not change with an increase in compartment
number. However, the simulations obtained within the framework of CAT/ACAT
algorithm-based model (Fig. 17.4b) demonstrate both a significant decrease in the
peak value of the time series of ChM concentration with an increase in compartment
number and a broadening of the time profile with an increase in compartment number.
By comparing Fig. 17.2b and 17.4b, we can conclude that the time series of ChM
concentrations calculated in various compartments do not depend significantly on the
ability of ChMs to attach to the endothelial cells, and this has been taken into account
in the CAT/ACAT model. Even under the condition of k_cm_bs = 0, a significant
decrease in the peak value of ChM concentrations and a broadening of the time
profile is observed with an increase in compartment number.
This means that the CAT/ACAT algorithm cannot be used to describe the dynamics
of the movement of any biological entity with blood flow. In contrast, the SBSAbased model enables us to correctly simulate both the movement of a biological
entity with blood flow and the dynamic changes in its concentration resulting from
chemical reactions or interactions with cells of the vessel wall. Hence, we propose
using the SBSA to model the dynamics of lipid spillover.
Prediction of spatial distribution of FAs and lipoproteins in adipose and liver
tissues In this section, we illustrate how the SBSA-based model of lipid spillover
can describe the time dynamics of free FAs, ChMs, and ChMRs in the selected portion of blood passing through various blood vessels located in adipose tissue and
liver tissue.
In our SBSA-based model, adipose tissue is described by 56 compartments and
the residence time of a portion of blood is estimated as 50.4 s (see Table 17.1).
Figure 17.5 shows the simulation of time dynamics of free FAs, ChMs, and ChMRs
in the selected blood portion passing through adipose tissue. At t = 0, the portion
of blood is located at the entrance to the adipose arteries and contains only ChMs,
i.e., the concentration of free FAs and ChMRs is zero. Then, the blood portion
sequentially passes through the adipose arteries (from 0 to 11 s), adipose capillaries
(from 12 to 45 s), and adipose veins (from 46 to 50.4 s). The simulation results show
that the concentrations of free FAs, ChMs, and ChMRs do not change when blood
passes through the arteries and veins, but when it passes through the capillaries of
adipose tissue, there is a decrease in the concentration of ChMs in the blood. This can
be explained in terms of the hydrolysis of the TGs of ChMs by LPL (see also Chap.
2.6). LPL catalyzes the production of free FAs and ChMRs from ChMs, and in fact,
it was seen that the concentrations of free FAs and ChMRs in the blood increased
as they passed through the capillaries of adipose tissue. It was also observed that as
the passage time for the portion of blood increased through the capillaries of adipose
tissue, the changes in the concentrations of free FAs, ChMRs, and ChMs became
more pronounced.
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Fig. 17.5 Spillover of fatty acids from chylomicrons to FFA fraction in adipose tissue. These
simulations represent the dynamics of the concentration of ChMs, ChMRs, and free FAs in the
blood portion flowing along the “Adipose” route. We selected the portion of the blood located in
the first compartment of the “Adipose” route at t = 0. Initial concentrations of ChMs, ChMRs, and
free FAs in the blood portion are equal to 20 nM, 0.0 nM, and 0.0 μM, respectively. Concentrations
of all other molecules/particles were assumed to be equal to zero. With each cardiac beat (i.e.,
each second), the portion of blood is transported to the next downstream compartment. Graphs
represent changes in ChM, ChMR, and free FA concentrations in the blood portion flowing along
the “Adipose” route

In a similar manner, we simulated the time dynamics of free FAs, ChMRs, and
VLDLs in the selected blood portion passing through liver tissue (see Fig. 17.6). Liver
tissue can be described as 17 compartments, and the residence time of a portion of
blood is estimated as 15.3 s (see Table 17.1). At t = 0, the portion of blood is located
at the entrance to the liver arteries and contains non-zero concentrations of free
FAs, ChMRs, and VLDLs. Then, the blood portion sequentially passes through
the liver arteries (from 0 to 3 s), liver capillaries (from 4 to 13 s), and liver veins
(from 14 to 15.3 s). The simulation results show that the concentrations of free FAs,
ChMRs, and VLDLs do not change when blood passes through the arteries and
veins, but passage through the capillaries of liver enriches the blood with VLDLs
and decreases concentrations of free FAs and ChMRs. This can be explained in
terms of the absorption of free FAs and ChMRs by hepatocytes (see also Chap. 2.6).
Hepatocytes use the absorbed FAs and ChMRs to assemble VLDLs with subsequent
release to the blood stream. It was seen that the concentration of VLDLs increased
as the blood passed through the capillaries of liver tissue. It was also observed that as
the passage time for the portion of the blood increased through the capillaries of liver
tissue, the changes in the concentrations of free FAs, ChMRs, and VLDLs became
more pronounced.
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Fig. 17.6 Spillover of fatty acids from FFA fraction and chylomicron remnants to VLDL in liver.
These simulations represent the dynamics of the concentrations of VLDLs, VLDLRs, and free FAs
in the blood portion flowing along the “Liver” route. We selected the portion of blood located in the
first compartment of the “Liver” route at t = 0. Initial concentrations of the VLDLs, VLDLRs, and
free FAs in the blood portion are equal to 100 nM, 50 nM, and 2.5 mM, respectively. Concentrations
of all other molecules/particles were assumed to be equal to zero. With each cardiac beat (i.e., each
second), the portion of blood is transported to the next downstream compartment. Graphs represent
changes in VLDL, VLDLR, and free FA concentrations in the blood portion flowing along the
“Liver” route

17.5

Conclusions

A new algorithm was developed, which enabled us to combine kinetic models describing changes in metabolite (lipoprotein) concentrations that occurred due to
biochemical transformations in blood and tissues, with the mathematical model of
the molecular movement in blood flow. The algorithm may be applied to integrate a
variety of experimental data and to understand the regulatory mechanisms underlying
MetS development and progression.
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